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Preface to ”The Molecular and Cellular Basis of
Retinal Diseases”
Our goal with this series of articles was to bring together many prominent vision scientists to
report on various aspects of ocular disease, with a focus on the use of animal models to elucidate the
underlying mechanisms of pathobiology involved. Rather than limit the focus to only certain aspects
of retinal research, we contacted a broad representation of vision scientists studying the retina, in the
hopes of compiling a more comprehensive overview of the field. We believe that you will find, herein,
a breadth of studies touching on many of the key areas of current retina research.
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Abstract: We sought to delineate the retinal features associated with the high-fat diet (HFD) mouse,
a widely used model of obesity. C57BL/6 mice were fed either a high-fat (60% fat; HFD) or low-fat
(10% fat; LFD) diet for up to 12 months. The effect of HFD on body weight and insulin resistance were
measured. The retina was assessed by electroretinogram (ERG), fundus photography, permeability
studies, and trypsin digests for enumeration of acellular capillaries. The HFD cohort experienced
hypercholesterolemia when compared to the LFD cohort, but not hyperglycemia. HFD mice developed
a higher body weight (60.33 g vs. 30.17g, p < 0.0001) as well as a reduced insulin sensitivity index
(9.418 vs. 62.01, p = 0.0002) compared to LFD controls. At 6 months, retinal functional testing
demonstrated a reduction in a-wave and b-wave amplitudes. At 12 months, mice on HFD showed
evidence of increased retinal nerve infarcts and vascular leakage, reduced vascular density, but no
increase in number of acellular capillaries compared to LFD mice. In conclusion, the HFD mouse
is a useful model for examining the effect of prediabetes and hypercholesterolemia on the retina.
The HFD-induced changes appear to occur slower than those observed in type 2 diabetes (T2D) models
but are consistent with other retinopathy models, showing neural damage prior to vascular changes.
Keywords: retinal phenotype; neural infarcts; vascular leakage
1. Introduction
Diabetes is now considered a worldwide epidemic [1,2]. Recent reports indicate that over 90% of
diabetic individuals have type 2 diabetes (T2D) [3,4]. The most common microvascular complication of
diabetes is diabetic retinopathy (DR) [2]. Despite a growing number of different approaches to arrest
DR, the incidence and prevalence of DR continues to rise [5]. The understanding of the pathogenesis
of DR remains incomplete [4], and this is, in part, due to the lack of readily available models that
completely recapitulate the metabolic phenotype [6]. The high-fat diet (HFD) mouse model has
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been described as a robust model for investigating obesity-associated T2D and its related metabolic
complications [7]. Studies have shown that HFD-fed mice develop obesity, impaired glucose tolerance,
and reduced insulin sensitivity [8,9] with systemic manifestations involving adipose tissue [10], liver [8],
and kidneys [11]. However, the ocular changes associated with the HFD model have not been fully
investigated. Moreover, the typical Western diet (WD; 40% fat) has also been given to rodents to
recapitulate obesity-driven pathology. However, to mimic the features of T2D, the administration of
low-dose Streptozotocin (STZ) is also given to the WD mice [12–14].
The retinal response to high fat exposure would likely involve local changes in the expression
of lipid transport proteins, such as the liver X receptors (LXRs). The LXRs are the key transcription
factors that regulate lipid and cholesterol metabolism [15]. While liver X receptor alpha (LXRα) is
expressed only in some tissues, the expression of liver X receptor beta (LXRβ) is ubiquitous [12].
Previously we showed that whole body LXRα/β deficiency resulted in the generation of increased
numbers of acellular capillaries, while LXR agonists improved DR in Streptozotocin (STZ)-induced
diabetes [12] and in diabetic Leprdb/db (db/db) mice [16]; however, it is not known if the WD modulates
the expression of LXR in the retina.
Retinopathy is typically characterized by macroglia activation and gliosis identified by glial
fibrillary acidic protein (GFAP) overexpression, which can be considered as a marker for retinal
damage [17,18]. In the healthy mammalian retina, GFAP is expressed only in astrocytes and not in Muller
cells. Following inherited or acquired retinal pathology, GFAP is expressed also in Muller cells [19,20].
GFAP expression in Muller cells has been widely used as a cellular marker for retinal pathology [21–25].
Hypoxia-inducible factor 1 alpha (HIF-1α) is known to be a key regulator of a tissue’s response to
hypoxia [26] and plays a role in obesity-induced metabolic syndrome. It has been shown that HFD
leads to gradual increase in HIF-1α and associated pathological changes in the liver [27,28]. However,
the role of HIF-1α in the retina of WD-fed mice is not known.
A better understanding of DR in obesity-driven models is needed and may facilitate the optimal
choice of disease models for future investigations. Thus, in the present study, we hypothesized that
HFD and WD feeding would result in a distinct retinal phenotype and a time course slower than
that observed in models of T2D, such as the db/db mouse [29] or the high fructose and high fat fed
mouse [30]. For this purpose, we characterized not only systemic endpoints of glucose and lipid
metabolism but also the function of the retina and development of retinal pathology, including retinal
vascular changes and changes in expression of the critical proteins LXRβ, HIF-1α, and GFAP.
2. Materials and Methods
2.1. Animals
All animal experiments were approved by the University of Alabama at Birmingham
(IACUC-20467, approved on 06/16/2016) and Georgetown University (animal project #2017-0059,
approved on 10/27/2017), and followed the Association for Research in Vision and Ophthalmology
Statement for the Use of Animals. Six to eight-week-old C57BL/6J mice were fed either a low-fat
diet (LFD) (10%kcal fat, 70%kcal carbohydrate, 20% protein), a Western diet (40% kcal fat, 43% kcal
carbohydrate, 17%kcal protein), or a HFD (60% kcal fat, 20% kcal carbohydrate, 20% kcal protein) for
up to 12 months. Diets were purchased from Research Diets, Inc, New Brunswick, NJ, USA. Full details
of the composition of each diet is given in Supplementary Table S1.
2.2. Body Composition, Glucose Tolerance, and Insulin Sensitivity Testing
The fat mass, lean mass, and water content of the animals were measured by magnetic resonance
imaging using EchoMRI (Echo Medical Systems, LLC, Houston, TX, USA). For glucose and insulin
tolerance tests, mice were fasted for 5-6 h, injected intraperitoneally with D-glucose at 1.5 g/kg of
lean mass and tail bled for glucose and insulin measurements. Blood glucose and insulin levels were
2
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measured 0, 15, 30, 45, 60, and 120 min after glucose administration. The insulin sensitivity index (ISI)
was estimated using the Matsuda–Defronzo method [31].
2.3. Electroretinogram (ERG)
ERGs were performed using a LKC Bigshot ERG system. Briefly, mice were dark-adapted
overnight. The animals were anesthetized with ketamine (80 mg/kg total body mass) and xylazine
(15 mg/kg total body mass), then dilated with atropine/phenylephrine under dim red light. Once dilated,
animals were exposed to 5 full-field white light flashes at 0.25 and 2.5 cd.s/m2 under scotopic conditions.
The animals were then light-adapted for 5 min and exposed to 10–15 full-field white light flashes at
10 and 25 cd.s/m2 under photopic conditions. Responses were averaged and analyzed using the LKC
EM software.
2.4. Fundus Photography and Fluorescein Angiography
Fundus photography and fluorescein angiography were performed using the Phoenix Micron IV
retinal imaging microscope (Phoenix Technology Group, Pleasanton, CA, USA). Briefly, mice were
anesthetized with ketamine and xylazine, then dilated with atropine/phenlylephrine, as described
above. Once dilated, the animals were placed on the instrument and fundus photographs
were taken. Animals were then given intraperitoneal injection of fluorescein (AK-FLUOR 10%,
Sigma Pharmaceuticals, North Liberty, IA, USA) and the retinal vasculature was imaged with blue
light illumination after 5–8 min when all the vessels were filled.
2.5. Acellular Capillaries Quantification
Trypsin digestion of the retina was performed according to a previously published protocol [32,33].
Briefly, eyeballs were enucleated and incubated in 4% paraformaldehyde overnight. Retinas were
isolated, washed, and digested in elastase solution (40 Units elastase/mL; Sigma-Aldrich, St. Louis,
MO, USA) to remove the non-vascular tissue. The vascular beds were mounted on glass slides
followed by staining with periodic acid–Schiff’s base and hematoxylin. About 5–6 fields from the
central to mid-periphery were imaged and the number of acellular capillaries per square millimeter
were quantified.
2.6. Immunohistochemistry
Immunohistochemical staining of mouse retinas was performed according to a previously
published protocol [34]. Briefly, mice were euthanized and eyes were immediately enucleated and fixed
in 4% paraformaldehyde (PFA) solution for 15 min. Cornea and lenses were carefully removed and
posterior cups were incubated in 15% sucrose solution in phosphate-buffered saline (PBS) overnight
at 4 ◦C after washing briefly in PBS. Posterior cups were transferred to 30% sucrose in PBS for 3–4 h,
then embedded in optimal cutting temperature (O.C.T) medium and immediately frozen on dry ice.
The frozen samples were stored at −80 ◦C until further processing. The sections were thawed at room
temperature for 4 h, washed in PBS for 5 min, and permeabilized with 0.25% Triton-X in PBS for 5 min at
room temperature. Sections were blocked with 10% horse serum in 1% bovine serum albumin (BSA) for
2 h then incubated with primary antibody diluted in blocking solution (1:100 dilution) overnight at 4 ◦C.
The antibodies used were rabbit anti-GFAP (Abcam, MA, USA), mouse mAB HIF-1α antibody (Novus
Biologicals, CO, USA), LXR-β polyclonal antibody (Invitrogen, IL, USA), rabbit anti-Vimentin (Cell
Signaling Technology, MA, USA), and isolectin GS-IB4 Alexa Fluor 568 (Life Technologies, OR, USA).
Sections were then washed and incubated in fluorescent-labeled secondary antibodies (goat anti-rabbit
IgG Alexa Fluor 488, Life Technologies, OR, USA) for 1 h at room temperature, followed by washing and
incubation with 4′,6-diamidino-2-phenylindole, dihydrochloride (DAPI) solution (Life Technologies,
OR, USA) for 5 min at room temperature. Finally, sections were washed and mounted with anti-fade
mounting medium (Vector Laboratories, CA, USA) for imaging. Image analysis was completed in
a masked fashion using four images taken at defined positions and quantified using ImageJ software.
3
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The analysis was performed in a masked fashion by three separate observers, then averaged. To achieve
unbiased results, positive and negative controls were included alongside experimental test and control
groups. Fluorescent microscopy was performed by trained masked operators. To address selection
bias in immunofluorescence, the entire areas of retinal cross-sections were imaged.
2.7. Statistics
All experiments were repeated at least 3 times. All data were assessed using one-way ANOVA.
When the results were significant, we determined which means differed from each other using Tukey’s
multiple-comparisons test. Results are expressed as mean± standard error of the mean (SEM). Statistical
analysis was performed using GraphPad Prism, with p < 0.05 considered statistically significant.
Only significant comparisons are shown in the figures. All the examiners were blinded to the identities
of the samples they were analyzing.
3. Results
3.1. HFD Mice Have Normal Glucose Levels but Are Insulin-Resistant
We first sought to validate our model by confirming in our cohort that HFD feeding led to
similar degrees of body weight gain as reported in the literature [10,35]. Mice on HFD showed
increased body weights by 4 weeks of feeding (p = 0.0020). This increase was sustained throughout
the 12-month observation period (Figure 1A). At 12 months, HFD mice had moderately higher lean
mass (difference of 5.580 ± 1.003g, p < 0.0001) and water content (difference of 4.517 ± 0.876, p = 0.0001)
but a markedly increased fat mass (difference of 21.15 ± 2.362, p < 0.0001) compared to LFD controls
(Figure 1B). Unexpectedly, chronic high-fat feeding did not cause hyperglycemia. Despite feeding
mice with a HFD for 12 months, the HbA1c levels were not different between HFD and LFD mice
(Figure 1C). At 12 months, there was no difference in fasting blood glucose levels (Figure 1D, basal) and
intraperitoneal glucose tolerance test (IP-GTT) did not show any significant differences between LFD
and HFD mice (Figure 1D). However, due to the very high levels of insulin in HFD mice (0.6 ng/mL
for LFD and 3.5 ng/mL for HFD; Figure 1E, basal), the insulin sensitivity index demonstrated that
HFD mice had much lower insulin sensitivity compared to LFD mice (Figure 1E,F). Also, plasma total
cholesterol levels were higher in HFD mice compared to LFD (174.4 vs. 114.9, p = 0.0008) (Figure 1G)
Figure 1. Cont.
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Figure 1. Body weight, glucose levels, and insulin sensitivity of high-fat diet (HFD) mice vs. low-fat
diet (LFD) mice. (A) Body weights as measured for mice on LFD (green) and HFD (red) for 12 months.
(* p < 0.000001; n = 6). (B) Lean mass, fat mass and water content of LFD mice vs. HFD mice.
(C) Glycated hemoglobin (HbA1c) levels measured for the mice after 6 months and 12 months.
(D–G) Glucose curves (p > 0.46 for all time points), insulin curves (p < 0.0018 for all time points),
insulin sensitivity index, and total cholesterol levels for LFD mice vs. HFD mice, respectively, following
intraperitoneal glucose tolerance test (IP-GTT) after 12 months of feeding.
3.2. HFD Mice Have Functional Deficits in Their Retinas
Full-field ERG under both scotopic and photopic conditions was performed at 6 months and
12 months of HFD feeding (Figure 2A–D). HFD mice at 6 months showed significantly reduced a-
and b-wave amplitudes under scotopic conditions (p = 0.00125 and p = 0.000002 for 0.25 cd.s/m2 and
2.5 cd.s/m2 stimulus luminance, respectively) but not photopic conditions when compared to LFD mice.
After 12 months of feeding of the respective diets, the difference was not significant (p = 0.183 and
5
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p = 0.154 for 0.25 cd.s/m2 and 2.5 cd.s/m2 stimulus luminance respectively) (Figure 2C,D). Interestingly,
when comparing 6 and 12 months of LFD feeding, the mice experienced marked reductions in both
the a- and b- waves under both photopic and scotopic conditions at 12 months (Figure 2E,F), but no
significant difference was noted in the HFD-fed mice (Figure 2G,H).
Figure 2. Assessment of retinal function of LFD mice versus HFD mice by electroretinogram (ERG).
The amplitudes of a-waves and b-waves were assessed under both scotopic and photopic conditions
for LFD mice and HFD mice after 6 months (A,B) and 12 months (C,D). LFD mice showed a significant
reduction in retinal response between 6 months and 12 months of feeding (E,F), but HFD mice did
not (G,H); (n = 4 for both groups).
6
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3.3. Fundus Photography shows Neural Retinal Lesions in HFD Mice
In humans, DR is associated with retinal lesions such as hemorrhages, microaneurysms, exudates,
and “cotton wool spots” [36]. Fundus photography using Micron IV demonstrated retinal pathology in
the HFD mice. Though not statistically significant, HFD mice showed a trend of increased numbers of
“lipid-laden-like” lesions (Figure 3A) after 6 months (p = 0.057). However, with 12 months of feeding,
HFD mice showed significantly higher number of lesions in the retina (Figure 3B).
Figure 3. Assessment of retinal lesions by fundus photography (A,B) and vascular leakage by fluorescein
angiography (C,D). HFD mice developed more neural infarcts ((A,B), white arrows) than LFD mice.
No infarct was observed for LFD after 6 months (A). However, vascular leakage was observed in HFD
mice after 12 months of feeding ((D), white arrows).
7
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3.4. Vascular Permeability Changes in HFD Mice
A hallmark of DR in humans is increased vascular permeability, ultimately leading to diabetic
macular edema in humans. To determine if HFD mice developed a breakdown in the blood–retinal
barrier, we assessed vascular leakage by fluorescein angiography (FA). At 6 months of HFD feeding,
FA did not show any evidence of retinal vascular leakage and were similar to FAs in LFD controls
(Figure 3C). However, after 12 months of HFD feeding, increased leakage of fluorescein was observed
in the retina compared to LFD control retinas (Figure 3D).
3.5. Acellular Capillary Formation in HFD Mice
A well-established feature of diabetic microvascular dysfunction is an increase in the number
of acellular capillaries in the retina, defined as basal membrane tubes lacking endothelial cells and
pericyte nuclei. At 12 months of HFD feeding, there was no significant increase in acellular capillary
numbers in the HFD mice (Figure 4B,C) compared to the LFD mice (Figure 4A,C). However, the HFD
retinas showed lower vascular densities compared to LFD retinas (Figure 4D).
Figure 4. Enumeration of acellular capillaries in LFD and HFD mice after 12 months of feeding. Red
arrows indicate acellular capillaries in the retinas of LFD (A) and HFD (B) mice. There was no significant
difference in the number of acellular capillaries between both groups (C) (p = 0.086). However, HFD
retinas showed lesser vascular densities compared to LFD retinas (D).
8
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3.6. Retinal Damage, Hypoxia, and Lipid Transport in WD Mice
While the HFD represents a diet with 60% fat content that is used as a model of obesity and
T2D, the WD with 40% fat content has garnered popularity as it represents a regimen closer to that
actually ingested by humans. Since the WD diet has lower fat content and is not associated with
hyperglycemia, we hypothesized that if retinal changes were present they would be subtle compared
to those we observed with HFD feeding. To test the validity of our hypothesis, we performed IHC
studies and first examined whether there was evidence of glial activation by examining expression of
the glial marker GFAP after 6 months of WD feeding. Although there was no statistically significant
difference (p = 0.88) in the total expression of GFAP between retinas of WD and LFD mice (Figure 5A–C),
increased expression of GFAP was observed in selected Vimentin-positive Muller cells in the WD
mice (Figure 5G–I) compared to LFD (Figure 5D–F). Increased expression of GFAP in Muller cells is
supportive of increased oxidative stress and inflammation in these cells, and suggests that the impact
of WD is not experienced uniformly across all Muller cells [37,38].
To assess whether WD feeding induced retinal hypoxia, changes in HIF-1α expression were
examined by IHC. After 6 months of WD feeding, a significant increase (p = 0.025) in expression of
HIF-1α was seen in WD mice (Figure 6D) compared to LFD mice (Figure 6C). This was not observed
after 3 months of WD feeding (Figure 6A,B). Quantitation of HIF-1α expression is shown in Figure 6E,
demonstrating that WD-fed mice exhibit higher levels than LFD-fed mice. Co-localization with isolectin,
a known vascular endothelial cell marker, showed increased expression of HIF- 1α in some endothelial
cells in WD mice (I–K) but not in LFD mice (F–H). Higher magnification images from two different
WD samples are shown in Figure 6L,M.
Retinal lipid content is regulated in part by liver X receptor beta (LXRβ) expression. We next
examined changes in LXRβ expression in the two experimental cohorts. In control mice, LXRβ localized
predominantly in the ganglion cell layer, as well as the inner nuclear layer (Figure 7A), which is the
location of the bipolar cells, horizontal cells, and amacrine cells. There was a significant reduction
in expression of LXRβ in WD only in the ganglion cell layer (p = 0.0079) after 3 months of feeding
(Figure 7B). However, after 6 months of WD feeding, WD mice (Figure 7E) showed significantly reduced
expression of LXRβ in the ganglion cell layer (p = 0.0374), inner nuclear layer (p < 0.0001), and outer
nuclear layer, as well as in the photoreceptors of the outer nuclear layer (p = 0.0020). The expression of
LXRβ was reduced after 6 months compared to 3 months of feeding in both LFD (p < 0.0001) and WD
(p < 0.0001) in the nuclear and ganglion cell layers, suggesting an age-related loss in LXRβ.
Figure 5. Cont.
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Figure 5. Retinal glial fibrillary acidic protein (GFAP) expression after 6 months of feeding. Some
Muller cells in Western diet (WD) retinas express GFAP (A,C, white arrows), but not in LFD (A,B),
indicating that the impact of WD is not uniform across all Muller cells. Co-localization with Vimentin,
a known Mueller cell marker, showed increased expression of GFAP in some Mueller cells in WD mice
(G–I) but not in LFD mice (D–F).
Figure 6. Cont.
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Figure 6. Retinal hypoxia-inducible factor 1 alpha (HIF-1α) expression after 3 and 6 months of WD
feeding. There was increased expression of HIF-1α in WD retinas (D, white arrows) compared to LFD
retinas (C), as shown by quantification (E). Also, there was no significant difference in expression of
HIF-1α after 3 months of feeding (A,B). Co-localization with isolectin, a known vascular endothelial
cell marker, showed increased expression of HIF-1α in some endothelial cells in WD mice (I–K) but not
in LFD mice (F–H). (L,M) Magnified merged images from two different WD samples.
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Figure 7. Retinal liver X receptor beta (LXRβ) expression after 3 and 6 months of feeding. After 3
months of either WD or LFD feeding, there was significant reduction in the expression of LXRβ in only
the ganglion cell layer of WD mice (B) compared to LFD mice (A). However, after 6 months of feeding,
there was reduced expression of LXRβ in the ganglion cell layer as well as inner and outer nuclear
layers of WD mice (E, white arrows) compared to LFD mice (D). Quantification of LXR in the inner
nuclear layer (INL) and outer nuclear layer (ONL) at 3 months shows reductions in the ganglion cell
(GC) layer (C). At 6 months, reductions are seen in the INL, ONL, and ganglion cell (GC) layer of the
WD-fed mice when compared to LFD mice.
4. Discussion
Diabetic retinopathy causes both neural and vascular defects, with neural deficits preceding
vascular changes [6,39–42]. Even before the onset of clinically detectable retinopathy, diabetic patients
have a reduced ERG implicit time [43] and high-frequency flicker amplitude [44]. Later, they experience
decreased vascular density [45]. In this study, we have shown that HFD feeding results in a suitable
model of prediabetes, with the HFD cohort exhibiting insulin resistance and hypercholesterolemia
without hyperglycemia. The retinopathy that is exhibited occurs over a slower time course than in
T2D models, where both hyperglycemia and hyperinsulinemia exist.
The HFD mouse has previously been described as a model for T2D [7,46], as C57BL/6J mice fed HFD
develop obesity and insulin resistance [47,48], but as we show in this study, this model has a distinct timeline
and different characteristics than those seen in T2D. We show that HFD mice have hypercholesterolemia
and insulin resistance but the absence of hyperglycemia, which is typical of T2D models.
In agreement with the literature, our study shows that mice fed a HFD have a sustained increase
in body weight [6,49,50]. As confirmed by EchoMRI, the increase in body weight is primarily due to
elevated body fat mass. After 12 weeks of feeding, HFD mice showed a two-fold increase in body
fat mass over control LFD mice. Despite the marked increase in fat mass, HFD mice did not develop
overt hyperglycemia. Glycated hemoglobin levels measured at 6 months and 12 months showed
that both groups had normal glycated hemoglobin, thus indicating a key difference between the
HFD model and other T2D rodent models, many of which are genetic. However, HFD mice develop
hyperinsulinemia (Figure 1E,F), and their insulin production is sufficient to maintain euglycemia,
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as indicated by their glycated hemoglobin levels. The marked hyperinsulinemia we observed is
supported by the literature [6,51–54]. In contrast, T2D in humans is characterized by not only insulin
resistance but also the presence of sustained hyperglycemia and elevated HbA1c levels. When only
insulin resistance is present, individuals are described as prediabetics [55,56].
Insulin resistance is believed to play a key role in diabetic neuropathy by increasing oxidative stress
and mitochondrial dysfunction [57,58], and may also drive the early neural retinal dysfunction that we
observed in our HFD mice. Thus, the HFD mice secrete sufficiently elevated insulin to maintain a normal
glucose level, and as such the HFD model may be better characterized as a prediabetes model. Importantly,
the incidence of prediabetes is often higher than that of diabetes [59]. The prevalence of prediabetes is also
increasing; it is estimated that more than 470 million people worldwide will be suffering from prediabetes
by 2030 [60]. Most importantly, the three classical microvascular complications, retinopathy, neuropathy,
and nephropathy, have all been documented in individuals with prediabetes [61].
While classifications of diabetes remain “glucose-centric”, our study draws attention to the importance
of earlier events, when glucose levels are still normal. Thus, in our model, hyperinsulinemia with
hypercholesterolemia will likely lead to the retinal pathology observed. Not surprisingly, these pathologies
take a longer time to develop than those typically seen when hyperglycemia is also present.
Systemic and retinal lipid abnormalities have been shown to promote retinal damage [16,62,63].
Previously, we demonstrated that diabetes-induced disruption of the LXR axis results in abnormal lipid
metabolism, inadequate vascular repair, and localized and systemic inflammation [16,64]. The LXRs
(LXRα and LXRβ) play important roles in cholesterol homeostasis [65]. They regulate the expression
of reverse cholesterol transporters [12]. Activation of LXRs using pharmacological agents repress
inflammatory genes such as TNF-α and IL-1β [66], inhibit the expression of pro-apoptotic factors [67],
and prevent the development of DR [12]. We showed that use of GW3965, an LXR agonist, resulted in
normalization of cholesterol homeostasis and repression of inflammatory genes, such as iNOS, IL-1β,
ICAM-1, and CCL2 in the retina [16]. We found that inadequate cholesterol removal due to deficiency
in LXR and reduced oxysterol production in the retina due to loss of cytochromes p450 27A1 and 46A1
resulted in widespread retinal pathology [68]. In the current study, we showed that concentrations of
40% fat in the diet were sufficient to reduce expression of LXR in the inner and outer nuclear layers.
Our study showed that HFD mice develop neural retinal deficits after 6 months of feeding, as both
a-waves and b- waves were reduced under scotopic conditions. Unexpectedly, the a- and b- wave
responses for LFD mice was significantly less after 12 months compared to the response after 6 months
of feeding (p < 0.01 for both scotopic and photopic conditions), which suggests that the LFD may
have detrimental effects on the neural retina. Because the composition of the diets must be isocaloric,
when the amount of fat is reduced, some other dietary component needs to be increased to compensate.
Inn the LFD, the amount of sucrose increases from 72 g to 354 g and 315 g of corn starch is also
added so that the LFD can be isocaloric with the HFD. However, this largely occurs at the expense of
making the diet high in carbohydrates. The literature supports that LFD may be detrimental [69–71].
While we were unable to find literature supporting the impact of LFD specifically on ERGs, the systemic
consequences of LFD may indirectly affect the retina, for example by reduced availability of fat-soluble
vitamins or changing retinal cholesterol metabolism. Moreover, the increased sucrose and cornstarch
in the LFD may have direct deleterious effects [72,73]. LFDs promote insulin resistance, and while
most of the research has been performed in humans, these findings may have relevance to murine
studies. LFD, typically considered a high carbohydrate diet, is known to promote inflammation [74–76].
A recent study compared ERGs in HFD fed rats, Streptozotocin (STZ) rats and type 2 diabetes (T2D)
rats at 6 months to controls. Kowluru found differences between the diabetic ERGs and controls, but
no differences between the ERGs of the HFD rats compared to controls; however, Kowluru did not
look at 12 month tests and the study was performed in rats, not in mice [77]. Thus, it is difficult to
compare these findings with our results.
While neural damage was detected at 6 months, the vascular damage was not observed until much
later. This is in agreement with Rajagopal et al. [6], who demonstrated that vascular damage was not
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observed at 6 months of HFD feeding. However, despite the absence of vascular damage after 6 months
of HFD, we observed the presence of “lipid-laden like” lesions, and also neural infarcts similar to what is
described in humans as “cotton-wool” spots. These lesions, which appeared to increase as the retinopathy
progressed in the HFD mice, could become a useful measure of retinal damage and may be sensitive enough
to use as a novel endpoint for the preclinical investigation of therapeutic agents.
GFAP is normally expressed in retinal astrocytes in rodents; however, during stress and
inflammation, Muller cells [37] respond by increasing GFAP expression. In this study, we show
that WD induces GFAP expression in selective Muller cells, supporting the presence of increased
stress and inflammation in the retina of these mice. Kim et al. have reported increased inflammation
in other tissues such as adipose tissue and intestines [78]. Lee et al. showed increased numbers of
activated macrophages in the retina of HFD mice [79]. In both humans and rodents, obesity-induced
diabetes is associated with hypoxia in tissues such adipose tissue, and suppression of HIF-1α mitigates
tissue-specific pathological changes associated with HFD [80]. The liver, brain, kidney, and heart
display tissue-specific regulation of HIF-1α under systemic hypoxia [81]. After 6 months, but not
after 3 months, we observed that HIF-1α expression is increased in the WD retinas compared to LFD
controls. Similar to our observation in the retina of 3-month-old mice on WD, Prasad et al. showed the
absence of pimonidazole staining in the kidneys of 10–11-week old db/db mice [82], also indicating the
absence of hypoxia response in the kidneys at this time point.
5. Conclusions
Our study demonstrates that HFD feeding generates a useful prediabetes model. Specifically,
the combination of hypercholesterolemia and insulin resistance are sufficient to induce retinal
dysfunction with a slower time course of development compared to T2D models such as the db/db
mouse. In agreement with reports describing diabetes models, we show that neural functional deficits
are the earliest indicator of damage in the retina of this prediabetes model before vascular changes.
Key molecular targets such as HIF-1α and the LXRs provide insights into the retinal pathobiology
observed in this hypercholesterolemic, hyperinsulinemic model. The appearance and frequency of
neural infarcts or “lipid-laden lesions” in the retina of HFD mice could represent a novel endpoint for
evaluation of therapeutic interventions.
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Abstract: Dehydrodolichyl diphosphate synthase (DHDDS) is required for protein N-glycosylation
in eukaryotic cells. A K42E point mutation in the DHDDS gene causes an autosomal recessive form of
retinitis pigmentosa (RP59), which has been classified as a congenital disease of glycosylation (CDG).
We generated K42E Dhdds knock-in mice as a potential model for RP59. Mice heterozygous for the
Dhdds K42E mutation were generated using CRISPR/Cas9 technology and crossed to generate
DhddsK42E/K42E homozygous mice. Spectral domain-optical coherence tomography (SD-OCT)
was performed to assess retinal structure, relative to age-matched wild type (WT) controls.
Immunohistochemistry against glial fibrillary acidic protein (GFAP) and opsin (1D4 epitope) was
performed on retinal frozen sections to monitor gliosis and opsin localization, respectively, while lectin
cytochemistry, plus and minus PNGase-F treatment, was performed to assess protein glycosylation
status. Retinas of DhddsK42E/K42E mice exhibited grossly normal histological organization from 1 to
12 months of age. Anti-GFAP immunoreactivity was markedly increased in DhddsK42E/K42E mice,
relative to controls. However, opsin immunolocalization, ConA labeling and PNGase-F sensitivity
were comparable in mutant and control retinas. Hence, retinas of DhddsK42E/K42E mice exhibited no
overt signs of degeneration, yet were markedly gliotic, but without evidence of compromised protein
N-glycosylation. These results challenge the notion of RP59 as a DHDDS loss-of-function CDG and
highlight the need to investigate unexplored RP59 disease mechanisms.
Keywords: retinitis pigmentosa; knock-in mouse model; congenital disorder of glycosylation; retina
1. Introduction
Retinitis pigmentosa (RP) represents a group of hereditary retinal degenerative disorders of diverse
genetic origins that have as their common trait the progressive, irreversible dysfunction, degeneration,
and demise of retinal photoreceptor cells, with rods initially undergoing these pathological changes
followed eventually by cones [1,2]. Relatively recently, a K42E point mutation in the dehydrodolichyl
diphosphate synthase (DHDDS) gene was shown to cause a rare, recessive form of RP (RP59;
OMIM #613861) [3–5]. DHDDS catalyzes cis-prenyl chain elongation in the synthesis of dolichyl
diphosphate (Dol-PP), which is required for protein N-glycosylation [6,7]. DHDDS catalyzes the
condensation of multiple units of isopentenyl pyrophosphate (IPP, also called isopentenyl diphosphate)
to farnesyl pyrophosphate (FPP, also called farnesyl diphosphate) to produce Dol-PP [8,9]. This is used
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as the “lipid carrier” onto which oligosaccharide chains are built that are ultimately transferred to specific
asparagine (N) residues on nascent polypeptide chains in the lumen of the endoplasmic reticulum (ER)
to form N-linked glycoproteins [10]. The monophosphate (Dol-P) is used as a sugar carrier, transferring
sugars from their corresponding sugar-nucleotide adducts (e.g., UDP-glucose, GDP-mannose, etc.) to
the growing Dol-PP-linked oligosaccharide chains in the ER. Mutations in rhodopsin that block its
glycosylation have been shown to cause retinal degeneration in vertebrate animals [11,12]. In addition,
pharmacological inhibition of protein N-glycosylation with tunicamycin has been shown to disrupt
retinal photoreceptor outer segment (OS) disc membrane morphogenesis in vitro [13], as well as to
cause retinal degeneration with progressive shortening and loss of photoreceptor OSs in vivo [14].
In the present study, we created a DHDDS K42E homozygous knock-in mouse model (hereafter
called DhddsK42E/K42E) of RP59—since K42E is the most prevalent point mutation in the RP59 patient
population [3–5]—to study its underlying pathological mechanism, with the working hypothesis
that defective protein N-glycosylation underlies the retinal dysfunction and degeneration observed
in human RP59. Herein, we present a description of the generation and initial characterization of
the phenotypic features of the DhddsK42E/K42E mouse model. Surprisingly, although we expected to
observe an early onset, progressive, and potentially severe retinal degeneration, this was not the case.
The retina appeared histologically intact and normal according to spectral domain optical coherence
tomography (SD-OCT) analysis for up to at least one year of age. However, there was evidence of
gliotic reactivity (glial fibrillary acidic protein (GFAP) immunostaining), despite the lack of obvious
neuronal degeneration or cell death/loss. Also, despite the homozygous mutation in Dhdds, we found
no evidence of compromised protein N-glycosylation in mutant mouse retinas.
2. Materials and Methods
2.1. Animals
Heterozygous (K42E/+) Dhdds knock-in (KI) mice were generated on a C57Bl/6J
background by Applied StemCell (Milipitas, CA, USA). Briefly, CRISPR guide RNA
(5′-TCGCTATGCCAAGAAGTGTC-3′ with PAM site AGG) was generated using in vitro
transcription and was used to create a double strand break in the murine Dhdds locus to
promote introduction of a single-stranded oligodeoxynucleotide (SSO) carrying the K42E mutation and
a second silent DNA polymorphism to eliminate the PAM recognition site required for cleavage by CAS9
(5′-ATTATCTGTTCTCTTCTACAGGCTGGCCCAGTACCCAAACATATCGCGTTCATAATGGACGGC
AACCGTCGCTATGCCAAGGAGTGTCAAGTGGAGCGCCAGGAGGGCCACACACAGGGCTTCA
ATAAGCTTGCTGAGGTGGGTGCGGGTGACAGAGCCTAGA-3′). Mouse zygotes were injected
with 100, 100, and 250 ng/μL of Cas9 enzyme, guide RNA, and SSO, respectively, which were then
transferred into pseudo pregnant CD-1 females. Three potential founder (F0) pups were identified out
of 13 mice tested, and an F0 founder was verified by DNA sequence analysis. Sequence-validated
heterozygous (DhddsK42E/+) mice were crossed to generate homozygous (DhddsK42E/K42E) mice, as
confirmed by PCR and DNA sequencing (see below). C57Bl/6J wild type (WT) mice, age- and
sex-matched, were used as controls. All procedures conformed to the ARVO Statement for the Use of
Animals in Ophthalmic and Vision Research, and were approved by the Institutional Animal Care and
Use Committee (IACUC) of the University of Alabama at Birmingham. All animals were maintained
on a standard 12/12 h light/dark cycle (20–40 lux ambient room illumination), fed standard rodent
chow, provided water ad libitum, and housed in plastic cages with standard rodent bedding.
2.2. PCR Genotyping and DNA Analysis
PCR primers were designed that spanned the targeted region (forward primer,
5′-TCTAGGCTCTGTCACCCGCA-3′ and reverse primer 5′-TCTAGGCTCTGTCACCCGCA-3′)
amplifying a 292 bp segment of DNA in both WT and DhddsK42E/K42E mice. For initial verification of the
knock-in, PCR products were sequenced in the UAB Heflin Center for Genomic Sciences. The presence
20
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of the knock-in sequence was confirmed in subsequent generations by restriction enzyme digestion
with StyI, which cleaves the knock-in allele only (data not shown). Knock-in alleles were independently
verified by Transnetyx, Inc. (Cordova, TN, USA) using proprietary technology. While the analysis was
set up to recognize and differentiate the knock-in mutation and the PAM site polymorphism, only the
knock-in mutation was maintained in all subsequent breeding.
2.3. Spectral Domain Optical Coherence Tomography (SD-OCT)
In vivo retinal imaging was performed as previously described in detail by DeRamus et al. [15],
using a Bioptigen Model 840 Envisu Class-R high-resolution SD-OCT instrument (Bioptigen/Leica, Inc.;
Durham, NC, USA). Data were collected from DhddsK42E/K42E and WT mice at postnatal day (PN) 1 (KI,
n = 5; WT, n = 9), 2 (KI, n = 4; WT, n = 8), 3 (KI, n = 5; WT n = 3), 8 (KI, n = 4; WT n = 5), and 12 months
(mos) (KI, n = 3; WT n = 3) to assess retinal structure. Layer thicknesses were determined manually
using Bioptigen InVivoVue® and Bioptigen Diver® V. 3.4.4 software and the data were analyzed and
graphed using Microsoft Excel software.
2.4. Immunohistochemistry (IHC)
Procedures utilized for fixation, O.C.T. embedment, and sectioning of mouse eyes were as described
in detail previously by Ramachandra Rao et al. [16]. In brief, eyes were immersion fixed overnight in
phosphate-buffered saline (PBS) containing freshly prepared paraformaldehyde (4% v/v), appropriately
cryopreserved, embedded in O.C.T., and cryosectioning was performed on a Leica Model CM3050 S
Cryostat (Leica Biosystems, Wetzlar, Germany). Retinal sections were first “blocked” with 0.1% BSA,
0.5% serum (species corresponding to secondary antibody host) in Tris-buffered saline containing
0.1% Tween-20 (TBST), then incubated for 1 h at room temperature with a rabbit polyclonal antibody
against glial fibrillary acidic protein (GFAP;, DAKO/Agilent, Santa Clara, CA, USA; 1:500 dilution
in TBST) and a mouse monoclonal antibody against the C-terminal epitope of opsin (1D4; Novus
Biologicals, Littleton, CO, USA; 1:500 dilution in TBST), followed by incubation with fluor-conjugated
secondary antibodies (AlexaFluor®-488 conjugated anti-mouse IgG, AlexaFluor®-568 conjugated
anti-rabbit IgG; Thermo Fisher Scientific, Waltham, MA, USA; 1:500 dilution in TBST). Sections were
then counterstained with DAPI and cover slipped with anti-fade mounting medium (Vectashield®;
Vector Laboratories, Burlingame, CA, USA) and viewed with a Leica TCS SPEII DMI4000 scanning
laser confocal microscope (Leica Biosystems). Images were captured using a 40X oil immersion (RI
1.518) objective under normal laser intensity (10% of laser power source), arbitrary gain (850 V) and
offset (–0.5) values, to optimize signal-to-noise ratio. Digital images were captured and stored as TIFF
files on a PC computer.
2.5. Lectin Cytochemistry
Paraformaldehyde-fixed eyes (as described above) were processed for paraffin embedment.
Paraffin sections of mouse eyes were then incubated (45 min at room temperature) with biotinylated
Concanavalin-A (ConA, B-1005; Vector Laboratories; 1:200 dilution in PBS), followed by incubation
with AlexaFluor®-488 conjugated streptavidin (Thermo Fisher Scientific; 1:500 dilution in PBS) and
AlexaFluor®-647-conjugated peanut agglutinin (PNA, L32460; Thermo Fisher Scientific; 1:250 dilution
in PBS), with or without pre-treatment (37 ◦C, overnight) with peptide:N-glycosidase F (PNGase-F,
200 U, P0704S; New England Biolabs, Inc., Ipswich, MA, USA). Sections were DAPI-stained and
mounted using Vectashield mounting media, and digital images obtained using scanning laser confocal
microscopy as described above [16].
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3. Results
3.1. Generation and Validation of K42E DHDDS Knock-In Mutation
K42E knock-in mice were generated commercially using CRISPR-Cas9 technology. The K42E
knock-in mutations in both heterozygous and homozygous mice were confirmed by DNA sequence
for one of the heterozygous F0 founder mice, which is shown in Figure 1. Both the A-to-G and
G-to-A transitions that lead to the K42E mutation and the Q44Q silent polymorphism, respectively, are
heterozygous (arrows). Intra-litter mating was done to establish at least fourth generation homozygous
mice that were used for all subsequent analyses. Heterozygous mice were initially characterized by
SD-OCT and histology and found not to differ from WT (not shown).
 
Figure 1. DNA sequence analysis of a tail DNA from a K42E/+ founder mouse. Tail DNA was amplified
with primers that cover a 292 bp segment spanning the target region. The sequence analysis confirmed
the presence (arrows) of the K42E (A-to-G) mutation and the Q44Q (G-to-A) polymorphism that was
included to eliminate the CRISPR-related PAM site.
3.2. SD-OCT Analysis Reveals No Evidence for Retinal Degeneration in DhddsK42E/K42E Mice
SD-OCT provides a non-invasive means of assessing retinal morphology in vivo. Qualitative
SD-OCT images obtained from wild type (WT) and DhddsK42E/K42E mice are presented in Figure 2.
From these images, it is clear that the gross morphology of the retina in the homozygous knock-in
animals, from PN 1 to 12 months of age, are comparable to that observed in fully mature, age-matched
WT control mice. All retinal histological layers were intact and of normal appearance. Hence, there was
no evidence of retinal degeneration, even up to one year of age.
We used SD-OCT to perform quantitative analysis of retinal morphology to compare ocular tissue
layer thicknesses in WT and knock-in mice. Figure 3 compares data obtained at PN 1, 2, 3, 8, and 12
mos for DhddsK42E/K42E mice, compared to age-matched WT control littermates. The data are shown
both with respect to outer nuclear layer (ONL) thickness (yellow and gray lines) as well as total neural
retina thickness (blue and orange lines) as a function of distance from the optic nerve head (ONH,
point 4 in each graph) along the vertical meridian, for both the inferior and superior hemispheres. No
differences in these quantitative metrics of retinal morphology were observed with respect to genotype,
consistent with the representative OCT images shown in Figure 2.
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Figure 2. Representative averaged SD-OCT images of retinas from (left panels: A,C,E,G,I) 1-, 2-, 3-, 8-
and 12-months (mos) old wild type (WT), and (right panels: B,D,F,H,J) 1-, 2-, 3-, 8-, and 12-months old
DhddsK42E/K42E mice. Abbreviations: IPL, inner plexiform layer; ONL, outer nuclear layer; ROS, rod
outer segment layer. No changes were observed at any age in retinas of DhddsK42E/K42E mice compared
to WT mice.
Figure 3. Analysis of the ONL thickness (yellow and gray lines) and total retinal thickness (blue and
orange lines) in WT and DhddsK42E/K42E mice ranging in age from PN 1 to 12 months. (A) 1 month, (B)
2 months, (C) 3 months, (D) 8 months, (E) 12 months. Outer nuclear layer (ONL) thickness and total
retina thickness measurements (in microns), as a function of genotype and distance from the optic nerve
head (ONH) along the vertical meridian in both the inferior and superior hemispheres. Genotypes: WT
and DhddsK42E/K42E mice. No significant differences were observed between the groups.
3.3. Gliotic Reactivity, Despite Lack of Overt Neural Retina Degeneration, in DhddsK42E/K42E Mice
We performed immunohistochemical analysis on frozen sections of fixed, O.C.T.-embedded
WT and DhddsK42E/K42E mouse eyes at PN 2 months of age, probing with antibodies against GFAP
23
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(polyclonal) and a C-terminal epitope of rod opsin (1D4 monoclonal). As shown in Figure 4, whereas
WT control retinas only exhibited GFAP immunoreactivity (pseudocolored red) along the vitreoretinal
interface, corresponding to astrocytes and Müller glia “end feet”, retinas from DhddsK42E/K42E mice
exhibited extensive, robust anti-GFAP labeling in a radial pattern. This extended throughout the inner
retinal layers to the outer plexiform layer (OPL), in addition to intense labeling along the vitreoretinal
interface. The latter results are indicative of massive gliotic activation, which is remarkable considering
the lack of overt retinal degeneration or loss of retinal neurons (per the SD-OCT data; see Figures 2
and 3). Gliosis in DhddsK42E/K42E mouse retinas was also detected at PN one month and persisted even
at PN six months of age (data not shown). Anti-opsin immunolabeling (pseudocolored green) was
comparable in both WT and DhddsK42E/K42E retinas. Notably, the label was confined to the OS layer;
there was no mislocalization of opsin to the plasma membrane of the cell in the IS or ONL layer—unlike
what is often observed in degenerating photoreceptor cells in various animal models—suggesting
normal trafficking of opsin to the outer segment, and consistent with a lack of overt photoreceptor
degeneration. It is worth noting that the green labeling in a few cells in the inner retina in Figure 4
is due to mouse-on-mouse binding of the monoclonal antibody to endogenous IgG in blood vessels.
It does not represent true anti-opsin immunolabeling.
 
Figure 4. Laser confocal microscopy images of (A) WT control and (B) DhddsK42E/K42E mouse retina
frozen sections at PN 2 months of age, stained with antibodies to GFAP (pseudocolor: red) and rod
opsin (pseudocolor: green), and counterstained with DAPI (blue). Scale bar (both panels) is 20 μm.
Abbreviations: OS, outer segment layer; IS, inner segment layer; ONL, outer nuclear layer; OPL,
outer plexiform layer; INL, inner nuclear layer; IPL, inner plexiform layer; GCL, ganglion cell layer.
Scale bar (both panels) is 20 μm.
3.4. Lack of Defective Protein Glycosylation in DhddsK42E/K42E Mouse Retinas
The N-linked oligo-saccharides of glycoproteins contain alpha-linked mannose residues as
constituents, which are cognate ligands for the lectin concanavalin A (Con A) [17]. Hence, ConA lectin
cytochemistry offers a reliable means of detecting the presence (or absence) of N-linked oligo-saccharides
in tissue sections of DhddsK42E/K42E mice, and a way to directly test the current hypothesis that RP59 is
driven by lack of glycosylation. This is because the synthesis of oligosaccharide chains in cells and
tissues obligatorily depends upon the presence of Dol-PP and Dol-P (which requires upstream DHDDS
activity). Furthermore, N-linked oligosaccharide chains are selectively susceptible to hydrolysis by
peptide:N-glycosidase F (PNGase-F) [18]; hence, tissue sections treated with PNGase-F should exhibit
a marked loss of Con A binding (serving as a true negative control), thereby mimicking the scenario
24
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where upstream DHDDS activity may be lacking. We performed ConA lectin cytochemical analysis on
retinal sections from WT control and DhddsK42E/K42E mice at PN six months of age, with and without
pre-treatment with PNGase-F. The results are shown in Figure 5.
Figure 5. ConA lectin cytochemical analysis of retinas from (A,B) WT control and (C,D) DhddsK42E/K42E
mice at PN 6 months of age, with (B,D) or without (A,C) pretreatment with PNGase-F. ConA binding
(green); PNA binding (magenta); DAPI counterstain (blue). Abbreviations are the same as in the
Figure 4 legend. Scale bar (all panels): 20 μm.
Normally, N-linked glycoproteins are present throughout the retina, being notably enriched in
photoreceptor cells and the synaptic endings of neurons (IPL, OPL). Hence, the inner and outer segment
layers (IS and OS, respectively), including the glycoconjugate-rich interphotoreceptor matrix (IPM), as
well as the inner and outer plexiform layers (IPL and OPL, respectively) were robustly labeled with
fluor-tagged ConA in untreated WT retinal sections (Figure 5 A). As expected, treatment of WT retinal
tissue sections with PNGase-F dramatically reduced the level of ConA binding throughout the retina
(Figure 5B). Notably, retinal sections from DhddsK42E/K42E mice also exhibited robust, pan-retinal ConA
binding (Figure 5C), comparable to that of WT controls. Upon treatment with PNGase-F, most of the
ConA staining was lost (Figure 5D). These results obviate any significant DHDDS loss-of-function in
DhddsK42E/K42E mice.
Peanut agglutinin (PNA) binds to the disaccharide Gal-β(1-3)-GalNAc in glycoproteins and
glycolipids [17]. Oligosaccharides containing this disaccharide are highly enriched in the extracellular
matrix surrounding cone photoreceptor outer segments (the “cone matrix sheath”) [19,20]. Thus,
PNA binding can be used to selectively label cone photoreceptors in retinal tissue sections, since rod
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photoreceptors and their associated “rod matrix sheath” lack such glycan chains [21]. Furthermore,
oligosaccharides containing Gal-β(1-3)-GalNAc are generally O-linked (e.g., through Ser or Thr
residues), rather than N-linked, and their synthesis is not dolichol-dependent in mammalian cells [22].
Furthermore, the PNA-binding disaccharide epitope is not susceptible to PNGase-F hydrolysis [17].
Hence, we expected to observe no appreciable differences in the binding of PNA to retinal tissue
sections from DhddsK42E/K42E retinas vs. WT controls, nor effects of PNGase-F treatment on PNA
binding, either with regard to labeling intensity or distribution. These expectations were realized,
as illustrated in Figure 5 (magenta staining, all four panels). Both DhddsK42E/K42E and control retinas
exhibited comparable distribution of PNA-positive cone matrix sheaths, suggesting persistence of
viable cone photoreceptors in the K42E mutants.
4. Discussion
Here, we have presented the generation and initial characterization of a novel mouse model of
RP59, where we have achieved global homozygous knock-in of the K42E Dhdds mutation specifically
associated with RP59 [3–5]. Based upon the clinical presentation of RP59 in human patients [3–5],
as well as the demonstrable importance of dolichol-dependent protein glycosylation in maintaining
the normal structure and function of the vertebrate retina [11–14], we expected to observe retinal
degeneration and retinal thinning in DhddsK42E/K42E mice, particularly in mice homozygous for the
K42E mutation. This expectation was also predicated on a preliminary report [23], using a similar K42E
mouse knock-in model, that claimed nearly 50% loss of OS length and reduction in ONL thickness by
about two-thirds at PN 3 months of age, compared to WT mouse retinas. However, we observed no
evidence of retinal degeneration in DhddsK42E/K42E mice up to one year of age. Furthermore, despite
the confirmed mutation of Dhdds, we found no evidence for defective protein N-glycosylation in the
retinas of these mice. The retinas were labeled robustly with fluor-tagged ConA lectin, irrespective
of genotype. These findings are in good agreement with observations made by Sabry et al. [24] who
found normal mannose incorporation into N-linked oligosaccharides using either siRNA silencing
of DHDDS in a HepG2 cell line or in RP59 (severe mutation) patient fibroblasts. The ConA binding
observed in our study is further consistent with observations made by Wen et al., who observed that
rather than any loss in dolichols, there was an alteration in dolichol chain lengths (increased D17:D18
ratio) in RP59 patients compared to normal human subjects, but without obvious hypoglycosylation
of serum transferrin [25]. These findings collectively suggest hypoglycosylation-independent retinal
degeneration in RP59, the mechanism of which still remains to be elucidated.
Understanding the pathophysiological and biochemical mechanisms underlying RP59 remains
limited due to the lack of a validated vertebrate animal model that faithfully mimics the key hallmarks of
the disease. Heretofore, only a zebrafish model of RP59 has been documented, using global knock-down
of DHDDS expression by injection of morpholino oligonucleotides at the one-cell embryo stage [26].
In that case, the fish exhibited defective photoresponses and their cone outer segments (as assessed
indirectly by PNA staining) were dramatically shortened, if not nearly absent. It should be noted that
zebrafish have a highly cone-rich retina, unlike humans or mice (which have highly rod-dominant
retinas). Also, the reduction and loss of PNA binding in the zebrafish knock-down retinas most likely
reflects degeneration and death of cone photoreceptors, with concomitant degeneration and loss of
their outer segments, due to their requirement for dolichol. Unlike the zebrafish Dhdds knock-down
model, the murine RP59 model generated in the present study exhibits robust PNA staining in the
outer retina, suggesting persistence of viable cone photoreceptors. In a parallel study (Ramachandra
Rao et al., unpublished), we have observed Dhdds transcript distribution in all retinal nuclear layers
by in situ hybridization, consistent with the fact that all cells require dolichol derivatives to support
protein N-glycosylation. Taken together, these findings suggest that the K42E Dhdds mutation does
not affect cone photoreceptor viability. Recently (Ramachandra Rao et al., manuscript submitted for
publication), we also generated a conditional Dhdds knockout mouse model, with targeted ablation of
Dhdds in retinal rod photoreceptors, using a Cre-lox approach; however, unlike the K42E knock-in
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model, the rod-specific Dhdds knockout model exhibits profound, rapid retinal degeneration, with
almost complete loss of photoreceptors by PN 6 weeks. Yet, there was no evidence of compromised
protein N-glycosylation prior to the onset of photoreceptor degeneration. In addition, as reported in
a companion article in this Special Issue of Cells [27], targeted ablation of Dhdds in retinal pigment
epithelium, (RPE) cells in mice also results in a progressive, but somewhat slower, retinal degeneration.
As pointed out by Zelinger et al. [4], the phenotype of RP59 only involves the retina; there is no
observable dysfunction or pathology in other tissues and organs in RP59 patients. Hence, those authors
speculated that the K42E mutation, “alters, rather than abolishes, enzymatic function, perhaps either
by reducing the level of DHDDS protein or by preventing requisite interactions between DHDDS and a
photoreceptor-specific protein” [4]. They also suggested, alternatively, that mutation of DHDDS might
result in, “a toxic accumulation of isoprenoid compounds,” such as occurs in various forms of neuronal
ceroid lipofuscinosis (e.g., Batten disease). While such speculations may turn out to be true, there is no
direct empirical evidence extant to support this hypothesis. It is also entirely possible, however, that
mutations (whether K42E or others) in DHDDS may affect its interactions with its enzymatic partner,
Nogo-B receptor (NgBR, encoded by the Nus1 gene) [8,9], with concomitant alterations in dolichol
synthesis and protein N-glycosylation [28,29]. At present, nothing is known about the expression of
Nogo-B receptor or its interactions with DHDDS, specifically in the retina. Our DhddsK42E/K42E mouse
line and retinal cell type-specific conditional DHDDS knockout mice offer potentially valuable model
systems in which to pursue further investigations along these lines. In addition, we are currently
pursuing studies employing dual, targeted ablation of DHDDS and NgBR in the retina. (See also the
article by DeRamus et al., in this Special Issue of Cells, regarding an RPE-specific DHDDS knockout
mouse model [27].)
Our findings bring into question the current concept that RP59 is a member of a large and diverse
class of diseases known as “congenital disorders of glycosylation” (CDGs) [30,31]. While, in principle,
it would be reasonable to consider RP59 as a CDG, due to the associated mutation(s) in DHDDS, there
is no direct evidence to demonstrate a glycosylation defect in the human retinal disease or in any
animal model of RP59 generated to date. The mechanism underlying the DHDDS-dependent retinal
degeneration in human arRP patients remains to be elucidated, but is more complex than simply
loss-of-function of DHDDS.
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Abstract: Patients with certain defects in the dehydrodolichyl diphosphate synthase (DHDDS) gene
(RP59; OMIM #613861) exhibit classic symptoms of retinitis pigmentosa, as well as macular changes,
suggestive of retinal pigment epithelium (RPE) involvement. The DHDDS enzyme is ubiquitously
required for several pathways of protein glycosylation. We wish to understand the basis for selective
ocular pathology associated with certain DHDDS mutations and the contribution of specific ocular
cell types to the pathology of mutant Dhdds-mediated retinal degeneration. To circumvent embryonic
lethality associated with Dhdds knockout, we generated a Cre-dependent knockout allele of murine
Dhdds (Dhddsflx/flx). We used targeted Cre expression to study the importance of the enzyme in
the RPE. Structural alterations of the RPE and retina including reduction in outer retinal thickness,
cell layer disruption, and increased RPE hyper-reflectivity were apparent at one postnatal month.
At three months, RPE and photoreceptor disruption was observed non-uniformly across the retina
as well as RPE transmigration into the photoreceptor layer, external limiting membrane descent
towards the RPE, and patchy loss of photoreceptors. Functional loss measured by electroretinography
was consistent with structural loss showing scotopic a- and b-wave reductions of 83% and 77%,
respectively, at three months. These results indicate that RPE dysfunction contributes to DHDDS
mutation-mediated pathology and suggests a more complicated disease mechanism than simply
disruption of glycosylation.
Keywords: retinal degeneration; retinitis pigmentosa; retinal pigment epithelium dystrophy; RPE
transmigration; Cre-Lox technology; mouse models
1. Introduction
Retinitis pigmentosa (RP) and related disorders are characterized by degeneration and loss of
photoreceptors, attenuation of retinal blood vessels, pigment deposits, and a waxy pallor of the optic
disc that result in impaired night vision and peripheral and central vision loss [1]. Defective protein
glycosylation in the retinal pigment epithelium (RPE) has been associated with retinal degeneration
elicited by photoreceptor abnormalities and impaired phagocytosis of aging photoreceptor outer
segment (OS) membranes [2–5]. One such example, dehydrodolichyl diphosphate synthase (DHDDS;
OMIM #608172), is an essential enzyme in the mevalonate pathway where it functions ubiquitously in
Cells 2020, 9, 771; doi:10.3390/cells9030771 www.mdpi.com/journal/cells31
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isoprenoid chain elongation to form dolichols that comprise 17–20 isoprene units. The phosphorylated
form of dolichol, dolichol pyrophosphate is necessary for N-glycosylation at specific residues in many
membrane proteins [6]. There is no known unique function for DHDDS in the retina, or in any other
ocular tissue. There are numerous N-glycosylated proteins in the retina and photoreceptors, such
as rhodopsin [7] and the cGMP-gated cation channel in rods. Additionally, in the RPE, there are
several glycosylated structural proteins, ion channels and transport proteins that contribute to the
transepithelial potential of the polarized RPE monolayer [8–10].
Mutations in the gene encoding DHDDS lead to a recessive form of RP called RP59 (OMIM #613861,
DHDDS, K42E), which was first identified in several families of Ashkenazi Jewish origin [11–13]. RP59
is considered to belong to the family of human genetic diseases known as “congenital disorders of
glycosylation” (CDGs) [14]. Two other mutations in the DHDDS gene (T206A and R98W), which occur
heterozygously with the K42E mutation, were also reported, but have not been studied in detail [15,16].
Patients with the K42E mutation in DHDDS exhibit all the cardinal features of RP as well as macular
changes [12], suggesting possible RPE involvement. While the K42E, T206A, and R98W mutations are
only associated with known RP symptoms, another mutation in the DHDDS gene has led to infant
morbidity at seven months of age [17].
As a first step to assess the role of DHDDS in specific retinal cell types and to understand the
molecular mechanism of RP59, we created a Cre-lox dependent line of mice that allows targeted, cell
type-specific deletion of Dhdds in cells of interest. Using a conditional knockout was necessary to
circumvent embryonic lethality associated with global knockout of Dhdds [18,19]. Here, we describe the
generation and characterization of a Dhddsflx/flx CreRPE mouse line (i.e., RPE-specific Dhdds knockout)
and its validation as a model of RPE atrophy and retinal degeneration. We show that RPE-specific
deletion of Dhdds induces structural and functional deficits in the RPE and the photoreceptors, which
suggests that RPE pathology may be a significant contributor to the retinal degeneration observed in
patients with RP59 mutations.
2. Materials and Methods
2.1. Generation of Dhddsflx/flx CreRPE Mice
A construct containing lacZ flanked by FLP-FRT and Dhdds exon 3 flanked by loxP sites from
the Knockout Mouse Project (KOMP, UC Davis, Davis, CA, USA) was linearized and introduced into
mouse ES cells (C57Bl/6J background) at the Roswell Park Cancer Institute (RPCI) Gene Targeting and
Transgenic Facility (Buffalo, NY, USA) using standard technology. To confirm the correctly targeted cells,
polymerase chain reaction (PCR) was performed with the primers listed below (see PCR Genotyping,
below). The lacZ cassette was excised with FLP-FRT recombinase, and excision was confirmed by
PCR. Mouse lines that carried the Dhdds loxP conditional knockout allele were crossed to generate
homozygotes and the latter were also crossed to a mouse line (on a C57Bl/6J background) carrying
a homozygous transgene expressing Cre recombinase under the control of the RPE-specific VMD2
(vitelliform macular degeneration 2) promoter [20,21]. RPE-specific expression of Cre in the VMD2
promoter-driven mouse line was confirmed by crossing those mice with a ZsGreen reporter mouse
line (B6.Cg-Gt(ROSA)26Sortm6(CAG-ZsGreen1)Hze/J, The Jackson Laboratory, Bar Harbor, ME, USA) and
examining the retinas by confocal fluorescence microscopy. Genotypes of offspring were confirmed by
PCR with Dhdds- and Cre RPE-specific primer pairs. All mice used in this study were treated following
the ARVO Statement on the Use of Animals in Ophthalmic and Vision Research and the policies of the
University of Alabama at Birmingham (UAB) Institutional Animal Care and Use Committee (IACUC).
This project was approved for animal use on April 2019 by the UAB IACUC and requires updated
approvals each year (protocol number IACUC-21270). All animals were maintained on a standard
12/12-h light/dark cycle, fed standard rodent chow, provided water ad libitum, and housed in plastic
cages with standard rodent bedding.
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2.2. PCR Genotyping
Mouse genomic DNA samples obtained from tail snips were verified by PCR using
primers Dhdds-FWD: 5′-GTGTCATCCCCTGCTGCAGAT-3′ and Dhdds-REV: 5′-TGGGTGTAGTG-
GCTCAGGTC-3′ for genotype identification of floxed Dhdds alleles designed in a region which was
conserved in both wild type (WT) and floxed alleles and also in the region flanking the loxP sites.
The expected PCR product sizes for the WT and floxed alleles are 393 and 517 bp, respectively,
thus differentiating WT, heterozygous floxed, and homozygous floxed alleles. PCR verification of
Cre transgene modification was carried out using the following forward and reverse primer sets
for Cre RPE 5′-AGGTGTAGAGAAGGCACTTAGC-3′ and 5′-CTAATCGCCATCT-TCCAGCAGG-3′,
respectively, yielding a 411 bp product. RPE specific expression and activity of Cre-recombinase in
VMD2-RPE Cre was verified by breeding these mouse lines against an ZsGreen reporter mouse strain
(B6.Cg-Gt(ROSA)26Sortm6(CAG-ZsGreen1)Hze/J, Stock# 007906; The Jackson Laboratory, Bar Harbor, ME,
USA) and monitoring ZsGreen expression in the retina.
2.3. Spectral-Domain Optical Coherence Tomography
Spectral-domain optical coherence tomography (SD-OCT) (840 nm; Bioptigen, Inc./Leica, Durham,
NC, USA) was used to obtain in vivo images of the retina at one, two, and three months of age.
OCT images were collected with Bioptigen InVivoVue® 1.4 software and Bioptigen Diver® 2.0 software
was used to analyze outer nuclear layer (ONL) thickness and full retinal thickness (F.R.T.) across all
retinal layers at five eccentricities spanning two-thirds of the retina centered at the optic nerve head.
A detailed description of this procedure has been reported previously [22]. F.R.T. was calculated from
the difference of markers 1 and 10 and ONL thickness was calculated from the difference between 5
and 6.
2.4. Fundus Examination and Fluorescein Angiography
Fundus examination was performed with a Micron IV digital fundus microscope (Phoenix
Technology Group, Pleasanton, CA, USA), using the mouse objective and hydroxypropylmethyl
cellulose 2.5% on the surface of the cornea. Digital images of the fundus were captured with dedicated
StreamPix® 6 digital software (NorPix, Inc., Montreal, Quebec, Canada) and processed using Adobe®
Photoshop® 6 (Adobe Systems, Inc., San Jose, CA, USA).
2.5. Visual Function Testing
Full-field scotopic and photopic electroretinograms (ERGs) were obtained as described in detail
previously using an OcuScience® HMsERG instrument (OcuScience, Henderson, NV, USA) [22].
Response amplitudes and implicit times of a-waves and b-waves representing the activity of
photoreceptors and bipolar cells, respectively, were quantified. In brief, mice were dark-adapted
overnight, anesthetized, and then placed on a heating pad to maintain body temperature. Following
pupil dilation with 2.5% phenylephrine and 1% tropicamide ophthalmic solutions, a thin silver wire
electrode was placed on the cornea (interfaced with methylcellulose and covered with a specially
designed contact lens) and referenced to a needle ground electrode in the cheek. The responses to
Ganzfeld flash stimuli, spanning a range of five log units, were measured and recorded; following
light adaptation to background illumination, cone-driven responses also were recorded.
2.6. Histology/Immunohistochemistry
The methodologies used in this study have been described in detail previously [23]. Briefly, for
conventional histology, eyes (n ≥ 4 per condition) were fixed by immersion in freshly prepared 4%
paraformaldehyde in 0.125 M Na-phosphate buffer, pH 7.4, at 4 ◦C overnight, embedded in paraffin, and
tissue sections (toluidine blue-stained) were viewed with an Olympus BH2 photomicroscope equipped
with a Nikon digital camera. Digitized images were collected and further analyzed with ImagePro
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Plus® software, Version 4.1 (Media Cybernetics; Rockville, MD, USA). For immunohistochemistry,
frozen sections of retinal tissue (embedded in Tissue-Plus™ Optimal Cutting Temperature (O.C.T.)
compound; Thermo Fisher Scientific, Waltham, MA, USA), obtained with a cryostat and collected on
glass microscope slides were incubated with suitable primary antibodies, with detection by application
of species-specific, fluor-conjugated secondary antibodies, counterstaining nuclei with DAPI, followed
by laser confocal immunofluorescence microscopy (Leica TCS SPE scanning confocal microscope; Leica
Microsystems Inc., Buffalo Grove, IL, USA), as previously reported [24].
2.7. Fluorescein Angiography
Fluorescein angiography was performed following intraperitoneal injection (i.p., 10 μL/gram
body weight) of a 10 mg/mL solution of AK-Fluor 10% (Sigma Pharmaceuticals; Liberty, IA, USA) in
PBS. Uptake of fluorescein and fundus imaging was monitored with a Micron IV Retinal Imaging
Microscope (Phoenix Technology Group, Inc., Pleasanton, CA, USA).
2.8. Electron Microscopy
Mouse eyes were processed for plastic embedment, ultramicrotomy, and EM analysis essentially
as described in detail previously [23]. Immediately after sacrifice, eyes were orientated by marking
the superior hemisphere along the vertical meridian at the limbus with a hot needle, before starting
the dissection. A cut was made in the superior cornea and the eyes were fixed for 2 h at 4 ◦C in fresh
0.1 M sodium phosphate buffer (pH 7.4), containing 2.5% (v/v) glutaraldehyde, 2.0% formaldehyde
and 0.025% CaCl2. After a 20–30 min primary fixation, the superior cornea and lens were removed,
and fixation was continued overnight. The fixed eyes were then rinsed with 0.1 M sodium cacodylate
buffer (pH 7.4) containing 0.025% CaCl2, and then post-fixed for 1 h in 1% osmium tetroxide in 0.1 M
sodium cacodylate buffer. After post-fixation, the eyes were rinsed twice in 0.1 M sodium cacodylate
buffer and once in distilled water, then dehydrated in graded ethanol series followed by propylene
oxide and infiltration overnight in Spurr’s resin. The eyes were then embedded in resin-filled BEEM®
capsules (Polysciences, Warrington, PA, USA) and allowed to polymerize in a 70 ◦C oven for 48 h.
Tissue sections were obtained with a Reichert–Jung Ultracut E® microtome using a diamond knife.
Thin (60–80 nm thickness) sections were collected on copper 75/300 mesh grids and stained with 2%
(v/v) uranyl acetate and Reynolds’ lead citrate. Sections were viewed with a JEOL 100CX electron
microscope at an accelerating voltage of 60 keV.
2.9. Serial Block-Face Scanning Electron Microscopy (SBF-SEM)
Samples prepared for TEM as described above were further processed by Thermo Fisher Scientific
(Waltham, MA, USA) using an Apreo VolumeScope™ serial block-face scanning electron microscope
(SBF-SEM). Excess resin was removed from the tissue using a Leica ultramicrotome. The trimmed
blocks were then glued to a SEM stub (Agar Scientific, AGG1092450) using a two-component silver
conductive epoxy, H20E EPO-TEK (Ted Pella, Inc.; Redding, CA, USA). To minimize charging of the
block by the electron beam, the bottom and sides of the block were sputter-coated with a 30 nm thick
gold film layer. The samples were then imaged on the VolumeScope™ operating in low vacuum mode
at 50 Pa and using a lens mounted backscattered detector. All of the data sets were imaged with an
accelerating voltage of 2.2 kV and a beam current of 100 pA using 1-μs dwell time combined with
two-line integration. Two regions of interest (ROIs) were acquired on the knock-out sample (KO-148).
For ROI1, 738 sections were collected with the internal microtome set to a 40 nm cutting thickness
(z resolution) with an area of 92.9 μm × 89.1 μm at 10 nm/pixel. For ROI2, 745 sections were collected
with an area of 97.6 μm × 96.3 μm using the same imaging condition as ROI1. For the wild type
sample (WT-146), an area of 92.9 μm × 89.1 μm was imaged at 10 nm/pixel using a cutting thickness
(z resolution) of 40 nm. The acquired data sets were finally aligned and visualized using 3D volume
rendering to highlight the RPE anomalies using Amira software (Thermo Fisher Scientific).
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2.10. Statistical Analysis
For ERG analyses, we evaluated differences between genetically modified vs. WT control mice
across flash intensities by performing repeated measures two-way ANOVA with Holm–Sidak post-hoc
analysis at each time point. To evaluate functional (visual acuity, a-wave and b-wave amplitudes and
implicit times) and structural (SD-OCT retinal layer thickness) parameters across time, we used a
two-way repeated measures ANOVA (time X treatment conditions) with Holm–Sidak post-hoc analysis.
For biochemical and quantitative immunohistochemical data, binary statistical comparisons between
specific genetically modified vs. WT control group data were analyzed using an unpaired Student’s
t-test.
3. Results
3.1. Generation of a Floxed Dhdds Mouse Line
The scheme used for the generation of a Dhdds conditional allele, employing a validated Dhdds
construct (from KOMP) and mouse embryonic stem cells (ESCs), is shown in Figure 1 (see Materials and
Methods, above). Clones from confirmed flippase recognition target (FRT)-excised alleles were used to
generate Dhdds heterozygous and homozygous mouse lines on a C57Bl/6J background.
Figure 1. Generation of Cre-dependent Dhdds conditional knockout (KO) mice. (A) A validated Dhdds
construct from the Knockout Mouse Project (KOMP) (U.C. Davis) was linearized and introduced into
mouse ESCs. (B) Transformed cells were treated with FLP-FRT recombinase and PCR was used to
verify lacZ cassette excision. (C) Clones from confirmed FRT-excised alleles were used to generate
Dhddsflx/flx- mice. (D) Pups carrying the Dhdds floxed allele were identified by coat appearance.
3.2. Validation of Retinal Cell Type-Specific Cre-Expressing Mouse Lines
To assess the specificity and efficiency of the Cre recombinase in the RPE, we cross-bred transgenic
mice expressing Cre recombinase (bred to homozygosity) with a ZsGreen Ai6 reporter mouse line, and
then evaluated ZsGreen expression in the retina by confocal fluorescence microscopy. As expected, WT
mouse retinas (a negative control) did not exhibit ZsGreen expression (Figure 2A). However, ZsGreen
fluorescence was detected in Cre recombinase-positive mice specifically in the RPE layer by 1 postnatal
(PN) month (Figure 2B), with >90% of the RPE cells being labeled. We subsequently confirmed that
Cre recombinase continued to be expressed robustly and specifically in the RPE for >3 months (data
not shown).
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Figure 2. Cre recombinase-dependent ZsGreen expression (green) in mouse retina. (A) Retina from a
postnatal (PN) one-month old CreRPE × ZsGreen reporter mouse, demonstrating ZsGreen expression
specifically in retinal pigment epithelium (RPE) cells. (B) Retina from an age-matched, wild type (WT)
mouse retina, demonstrating lack of ZsGreen expression. Nuclei counterstained with DAPI (blue).
Abbreviations: IS, photoreceptor inner segment layer; OS, photoreceptor outer segment layer; ONL,
outer nuclear layer; OPL, outer plexiform layer. Scale bars (both panels): 20 μm.
3.3. RPE-Specific Ablation of Dhdds Causes a Geographic Atrophy-Like Phenotype and Retinal Degeneration,
Involving Photoreceptors
In vivo retinal imaging using SD-OCT (Figure 3) showed comparable normal layer stratification
in WT, CreRPE and Dhdds+/flx CreRPE age-matched mice in each group. However, Dhddsflx/flx CreRPE
mice showed altered hyper-reflectivity at all ages (indicated by red arrows, Figure 3), indicative of
pathologic changes and a reduction in outer retinal layer thickness.
Figure 3. SD-OCT revealed structural changes in Dhddsflx/flx CreRPE mice at all ages. OCT scans
were performed at 1, 2, and 3 months (m) postnatal for each genotype. (A) WT, (B) CreRPE,
(C) Dhdds+/flx CreRPE all showed normal layer stratification. (D) Dhddsflx/flx CreRPE showed alterations
of hyper-reflectivity at all ages, indicative of pathologic changes (red arrows) and reduction in layer
thickness, particularly in the outer retina. IPL, inner plexiform layer, ROS, rod outer segment. Scale bar
(shown in WT 1 m panel): 50 μm, applies to all panels.
“Spidergram” plots of average thickness values (in mm) vs. retinal eccentricity (distance from the
optic nerve head (ONH) along with vertical meridian) for the outer nuclear layer (ONL) and FRT are
shown in Figure 4. No significant differences were observed when comparing WT, heterozygous, or
Cre-only mice for both ONL and FRT measurements. However, Dhddsflx/flx CreRPE mice showed a
significant reduction (vs. WT) in ONL and F.R.T. values at all ages analyzed (n ≥ 4, all p < 0.001).
Histologically, at PN 3 months, light micrograph images revealed that all retina layers in mice
lacking Cre expression appeared normal (Figure 5A and Supplementary Materials, Figure S1A).
In contrast, the age-matched Dhddsflx/flx Cre RPE mice displayed a geographic atrophy-like RPE
appearance with the most degeneration observed mid-centrally throughout the retina (Supplementary
Materials, Figure S1B). There were regions of well-preserved Dhddsflx/flx Cre RPE retina that
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showed severe RPE pathology (Figure 5B). Notably, the descent of the external limiting membrane
(ELM) [25] towards Bruch’s membrane was also observed (Figure 5C,E). There was a near-total loss of
photoreceptors and RPE within the most affected regions (Figure 5D). Very well-preserved regions
were also observed in the periphery (Figure 5F).
Figure 4. Quantitative morphometric analysis of WT, CreRPE, Dhdds+/flx CreRPE, and Dhddsflx/flx
CreRPE mice SD-OCT data. Average OCT measurements at each eccentricity revealed no significant
differences when comparing WT, CreRPE and Dhdds+/flx CreRPE mice for both outer nuclear layer
(ONL) and F.R.T. thickness measurements (n = 4 for all genotypes, except for WT at one month (1 m;
n = 8) and two months (2 m; n = 5). However, significant changes were observed when comparing WT
and Dhddsflx/flx CreRPE mice at any age with respect to both ONL and F.R.T. values.
Figure 5. Pathology observed in Dhddsflx/flx Cre RPE mouse retina. (A) Dhddsflx/flx retina without Cre
expression appears normal. (B–F) Five regions of a retina from a Dhddsflx/flx CreRPE mouse expressing
Cre in RPE are shown. (B,F) Relatively well-preserved peripheral retina with some photoreceptor loss,
outer segment (OS) shortening, and differing severity of RPE pathology are shown (arrow in panel
B points to severely compromised RPE. (C,E) Transition zones of severe to mild retinal pathology
showing loss of photoreceptors, severe compromise of RPE and external limiting membrane (ELM)
descent (arrows). (D) A more central region of the retina showing severe cell loss in both the retina and
RPE. Scale bars (all panels, except F): 20 μm; scale bar, panel F: 10 μm. ROS, rod outer segments; ONL,
outer nuclear layer, INL, inner nuclear layer; IPL, inner plexiform layer, GCL, ganglion cell layer.
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Additional pathology was revealed by higher magnification EM analysis (Figure 6, panels
C–O). In contrast, Dhddsflx/flx retinas without Cre expression were indistinguishable from WT retinas
(Figure 6A,B). The two areas most affected showed severe RPE dystrophy with concomitant degeneration
and loss of photoreceptor cells (Figure 6C,D,F,G,J,M–O). ELM descent was apparent in areas where
there was a transition from milder to more severe pathology (* in panels D–F,J). RPE cell transmigration
was apparent in the outer retina (arrows, panels G,J,O,L). Thus, compared to WT neural retina and RPE,
the observed RPE anomalies including migration of nucleus and RPE melanosomes, displacement of
the ELM, and shortened misshaped outer segments throughout the retina were seen in the Dhddsflx/flx
CreRPE mice.
Figure 6. High magnification observation of Dhddsflx/flx CreRPE retina. EM images of 3m (A,B)
Dhddsflx/flx and (C–O) Dhddsflx/flx CreRPE mice. Mice homozygous for the floxed Dhdds allele (Dhddsflx/flx)
are not distinguishable from WT. (A) Rod outer segments are properly aligned and all retinal layers are
intact (only rod inner and outer segments and the outer nuclear layer are shown). (B) The RPE shows
normal thickness and melanin distribution. (C–O) Examples of mildly and severely compromised
RPE and retina in Dhddsflx/flx CreRPE mice. Severe RPE and outer retina degeneration is concentrated
mid-centrally on both sides of the optic nerve head (see histology, Figure 5, and Supplementary Materials,
Figure S1). Severe RPE/PR atrophy is observed in the most affected central regions (C–F,I,J,O). External
limiting membrane (ELM) descent (*) towards the RPE is apparent in the transition regions from
severely affected to more intact regions (D–F,J). Transmigration of RPE cellular material into the ROS
space (arrows) is also seen (G,J,L,O). Extended RPE basal fenestrations (arrowheads, I) are apparent in
the most affected regions (D,I). Outside of the central region of severe degeneration are regions with
compromised but still apparent retinal and RPE layers (K–N). Scale bars (all panels, except I): 10 μm;
panel I, 2.5 μm.
To further examine the effects of Dhdds deletion in the RPE, serial block face-scanning electron
microscopy was used to examine a ~100 μ3 region of the Dhddsflx/flx retina across an area of transition
from milder to more severe pathology (Supplementary Materials, Videos S1–3). In WT mice, the
retina appeared normal in all layers across the entire block. Examination of two regions of the
Dhddsflx/flx Cre RPE retina showed areas of severe compromise as well as areas where retinal histology
was more well-preserved. Transmigration of RPE nuclei and melanosomes into the photoreceptor
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region (subretinal space and photoreceptor outer segment layer, and even deeper, into the ONL) was
also apparent.
3.4. Altered Scotopic and Photopic ERG Amplitudes in Dhddsflx/flx CreRPE Mice
Analysis by ERG (Figure 7) showed that both homozygous and heterozygous Dhddsflx/flx CreRPE
mice exhibited reduced scotopic ERG a- and b-wave responses. At PN 1 month, scotopic a-wave
responses (289 ± 42 μV; n = 5) were significantly reduced in Dhddsflx/flx CreRPE mice compared to WT
mice (395 ± 14 μV; n = 8; p < 0.05). Scotopic b-wave responses also were reduced for both Dhdds+/flx
CreRPE (772 ± 42 μV; n = 20) and Dhddsflx/flx CreRPE (479 ± 69 μV; n = 5) mice, compared to WT mice
(934 ± 38 μV; n = 8; p < 0.01). At PN 2 months of age, Dhddsflx/flx CreRPE scotopic ERG a-wave (223 ±
48 μV; n = 10) and b-wave (477 ± 88 μV; n = 10) responses and Dhdds+/flx CreRPE a-wave (305 ± 19 μV;
n = 10) and b-wave (557 ± 64 μV; n = 10) responses were significantly reduced compared to the WT
a-wave (366 ± 10 μV; n = 15) and b-wave (935 ± 27 μV; n = 15) responses (p < 0.005 for all comparisons).
At PN 3 months, scotopic a-wave amplitudes were reduced only in Dhddsflx/flx CreRPE (60 ± 48 μV;
n = 6) compared to WT mice (354 ± 16 μV; n = 18; p < 0.001); b-wave responses were reduced in both
Dhdds+/flx CreRPE (662 ± 88 μV; n = 6) and Dhddsflx/flx CreRPE (150 ± 105 μV; n = 6) mice compared to
WT mice (914 ± 35 μV; n = 18) p < 0.05 and p < 0.01, respectively).
Figure 7. Scotopic ERG analysis of WT, Dhdds+/flx CreRPE, Dhddsflx/flx CreRPE mice. Maximum
responses to saturating light stimuli showed significant decreases in (A) a-wave and (B) b-wave
amplitudes for Dhdds+/flx CreRPE and Dhddsflx/flx CreRPE when compared to WT mice at 1, 2 and 3
postnatal months. Statistical significance: * p < 0.05, ** p < 0.01, *** p < 0.001.
The photopic a-wave and b-wave responses (Figure 8) at PN 1 month were not different when
comparing WT (n = 5) and Dhdds+/flx CreRPE (n = 13) mice, however the photopic responses of
Dhddsflx/flx CreRPE mice (n = 4) were significantly lower. Photopic ERG responses were significantly
different only for Dhdds+/flx CreRPE a-wave (29 ± 2 μV; n = 4; p < 0.01), but not b-wave, responses at PN
2 months of age. In Dhddsflx/flx CreRPE mice, b-wave (86 ± 19 μV; n = 6) amplitudes were significantly
reduced (p < 0.01), compared to WT mice (n = 13), but not the a-wave responses. At PN 3 months,
Dhddsflx/flx CreRPE mice exhibited significant functional impairment in the photopic a-wave (2 ± 1 μV;
n = 4) and b-wave (7 ± 1 μV; n = 4) responses compared to WT a-wave (14 ± 1 μV; n = 9) and b-wave
responses (144 ± 8 μV; n = 9; p < 0.001 for all comparisons).
Optokinetic reflex (OKR) analysis (Supplementary Materials, Figure S3), a measure of retina-to-
brain transmission (i.e., visual capacity), showed reductions in photopic (4–31%) and scotopic (8–29%)
contrast sensitivity over the range of 0.031 to 0.272 c/d in PN 3-month old Dhddsflx/flx CreRPE mice
(p < 0.05), compared to WT controls of the same age. However, no differences in spatial frequency
(a measure of visual acuity) were observed between the different mouse lines. This is partly evident in
the OKR scotopic and photopic plots, which show a similar high-frequency cut-off for all three mouse
lines examined.
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Figure 8. Photopic ERG analysis of WT, CreRPE Dhdds+/flx, CreRPE Dhddsflx/flx mice. (A) a-wave
responses were significantly lower in CreRPE Dhdds-/- at 1 (n = 4) and 3 (n = 4) months postnatal
compared to WT (one month (1 m), n = 5; three months (3 m), n = 9) mice. (B) Photopic b-wave
amplitudes for Dhdds+/flx CreRPE mice showed no statistically significant differences when compared to
WT mice at 1 (n = 13) and 2 (n = 4) postnatal months, but were reduced by 3 months (n = 4). In contrast,
the responses of Dhddsflx/flx CreRPE mice (two months (2 m), n = 6) were significantly lower when
compared to WT mice at all postnatal ages examined. Statistical significance: * p < 0.05, ** p < 0.01,
*** p < 0.001.
4. Discussion
Studies involving genetic screening of families with autosomal recessive retinitis pigmentosa
have implicated a founder missense mutation (K42E) in the gene encoding DHDDS [12,26]. DHDDS is
required for N-glycosylation of proteins by adding multiple copies of isopentenyl pyrophosphate (IPP)
to farnesyl pyrophosphate (FPP) to produce dehydrodolichyl diphosphate (Dedol-PP), a precursor of
dolichol, which is utilized as a sugar carrier in protein glycosylation in the endoplasmic reticulum [6].
Even though the generation of isoprenoid chains is complex, involving multiple enzymes and enzyme
complexes [27], only DHDDS and Nogo-B receptor are required for long-chain isoprenoid synthesis
(C70-C120) [28]. Previous studies have reported that mutations in the opsin gene that abolish N-linked
glycosylation cause retinal degeneration [28–30]. To understand the basis for the ocular pathology
associated with DHDDS mutation, we utilized a Cre recombinase conditional knockout (Dhddsflx/flx
CreRPE) driven under the control of the RPE-specific VMD2 promoter to achieve RPE-targeted excision
of the loxP-modified Dhdds gene, which renders the enzyme non-functional.
The VMD2 construct was originally generated to be conditional on the presence of doxycycline;
however, we found that the mice displayed a phenotype in the absence of doxycycline induction.
While we cannot rule out the presence of some level of doxycycline in the standard chow mouse diet, it
is more likely that Cre expression was due to “leaky” expression, which bypassed doxycycline control,
as confirmed in Figure 2. Since the promoters used for cell-specific targeting of Cre expression turn
on after development is complete, developmental changes that would otherwise preempt retina/RPE
development were not observed.
The expression of Cre recombinase in the Cre lines was confirmed using a ZsGreen reporter
strategy. The Dhddsflx/flx CreRPE mice exhibited about 90% coverage of Cre expression by PN 1 month
(Figure 2) which persisted up to 3 months at least. We crossed the conditional Dhddsflx/flx lines with
heterozygous VMD2 Cre lines to generate homozygous Dhddsflx/flx mice with RPE-specific knockout of
DHDDS expression as the model for our study.
In vivo imaging suggested that ONL thickness and F.R.T. were comparable between age-matched
WT and Dhdds+/flx CreRPE mice, but significantly reduced in Dhddsflx/flx CreRPE mice. While the
specific pathology is observed in much greater detail in the histological (light microscopy; Figure 5)
and ultrastructural (electron microscopy; Figure 6) images provided, it is clear that the pathology
indicated in the SD-OCT tomograms (Figure 3D) is consistent with the histological observations.
This altered structural integrity of Dhddsflx/flx CreRPE retinas also corresponded to a significant decrease
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in a-wave and b-wave compared to age-matched WT at all flash intensities. Unexpectedly, the scotopic
a- and b-waves also were reduced in Dhdds+/flx CreRPE mice, which may suggest a functional change
that occurs prior to any obvious retinal structural changes and suggests that 50% DHDDS activity
is insufficient in the RPE to maintain the required enzymatic activity level. Thus, carriers of Dhdds
mutations also may develop visual defects, depending on the nature of the mutation, and other
factors, such as genetic background and environment. This agrees with the rod-cone dystrophy
reported in patients with autosomal recessive RP [16]. However, we cannot rule out the expression of a
truncated protein that leads to a gain of function. This could explain the significant attenuation of
the photoresponse in mice heterozygous for the floxed allele (Figures 7 and 8). It could also possibly
explain the manifestation of the disease only in ocular tissues, if the gain of function is due to specific
targeting of retina-specific protein complexes. Further experimentation will be required to sort this out.
We carried out further experiments to examine the fundus of older Dhddsflx/flx CreRPE mice at
6, 8 and 10 months PN. These fundus images obtained with fluorescein angiography showed the
classical signs of RP including abnormal pigmentation in 8-month old Dhddsflx/flx CreRPE mice; vascular
changes, including microaneurysms, increased vessel tortuosity and attenuation, were also observed
by 6 months of age (Supplementary Materials, Figure S2).
Originally it was proposed that the cause of the pathology in DHDDS-related RP patients (RP59)
is defective glycosylation of rod opsin because of reduced DHDDS enzyme activity [12,26]. While this
assumption may explain the classic RP symptoms observed, it fails to explain the AMD-like macular
involvement. Interestingly, Lam and colleagues [11] found no N-glycosylation deficiency in RP59
patients, based upon isoelectric focusing gel analysis of plasma transferrin (a systemic glycoprotein).
In addition, in a related study (Rao et al., manuscript submitted for publication), utilizing a rod
photoreceptor-specific knockout of Dhdds in mice, we found no evidence for a resulting lack of protein
glycosylation in the retina; yet, there was a rapidly progressing photoreceptor degeneration, resulting
in complete loss of photoreceptors by PN 6 weeks of age. Also, in a companion article in this Special
Issue [31], we generated a mouse model harboring the global K42E homozygous Dhdds mutation
associated with RP59 patients, but observed no retinal degeneration, even out to 9 postnatal months of
age. Clearly, mutations that only partially diminish enzymatic activity would be far less severe than a
complete ablation of the gene encoding the enzyme.
5. Conclusions
From these observations, we conclude that targeted ablation of Dhdds selectively in RPE cells
results in perturbation of DHDDS-dependent processes, resulting in structural and functional deficits
in both the RPE and photoreceptors, in a manner resembling geographic atrophy. The degeneration
progresses relatively slowly (compared to the rod-specific Dhdds ablation model) over the course of a
few months, rather than weeks.
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Abstract: Retinal homeostasis is under both diurnal and circadian regulation. We sought to investigate
the diurnal expression of autophagy proteins in normal rodent retina and to determine if this is
impaired in diabetic retinopathy. C57BL/6J mice and Bio-Breeding Zucker (BBZ) rats were maintained
under a 12h/12h light/dark cycle and eyes, enucleated over a 24 h period. Eyes were also collected from
diabetic mice with two or nine-months duration of type 1 diabetes (T1D) and Bio-Breeding Zucker
diabetic rat (BBZDR/wor rats with 4-months duration of type 2 diabetes (T2D). Immunohistochemistry
was performed for the autophagy proteins Atg7, Atg9, LC3 and Beclin1. These autophagy proteins
(Atgs) were abundantly expressed in neural retina and endothelial cells in both mice and rats.
A differential staining pattern was observed across the retinas which demonstrated a distinctive
diurnal rhythmicity. All Atgs showed localization to retinal blood vessels with Atg7 being the most
highly expressed. Analysis of the immunostaining demonstrated distinctive diurnal rhythmicity, of
which Atg9 and LC3 shared a biphasic expression cycle with the highest level at 8:15 am and 8:15 pm.
In contrast, Beclin1 revealed a 24-h cycle with the highest level observed at midnight. Atg7 was also
on a 24-h cycle with peak expression at 8:15 am, coinciding with the first peak expression of Atg9 and
LC3. In diabetic animals, there was a dramatic reduction in all four Atgs and the distinctive diurnal
rhythmicity of these autophagy proteins was significantly impaired and phase shifted in both T1D
and T2D animals. Restoration of diurnal rhythmicity and facilitation of autophagy protein expression
may provide new treatment strategies for diabetic retinopathy.
Keywords: diurnal rhythm; autophagy; retina; diabetes; diabetic retinopathy
1. Introduction
Macroautophagy (hereafter referred to as autophagy) is an evolutionarily conserved cellular
catabolic mechanism that facilitates the degradation of damaged cellular organelles and proteins,
by targeting them to the lysosomes and recycling the macromolecules for the rebuilding of cellular
machinery [? ? ? ]. Autophagy undergoes rhythmic variation in accordance with circadian patterns
of rest/activity and feeding in adult mammals [? ]. Dysregulated autophagy has been implicated in
several neurodegenerative disorders, hepatitis, cancer, aging associated diseases and in the general
aging process [? ? ? ? ? ]. Recently, a growing body of evidence indicates that dysregulated autophagy
is also linked to diabetes [? ? ? ? ].
The disruption of circadian rhythm has a profound negative impact on health and is associated
with elevated risk for several diseases [? ]. The physiological relevance of an altered circadian rhythm
in diabetes is evidenced by the observation of a high incidence of myocardial dysfunction, acute
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coronary syndrome, sudden cardiac death, and ischemic stroke in diabetics during the night, compared
to a higher frequency during the day in non-diabetics [? ? ? ? ]. In diabetic conditions, Bmal1 and
Clock are inactivated, causing deregulated glucose homeostasis and suppressed diurnal variation in
glucose and triglycerides, along with reduced gluconeogenesis [? ]. Streptozotocin (STZ)-induced type
1 diabetes (T1D) in mice exhibits altered phase of the circadian clock in the heart [? ] and a significant
reduction of circadian sensitivity to low-intensity light in the retina [? ]. Furthermore, STZ-mice
develop a deficiency in their ability to re-entrain the circadian rhythm when subjected to a phase
advance of the 12L/12D cycle [? ]. Bio-Breeding Zucker diabetic rat (BBZDR/Wor) and Goto-Kakizaki
rat type 2 diabetes (T2D) models also show impairment of the molecular clock, suggesting that the
disruption of the circadian clock is a common phenomenon in both T1D and T2D [? ? ].
Several hallmarks of diabetic retinopathy can be recapitulated in rodent retina deficient of clock
genes [? ? ]. Reduced tube formation and increased senescence of endothelial cells coupled with
impaired progenitor-mediated repair is observed in Per2 mutant mice, emphasizing the importance of
the circadian clock in retinal homeostasis [? ]. Recent studies on autophagy in the retina have shed light
on the association of key molecules of the autophagic pathway with phagocytosis of photoreceptor
outer segments (POS) by the retinal pigmented epithelium (RPE) [? ? ]. Photoreceptor disk shedding
has been widely reported to exhibit diurnal rhythmicity in the retina [? ? ] and the tight coupling of
phagocytic ingestion and autophagic degradation of the POS to this diurnal rhythm is a critical aspect
of retinal homeostasis [? ? ].
The role of the peripheral clock and diurnal variation on the regulation of autophagy in the
normal and diabetic rodent retinas and the fate of autophagy in the diabetic retina remain unexplored.
Understanding these control mechanisms may help find effective treatments for diabetic retinopathy.
In this study, we demonstrate that the spatial distribution and temporal expression of autophagy
proteins show a diurnal rhythm and that this is depressed and phase shifted in the diabetic retina.
2. Materials and Methods
2.1. Experimental Animals
All animal procedures were performed in accordance with a) protocols approved by the
Institutional Animal Care and Use Committees at University of Florida, Gainesville, FL, USA
(#CR-201106001), Michigan State University, Lansing, MI, USA (#Busik09/14-160-00, and Indiana
University, Indianapolis, IN, USA (#10574 MD/R), b, the National Institutes of Health Guide for Care
and Use of Laboratory Animals and c) the ARVO Statement for the Use of Animals in Ophthalmic
and Vision Research. Male C57BL/6J mice were purchased from Jackson Labs at 6 weeks of age and
male BBZDR/wor T2D rats and lean heterozygote nondiabetic control littermates were obtained from
biomedical research models (BRM, Inc.) Worcester, Massachusetts at 5 months of age. C57BL/6J
mice (n = 240) and BBZ rats (n = 75) were maintained on a standard 12/12 h light/dark cycle (6.00
am lights on/6.00 pm lights off). T1D was induced in eight-week-old C57BL/6 mice (n = 120) by
five consecutive intraperitoneal injection of freshly prepared streptozotocin (STZ) solution with the
concentration of 40mg/kg body weight in 0.1M/citrate buffer, pH 4.5 as previously described [? ?
]. The control group received sodium citrate buffer (vehicle) alone. Diabetes was confirmed by
two consecutive blood glucose levels >240 mg/dl, using the AlphaTrak® blood glucose monitor and
test strip system (Abbot laboratories, Irvine, CA, USA), according to the manufacturer’s instruction.
No animal used in this study required insulin injections. Eyes from one group were collected at
2 months following establishment of diabetes and the second cohort 9 months after diabetes induction
(the age of the animals at these time points being 4 and 11 months, respectively). We also investigated
inbred Bio-Breeding Zucker (BBZDR)/wor T2D rats (n = 37) and age-matched controls (n = 38) [? ].
BBZDR/wor rats spontaneously became diabetic at ~10 weeks of age and were maintained for 4 months
after the onset of diabetes. A second group of C57BL/6J mice (n = 24) were dark adapted for 48 h before
sacrifice and referred to as being on the dark/dark cycle. In all groups, animals were euthanized by
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deep anesthesia with isoflurane followed by cervical dislocation and eyes were immediately enucleated
every 2 or 3 h over a 24 h period and prepared for immunofluorescence staining. For animals in the
dark cycle, euthanasia and enucleation were performed in a dark room under a red safe light. For each
set of experiments, all animals were started at the same time point to clearly identify any phase shift
in peak or trough of ATG expression. The number of biological replicates of the enucleated eyes at
each time point is n = 10 for mice and n = 3 for rats. Only one eye from each animal was used in
the assessment.
2.2. Immunofluorescence Microscopy
Eyes were processed for standard paraffin embedding and 4 μm sections were prepared. Rodent
Decloaker (Biocare Medical LLC, Concord, CA, USA Catalog# RD913L) was used to unmask antigens
and non-specific binding was blocked with 10% normal goat sera and 5% BSA for 1 h at room
temperature. Sections received either mouse monoclonal anti-Beclin1 (BD Transduction Lab, San
Jose, CA, USA, Cat#612112), or rabbit polyclonal antibodies against Atg7, Atg9 and LC3 (provided
by Dr. Dunn, Department of Anatomy and Cell Biology, University of Florida, Gainesville, FL, USA),
diluted in phosphate buffered saline (PBS) with 1% normal goat sera plus 1% bovine serum albumin
(BSA) (Beclin1 1:20; Atg7- 1:300; Atg9 and LC3 - 1:100). After washing, sections were incubated with an
appropriate FITC-conjugated secondary antibody for 1 h. In some sections, colocalization of autophagy
proteins within the retinal vasculature was confirmed by dual staining with the endothelial cell marker,
TRITC-agglutinin (Vector Labs, Burlingame, CA, USA, Cat#RCA120). Sections were covered with
Vectashield mounting medium/DAPI (Vector Labs, Inc.). Sections were viewed using a Zeiss Axioplan
2 Upright Fluorescence Microscope with Qimage/QCapture software Version 8 (QImaging Corporate,
Surrey, British Columbia, Canada). Omission of the primary antibody was the baseline control and all
the fluorescence photographs were obtained under the same scaled conditions.
2.3. Grading of Immunostaining
Three independent masked observers, using a previously described grading system [? ? ], graded
the intensity of the immunoreactivity for each antibody in transverse retinal sections. The intensity
of labeling was graded qualitatively as: 10, strong bright intense immunoreactivity, 9, bright intense;
8, uniformly intense; 7, patchy and intense; 6, uniform and moderate; 5, patchy and moderate; 4,
uniform and weak; 3, patchy and weak; 2, uniform and very weak; 1, patchy and very weak; and 0,
none. A mean score ±SEM for each group was determined from the scores of all graders for each
retina structure.
2.4. Trypsin Digestion and the Detection of Superoxide
The retinal vasculature was prepared as previously described [? ]. Briefly, mouse eyes were
fixed overnight in 4% paraformaldehyde, freshly made in PBS. The retinas were dissected from the
eye cups, kept in water overnight, and digested in 3% trypsin (Invitrogen-Gibco, Grand Island, NY,
USA) for 3 h at 37 ◦Celcius. The tissue was mounted carefully on a glass slide under a dissection
microscope. The tissue was stained with PAS-H&E (periodic acid Schiff–hematoxylin and eosin;
Gill No.3; Sigma-Aldrich), according to the instruction manual. The images were taken using a
Zeiss light microscope equipped with a digital camera (AxioCam MRC5, Axiovert 200; Carl Zeiss
Meditec, Inc., Dublin, CA, USA), using 20X objective lenses. Eight to ten representative fields from
each quadrant of the retina were imaged and the number of acellular capillaries per square millimeter
of retina were quantified.
For detecting the reactive oxygen species (ROS), the superoxide indicator, hydroethidine, was
used to detect the production of superoxide radicals, as previously described [? ]. Superoxide
oxidizes hydroethidine to yield a red fluorescent signal at approximately 600 nm. Mice received two
intraperitoneal injections, 15 min apart, of freshly prepared hydroethidine (20 mg/kg; Invitrogen) and
were euthanized 18 h after injection. The fluorescence intensity was measured in the neural retina
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using a fluorescent plate reader (BioTek, Winooski, VT, USA) and a spectrofluorometer (FLUOstar
Optima; BMG Labtechnologies, Cary, NC, USA). The relative fluorescence intensity was calculated by
normalizing to protein concentration.
2.5. Statistical Analysis
The diurnal data are time series data, and single cosine analysis was employed to fit the data.
The data was considered as diurnal oscillation by a zero-amplitude test, with a p-value less than
0.05. All experiments were assessed by comparing two groups mean scores from control animals and
diabetic animals using a Student’s t-test, plus ANOVA for multiple comparisons by using Prism®
statistical software ver. 5 (GraphPad, La Jolla, CA, USA) with differences of p value < 0.05 were
considered statistically significant. Results are expressed as mean ± SEM.
3. Results
3.1. Autophagy Proteins Exhibit Diurnal Expression/Localization in Normal Mouse Neural Retina
To determine if autophagic protein expression in the neural retina had an intrinsic diurnal rhythm,
we assessed the expression and localization of four autophagy proteins, Atg7, LC3, Atg9 and Beclin1 in
the normal retinas of young mice (age = 3 months) that were maintained under standard 12 h light/12 h
dark conditions. When we examined the tissue at two-hour intervals over a 24 h period, these proteins
exhibited not only a distinct diurnal rhythm, but remarkably showed distinct staining patterns across
the layers of the neural retina in mice (????). Atg9 and LC3 exhibited a biphasic 12/12 h circadian cycle
with zenith at 8:15 AM and 8:15 PM and nadir at 2:15 AM and 2:15 PM (p < 0.05) (Figure ??A–D). By
contrast, Atg7 and Beclin1 expression showed a monophasic rhythm and the overall expression of
these proteins was much lower than either Atg9 or LC3 (Figure ??E–H). The expression of Atg7 started
to rise at 4:15 AM, peaked at 8:15 AM and gradually decreased until 10:15 AM (p < 0.05) (Figure ??E–G).
Beclin1 expression was highest at around midnight and reached lowest levels at midday (p < 0.05)
(Figure ??F–H). Omission of the primary antibody showed no staining in mouse retina (Figure ??D).
An assessment of the staining pattern of the proteins at zenith revealed that Atg9 and LC3 were
localized throughout the retina, predominantly within the retinal ganglion cell (RGC) layer, inner (INL)
and outer nuclear layer (ONL) (Figure ??A,B). Atg7 was only weakly localized to the neural retina in
both the inner and outer nuclear layers and showed stronger localization in the photoreceptor outer
segment. Beclin1 staining was detected throughout the retina, with highest intensity in the inner and
outer plexiform layers and in the photoreceptors. Closer observation of the retina revealed that ATG7
and 9 showed remarkably strong association within the inner retinal vasculature (Figure ??C).
Using dual staining for endothelial cells and autophagy proteins, we confirmed that Atg9, LC3,
Atg7 and Beclin1 were all expressed in both the inner and outer retinal plexus of the retinal vasculature
(Figure ??C).
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Figure 1. Autophagy proteins exhibited diurnal expression/localization in normal mouse neural retina.
Retina were harvested every 2 h over a 24 h time period. Antibodies for autophagy proteins (ATGs)
ATG9, Microtubule-associated protein 1A/1B-light chain 3 (LC3), ATG7 and Beclin1 (BECN) were used
to detect respective protein expression (green) in the retina, Tetramethylrhodamine (TRITC) agglutinin
for vessels (red) and DAPI (blue) shows nuclear staining. Distinct diurnal rhythmic patterns of the
autophagic proteins Atg9 and LC3 expressions (A,B) revealed a biphasic diurnal cycle (12/12 h), with
peaks at 8:15 AM and 8:15 PM and lowest levels at 2:15 AM and 2:15 PM (C,D). Atg7 and Beclin1
(BECN) expressions (E,F) were on a monophasic 24 h cycle. Atg7 expression peaked at 8:15 AM and
lowest levels were at 10:15 AM. The peak of Beclin1 expression was at midnight and lowest levels were
observed during the late morning (H). All animals were maintained in a standard 12/12 h light/dark
phase with lights ON at 6:00 AM and lights OFF at 6:00 PM. The error bars in the diurnal plots represent
the mean+SEM and diurnal oscillation had a p-value less than 0.05.
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Figure 2. Localization of autophagy proteins in normal mouse retina and vasculature. Animals were
kept in tight 12/12-h light/dark cycle before the experiment. Antibodies for ATG9, LC3, ATG7 and
Beclin1 (BECN) were used to detect respective protein expression (green) in the retinas with different
staining patterns and DAPI was used to stain nuclei (blue) (A). Agglutinin, an endothelial cell marker,
conjugated with TRITC (red) was used to co-localize with antibodies specific to individual autophagy
proteins (FITC) in the retinal vasculature (B). High magnification images demonstrated autophagy
protein localization to the endothelial cells and pericytes of the retinal vasculature (C). No fluorescence
was observed with omission of the primary antibody in the mouse retina. Using agglutinin staining,
the section displayed retinal vascular patterns with normal architecture (D). Omitted autophagy
primary antibody in rat retina also was negative (E). The arrows indicate autophagy protein localization
to retinal vessels. RGC, retina ganglion cell; IPL, inner plexiform layer; INL, inner nuclear layer; OPL,
outer plexiform layer; ONL, outer nuclear layer; IS, inner segment; OS, outer segment; RPE, retinal
pigment epithelium.
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3.2. Autophagic Activity in the Retina Is Tightly Entrained by Light
We repeated immunohistochemistry of ATG9, ATG7, LC3 and Beclin1 in the retina (and the retinal
vasculature) of 48 h dark adapted mice and compared the results to those of 12/12 h light/dark adapted
mice. The immunohistochemistry data indicated that the periodic oscillations, as well as overall levels
of the autophagic proteins ATG9 and LC3, were attenuated in the 48 h dark adapted mice retina
when compared to the 12/12 h dark/dark controls, both in the retina and the vasculature (Figure ??A).
Similarly, peaks in Atg7 and Beclin1 were phase shifted compared to the light/dark controls and overall
expression levels were reduced (Figure ??B). We concluded that diurnal oscillations in autophagic
activity in the murine retina depend, at least in part, on light-effected entrainment.
 
Figure 3. Immunohistochemistry confirmed alterations in diurnal patterns of autophagic gene
expression upon light cycle disruption.
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Mice were separated into two groups. One group was kept under 12/12-h light/dark cycle and the other
group was kept in the dark for 48-h (dark/dark), before being euthanized. Samples were collected
every 3 h for 24 h and were analyzed by immunohistochemistry for autophagic markers (A) ATG9 (B)
LC3 (C) ATG7 and (D) Beclin1 (BECN). Autophagy protein expression is green, TRITC agglutinin for
vessels red and DAPI nuclear staining blue. The arrows indicate autophagy protein localization to
retinal vessels. RGC, retina ganglion cell; INL, inner nuclear layer; OPL, outer plexiform layer; ONL,
outer nuclear layer; RPE, retinal pigment epithelium. The error bars in the circadian plots represent the
mean + SEM and diurnal oscillation had a p-value less than 0.05.
3.3. Diurnal Rhythmicity of Expression of Autophagic Proteins Is Dampened in T1D
Having established that autophagy in the retina possesses a diurnal rhythm, we next examined the
rhythmicity of autophagy proteins in T1D. We chose mice from 2- and 9-months duration of diabetes
to assess the expression of autophagic proteins. To confirm that our T1D mice exhibited the expected
retinopathy features [? ? ], we performed trypsin-digests of the retina from nondiabetic C57BL/6J
(Figure ??A, left) and T1D (Figure ??A, right). T1D mice exhibited an increase in the number of acellular
capillaries per unit area. Quantitative measurements of acellular capillaries suggested a dramatic
4-fold increase, in contrast to the age-matched nondiabetic mouse of retinas that showed a normal
vascular pattern (Figure ??B). These eyes showed significantly higher levels of superoxide anions in
the neural retina, typical of retinopathy in this model (Figure ??C).
 
Figure 4. Evaluation of acellular capillary formation and superoxide anion generation in T1D mice.
Representative images of trypsin-digested retinal vascular preparations from 4-month old control mice
and 4-month old mice with 2-month duration of T1D (A) The arrow indicates an acellular capillary.
Quantitative measurement of acellular capillaries was significantly increased in diabetic eyes (n = 6). (B)
STZ-induced diabetic retina showed >1.5 fold increase in superoxide anion levels, p < 0.01 (C) The errors
bars represent SEM.
While immunohistochemistry results from 4-month old normal control mice corresponded with the
respective results shown in ????, we observed a dramatic attenuation of diurnal rhythmicity (amplitudes),
as well as overall levels of the autophagic proteins in the T1D mice retina (Figure ??). This loss of
amplitude was noted for ATG9, LC3 and Beclin1 expression in the diabetic retina, in either duration of
diabetes group when compared to the respective age-matched controls (????). ATG7 exhibited a shift in
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phase in both the retina and the vasculature of mice with 2-month duration of diabetes while in mice with
9-months duration of diabetes the phase-shift was prominent in the retina and there was no significant
variation in expression between time-points in the retinal vasculature (Figures ??B and ??B).
Figure 5. Impairment of diurnal rhythmicity of autophagy in T1D mice with two-months duration of
diabetes. Retinas were collected from C57Bl/6J mice with two-months duration of T1D and age-matched
control mice. Immunostaining and intensity analyses of retina and retinal vasculature demonstrated
a dramatic loss of oscillatory amplitude of autophagic protein expression in the diabetic animals
compared to normal mice (A,B). Autophagy protein expression is green, TRITC agglutinin for vessels
red and DAPI nuclear staining blue. The arrows indicate autophagy protein localization to retinal
vessels. RGC, retina ganglion cell; INL, inner nuclear layer; OPL, outer plexiform layer; ONL, outer
nuclear layer; RPE, retinal pigment epithelium. Loss and phase-shifting of diurnal rhythmicity in
diabetic retinopathy is demonstrated in single cosine plots, with ordinary least square fitted (p < 0.01,
n = 10). All animals were maintained in a standard 12/12-h light/dark phase with lights ON at 6:00 AM
and lights OFF at 6:00 PM. The error bars in the circadian plots represent the mean+SEM and diurnal
oscillation had a p-value less than 0.05.
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Figure 6. Impairment of diurnal rhythmicity of autophagy in T1D mice with nine-months duration of
diabetes. Retinas were collected from C57Bl/6J mice with nine-months duration of T1D and age-matched
control mice. Immunostaining and intensity analyses of retina and retinal vasculature demonstrated
a dramatic loss of oscillatory amplitude of autophagic protein expression in the diabetic animals
compared to normal mice (A.B). Autophagy protein expression is green, TRITC agglutinin for vessels
red and DAPI nuclear staining blue. The arrows indicate autophagy protein localization to retinal
vessels. RGC, retina ganglion cell; INL, inner nuclear layer; OPL, outer plexiform layer; ONL, outer
nuclear layer; RPE, retinal pigment epithelium. Loss and phase-shifting of diurnal rhythmicity in
diabetic retinopathy is demonstrated in single cosine plot with ordinary least square fitted (p < 0.01,
n = 10). All animals were maintained in a standard 12/12-h light/dark phase with lights ON at 6:00 AM
and lights OFF at 6:00 PM. The error bars in the circadian plots represent the mean+SEM and diurnal
oscillation had a p-value less than 0.05.
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3.4. Autophagy Proteins Were Suppressed Severely in T2D Rats
We next examined autophagy in the retina of T2D rats following 4-months duration of diabetes
(Figure ??). The normal age-matched rats selected as controls demonstrated a similar staining pattern
of immunohistochemistry across the retina as were observed in normal mice (Figure ??A–D). Atg9
(Figure ??A) and LC3 (Figure ??B) were mainly present in the ganglion cell layer, inner and outer
nuclear layers in the normal rat retina, similar to what was observed in normal mice (Figure ??) but
their expression was dramatically decreased in the retinas of the diabetic animals by 49% to 58%,
respectively. For better demonstration of changes in autophagic protein levels in the vasculature of
diabetic retinas, we showed higher magnification images. Both Atg9 and LC3 clearly distributed
within the retinal endothelia of normal rats but were completely absent from the endothelia of the
diabetic retinas (Figure ??E,F). Atg7 was strongly expressed in normal retinal vessels near the ganglion
cells layer, meanwhile the small vessels in inner and outer plexus layers were also stained (Figure ??C).
Semi-quantitative analysis revealed that the level of Atg7 was deceased by 52%, p < 0.05 in diabetic
retinas. Diabetic retina also displayed pathologic changes in retina vessels, which appeared to be
abnormally protruded toward the intravitreous cavity. Beclin1 staining was detected across the retina,
including retinal vessels in the plexus and photoreceptors, however, Beclin1 staining was diminished in
diabetic retinas by 53%, p < 0.01 (Figure ??D). Quantitative analyses of autophagic proteins in the retina
of control and diabetic mice demonstrated, not only suppressed levels, but also revealed impairment
in diurnal rhythmicity in T2D rats. Expression of Atg9 and LC3 were severely suppressed with
insignificant biphasic oscillatory pattern and ATG7 and Beclin1 were phase-shifted by approximately
for 4–6 h. We concluded that disruption in autophagy is a characteristic phenomenon of both T1D
and T2D.
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Figure 7. Impairment of diurnal rhythmicity of autophagy in T2D rats. Eyes were collected from
6.5-month old BBZDR/wor type 2 diabetic rats with 4-month duration of diabetes and the normal
age-matched rats selected as controls. Immunostaining demonstrated a dramatic decrease in amplitude
of diurnal rhythmicity of autophagic protein expression in the retina of the diabetic animals compared to
normal rats. Representative micrographs of immunostained sections at 8:15 am are shown for (A) ATG9,
(B) LC3 (C) ATG7 (D) Beclin1 (BECN). Autophagy protein expression is green, TRITC agglutinin for
vessels red and DAPI nuclear staining blue. The arrows indicate autophagy protein localization to
retinal vessels. RGC, retina ganglion cell; INL, inner nuclear layer; OPL, outer plexiform layer; ONL,
outer nuclear layer; RPE, retinal pigment epithelium. ATG7 and Beclin1 displayed phase-shifting in the
diurnal oscillation (C) and (D) respectively. Loss and phase-shifting of diurnal rhythmicity in diabetic
retinopathy is demonstrated in single cosine plot with ordinary least square fitted (p < 0.01, n = 10).
High magnification images confirmed the loss of autophagy proteins ATG9 and LC3 in the retinal
vasculature (E). All animals were maintained in a standard 12/12-h light/dark phase with lights ON at
6:00 AM and lights OFF at 6:00 PM. The error bars in the circadian plots represent the mean + SEM and
diurnal oscillation had a p-value less than 0.05.
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4. Discussion
Autophagy is a critical and indispensable housekeeping process in the cells of the retina. Numerous
reports support the functional relevance of autophagy in specific cells of the retina and how dysregulated
autophagy contributes to retinal malfunction and degeneration [? ? ? ? ? ? ]. While acute short-term
noxious stimuli (e.g., nutrient deprivation; hypoxia and endoplasmic reticulum (ER) stress; oxidative
stress arising from light, lipofuscin, POS phagocytosis by RPE or mitochondrial ROS generated in
retinal cells (which have a generally high metabolic rate)) can stimulate autophagy as a generally
cytoprotective mechanism, it must be acknowledged that diurnal basal autophagic modulation is
a critical factor in abrogating the unavoidable regular cellular damage that occurs during the basic
functioning of retinal cells. An efficient regulatory molecular circuit is required in the retina, that
would modulate both the intensity and duration of basal autophagic activity in specific cell types and
thus meet their regular housekeeping demands [? ]. Previous studies have suggested the existence
of autophagic rhythm in rodent heart muscles and liver, as well as kidney proximal tubules [? ? ? ].
In this study, we establish the existence of diurnal regulation of autophagic activity, in both the neural
and vascular cells of the retina. We show evidence that certain autophagic markers like Beclin1, ATG9
and LC3 are highly expressed across the retina, while ATG7 shows preferential staining patterns and is
enriched only in certain layers (????). The first report on diurnal rhythmicity in autophagy in the retina
recorded increased autophagosome formation following outer disk shedding in rat photoreceptors [? ].
Our results regarding the biphasic oscillation of diurnal rhythmicity of LC3 expression agree with the
findings in a report by Yao et al. 2014, who also observed two peaks of elevated autophagic activity [?
]. Our results in Figure ?? make a strong argument in favor of the influence of external stimuli such as
light for the entrainment and maintenance of healthy amplitudes of oscillation of autophagic protein
expression in the retina. However, we observed that even in the absence of light entrainment, the retina
continued to display rhythmicity in ATG7, ATG9, LC3 and BECN, but were lower in amplitude and
out of phase, suggesting that there may be an intrinsic diurnal rhythm of autophagy in the retina not
dependent on light entrainment.
Our study encompasses autophagy in aging and diabetic conditions. We successfully demonstrate
that perturbed autophagy is a characteristic feature of aging. It has been suggested that macroautophagy
suffers a decline with aging and is replaced partly by other forms of autophagy [? ]. It remains to be
determined if other forms of autophagy i.e., the chaperone mediated autophagy and microautophagy
are also under regulation by the circadian system and, if so, whether their rhythmicity is affected in
aging and disease. In addition to the above, our study reveals that the level of disruption in T1D and
T2D is significant, not only in younger mice, but also in older animals (????). Compared to age-matched
control mouse retinas, the dramatic deviations in the oscillatory patterns or the overall levels of one or
more Atgs in both two- and nine-month old diabetic mouse retina could be an indication of faulty
housekeeping and pathological outcomes, such as the accumulation of damaged mitochondria and
ROS production [? ? ? ? ].
A limitation of this study is that it relies on immunohistochemistry to determine changes in the
expression of autophagy proteins throughout the neural retina. We did not attempt to confirm our
findings by assessing gene expression or protein levels using Western blot. Neither did we assess
autophagic flux by determining the LC3II:LC3I ratio. The reasons for this were a combination of the
large number of animals needed; regional/cell-specific changes would be masked in whole retinal
preps and the non-canonical role of LC3 in retinal and immune cell phagocytosis [? ] could complicate
the analysis of the autophagic flux. Furthermore, based on our data, there is a need to determine the
mechanistic link between diurnal changes and autophagy in the neural retina. There is considerable
evidence that diurnal/circadian rhythm is associated with the induction of autophagy [? ? ], a key
regulator of autophagy; the mechanistic target of rapamycin (mTOR) is regulated by the circadian
clock [? ] and the circadian regulation of metabolism is mediated through reciprocal signaling between
the clock and metabolic regulatory networks such as autophagy [? ]. Recently, Ryzhikov and colleagues
reported that diurnal rhythms spatially and temporarily organize autophagy [? ]. They reported that
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basal autophagy rhythms could be resolved into two antiphase clusters that were distinguished by the
subcellular location of targeted proteins. Daytime autophagy was directed towards cytosolic proteins
and proteosomal degradation, while nighttime autophagy was directed towards ER and mitochondrial
removal. There is now a need to better understand the mechanistic control of these processes.
As mentioned above, autophagy in diabetes and related diseases has become an area of intense
research, with focus on how this pathway may be targeted in synergy, with other therapeutic approaches
to encourage a better clinical outcome. Our study, along with other recent reports, adds a novel
extension to the mammalian diurnal rhythmicity in its relevance in regulation of biological processes.
It provides a novel link between dysregulated autophagy and disrupted diurnal rhythm in the aging
and diabetic retina and suggests that our analyses of myriad biological processes in the retina should
be reconsidered from a diurnal perspective, in order to better comprehend age-related vision loss and
disease pathology.
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Abstract: Inherited retinal dystrophies (RDs) are heterogenous in many aspects including genes
involved, age of onset, rate of progression, and treatments. While RDs are caused by a plethora
of different mutations, all result in the same outcome of blindness. While treatments, both gene
therapy-based and drug-based, have been developed to slow or halt disease progression and prevent
further blindness, only a small handful of the forms of RDs have treatments available, which are
primarily for recessively inherited forms. Using immunohistochemical methods coupled with
electroretinography, optical coherence tomography, and fluorescein angiography, we show that in
rhodopsin mutant mice, the involvement of both the innate and the autoimmune systems could be a
strong contributing factor in disease progression and pathogenesis. Herein, we show that monocytic
phagocytosis and inflammatory cytokine release along with protein citrullination, a major player in
forms of autoimmunity, work to enhance the progression of RD associated with a rhodopsin mutation.
Keywords: retinal degeneration; immunity; autoimmunity; rhodopsin; citrullination;
retinitis pigmentosa
1. Introduction
Inherited retinal dystrophies (RDs) are the result of mutations in genes associated with cells of
the outer retina, primarily rod and cone photoreceptors and retinal pigment epithelium (RPE) [1].
RDs are often highly heterogenous in every aspect of the disease, from the age of onset to the rate of
progression, to the very mechanisms underlying the pathogenesis [2]. In order to study the molecular
mechanisms of pathogenesis underlying retinal disease, numerous animal models, mostly in mouse,
have been generated, carrying genetic defects in several genes causing the disease. A major cause of
RDs, specifically, autosomal dominant retinitis pigmentosa (RP), is the presence of dominantly inherited
mutations in the gene for the rod photoreceptor protein rhodopsin [2]. While most rhodopsin mutations
cause protein misfolding and subsequent apoptosis, the more severe mutations result in improper
rhodopsin trafficking and can lead to a subsequent loss of outer segment formation [2]. These mutations
result in improper localization of both normal and mutant rhodopsin to the cellular membrane of the
inner segment, nuclear, and axonal regions of the rod photoreceptor cells [1]. Two rhodopsin mutations
resulting in the earliest onset of retinal degeneration, rhodopsin Ter349Glu and Gln344Ter, behave in
this manner [2]. In recent years, many studies have shown the involvement of the immune system
in the pathogenesis of many retinal diseases including glaucoma, age-related macular degeneration
(AMD), RP, and others [3,4]. Also brought to light is the role of autoimmunity in RDs including
AMD and RP [3,5–8]. While the eye is immune-privileged, the homeostatic disruptions caused by the
progression of RDs can allow for a loss of this immune-privileged status, mainly due to the breakdown
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of the blood retinal barrier and choroidal neovascularization. In this study, we show the involvement
of pro-inflammatory pathways in the progression of rhodopsin-mediated RD using the Ter349Glu
rhodopsin knock-in mouse model of the disease, including monocytic phagocytosis and activation of
the Janus Kinase/Signal Transducer and Activator of Transcription (JAK/STAT) pathway. We also show
the presence of known autoimmunity proteins and protein modifications in the rhodopsin Ter349Glu
mutant mouse.
2. Materials and Methods
2.1. Measuring Electrical Function in the Ter349Glu Rhodopsin Knock-in Mouse by Electroretinogram (ERG)
Wild-type (+/+, WT), Ter349Glu rhodopsin heterozygous and homozygous mice at one month
of age were dark-adapted overnight (O/N). The following day, the mice were anesthetized using
ketamine/xylazine (14.3 mg/mL ketamine/2.8 mg/mL xylazine in PBS, pH7.4), and ERGs were performed.
Dark-adapted flashes (505 nm stimulus) of varying intensities were achieved using neutral density
(ND) filters of nominal optical densities (OD) 4.8, 1.4, 3.6, 2.4, 1.8, 1.2, 0.6, and 0.0. A dark-adapted green
camera flash performed with no attenuation. Data were analyzed using Labview and IgorPro software.
2.2. Monitoring the Ter349Glu Rhodopsin Knock-in Mouse Retina for Vascular and Laminar Abnormalities
WT and Ter349Glu homozygous mice at 4 weeks of age were anesthetized using ketamine/xylazine
(14.3 mg/mL ketamine/2.8 mg/mL xylazine in PBS, pH7.4). The mice were subsequently examined by
optical coherence tomography (OCT) (Bioptigen 840 nm Spectral Domain-OCT, Durham, NC, USA)
to measure retinal thickness and assess for structural anomalies. After OCT, the mice were injected
intraperitoneally with 100 μL of 4% fluorescein, and the retinas were imaged approximately 1 to
2 minutes post-fluorescein injection by fluorescein angiography (FA), using a 488 nm lamp co-equipped
with a Micron III digital microscope (Phoenix Laboratories, Mukilteo, WA, USA) to assess the retinal
vasculature for abnormalities including neovascularization, retinal hemorrhage, and vessel alterations.
2.3. Immunohistochemical Survey for Inflammatory Markers in the C-Terminal Mutant Rhodopsin Knock-in
Mouse Retina
Whole eyes from WT, Ter349Glu rhodopsin heterozygous and homozygous mice 4, 8, and/or
12 weeks of age were fixed in 4% paraformaldehyde (PFA) in PBS, pH 7.4, overnight at 4 ◦C, cryoprotected
in 30% sucrose in PBS, pH 7.4, frozen in optimal cutting temperature medium, and cryosectioned into
10 μm-thick sections. After washing away the medium, sections were prepped for immunolabeling
using heat-mediated antigen retrieval in 10 mM sodium citrate, pH 6.0, with 0.05% Tween-20 for 1 h.
After cooling, the slides were washed in PBS and subsequently blocked in 10% goat serum/5% BSA/0.5%
Triton X-100 in PBS for 1 h at RT. Following blocking, labeling for markers of retinal inflammation
including activated macrophages (F4/80), phosphorylated STAT3 (pSTAT3), and suppressor of cytokine
signaling 3 (SOCS3) was performed using fluorescent immunohistochemistry. For both pSTAT3
(Cell Signaling Technology, Danvers, MA, USA) and SOCS3 (abcam, Cambridge, United Kingdom)
labeling, a goat anti-rabbit IgG secondary antibody conjugated to horseradish peroxidase (HRP) was
allowed to bind the primary antibodies, and Cy3-Tyramide Signal Amplification (TSA, Perkin Elmer,
Waltham, MA, USA) was used to visualize the proteins. Briefly, TSA uses the peroxidase activity of
HRP to generate reactive oxygen species from peroxide. These reactive oxygen species then oxidize
and covalently bind the Cy3-conjugated tyramide molecule to the nearby proteins including the
antigen/antibody complex, thus amplifying the signal. Macrophage labeling was performed using an
antibody to F4/80-antigen (Bio-Rad, Hercules, CA, USA) followed by a goat anti-rat IgG secondary
antibody conjugated to AlexaFluor488 (Invitrogen, Carlsbad, CA, USA). All sections were co-labeled for
rhodopsin using B6-30N or K62-82 (provided by W. Clay Smith, University of Florida, Gainesville, FL,
USA) and goat anti-mouse IgG1 or IgG3 conjugated to AlexaFluor488 (Invitrogen). Labeling for Müller
cells was performed using an antibody against glial fibrillary acidic protein (GFAP, EMD Millipore,
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Burlington, MA, USA) followed by goat anti-mouse secondary IgG1 conjugated to AlexaFluor647
(Invitrogen). All images were captured as Z-stacks and expressed as maximum intensity projections.
2.4. Analysis of Retinal Citrullination in the Ter349Glu/Ter349Glu Rhodopsin Mouse Retina by Fluorescent
Immunohistochemistry
Whole eyes from 10- to 12-week-old mice were fixed in 4% PFA in PBS, pH 7.4, overnight at
4 ◦C, cryoprotected in 30% sucrose in PBS, pH 7.4, frozen in optimal cutting temperature medium,
and cryosectioned into 10 μm-thick sections. After washing away the medium, the sections were
treated using heat-mediated antigen retrieval by boiling in 10 mM sodium citrate, pH 6.0, with 0.05%
Tween-20 for 1 h. After cooling, the slides were washed in PBS and subsequently blocked in 10% goat
serum/5% BSA/0.5% Triton X-100 in PBS for 1 h at RT. Following blocking, the sections were incubated
with primary antibodies against peptidyl arginine deiminase 4 (PAD4, ProteinTech, Rosemont, IL,
USA) and citrullinated peptides (Clone F95, EMD Millipore, Burlington, MA, USA) O/N at 4 ◦C.
After washing in PBS, the slides were probed using goat anti-rabbit IgG conjugated to AlexaFluor488
(Invitrogen) and goat anti-mouse IgM conjugated to AlexaFluor555 (Invitrogen), and the nuclei were
labeled with DAPI (Invitrogen). After washing in PBS, the slides were mounted using Prolong Diamond
Anti-Fade Mountant (Invitrogen) and imaged using a Zeiss 710 Laser Scanning Confocal Microscope
(Zeiss, Oberkochen, Germany). All images were captured as Z-stacks and expressed as maximum
intensity projections.
3. Results
3.1. Loss of Functional ERG in Early-Onset RD
Patients expressing the Ter349Glu mutant rhodopsin experience a loss of photoreceptor function
earlier in life, resulting in early and rapid central vision loss, when compared to other mutants of
rhodopsin [9]. We tested if the Ter349Glu knock-in mouse displayed a similar early-onset (4 weeks of
age) loss of visual capacity by ERG (Figure 1). Compared to +/+mice (n = 5), the Ter349Glu/Ter349Glu
mice (n = 5) showed an increase in the threshold of the dark-adapted b-wave by three orders of
magnitude, with a maximum amplitude about 25% that of +/+ mice, while the maximum a-wave
amplitude was only about 6% that of +/+ mice. This indicated a drastic loss of rod photoreceptor
function. Interestingly, when compared to +/+ and Ter349Glu/Ter349Glu mice, Ter349Glu/+mice (n = 4)
appeared to have a gain of function with an increase in sensitivity and a decrease in response latency
without significant changes in amplitudes.
3.2. Effects of RD-Associated Photoreceptor Loss on Retinal Vasculature and Laminar Architecture
In cases of RP, retinal degeneration exerts effects on both retinal vasculature and laminar architecture
in the forms of attenuated vessels and outer nuclear layer (ONL) thinning, respectively [10]. To examine
the Ter349Glu/Ter349Glu retina for such abnormalities, FA and OCT were performed on 4-week-old
+/+ and Ter349Glu/Ter349Glu animals in triplicate (Figure 2). Using FA, when compared to +/+
mice, Ter349Glu/Ter349Glu mice exhibited heterogeneous types and degrees of vascular abnormalities.
The most common anomalies included attenuated vessels, tortuous vessels indicating hyperoxia,
and reduced retinal venous and arterial vessel numbers. Using OCT, Ter349Glu/Ter349Glu mice
exhibited the expected thinning of the ONL; however, at the interfaces between choroid, RPE, and rod
outer segments (ROS)/ rod inner segments (RIS) layers the mice also exhibited a possible edema, likely
due to loss of contacts between the RPE and the photoreceptors, associated with the lack of ROS.
This edema was observed extending to varying degrees both inferiorly and superiorly to the optic
nerve. Representative images were taken from the retina inferior to the optic nerve.
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Figure 1. Electroretinogram (ERG) responses decline in mice expressing Ter349Glu rhodopsin.
Using ERG to record extracellular potential differences across the retina, the electrophysiological
function of +/+, Ter349Glu/+, and Ter349Glu/Ter349Glu mice was monitored by measuring a-,
b-waves, and response latencies (Time-to-Peak, TTP) under increasing stimulus intensities (A,C,E).
Graphs compare maximum average wave amplitudes and TTP (B,D,F) under dark-adapted conditions.
Data analyzed using two-tailed T-test and expressed as the mean ± S.E.M. *, p < 0.05; **, p < 0.01;
***, p < 0.001; ns, not significant.
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Figure 2. Ter349Glu rhodopsin knock-in mouse retina exhibits both vascular and laminar abnormalities.
(A–D) Utilizing fluorescein angiography (FA), the state of the retinal vasculature of 4-week-old +/+
(A,B) and Ter349Glu/Ter349Glu (C,D) mice was examined. Abnormal phenotypes varied in severity
among mice, with overall attenuated retinal vessels and tortuous retinal vessels (arrowheads) being
commonplace amongst all mice examined. (E,F) Optical coherence tomography (OCT) was used
to examine the retinas of 4-week-old +/+ (E) and Ter349Glu/Ter349Glu mice (F) for architectural
abnormalities. Ter349Glu/Ter349Glu mice exhibited thinning of the outer nuclear layer (ONL) and
patches of varying degrees of separation among the choroid, retinal pigment epithelium (RPE),
and photoreceptors (block arrow), indicative of edema. Retinal thickness (red calipers) = 240 μm (E)
and 180 μm (F); ONL (green calipers) = 60 μm (E) and 50 μm (F).
3.3. Activated Monocytes Are Present in RD Retinas from Rhodopsin Mutant Knock-in Mice
The retina contains resident macrophages similarly to the cortex, known as microglia, and these
cells remain in the inner retinal layers under normal physiological conditions. Here, they remain
in an inactivated state unless triggered by cytokine signaling or apoptotic signals [11]. Other types
of leukocytes are typically not resident in the retina, and evidence of these cells in ocular tissues is
indicative of retinal inflammation. Damage to retinal and choroidal vessels can allow leakage of
not only blood-borne macrophages into the retina, but also cytokines, antibodies, and a plethora of
other inflammatory factors [12]. Unfortunately, no method exists to differentiate between microglia
and blood-borne macrophages; however, due to the observation of abnormal vasculature and retinal
edemas, we chose to monitor the +/+ and Ter349Glu/Ter349Glu retinas for activated macrophages
as a whole, using an antibody against F4/80 antigen, a cell surface glycoprotein expressed upon
macrophage maturation (Figure 3). F4/80-positive macrophages were found in multiple animals from
the Ter349Glu/Ter349Glu cohort at 12 weeks of age, with the most labeling observed in sections from
Ter349Glu/Ter349Glu animals where nearly the whole retina was degenerated. Macrophages remained
in the outer retina after almost total rod cell death (12 weeks). These macrophages were not observed
in +/+ sections from any animal (n = 3 at all ages).
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Figure 3. Retinas from retinal dystrophy (RD) mice exhibit monocyte activation. Using fluorescent
immunohistochemistry, the presence of activated macrophages was examined in +/+ (A–C)
and Ter349Glu/Ter349Glu (D–F) mice at 12 weeks of age. Retinal sections were labeled with
anti-F4/80 antigen (green) and K62-82 (rhodopsin, red) antibodies. Nuclei were labeled with DAPI
(blue). Autofluorescence in the choroid was observed in the red channel. CC, choriocapillaris; ROS,
rod outer segments; RIS, rod inner segments; OPL, outer plexiform layer. Scale bars = 20 μm.
3.4. Activation of the Pro-Inflammatory JAK/STAT Pathway and Its Inhibitor SOCS3 in RD
STAT3 is a downstream signaling partner of JAK. In inflammatory conditions, STAT3 is activated
when cytokines such as IL-6, ciliary neurotrophic factor, leukemia inhibitory factor, and others
bind to and activate the glycoprotein 130 (gp130) receptor [13]. Gp130 activates JAK, which in
turn phosphorylates STAT proteins (pSTAT). Upon phosphorylation, pSTATs form both homo- and
heterodimers, allowing nuclear entry and activation of gene transcription. The protein SOCS3 works
as a negative regulator of the JAK/STAT pathway by binding the gp130 receptor and JAK together
and blocking active sites involved in phosphorylation of STAT3, thus prohibiting further signal
transduction [14]. In instances where inflammatory signaling needs to be slowed or stopped,
SOCS3 works to perform this task. To examine the Ter349Glu knock-in mouse retina for inflammatory
cytokine signaling, retinas from both +/+, Ter349Glu/+, and Ter349Glu/Ter349Glu mice were labeled
with an antibody against pSTAT3 (Figure 4). We found that +/+ retinas showed no STAT3 activation
across all ages, while the Ter349Glu/+ and Ter349Glu/Ter349Glu mice exhibited increasing activation
with age, beginning at 8 weeks and 4 weeks, respectively (n = 3 for all ages).
Early pSTAT3 activation began in the inner nuclear layer (INL) and, by 12 weeks, extended to
the RPE. The location of the activated nuclei in the INL suggested the nuclei belonged to Müller
cells. Indeed, co-labeling for GFAP, a marker of gliosis in Müller cells, showed Müller cells to be
pSTAT3-positive (Figure 5).
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Figure 4. JAK/STAT pathway is activated in Ter349Glu rhodopsin knock-in mouse retina. Activation of
the JAK/STAT pathway was examined using fluorescent immunohistochemistry on retinas from WT (+/+,
A–C), Ter349Glu heterozygous (Ter349Glu/+, D–F), and Ter349Glu homozygous (Ter349Glu/Ter349Glu,
G–H) mice. Retinal sections were treated for antigen retrieval and labeled for phosphorylated STAT3
(pSTAT3, red) and rhodopsin (green). Nuclei were labeled with DAPI (blue). Arrowheads (>), areas of
JAK/STAT activation; OS, outer segments; IS, inner segments; INL, inner nuclear layer. Scale bar =
20 μm.
Since Müller cells maintain retinal homeostasis, this finding suggests they may act to respond to
inflammatory cytokines, as STAT3 activation indicates the presence of pro-inflammatory cytokines in
the neural retina, likely being released from activated macrophages within the retina. It should be
noted that in these images, labeling for rhodopsin can be seen in the ONL even though rhodopsin is not
normally localized in large amounts in this region. This is likely an artifact due to a heightened number
of anti-rhodopsin epitopes following the antigen retrieval process. Labeling for SOCS3 revealed
minimal expression in +/+ retinas while, similarly to pSTAT3, Ter349Glu/+ and Ter349Glu/Ter349Glu
mice began expressing SOCS3 in the neural retina and RPE at 4 weeks of age; with time, the expression
increased in Ter349Glu/Ter349Glu mice and decreased in Ter349Glu/+mice (Figure 6, n = 3 at all ages).
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Figure 5. Identification of Müller cell nuclei as INL centers for STAT3 activation. To assess which retinal
cells exhibited STAT3 phosphorylation, labeling was performed on +/+ (A,B) and Ter349Glu/Ter349Glu
(C,D) animals for glial fibrillary acidic protein (purple), a marker of astrocytes and gliotic Müller cells,
rhodopsin (green), and pSTAT3 (red). Nuclei were labeled with DAPI (blue). Arrows show red nuclei
surrounded by purple. Scale bar = 20 μm.
Figure 6. The JAK/STAT antagonist SOCS3 is expressed in Ter349Glu rhodopsin knock-in mouse retina.
Using fluorescent immunohistochemistry, the expression of SOCS3, an antagonist to the JAK/STAT
pathway, was examined in retinas from wild-type (WT,+/+, A–C), Ter349Glu heterozygous (Ter349Glu/+,
D–F), and Ter349Glu homozygous (Ter349Glu/Ter349Glu, G–I) mice. Retinal sections were treated for
antigen retrieval and labeled for SOCS3 (red) and rhodopsin (green). Nuclei were labeled with DAPI
(blue). GCL, ganglion cell layer; arrowheads (<), SOCS3 labeling. Scale bar = 20 μm.
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3.5. Cell-Specific Expression of PAD4 and Heightened Citrullination in Early-Onset RD
Recent studies have shown an increase in the expression of the deiminating enzyme PAD4 and
increased citrullination in the event of ocular insult of the anterior segment [15]. Due to the inherent
ability of citrullinated proteins to cause autoimmunity [16–22] and our previous finding that PAD4 is
the primary retinal PAD in mouse [23], we tested the Ter349Glu retina for changes in PAD4 expression
and citrullination compared with WT retina at 10 to 12 weeks of age (Figure 7). WT retina exhibited
expression of PAD4 and exhibited INL nuclear citrullination, as shown previously [23]; however,
the Ter349Glu retina exhibited higher levels of citrullination, much of it spanning the entire retina.
This was observed in parallel with PAD4 expression increases, especially in the photoreceptors.
 
Figure 7. Expression of PAD4 and citrullination of retinal proteins in normal and degenerated states.
WT (+/+, A–C) and Ter349Glu/Ter349Glu (D–F) mice at 10 to 12 weeks of age were labeled for PAD4
(green) and citrullinated peptides (red). Nuclei were labeled with DAPI (blue). Arrowheads (<), areas
of increased citrullination in ONL; OS/IS, photoreceptor outer and inner segments; IPL, inner plexiform
layer; Scale bar = 20 μm.
4. Discussion
Increasing amounts of evidence linking the immune system to ocular disease has emerged in
the last decade. Studies focusing on glaucoma, AMD, RP, and other RDs have continued to show
increased presence of many immune components including monocytes (blood-borne and resident),
pro- and anti-inflammatory cytokines, and autoantibodies in many models of these diseases [24–26].
While all of these diseases present an initial insult of genetic and/or environmental origins, these
findings overwhelmingly implicate the immune system in the pathogenesis of RDs. For example,
the prevalence of single-nucleotide polymorphisms in the genes coding for complement factor H,
complement factor I, as well as many other components of the innate immune system bolster the
chances of developing AMD in otherwise normal patients [27,28]. In addition, models of glaucoma
have shown the presence of macrophages and T-lymphocytes in the eye along with autoantibodies
to proteins of the retina [3,4,29,30]. Models of RP have also shown similar features, including
monocytic phagocytosis of both diseased and healthy retinal cells as well as numerous cytokines such
as interleukin-1, interleuken-6, vascular endothelial growth factor, and others [4,31,32]. While the
molecular mechanisms of the primary genetic assault have been teased out by copious amounts of work
using cell culture and animal models for many RDs (i.e., loss of outer segment formation, disrupted
visual cycle, etc.) [1,2,33], the full mechanisms of pathogenesis and progression of RDs still need
thorough investigation before we fully understand them. In our findings, the Ter349Glu/Ter349Glu mice
exhibited an almost complete loss of photoreceptor function by ERG; however, the Ter349Glu/+mice
had heightened a and b waves while also showing a decrease in b wave latency compared to the +/+
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animals. This phenomenon might be explained by the expression levels of mutant rhodopsin compared
to WT rhodopsin, as Ter349Glu rhodopsin expression levels are less than half of the WT levels [2].
This lower level of expression while still having 50% WT rhodopsin could result in a somewhat thinner
outer segment with less rhodopsin protein in the discs, thus allowing for faster rates of diffusion of the
phototransduction cascade components, decreasing the response latency, while normal WT rhodopsin
activates the cascade, enhancing the signal. We also showed that animals with more advanced RD had
significant numbers of macrophages, a feature found in many RDs, as well as activation of a known
pro-inflammatory pathway (JAK/STAT). Interestingly, the Ter349Glu/+mice showed SOCS3 expression
in the inner retinal layers early in life (4 weeks of age), with a dramatic decrease in expression with
age, while the +/+ mice had minimal SOCS3 expression, which peaked at 8 weeks of age, and the
Ter349Glu/Ter349Glu mice exhibited a somewhat constant SOCS3 expression in the outer retina and
RPE. While the relatively stable SOCS3 expression in the Ter349Glu/Ter349Glu mice is explainable when
compared to the levels of STAT3 phosphorylation which was present throughout the first 3 months
of the animals’ life, the stark difference in SOCS 3 expression the Ter349Glu/+ mice remains to be
elucidated. More experiments examining the activation and deactivation of the proinflammatory
JAK/STAT pathway are needed to better understand these expression differences. Further work will aim
at pinning down the cytokines responsible for pathway activation; experiments inhibiting the pathway
activation using antagonists to the JAK/STAT pathway and/or those inhibiting specific cytokine(s) will
better underpin this pathway’s role in RD. Due to the nature of STAT3 role in numerous developmental
pathways [13], a more targeted approach to delivering inhibitory compounds directly to the eye would
be necessary. Future experiments will also work to decrease the number of activated macrophages
in RD models to attempt to rescue some photoreceptor degeneration due to excessive phagocytosis
and/or macrophage-derived cytokines. Work is already underway testing the inhibition of PAD4 in
RD models to rescue retinal cells, retinal function, or both [34]. This work will be achieved using
PAD4-deficient mice as well as inhibitors of the enzyme. Due to the excessive citrullination observed in
Ter349Glu/Ter349Glu mice, it is not far-fetched to think that lowering or preventing this post-translation
modification from occurring could lead to a slower rate of disease progression, allowing for not only
longer lasting vision in patients affected but also an extended opportunity to correct the genetic insult,
thus preventing further retinal degeneration. In all, our work further contributes to the increasing
volume of studies indicating a role of the immune system in RDs as well as provides possible targets
for the treatment of these debilitating blinding diseases.
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Abstract: Degenerative diseases affecting retinal photoreceptor cells have numerous etiologies and
clinical presentations. We clinically and molecularly studied the retina of a 70-year-old patient with
retinal degeneration attributed to autoimmune retinopathy. The patient was followed for 19 years for
progressive peripheral visual field loss and pigmentary changes. Single-cell RNA sequencing was
performed on foveal and peripheral retina from this patient and four control patients, and cell-specific
gene expression differences were identified between healthy and degenerating retina. Distinct
populations of glial cells, including astrocytes and Müller cells, were identified in the tissue from the
retinal degeneration patient. The glial cell populations demonstrated an expression profile consistent
with reactive gliosis. This report provides evidence that glial cells have a distinct transcriptome in
the setting of human retinal degeneration and represents a complementary clinical and molecular
investigation of a case of progressive retinal disease.
Keywords: autoimmune retinopathy; retinal degeneration; Müller cell; single-cell
1. Introduction
Photoreceptor cells are highly specialized, terminally differentiated neurons that detect photons
of light and transmit this information to bipolar cells in the retina. Unfortunately, their exacting
structural and metabolic requirements make them very susceptible to a large number of acquired
and genetic sources of injury, leading to irreversible vision loss [1]. Degenerative diseases affecting
photoreceptor cells have multiple etiologies. For example, genetic variants in over 100 genes have been
shown to cause heritable photoreceptor degeneration [2]. However, photoreceptor degeneration can
also be immune mediated, as in the case of autoimmune retinopathy (AIR), where circulating retinal
autoantibodies lead to inflammation and downstream photoreceptor destruction [3]. Photoreceptor
loss can also occur secondary to damage or dysfunction of adjacent cells and extracellular structures;
for example, diseases affecting the retinal pigment epithelium (RPE), Bruch’s membrane, or choroid
can lead to increased oxidative stress and decreased metabolic support to the outer retina [4].
One approach for studying retinal degeneration is to characterize transcriptomic changes within
diseased retina using microarrays or, more recently, next-generation sequencing of cDNA libraries
(RNA sequencing, or RNA-Seq). Conventional gene expression studies with RNA-Seq have analyzed
pools of retinal RNA from numerous cell types [5,6]. However, the high degree of cellular complexity
and diversity in the human retina can prevent detection of even large gene expression changes that are
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restricted to specific classes of cells that are relatively unrepresented in the pool [7]. This concern has
been largely obviated by the development of single-cell RNA sequencing, which has recently been
employed to characterize the transcriptome of individual retinal cell populations. The neural retina
is well suited for dissociation into single-cells, and protocols for recovery of viable, singlet cells are
well established [8,9]. Such protocols facilitated the exploration of the murine retina transcriptome in
the first report of Drop-Seq single-cell RNA sequencing [10]. Since this initial investigation, several
additional studies have described the transcriptome of murine retina [10–12] and more recently,
human retina [13–15] at the single-cell level.
In this report, we describe the clinical course of a 70-year-old patient with progressive photoreceptor
degeneration attributed to AIR. We perform single-cell RNA sequencing on paired foveal and peripheral
retinal samples from this patient and four unaffected control patients to investigate how different
populations of retinal cells respond to photoreceptor degeneration. A total of 23,429 cells were recovered
in this experiment, including 7189 cells from the AIR patient. This study provides insight into the
responses of the retina to a blinding inflammatory condition at the cellular and transcriptional levels.
2. Materials and Methods
Human Donor Eyes: Eyes from the human donors utilized for this study were acquired from
the Iowa Lions Eye Bank in accordance with the Declaration of Helsinki and following full consent
of the donors’ next of kin. The Institutional Review Board at the University of Iowa has judged that
experiments performed on the donated eyes of deceased individuals does not fall under human subjects
rules. All of the experiments in present paper were on the eyes of deceased individuals donated to
science by the donors’ next of kin. The work we performed in this paper was not human subjects
research. Donor information is presented in Table 1. All tissue was received in the laboratory within
7 h post-mortem and processed immediately. A 2 mm foveal centered punch and an 8 mm peripheral
retinal punch from the inferotemporal region centered on the equator were acquired with a disposable
trephine from each donor. For the AIR donor, the OS was used for single-cell RNA sequencing and the
OD was preserved in freshly generated 4% paraformaldehyde in phosphatidylcholine buffer solution.
Frozen sections from the macula and peripheral retina were prepared as described previously [16].
Sections were stained with hematoxylin-eosin stain.
Table 1. Sample information from the donor eyes utilized in this study. Note that donor eyes 1–3 serve




Eye Cause of Death Ophthalmologic History
Donor 1 89 Male 5:21 OD Cancer Early stage glaucoma documented;histologically normal
Donor 2 54 Male 5:29 OD Cardiac arrest No records received; histologicallynormal
Donor 3 82 Female 4:18 OD Cardiopulmonaryarrest
No ophthalmic records; histologically
normal
Donor 4 76 Male 5:14 OS Respiratoryfailure/cancer
posterior vitreous detachment OU,
nuclear sclerosis OU; histologically
normal
Donor 5 70 Male 6:36 OS Chronic obstructivepulmonary disease AIR, see results 3.1
Dissociation for single-cell analysis: The overlying retinal tissue was peeled off of the retinal
pigment epithelium and choroid. Retinal tissue was subsequently dissociated in 20 units/mL of papain
with 0.005% DNase I (Worthington Biochemical Corporation, Lakewood NJ) for 1.25 h on a shaker at
37 ◦C. Dissociated cell suspensions were frozen in DMSO-based Recovery Cell Culture Freezing Media
(Life Technologies Corporation, Grand Island NY) in a Cryo-Safe cooler (CryoSafe, Summerville SC) to
cool at 1 ◦C/min at −80 ◦C for 3–8 h before storage in liquid nitrogen.
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Sample Preparation: Cryopreserved retinal samples were rapidly thawed and resuspended in
phosphatidylcholine buffer solution with 0.04% non-acetylated bovine serum albumin (New England
Biolabs, Ipswich, MA, USA) at a concentration of 1000 cells/μL. Viability analysis was performed
with the Annexin V/Dead Cell Apoptosis Kit (Life Technologies Corporation, Eugene, OR, USA),
with viability >90% using the Countess II FL Automated Cell Counter (ThermoFisher Scientific,
Waltham, MA, USA). Next, single cells were captured and barcoded using the Chromium system v3.0
chemistry kit (10X Genomics, Pleasanton, CA, USA). Barcoded libraries were pooled before sequencing
on the HiSeq 4000 platform (Illumina, San Diego, CA, USA), generating 150 base pair paired-end reads.
Immunohistochemistry: Immunohistochemical experiments were performed on frozen tissue
sections from donor eyes fixed in 4% paraformaldehyde. Sections were blocked with 1 mg/mL of
bovine serum albumin before one-hour incubation with anti-ANXA1 (1:1.7, Developmental Studies
Hybridoma Bank, Iowa City, IA) or Blue Cone Opsin (1:200, Millipore, AB5407), Red/Green Cone Opsin
(1:200, Millipore, AB5405), and RetP1 (1:1000, Thermo Scientific). Sections were subsequently washed
and incubated with Alexa-546-conjugated anti-mouse IgG (1:200, Invitrogen) or Alexa-488-conjugated
anti-mouse IgG (1:200, Invitrogen) and Alexa-546-conjugated anti-rabbit IgG (1:200, Invitrogen).
Each secondary antibody was supplemented with 100 μg/mL diamidino-phenyl-indole (DAPI, Sigma).
Sections were incubated for 30 min before washing and cover slipping. Negative controls were included
by omitting each primary antibody. Sections were photographed with an epifluorescent microscope
(Olympus BX41) equipped with a digital camera (SPOT-RT; Diagnostic Instruments).
Computational Analysis: In addition to the two new donors sequenced for this study, we recently
reported single-cell RNA sequencing on paired foveal (2 mm) and peripheral neural retina isolated
from three human donors [13] with identical sample processing. FASTQ files from the previous
experiment (n = 3 paired samples, donors 1-3; GSE130636) and the current experiment (n = 2 paired
samples, donors 4–5) were utilized for downstream analysis. Briefly, FASTQ files were generated
from basecalls with the bcl2fastq software (Illumina, San Diego, CA, USA) by the University of Iowa
Institute of Human Genetics. Next, FASTQ files were mapped to the hg19 genome with CellRanger
(v3.0.1) [17]. Cells with unique gene counts fewer than 200 were filtered, and cells with greater than
7000 unique genes per cell were removed to eliminate potential doublets. Libraries were aggregated to
the same effective sequencing depth, and log-normalization of aggregated reads was performed with
Seurat (v2.3.4) using a scale factor of 10,000 [18]. All raw and processed data have been deposited in
NCBI’s Gene Expression Omnibus (GSE142449).
3. Results
3.1. Patient Description
The patient initially presented to the neuro-ophthalmology service at the age of 51 for evaluation
of decreased peripheral visual fields and photopsias in both eyes. He had no family history of inherited
retinal degeneration. At presentation, his visual acuity was 20/20 in each eye, but he was found to have
peripheral visual field loss. Ophthalmoscopic examination early in his disease course showed granular
juxtapapillary pigmentary changes and mild vascular attenuation in both eyes. Electroretinogaphy
(ERG) at presentation was consistent with widespread retinal dysfunction affecting both rods and
cones. He experienced relatively rapid progression of his visual field loss and was seen by the inherited
retinal degeneration service with concern for retinitis pigmentosa versus autoimmune retinopathy
(AIR). Cancer-associated retinopathy was also considered, but his workup for malignancy was negative
and his ERG was felt to be inconsistent with a paraneoplastic process at that time.
He ultimately developed peripheral bone-spicule-like pigmentary changes in both eyes
(Figure 1A,B, 7 years after initial presentation) and progressive visual field constriction (Figure 1C,D,
8 years after initial presentation). Molecular evaluation for an inherited retinal degeneration, including
whole exome sequencing, was performed but failed to identify a genetic etiology for his condition (for
methods see [2]). He developed colon cancer several years after presentation, but this was thought to
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be unrelated to his ocular disease. He was given a presumed diagnosis of autoimmune retinopathy
and ultimately required treatment for cystoid macular edema with intravitreal steroids.
 
Figure 1. Clinical findings in a patient with retinal degeneration. (A,B): Montage color fundus
photographs of the right (A) and left (B) eyes. There was granular, retinal pigment epithelial atrophy in
the mid-periphery of both eyes, in addition to peripheral bone-spicule-like pigmentary changes and
pigment clumps in both eyes. Arteriolar attenuation was notable in both eyes. (C,D): Goldman visual
fields of the right (C) and left (D) eyes. There was severe constriction of the peripheral visual field in
both eyes.
At the time of his last follow up with the retina service at the age of 69, his visual acuity was
20/40 + 1 in the right eye and 20/100 in the left eye with stable peripheral pigmentary changes in
both eyes, and no cystoid macular edema. At age 70, the patient expired and donated his eyes for
ophthalmic research. Evaluation of the patient’s serum with Western blotting revealed the presence of
antibodies that reacted with a 23 kilodalton protein in human retina.
3.2. Histological Findings
Sections from an eye with normal ocular history (Figure 2A), from the macula of the AIR donor
(in the OD, the eye with better visual acuity) (Figure 2B), and from the periphery of the AIR donor
(Figure 2C,D) were acquired. The macula of the AIR donor showed a loss of rod photoreceptors with
only a single layer of attenuated cone cells remaining. In spite of the photoreceptor cell loss, the RPE
was confluent and the inner retina appeared intact, with discrete inner nuclear layers and ganglion
cell layers. In the periphery, the AIR donor showed complete loss of inner and outer segments and of
the outer nuclear layer (Figure 2C). Considerable pigment migration into the inner retina was also
observed in the periphery of the AIR donor (Figure 2D).
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Figure 2. Histological and immunohistochemical investigation of the autoimmune retinopathy (AIR)
and control donors. (A–D). Hematoxylin and eosin staining of the AIR and control donors. Sections
from the periphery of a control donor (donor 2) (A), the macula (OD) of the AIR donor (B), and the
periphery of the AIR donor (C,D). The AIR macula demonstrates intact ganglion cell and inner nuclear
layers with attenuated cone photoreceptor outer segments. In contrast, in the periphery of the AIR
donor complete loss of the outer nuclear layer (C) and retinal pigment epithelium (RPE) pigment
migration into the inner retina (D) is observed (*). (E,F): Cone opsins (blue cone opsin and red/green
cone opsins) are labeled in red while RetP1 is labeled in green. (E): A macula from a donor with normal
ocular history demonstrates abundant labeling of cone opsins and rhodopsin. Of note, the RPE below
the photoreceptors is out of frame. (F) The macula from the AIR donor demonstrates a complete lack of
rod photoreceptors with rare, extremely attenuated cone photoreceptors (arrows). Autofluorescent
lipofuscin from the RPE appears below the photoreceptor cells. Scalebar (100 microns) for all subpanels
is provided in (E).
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Cone and rod photoreceptor cells were also visualized with fluorescent immunohistochemistry
(IHC). Within the macula of a donor with normal ocular history, abundant cone opsin and rhodopsin
labeling was observed (Figure 2E). In contrast, the AIR donor demonstrates complete loss of the rod
specific opsin rhodopsin as well as extreme attenuation of cone photoreceptors (Figure 2F).
3.3. Single-Cell Gene Profiling of Diseased Cell Populations
Paired foveal and peripheral retinal punches were acquired from each of the five donors. While the
four control donors had grossly normal retinas upon examination in the laboratory (Figure 3A),
the donor with AIR had abundant peripheral pigmentation with a mostly unaffected macula (Figure 3B).
After gentle dissociation, single-cell RNA sequencing was performed on each foveal and peripheral
sample, and a total of 23,429 cells were recovered after filtering (Figure 3C). A total of 23 clusters were
identified, and expression profiles were used to assign each cluster to its corresponding retinal cell
type (Figure 3D). All major populations of retinal neurons, as well as supporting retinal endothelial
cells, pericytes, glial cells, and microglia, were identified.
Next, the distribution of recovered cell types was compared between the AIR donor and the
four control donors (Table S1). As the cellular composition of the retina varies between the fovea
and periphery, comparisons were stratified by region. Within the fovea, cone photoreceptor cells are
more abundant than rod photoreceptor cells, and cone photoreceptor cells synapse one-to-one with
bipolar cells and upstream retinal ganglion cells (Figure 4A). The fovea centralis comprises the central
0.65-0.70 mm of the retina, consisting exclusively of cone photoreceptor cells and excluding vascular
elements [19]. Our use of 2 mm foveal centered punches completely captures the fovea centralis but
also includes some central rod photoreceptors and retinal endothelial cells. In the four control donors,
all major populations of inner retinal neurons were recovered from the fovea (Figure 4B). No RPE
cells were detected, suggesting that the foveal retinal punch was well separated from the underlying
RPE and choroid. Unlike the control donors, no rod photoreceptor cells were detected in the foveal
punch from the donor with AIR. However, a similar proportion of foveal cone photoreceptor cells
were recovered in the AIR donor and the control donors. In addition, the AIR donor demonstrated a
moderate increase in the proportion of recovered foveal bipolar and Müller cells.
In the periphery, rod photoreceptor cells were predominant, and peripheral bipolar cells receive
input from multiple rod photoreceptor cells (Figure 4D). In the four control donors, peripheral rod
photoreceptor cells were much more abundant than cone photoreceptor cells, and relatively few
microglia or astrocytes were detected (Figure 4E). In contrast, only a single rod photoreceptor cell was
recovered from the periphery of the AIR donor while microglia and astrocyte cells were recovered in
much higher frequency. In addition, a small proportion of RPE cells were recovered from the periphery
of the AIR donor, consistent with the histological observation of peripheral RPE migration into the
retina (Figure 2D).
Next, the transcriptomic consequences of photoreceptor degeneration in the AIR donor were
investigated. For each cell type, gene expression was compared between cells originating from
the AIR donor and the control donors, and the proportion of significantly differentially expressed
genes (adjusted p-value < 0.05) that exhibited an absolute log fold-change in expression greater
than 0.5 was calculated. As gene expression within a single cell type can vary between the fovea
and the periphery [13], this analysis was again stratified by region. Within the fovea, Müller cells
and horizontal cells demonstrated modest expression differences, with a total of 1.1% and 1.2% of
assayed genes significantly enriched in the AIR Müller cell and horizontal cell populations, respectively
(Figure 4C). A greater proportion of differentially expressed genes between the AIR and control donors
were identified in the periphery (Figure 4F). Müller and astrocyte glial cells both demonstrated a
modest proportion of genes significantly enriched in the periphery of the AIR donor (1.3% and 2.1%,
respectively), as did microglia and horizontal cells (2.2% and 2.6%, respectively). Differential expression
results for each comparison are shown in detail in Table S2.
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Figure 3. Single-cell RNA sequencing of the AIR donor. (A,B): Five human donor eyes were used for
this study. A gross image of a control eye (donor 4) (A) and the AIR eye (donor 5) (B) are included.
From each eye, a 2 mm foveal centered punch (red) and an 8 mm peripheral punch isolated from the
inferotemporal region (blue) were acquired and gently dissociated. Scalebar (A) is 5 mm. (C): Single-cell
RNA sequencing of retinal cells from the AIR donor and four control patients. A total of 23,429 cells
were recovered after filtering. Unsupervised clustering of cells resulted in 23 clusters, which are
visualized with uniform manifold approximation and projection (UMAP) dimensionality reduction,
where each point represents the multidimensional transcriptome of a single-cell and each cluster of
cells is depicted in a different color. (D): Violin plots depict the expression of cell-type specific genes
across the 23 identified clusters. Per = peripheral retina. AIR = autoimmune retinopathy. RPE = retinal
pigment epithelium. RGC = retinal ganglion cell.
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Figure 4. Library composition of recovered cells. (A): In the fovea, cone photoreceptor cells synapse
with one bipolar cell, which synapse with one retinal ganglion cell. (B): The proportion of each cell
type recovered from the fovea of the four control donors and the autoimmune retinopathy donor.
No foveal rods were recovered from the AIR donor. (C): In order to visualize the degree of gene
expression differences within each population of cells between the AIR and control donors, differential
expression analysis was performed. In each cell type, the number of differentially expressed genes
that were enriched in the AIR donor and the control donors were enumerated and divided by the
total number of expressed genes (in at least 10% of cells). For example, 1.09% of foveal Müller cell
genes were significantly enriched in the AIR donor (dark grey), while 0.57% of foveal Müller cell
genes were significantly enriched in the control donors (light grey). (D): In the periphery, multiple rod
photoreceptor cells synapse with a single bipolar cell. (E): The proportion of each cell type recovered
from the periphery of the four control donors and the periphery of the AIR donor. (F): As in (C),
the proportion of differentially expressed genes between the AIR and control donors was performed in
each cell type. More genes were differentially expressed in the periphery compared to the fovea (C).
As no RPE cells originated from control donors, differential expression could not be performed in the
periphery for this cell type.
While most clusters contained cells from each of the five donors, Clusters 4–6 were comprised
predominantly of cells from the periphery of the AIR patient (each cluster possessing >85% of cells
from the AIR donor) (Figure 5A). Therefore, gene expression patterns from these clusters were further
investigated. Cluster 4 was classified as astrocytes (Figure 5C,D). Cells in this cluster demonstrated
high expression of the glial fibrillary acid protein (GFAP), which is widely expressed in astrocytes
responding to neuronal injury [20], and the astrocyte-specific inflammatory cytokine IFITM3 [21].
A total of 624 cells were recovered in Cluster 4 and 551 of them (88%) originated from the periphery of
the AIR donor. Differential expression analysis was performed to investigate if astrocytes from the AIR
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donor demonstrated a reactive gene expression profile (Figure S1). Astrocytes from the AIR donor
were enriched for SOCS3 [22], SLPI [23], and CH25H [24], genes that have all been previously found
to be expressed in astrocytes responding to CNS injury. In addition, reactive glial cells are involved
in inflammatory responses, and have been shown to increase the production of pro-inflammatory
chemokines [25]. The chemokine CXCL2 was highly enriched (logFC = 1.47) in peripheral astrocytes
from the AIR donor.
Cluster 5, with 98% of cells originating from the periphery of the AIR donor, was interpreted as
Müller glial cells. Cells in this cluster highly expressed the Müller cell genes RLBP1 and CRALBP1
(Figure 5E). Six additional clusters of Müller glia were identified, which largely separated Müller cells
of peripheral (Clusters 6–10) and foveal (Clusters 11–2) origin (Figure 5A). As previously shown in
monkey [26] and human [13] retina, foveal and peripheral Müller cells have distinct gene expression
profiles (Figure 5G). Interestingly, foveal Müller cells from the AIR donor clustered with foveal Müller
cells from the other four donors, and differential expression analysis yielded relatively few expression
differences (log fold-change greater than 1.25) (Figure 5H). NFKBAI, which has been previously
associated with glial cell degeneration, [27] was the most upregulated gene in the AIR donor’s foveal
Müller cells.
In contrast, the majority of peripheral Müller cells from the AIR donor formed their own cluster
(Cluster 5). Differential expression revealed numerous expression differences between peripheral
Müller cells from the AIR donor versus peripheral Müller cells from other donors (Figure 5I). Among the
first hallmarks of reactive gliosis is the increased expression of intermediate filament proteins [28].
The intermediate filament gene GFAP (logFC = 2.54) was the most enriched gene in Müller cells from
the AIR donor, which was also observed to be more abundant in the AIR donor at the protein level
(Figure S2). In addition, peripheral Müller cells from the AIR donor were enriched for ANXA1 and
ANXA2, which have been shown to be upregulated in reactive glial populations in the brain [29].
Immunofluorescent IHC also demonstrates increased ANXA1 labeling in cells of the AIR donor
(Figure 5B), which co-localizes with GFAP expression (Figure S3).
Cluster 6, with 99% of cells originating from the periphery of the AIR donor, was interpreted as
retinal pigment epithelium (RPE) cells (Figure 5F). Cells in this cluster demonstrated high expression
of SERPINF1 (the gene encoding PEDF) and RLBP1 (the gene encoding cellular retinaldehyde binding
protein). Although retinal samples were dissected away from the underlying RPE and choroid,
the recovery of RPE cells suggests that either some RPE cells migrated into the inner retina or remained
adhered to the outer retina after dissection, consistent with both the clinical observation of bone spicule
like pigmentation in the patient’s neurosensory retina (Figure 1A–B) and the morphological finding of
pigment migration into the inner retina (Figure 2D).
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Figure 5. Exploration of autoimmune retinopathy dominant clusters. (A): The library composition
of each cluster is displayed, with cells originating from the control foveas represented in shades of
blue while cells originating from the control peripheries are in shades of green. Cells originating
from the AIR donor are colored light red (fovea) or dark red (periphery). Three clusters (Cluster 4–6)
consist predominantly of cells from the periphery of the AIR donor. (B): Immunofluorescent labeling of
ANXA1 in the retina of a control donor (left) and the AIR donor (right). The AIR donor demonstrates
increased ANXA1-labeling of the inner retina. Scale bar = 100 microns. (C): Violin plots of SOCS3,
GFAP, RLBP1, and SERPINF1 expression are used to classify the cell types of clusters 4–6. (D): Cluster 4
specifically expressed SOCS3, which is enriched in reactive astrocytes. (E): Cluster 5 and Clusters 7-12
express the Müller cell specific gene RLBP1. (F): Cluster 6 expresses the RPE-specific gene SERPINF1.
(G): Healthy foveal and peripheral Müller cells have distinct gene expression profiles. The variable
delta percent along the x-axis represents the proportion of foveal Müller cells that express the gene
of interest minus the proportion of peripheral Müller cells that express that gene. (H): Foveal Müller
cells originating from the control donors have similar gene expression profiles to foveal Müller cells
originating from the AIR donor. (I): In contrast, peripheral Müller cells from control versus the AIR
donor demonstrated more transcriptomic differences. Genes with a log fold-change greater than 1.0
and a delta percent greater than 0.35 are labeled in (G–I).
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4. Discussion
Autoimmune retinopathy (AIR) is a blinding, immune-mediated inflammatory condition in which
anti-retinal antibodies result in retinal cell destruction. In most cases, photoreceptor cells are the
primarily targeted cell type, although antibodies against bipolar cells have also been reported [30].
The clinical presentation of the patient in this report follows the classical trajectory of sudden, bilateral
loss of peripheral vision, consistent with rod photoreceptor cell dysfunction [31]. The etiology of AIR
is broadly subdivided into paraneoplastic and non-paraneoplastic disease. Identifying anti-retinal
antibodies can support a diagnosis of AIR, however unaffected individuals may also have circulating
anti-retinal antibodies, limiting the specificity of this diagnostic assay [32,33].
Consistent with the clinical history of peripheral visual deterioration, histological examination of
the AIR patient revealed a profound loss of both cone and rod photoreceptor cells and destruction of
the inner and outer photoreceptor segments in the periphery (Figure 2C). However, in the macula,
rare attenuated cone photoreceptor cells were still present (Figure 2F). Single-cell RNA sequencing
supported these clinical and histological findings. Only a single rod photoreceptor cell was recovered
from the periphery of the AIR donor while numerous foveal cones were recovered. In addition,
single-cell RNA sequencing identified the presence of RPE cells in the periphery of the AIR donor,
as was observed on histological examination (Figure 2D). Gene expression comparisons between
the AIR donor and the four control donors were remarkably similar for most cell types. However,
peripheral astrocytes and Müller glial cells were more abundant and demonstrated unique expression
signatures in the AIR patient. Collectively, these expression data corroborate the clinical and histologic
findings and provide evidence that single-cell RNA sequencing can be a complementary tool for
investigating the molecular features of a human retinal disease.
The retina contains two major classes of glial cells: Müller cells and astrocytes. Müller cells are
elongated cells that extend from the external limiting membrane (apical end) to the internal limiting
membrane (basal feet). Müller cells provide metabolic and structural support to retinal neurons,
ensheathing neural somas and comprising an important part of the blood retina barrier. Astrocytes
also metabolically support the retina, however astrocytes do not originate from the embryonic retinal
neuroepithelium but rather enter the retina by migrating along the developing optic nerve [34].
As opposed to Müller cells, astrocytes are star-shaped cells with radiating processes located in the nerve
fiber and ganglion cell layers. Both astrocytes and Müller glial cells are capable of responding to retinal
injury and exerting neuroprotective effects on the retina in a process known as reactive gliosis [35].
In this wound response process, glial cells proliferate and undergo changes in gene expression for
improved neuronal protection and repair [36,37].
In the donor with AIR, the transcriptional response of the glial cells can likely be attributed to their
interactions with degenerating retina. Within the fovea, where the retina clinically and histologically
was most intact, Müller cells from the AIR donor were transcriptionally similar to foveal Müller cells
from the control patients. Yet in the peripheral retina, where the AIR donor experienced progressive
visual field loss and a complete loss of the outer nuclear layer, peripheral Müller cells segregated into a
distinct cluster and demonstrated a reactive gliotic phenotype (Figure 5I). Likewise, many astrocytes
were recovered from the periphery of the AIR donor that expressed genes implicated in reactive gliosis
(Figure S1). Reactive astrogliosis is marked by astrocyte proliferation and migration, which may have
led to an increased number of peripherally localized astrocytes available for recovery in the AIR donor,
consistent with recent single-cell RNA sequencing studies characterizing microglial proliferation in
response to retinal damage in mice [38]. Collectively, the gliotic injury response induced by Müller
cells and astrocytes has many neuroprotective benefits, yet chronic gliotic activation can further injure
retinal neurons and disrupt the blood–retinal barrier, leading to worsening vision [39,40]. In the setting
of chronic retinal injury, interventions that modulate gliotic activation may optimize preservation of
remaining retinal function [41].
While glial cells from the AIR donor demonstrated reactive transcriptional changes, most inner
retinal cell populations from this donor had remarkably similar gene expression profiles to the control
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donors (Figure 4C,F). Likewise, histological examination revealed preserved inner retinal morphology
with discrete inner nuclear and ganglion cell layers (Figure 2B,C). Collectively, these findings suggest
that even in the setting of photoreceptor cell degeneration, the inner retinal wiring remains largely
undamaged. The presence of morphologically and transcriptomically normal inner retinal cells is
promising for prospective photoreceptor degeneration treatments, including autologous retinal cellular
replacement strategies [42].
There are several limitations to this study. First, AIR is a rare retinal disease, preventing us from
including multiple patients with this condition in this investigation. As a result, gene expression
differences between the AIR donor and the four control donors are valuable for hypothesis generation
but should be interpreted with caution. Second, while all samples had identical sample processing,
certain cell types might have a selective advantage in cellular recovery for single-cell RNA sequencing.
Recovered proportions of cells at the single-cell level (Figure 4B,E) should not be interpreted as the
true cellularity of the retina.
This study provides a complementary investigation of the clinical and molecular response of
the retina in AIR. Clinical, histologic, and transcriptomic evidence identify the loss of cone and rod
photoreceptor cells with relative preservation of inner retinal cell types. The gliotic transcriptional
profile of astrocyte and Müller glial populations observed in this case provides some new insight into
the retina’s response to photoreceptor degeneration.
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Abstract: Sorsby’s fundus dystrophy (SFD) is an inherited blinding disorder caused by mutations in
the tissue inhibitor of metalloproteinase-3 (TIMP3) gene. The SFD pathology of macular degeneration
with subretinal deposits and choroidal neovascularization (CNV) closely resembles that of the
more common age-related macular degeneration (AMD). The objective of this study was to gain
further insight into the molecular mechanism(s) by which mutant TIMP3 induces CNV. In this study
we demonstrate that hyaluronan (HA), a large glycosaminoglycan, is elevated in the plasma and
retinal pigment epithelium (RPE)/choroid of patients with AMD. Mice carrying the S179C-TIMP3
mutation also showed increased plasma levels of HA as well as accumulation of HA around the RPE
in the retina. Human RPE cells expressing the S179C-TIMP3 mutation accumulated HA apically,
intracellularly and basally when cultured long-term compared with cells expressing wildtype TIMP3.
We recently reported that RPE cells carrying the S179C-TIMP3 mutation have the propensity to induce
angiogenesis via basic fibroblast growth factor (FGF-2). We now demonstrate that FGF-2 induces
accumulation of HA in RPE cells. These results suggest that the TIMP3-MMP-FGF-2-HA axis may
have an important role in the pathogenesis of CNV in SFD and possibly AMD.
Keywords: sorsby’s fundus dystrophy; hyaluronan; neovascularization; retina
1. Introduction
Sorsby’s fundus dystrophy (SFD) is a dominantly inherited, degenerative disease of the macula
that is characterized by bilateral loss of central vision as a consequence of choroidal neovascularization
(CNV) [1–6]. Specific mutations in the tissue inhibitor of metalloproteinase 3 (TIMP3) gene involving
exon 5, exon 1 or the intron 4-exon 5 boundary have been shown to be causative [7–14]. In comparative
studies using TIMP3 deficient mice, S179C-TIMP3 transgenic mice and in vitro culture experiments
we have determined that TIMP3 partially inhibits angiogenesis by blocking the binding of vascular
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endothelial growth factor (VEGF) to VEGF Receptor 2 (VEGFR2). We have also demonstrated that
the S179C-TIMP3 mutant protein induces angiogenesis via VEGF and fibroblast growth factor 2
(FGF-2) [15–21].
TIMP3 is produced constitutively by the retinal pigment epithelium (RPE) and choroidal
endothelial cells [2,20]. It is a normal component of Bruch’s membrane [22] and binds to
sulfated glycosaminoglycans of the extracellular matrix (ECM) [23,24]. Hyaluronan (HA) is a
large glycosaminoglycan that is a significant component of peri-cellular and extracellular matrices.
HA is essential for numerous physiological functions that are dependent on its chain size and
its interactions with various effector proteins and receptors [25]. HA has been implicated in
the regulation of neovascularization and endothelial barrier function [26]. While studies have
demonstrated that signaling via HA and its cell surface receptor CD44 accentuates CNV in mice using
a laser-induced model [27], the exact molecular mechanism by which HA regulates tissue remodeling
and neovascularization is unknown.
We have recently reported that RPE cells expressing mutant TIMP3 secrete increased amounts of
FGF-2 [28] and that this contributes to increased angiogenesis. FGF-2 has been shown to be important
in tumor angiogenesis, but its role in CNV has been less well studied. The most direct evidence for a
role of FGF-2 in CNV comes from studies in which Flk1-Cre or Tie2-Cre mediated deletions of FGF
receptor 1 (FGFR1) and FGF receptor 2 (FGFR2) in endothelial cells resulted in reduced laser-induced
CNV in mice [29]. Extracellular matrix components such as heparan sulfate proteoglycans (HSPGs)
bind and regulate the activity of growth factors such as FGF-2 [30] and have a critical role in the
regulation of neovascularization [31]. In addition, the observation that activation of the FGFR-STAT3
pathway can induce a hyaluronan-rich microenvironment that can affect tumor growth [32] led us
to test the hypothesis that in addition to VEGF, FGF-2 and hyaluronan also have critical roles in the
increased neovascularization induced by mutant TIMP3 in Sorsby’s fundus dystrophy.
2. Materials and Methods
2.1. Human Samples
Patients with AMD and controls (without AMD or any other retinal disease) were recruited from
the eye clinics at Cole Eye Institute under Cleveland Clinic Foundation approved IRB protocols. Plasma
samples were prepared and stored at −80 ◦C. Samples from patients (n = 49, with 26 males and 23
females) given a clinical diagnosis of geographic atrophy or CNV and age-matched controls (n = 59
with 28 males and 31 females) were included in this pilot study to evaluate HA in the plasma. Normal
and/or AMD post-mortem eyes were obtained from the Cleveland Eye Bank, the National Disease
Research Interchange (Philadelphia, PA, USA) or from the Cole Eye Institute Eye Tissue Repository
through the Foundation Fighting Blindness (FFB) Eye Donor Program (Columbia, MD, USA). All
post-mortem tissue were obtained in accordance with the policies of the Eye Bank Association of
America and the Institutional Review Board of the Cleveland Clinic Foundation (IRB#14-057). Eye
bank records accompanying the donor eyes indicated whether the donor had AMD or no known
eye diseases. The analyzed tissue included FFB donations #714 (82 y.o.), #781 (80 y.o.), #711 (83 y.o.),
#722 (90 y.o.), #716 (80 y.o.) and #739 (90 y.o.), identified as AMD. Postmortem eyes from a 95 (#784),
92 (#979) and a 91 year-old donor without a history of retinal disease were used as controls. Eyes
were enucleated 4 to 22 h postmortem and fixed in 4% paraformaldehyde and 0.5% glutaraldehyde in
phosphate buffer. The globes were stored in 2% paraformaldehyde in D-PBS.
2.2. Mice
All mice utilized in this study were housed in the Cole Eye Institute vivarium under approved
Institutional Animal Care and Use Committee (IACUC) protocols. All procedures on the mice were
in accordance with ARVO statement for the Use of Animals in Ophthalmic and Vision Research and
conformed to the National Institutes of Health Guide for the Care and Use of Animals in Research
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and to the ARVO statement for the use of animals in ophthalmic and vision research. Timp3+/S179C
mice were generated in the laboratory of Dr. Bernhard Weber using site-directed mutagenesis and
homologous recombination in embryonic stem (ES) cells to generate mutant ES cells carrying the
Timp3S179C allele. Heterozygous breeding of Timp3+/S179C [33] produced homozygous Timp3S179C/S179C
mice and age-matched littermate controls in a C57BL6 background. Similarly, heterozygous Timp3+/-
mice [34] were bred to generate Timp3-/- knockouts and TIMP3+/+ littermate controls. Eyes were
enucleated following euthanasia and fresh frozen in tissue-plus optical cutting temperature embedding
medium (Scigen, #4583) for sectioning and histology. Blood samples were collected via cardiac puncture
and plasma prepared via standard protocols.
2.3. Hyaluronan Enzyme-Linked Immunosorbent Assay (ELISA)
Plasma from human patients with and without AMD and from SFD mouse models were measured
for HA contents by solid-phase sandwich ELISA in 96-well plates (Costar, #9018) using the Hyaluronan
Duo-Set ELISA kit (R&D Systems, #DY3614-05).
2.4. Immunofluorescence
Retina sections and flat-mounted ARPE-19 cells grown on polyester trans-wells were fixed for
5 min in 4% paraformaldehyde and blocked in 1% bovine serum albumin with 0.1% Triton X-100 in
phosphate-buffered saline. Human sections were processed with melanin bleaching kit to remove
autofluorescence (Polysciences, Inc., Warrington, PA, USA, #24883A-B). Samples were incubated
overnight with biotinylated HA binding protein, (Millipore Sigma, #385911) or primary antibodies
(anti-ezrin, clone 3C12, Invitrogen, Carlsbad, CA, USA #MA5-13862) in humidified chambers at 4
◦C. Subsequently, secondary antibodies (anti-mouse AlexaFluor 594, streptavidin-AlexaFluor 488,
streptavidin-AlexaFluor 647, all from ThermoFisher Scientific, Waltham, MA, USA) were incubated with
samples at room temperature for one hour in the dark. Rhodamine-phalloidin (Thermo Fisher Scientific,
R415) was incubated together with secondary antibodies. Then, 4′,6-diamidino-2-phenylindole (DAPI)
was used to stain nuclei of murine sections and cell culture mounts and SYTOX green (ThermoFisher
Scientific, #S7020) was used to stain nuclei in human sections. Imaging by confocal microscopy was
performed (Leica TCS-SP8, Exton, PA, USA). The localization of Bruch’s membrane was determined by
its autofluorescence at 405 nm.
2.5. Hyaluronidase Treatment of Retina Sections
Hyaluronidase from Streptomyces hyalurolyticus (Millipore Sigma, Burlington, MA USA, #H1136)
was used to treat retina sections as described previously [35]. Streptomyces hyaluronidase was
resuspended in 0.1 M sodium acetate buffer, pH 5.0, at 100 U/mL. To prevent any nonspecific digestion,
the following protease inhibitors were added to the sodium acetate buffer: 1 mM iodoacetic acid,
1 mM phenylmethyl sulfonylfluoride, 1 mM EDTA, 1 μg/mL pepstatin A, 250 μg/mL ovomucoid.
Hyaluronidase solution (100 mU/mL of hyaluronidase in PBS with CaCl2 (0.1 g/L) and MgCl2 (0.1 g/L))
was applied onto the sections for 3 h at 37 ◦C. Slides were subsequently fixed in 4% paraformaldehyde
and examined by fluorescence microscopy.
2.6. Cells and Reagents
ARPE-19 cells stably expressing S179C-TIMP3, wild-type-TIMP3 (WT), or vector alone were
reported previously [19]. Cells were expanded in DMEM-F12 with 10% FBS before transfer to polyester
inserts coated with mouse laminin (Corning Inc., Corning, NY, USA, #23017). 720,000 cells and
100,000 cells were plated per well in each well of a 12-well plate or 24-well plate, respectively using
a previously published protocol [36]. Essentially, ARPE-19 cells were cultured for at least 2 weeks
in nicotinamide-supplemented media with 1% FBS. Media were replaced twice per week. Cells
were serum-starved for 24 h before treatment with the FGF Receptor inhibitor BGJ-398 (Selleckchem,
Houston, TX, USA, #S2183) for 48 h. Similarly, cells were treated with FGF-2 (Gibco from Thermo
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Fisher Scientific, #13256-029) with the required cofactor heparin sodium salt (1 μg/mL, Sigma Aldrich,
#H3149) for 48 h after serum starving for 24 h.
2.7. Quantitation of Immunofluorescence by Integrated Density Analysis
Fluorescence intensity of HABP staining was quantified using integrated density analysis as
previously described [37,38]. For all the RPE cell culture confocal microscopy images, fluorescence was
quantitated using a standard measure of integrated density, which is the product of area and mean
gray value. A custom written automated image analysis code was developed using Matlab (MATLAB
2019a, The MathWorks, Inc., Natick, MA, USA) for separating the desired color channel from the image,
thereby obtaining the total area (in pixels), the mean gray value, and the integrated density.
2.8. In Vivo Imaging and Laser Injury Model
Laser mediated CNV was induced as described previously [28]. Briefly, mice were anesthetized
with 65–68 mg/kg sodium pentobarbital delivered intra-peritoneally. Topical 0.5% procaine solution
was applied for cornea anesthesia. Following anesthesia, pupils were dilated with 0.5% topical
tropicamide/phenylephrine combination drops (Santen Pharmaceuticals, Osaka, Japan).
Four laser spots were placed in the superior, superior-temporal, or superior-nasal quadrants of the
fundus using a green solid-state laser (Oculight by Iridex Corp., Mountain View, CA, USA) (532 nm;
2500 mW; 0.50 s pulse duration; 50 μm spot size) using a slit lamp delivery system and a microscope
coverslip placed and affixed to the cornea with a drop of Systane Ultra artificial tears (Alcon, Ft Worth,
TX, USA). All animals were scanned immediately after laser injury with optical coherence tomography
(Envisu R2210 UHR Leica Microsystems Inc., Wetzlar, Germany) to confirm successful RPE-Bruch’s
membrane rupture, an endpoint in laser-induced CNV models.
2.9. Statistical Analysis
All parameters in the study were distributed normally. Data are expressed as mean ± SEM.
Differences were tested by unpaired t-test (Figure 1, Figure 2 and Figure 3) or by using multiple
t-tests employing two-stage linear step-up procedure of Benjamini, Krieger and Yekutieli, with a false
discovery rate set to 1% (Figure 4 and Figure 5). Each group was analyzed separately without the
assumption of consistent standard deviation. p < 0.05 values were considered statistically significant.
Statistical analysis was performed with GraphPad Prism 7.03 (GraphPad Software, Inc., San Diego,
CA, USA).
3. Results
3.1. Hyaluronan is Elevated in Plasma and RPE/Choroid of Patients with AMD
Age-related macular degeneration (AMD) is usually seen as two main types. “Dry” AMD where
deposits called drusen develop in the macular region that ultimately progress to a late stage in which
there is atrophy of the macula (geographic atrophy). “Wet” AMD describes AMD in which patients
develop abnormal growth and leakage of the choroid vessels beneath and into the retina, termed
choroidal neovascularization (CNV). HA contents were measured in plasma from patients with late
stage AMD (geographic atrophy or choroidal neovascularization) and from age-matched controls
without the disease. ELISA analysis (Figure 1A) indicates that HA contents were significantly increased
in the plasma of patients with late-stage AMD (mean ± SEM: 111.8 ± 5.78 ng/mL) compared with
plasma of controls without AMD (32.91 ± 5.75).
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Figure 1. Hyaluronan HA is increased in circulation and in the RPE of age-related macular degeneration
(AMD) patients. (A) HA was increased in plasma from patients with late-stage AMD (GA or CNV)
compared to age-matched, normal controls. Data are presented as mean ± SEM (B–J) Representative
human retina sections stained with HA binding protein (HABP) (B) Human retina section stained with
streptavidin-AlexaFluor 647 in the absence of HA binding protein serves as a specificity control. (C–J)
Human retina sections stained with streptavidin-AlexaFluor 647 in the presence of HA binding protein.
HA is increased in the RPE in patients with dry AMD (D,H), wet AMD (E,I), and around drusen (F,J)
compared to the RPE from an aged-match normal control (C,G). 40× images (B–F), 63× images (G–J).
Green: HA; red: Bruch’s membrane determined by its autofluorescence at 405 nm; blue: DAPI. Asterisks
indicate drusen (F,J). GA—geographic atrophy; CNV—choroidal neovascularization; ONL—outer
nuclear layer; RPE—retinal pigment epithelium; Ch—choroid; DAPI—4′,6-diamidino-2-phenylindole.
To evaluate the distribution of HA in the retina under physiological and pathological conditions,
sections from post-mortem human donor eyes from 3 controls and 6 AMD (4 dry and 2 wet AMD)
patients were stained for HA using biotinylated HA binding protein (HABP). HA was found to be
localized predominantly in the choroid of normal eyes (Figure 1C) as described previously [39,40].
Increased deposition of HA was seen around the RPE in AMD eyes (both in the dry (Figure 1D,H) and
wet AMD specimens (Figure 1E,I)). HA was particularly enhanced in drusen and in areas of atrophy
(Figure 1F,J) in AMD specimens. The sections stained with secondary antibody alone serves as a
specificity control and shows minimal staining compared with sections stained with HABP (Figure 1B).
3.2. Increased Plasma HA and Accumulation of HA in the RPE of SFD Mice
We utilized two mouse models to study the potential role of TIMP3 in the regulation of HA in
the retina: mice lacking TIMP3 [34] and mice carrying the S179C-TIMP3 SFD mutation [33]. Plasma
from S179C-TIMP3 and TIMP3-KO mice at 4–6 weeks of age was collected and HA contents were
analyzed by ELISA. HA content of plasma was significantly increased in mice lacking TIMP3 as well
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as in mice carrying the S179C-TIMP3 mutation (Figure 2A), suggesting that TIMP3 may be important
in regulating HA.
 
Figure 2. HA is increased in circulation and in the RPE and choroid in mouse models of Sorsby’s fundus
dystrophy. (A) HA was increased in plasma from S179C-TIMP3 knockin mice (Timp3S179C6/S179C) and
TIMP3-KO (Timp3-/-) mice compared to wild-type (WT) littermates. (n ≥ 5). Data are presented as mean
± SEM. (B) Mouse retina sections stained with biotinylated HA binding protein (HABP) in the absence
(upper panel) or presence (lower panel) of hyaluronidase to detect HA. HABP staining is specific for
HA as shown by the absence of staining in sections treated with hyaluronidase (lower panel). Green:
HA; blue: DAPI. (C–H) Representative images of HA staining of mouse sections from wild-type (WT)
mice (C,F), S179C-TIMP3 mutant mice (D,G) and TIMP3-KO mice (E,H). HA is increased in the RPE
and choroid of S179C-TIMP3 (D) and TIMP3-KO (E) mice compared to wild-type (WT) littermate
controls (C). HA (green) is predominantly localized to the basal surface of the RPE (**) (F–H) and not to
the apical surface (*) as shown by co-staining with ezrin, a marker for the apical microvilli of RPE (red).
40× images (C–E); 63× images (F–H). n ≥ 3 for all immunohistochemistry data.
To determine if there was a similar correlation between the plasma HA levels and the accumulation
of HA in the RPE as observed in human sections with AMD, we evaluated accrual of HA in the retinas
of mice (8 weeks of age) lacking TIMP3 or carrying the SFD mutation. Cryosections of retina from
mice of each specific genotype and wild-type littermates were stained for HA content with HABP. To
ascertain that HABP binds HA specifically, sections were treated with hyaluronidase prior to staining
with HABP. Indeed, pre-treatment with hyaluronidase resulted in absence of staining with HABP
(Figure 2B, lower panel). S179C-TIMP3 mice (Figure 2D) and TIMP3-KO mice (Figure 2E) show
increased accumulation of HA beneath the RPE and in the choroid compared to that seen in wildtype
littermates (Figure 2C). Staining with antibodies to ezrin served as a marker for RPE apical microvilli
(Figure 2C–H), and the higher magnification images (Figure 2F–H) confirmed the RPE localization of
HA to the basal surface of the cells.
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To identify the potential mechanism by which S179C-TIMP3 regulates HA we utilized stable
human RPE lines (ARPE-19) expressing S179C-TIMP3 [20]. ARPE-19 cells (expressing S179C-TIMP3,
wildtype TIMP3 (WT-TIMP3) and empty vector (Vector)) were cultured for 2–6 weeks in 1% serum
on trans-well inserts and stained for HA. Increased accumulation of HA was observed in RPE cells
expressing S179C-TIMP3 (Figure 3C,G) compared with cells transfected with empty vector (Figure 3A,G)
or expressing wildtype TIMP3 (Figure 3B,G). The accumulation was predominantly intracellular and
apical in the RPE (Figure 3D–F). There appear to be multiple layers of S179C-TIMP3 RPE cells on the
transwell compared with a single monolayer for WT-TIMP3 and vector cells, which might suggest
epithelial-mesenchymal transition.
Figure 3. HA is increased in S179C-TIMP3 RPE cells in culture. (A–C) ARPE-19 cells expressing S179C-
TIMP3 grown in culture for at least 2 weeks on trans-well inserts have increased HA (C) compared
to WT-TIMP3 expressing cells (B) or vector only controls (A).(D–F) Z-plane images of HA in RPE
monolayers grown on trans-well inserts show increased intracellular HA in S179C-TIMP3 cells. Green:
HA; blue: DAPI. (G) Fluorescence intensity was quantitated by integrated density measurement (n ≥ 4,
for each cell line). Data are presented as mean ± SEM.
3.3. FGF-2 Contributes to HA Accumulation in the RPE
We have recently reported that RPE cells expressing S179C-TIMP3 secrete higher amounts of
FGF-2 compared with control cells [28]. Previous studies have suggested that FGF signaling has the
propensity to increase HA accumulation [32]. To experimentally test this hypothesis in RPE cells, we
evaluated the ability of FGF-2 to induce HA accumulation in primary porcine RPE cells. Cells cultured
for 3 weeks on trans-well inserts in 1% serum were treated with 0 ng/mL, 10 ng/mL, 25 ng/mL, or
100 ng/mL of FGF-2 in the presence of 1 μg/mL heparin, a cofactor for FGF receptor signaling. FGF-2
induced HA accumulation in a dose-dependent manner (Figure 4A–I) with maximum HA deposits
being observed with a dose of 25 and 100 ng/mL (Figure 4D,H). This was confirmed by quantitation
of fluorescence by integrated density measurements (Figure 4I). The FGF-2 induced accumulation of
HA was seen predominantly on the apical surface of the RPE with increased basal and peri-cellular
accumulation at higher doses (Figure 4E–H).
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Figure 4. FGF-2 induces HA accumulation in primary RPE cells. (A–D) FGF-2 induced HA accumulation
in primary porcine RPE cells in a dose-dependent manner (A) 0 ng/mL, (B) 10 ng/mL, (C) 25 ng/mL,
(D) 100 ng/mL. Fluorescence intensity was quantitated by integrated density measurement (I) (n ≥
4, for each cell line). Data are presented as mean ± SEM (E–H) Z-plane images show that increased
concentrations of FGF-2 induce increased apical accumulation of HA in addition to some peri-cellular
and basal deposits of HA at high doses of FGF-2. Green: HA, red: phalloidin; blue: DAPI.
To determine if the accumulation of HA seen in RPE cells expressing S179C-TIMP3 was a
consequence of increased FGF signaling, cells (RPE cells expressing S179C-TIMP3, wildtype TIMP3 or
empty vector) were treated with BGJ-398, an FGF receptor inhibitor. 10 μM BGJ-398 decreased HA
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content in RPE cells expressing S179C-TIMP3 (Figure 5C,F,H,I) and WT-TIMP3 (Figure 5B,E,I) but
not vector only transfected cells (Figure 5A,D,I) when compared with their respective untreated cells
that served as controls (Figure 5A: vector, 5B: WT-TIMP3 and 5C,G: S179C-TIMP3). Quantitation of
fluorescence by integrated density analysis revealed that 10 μM BGJ-398 decreased HA accumulation
in S179C-TIMP3 cells 63.1% (SD = 0.241) and only 43.4% (SD = 0.291) in wildtype cells (Figure 5I).
Quantitation confirmed that BGJ-398 had no significant effect on vector only cells (Figure 5I), suggesting
an FGF-specific mechanism for HA accumulation in S179C-TIMP3 cells.
Figure 5. Inhibition of FGF signaling decreases HA accumulation in S179C-TIMP3 RPE cells. Vector
only (A), WT-TIMP3 (B), and S179C-TIMP3 (C) expressing ARPE-19 cells were grown on trans-well
inserts for 4 weeks before treatment with FGF receptor inhibitor BGJ-398. Treatment with BGJ-398
decreased HA accumulation in S179C-TIMP3 expressing RPE cells (F,H,I) and to a lesser extent in
WT-TIMP3 expressing cells (E,I) but has no effect on control vector RPE cells (A,D,I). (I) Control (Black
Bar) indicates respective untreated cells compared with BGJ-398 treated cells (Grey bar). (G,H) Z-plane
images of S179C-TIMP3 cells in the absence (G) and presence (H) of 10 μM BGJ-398 S179C-TIMP3
cells show an overall reduction in HA accumulation, including intracellular HA, after treatment with
BGJ-398. Green: HA; blue: DAPI. (I) data are presented as mean ± SEM (n ≥ 6).
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3.4. Increased HA is Associated with CNV in AMD and SFD
Sections of post-mortem eyes from a patient with CNV showed significant HA deposition around
the RPE (Figure 6C,D) when compared with control eyes (Figure 6A,B). While S179C-TIMP3 mice do
not demonstrate a florid SFD phenotype as seen in humans, they do have increased susceptibility to
experimental laser-induced CNV [28] as do the TIMP3-KO mice [41]. We have previously shown that
FGF-2 from S179C-TIMP3 RPE cells can stimulate angiogenesis [28]. Since FGF-2 contributes to HA
accumulation in the RPE and to angiogenesis, we evaluated if HA content and distribution was altered
in laser-induced CNV lesions in S179C-TIMP3 mice. As described previously lesions in S179C-TIMP3
mice were larger and leakier compared to controls [28]. Increased HA accumulation was observed in
CNV in S179C-TIMP3 mice (Figure 6H–J) when compared to lesions in control mice (Figure 6E–G)
which appears to be a consequence of altered distribution to the CNV lesions in S179C-TIMP3 mice.
Figure 6. HA is increased in choroidal neovascular lesions in AMD patients and in S179C-TIMP3 mice.
(A–D) HA is increased in the RPE in a patient with CNV (C,D) and in the CNV lesion compared to
the RPE of a normal patient (A,B). Green: HA; blue: nuclei; red: Bruch’s membrane. Arrows indicate
RPE, double asterisks indicate CNV lesion. (E–G) HA is increased in laser-induced CNV lesions in
S179C-TIMP3 mice compared to wild-type (WT) littermates 5 days post injury. (E,H) Arrows indicate
CNV lesion. (F,I) Brightfield image overlaid on fluorescent image shows disruption of RPE and Bruch’s
membrane. (G,J) HA accumulation is diffuse and appears predominantly in the borders of the lesion
in WT (E–G) compared to dense mass within the lesions of S179C-TIMP3 mice (H–J). Green: HA;
blue: nuclei.
4. Discussion
Sorsby’s fundus dystrophy (SFD) is a rare macular dystrophy characterized by vision loss due
to persistent choroidal neovascularization [1–6]. SFD is an autosomal dominant, fully penetrant
degenerative disease of the macula and is notable for its similarity in histopathological features
to AMD [3–6]. The majority of SFD patients develop CNV, as well as confluent, 20–30 μm thick,
amorphous deposits between the basement membrane of the RPE and Bruch’s membrane. TIMP3
and/or its downstream substrates have been postulated to have a role in the pathogenesis of both SFD
and AMD, because accumulation of TIMP3 has been observed in subretinal deposits in SFD [42] as
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well as in AMD drusen [43–45]. In this study, we show that hyaluronan accumulates around the RPE
in AMD as well as in CNV lesions of mice expressing S179C-TIMP3.
One interesting observation from our studies was the increase in HA in the plasma of patients with
AMD as well as in mice lacking TIMP3 or carrying the S179C-TIMP3 mutation. Although we observe
significant differences in the plasma levels of HA in patients with advanced AMD (GA and CNV),
the number of patients analyzed (n = 49 controls) and n = 59 (AMD) is not sufficient to determine if
this is of prognostic value. In addition, we did not have access to samples from patients at different
degrees of severity to be able to draw conclusions with this or the rate of progression of the disease.
Future studies are warranted to address this question. While patients with SFD generally demonstrate
disease localized to the retina, our results may be a consequence of ubiquitous expression of TIMP3
in a variety of tissues in the body [46] which could potentially explain the systemic increase in HA.
Whether there is accumulation of HA in other tissues in S179C TIMP3 mice has not been evaluated.
Our studies with RPE cells suggest that the increase in HA in these cells is likely a consequence
of increased FGF. A recent study [47] suggests that TIMP proteins can control FGF-2 bioavailability
in skeletal tissue and the same might be true of multiple tissues leading to systemic increase in HA
in the plasma. The exact mechanism by which TIMP3 regulates FGF bioavailability in the RPE is
currently unknown, but it is highly likely that the TIMP-metalloproteinase axis likely has a key role.
The extracellular matrix (ECM) serves as a high capacity reservoir for FGF-2 and early studies have
demonstrated that matrix metalloproteases (MMPs) have the ability to mobilize FGF-2 to a soluble
phase that results in receptor activation [48]. Additional studies identifying the molecular mechanisms
by which TIMP3 regulates FGF-2 bioavailability will provide insight into the pathophysiology of
the disease.
FGF-2 is sufficient to increase HA accumulation and distribution in the RPE, and blocking FGF
signaling in S179C-TIMP3 RPE cells brings HA levels back to normal. The mechanism by which
FGF-2 increases HA accumulation is not understood. HA is endogenously synthesized by a family of
membrane-integrated glycosyltransferases, called hyaluronan synthases (HAS 1-3) and is exported
directly into the ECM [49,50]. Hyaluronidases (HYAL1-2) are a class of enzymes that degrade HA [51].
A balance between HA synthesizing and degrading activity keeps HA at physiological levels. In order
to determine the mechanism of accumulation of HA in the RPE in SFD, we performed quantitative
PCR analysis of HAS1-3 and HYAL1-2 from RPE isolated from S179C-TIMP3, TIMP3-KO mice and
wildtype littermate controls. Interestingly, we observed no changes in gene expression of any of these
enzymes in the mutant mice (Supplementary Figure S1). Therefore, at least in the RPE in SFD mice,
the differences in HA content are not due to increased expression of the synthases nor decreased
expression of canonical degradation enzymes. However, there are other possibilities that need to be
explored in the future. HA production could be modulated by decreasing enzyme recycling from
endosomes back to the cell surface as seen in keratocytes [52]. Additionally, there is a possibility
that other non-canonical hyaluronidases such as KIAA1199 [53] and Tmem2 [54] could be involved.
Alternatively, as previously reported degradation might be prevented by increased binding proteins
on HA and leading to net accumulation [55].
HA has been shown to exhibit a diverse array of biological functions including a role in the
response to tissue damage and inflammation [56]. Our studies demonstrating accumulation of HA in
laser-induced CNV lesions corroborates previous studies [27]. This study also reported an increase
in CD44 and HAS2 mRNA following laser injury [27]. It is possible that the increased accumulation
of HA in laser-induced CNV lesions in S179C-TIMP3 mice might result from similar increases in
mRNA transcription.
Chronic low-grade inflammation has been suggested to contribute to age-related macular
degeneration [57]. In the laser-induced mouse model of CNV, inflammatory processes have been shown
to play a role in the development and regression of the lesions. A number of reports link HA remodeling
to the modulation of neuroinflammation with low-molecular weight HA being pro-inflammatory and
high molecular weight HA being anti-inflammatory [58–60]. While we see increased deposition of HA
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in and around the RPE, we have not determined its physical properties such as size and molecular
weight distribution in the tissue.
The receptor engagement of HA in the retina or it’s downstream signaling under physiological or
pathological conditions has not yet been identified and will be important as we determine its exact role
in the pathology of macular degenerative disease. In our study we demonstrate that primary porcine
RPE cells deposited HA predominantly on the apical surface under physiological conditions similar to
what had been previously reported for human RPE cells [61]. Our data revealed that FGF-2 induced
HA accumulation apically as well as between cells and on the basal surface, suggesting that in addition
to increased total HA content, the distribution of HA may be important for disease pathogenesis and
warrants further investigation. We have recently reported that the secretion of FGF-2 by RPE cells
expressing S179C-TIMP3 led to increased angiogenesis [28]. Whether HA is modified in the endothelial
glycocalyx as a consequence of FGF-2 has not been studied and might provide further insight into the
pathogenesis of CNV in AMD and SFD leading to the identification of novel therapeutic approaches.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4409/9/3/608/s1,
Figure S1: RNA was isolated from mouse RPE using the Simultaneous RPE cell Isolation and RNA Stabilization
method (SRIRS method) using the RNA Plus Mini Kit (Qiagen). Quantitative PCR was performed following
reverse transcription using TaqMan probes for the mouse genes Has1 (A), Has2 (B), Has3 (No signal), Hyal1 (C),
Hyal2 (D), and 18S ribosomal RNA (rRNA) (Applied Biosystems). 18S rRNA was used as endogenous control for
each gene tested. mRNA expression was calculated using 2-ΔΔCt method and shown relative to expression in
wildtype littermate mice.
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Abstract: Inherited retinal degeneration (RD) leads to the impairment or loss of vision in millions of
individuals worldwide, most frequently due to the loss of photoreceptor (PR) cells. Animal models,
particularly the laboratory mouse, have been used to understand the pathogenic mechanisms that
underlie PR cell loss and to explore therapies that may prevent, delay, or reverse RD. Here, we reviewed
entries in the Mouse Genome Informatics and PubMed databases to compile a comprehensive list
of monogenic mouse models in which PR cell loss is demonstrated. The progression of PR cell
loss with postnatal age was documented in mutant alleles of genes grouped by biological function.
As anticipated, a wide range in the onset and rate of cell loss was observed among the reported models.
The analysis underscored relationships between RD genes and ciliary function, transcription-coupled
DNA damage repair, and cellular chloride homeostasis. Comparing the mouse gene list to human
RD genes identified in the RetNet database revealed that mouse models are available for 40% of the
known human diseases, suggesting opportunities for future research. This work may provide insight
into the molecular players and pathways through which PR degenerative disease occurs and may be
useful for planning translational studies.
Keywords: visual photoreceptor cell loss; mouse genetic models; retinitis pigmentosa; Leber
congenital amaurosis; ciliopathies
1. Introduction
Inherited forms of retinal degeneration (RD) encompass a genetically and clinically heterogeneous
group of disorders estimated to cause vision impairment and loss in more than 5.5 million individuals
worldwide [1,2], with 282 mapped and identified retinal degenerative disease genes documented in
the RetNet human database [3]. Animal models, such as non-human primates [4], dogs [5], mice [6,7],
zebrafish [8], and fruit flies [9], have been used to identify candidates for human retinal disease
genes, to elucidate pathological mechanisms, and to serve as a resource for exploring therapeutic
approaches. As potential therapies for retinal diseases are investigated, the need for animal models
increases. Information about the disease onset and rate of progression, the pathogenic pathways
involved, and the genetic background in which the disrupted genes are situated are all factors that
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must be considered when selecting appropriate models for testing therapeutics. These factors will also
play a role in interpreting the outcome of treatment studies.
The purpose of this review is to compile a searchable list of mouse models of inherited retinal
diseases caused by single gene mutations that specifically lead to the post-developmental rod and/or
cone photoreceptor (PR) cell loss. To identify these models, we reviewed mouse-specific data available
in the Mouse Genome Informatics (MGI) and National Center for Biotechnology Information (NCBI)
databases at The Jackson Laboratory (JAX) and National Institutes of Health (NIH), respectively.
We recorded, when available, PR cell loss data from publications describing mutant alleles of the genes
identified. We also included representative fundus photographs and optical coherence tomography
(OCT) images of selected mouse models from the Eye Mutant Resource (EMR) and the Translational
Vision Research Models (TVRM) programs at JAX as examples of the retinal phenotypes found among
mouse models that fit our criteria. We attempted to cluster genes based on the function and then
compared the progression of PR cell loss among these clusters to provide potential insights into disease
mechanisms. We also compared our list of mouse genes associated with PR cell loss with the RetNet
gene list, to highlight mouse models for specific retinal diseases, to reveal opportunities to create novel
models, and to identify candidate genes within human loci for which a causative gene is currently
unknown. Finally, we coordinated with the MGI team to incorporate our annotations into the MGI
database, which will allow future analyses using tools available through that platform. It is hoped that
our work will be useful as a resource for investigators to assist in the selection of appropriate mouse
models within and across functional clusters in new studies to understand and develop treatments for
human retinal degenerative disease.
In the three decades since the genes linked to PR loss phenotype were first identified in the
mouse and human [10–12], rapid progress in understanding the genetic basis of inherited RD has been
summarized in many excellent reviews. Many of the topics presented in the current article have been
discussed previously in reviews of mouse RD models [6,7,13,14] and in summaries of our work at
JAX [15–21]. Although we have made every effort to acknowledge the many contributions to this field,
we note that there is a large body of relevant literature and apologize in advance to authors whose
reviews or articles we may have inadvertently overlooked.
2. Background
2.1. Photoreceptor (PR) Cell Structure
PR cells are sensory neurons within the retina that detect light and signal this event to other
cells. Since PR cells are essential for vision, their loss can dramatically and negatively affect the
quality of life. PR cells include rod and cone cells (Figure 1a,b) that occupy the outermost layers of
the neurosensory retina. Although intrinsically photosensitive retinal ganglion cells have also been
described as photoreceptors [22], we did not include them in this review, as their contribution to RD is
unknown. Rod and cone photoreceptors possess unique structures that serve to compartmentalize
processes that are critical for cell function and maintenance.
• The outer segment (OS), which is cylindrical in rod PR cells and tapered in cones, contains
phototransduction proteins that sense light and amplify the ensuing signal, culminating in PR
cell hyperpolarization (Figure 1c). Much of the phototransduction apparatus is localized to
double-bilayer discs formed by evagination of the plasma membrane at the base of the OS. These
discs are largely internalized in rods except at the base of the OS, but remain contiguous with the
plasma membrane in cones to yield a highly convoluted OS surface [23].
• The OS is stabilized by a ciliary axoneme, which runs through much of its length (Figure 1d;
Ax). At the proximal end of the axoneme, the connecting cilium, analogous to the transition zone
in other cilia (Figure 1d; CC-TZ), serves as a conduit through which all membrane and protein
components destined for the OS are thought to pass. At the base of the connecting cilium lies the
basal body (Figure 1d; BB), a cylindrical organelle derived from the mother centriole. Altogether
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these structures represent a modified primary cilium that encompasses an extensive network of
protein complexes that transport proteins and lipids and shares characteristics with primary cilia
in many other cell types. The ciliary networks also function to prevent the flow of OS components
to other parts of the cell and may associate with the intracellular trafficking apparatus to ensure
the directed movement of needed components to the OS.
Figure 1. Retinal tissue organization emphasizing cell types and subcellular structures that may be
sites of pathological processes in mouse models of photoreceptor (PR) cell loss. (a) A radial section of
the posterior eye stained with hematoxylin and eosin shows the layered structure of the retina. CH,
choroid; RPE, retinal pigment epithelium; IS, inner segment; OS, outer segment; ONL, outer nuclear
layer; OPL, outer plexiform layer; INL, inner nuclear layer; IPL, inner plexiform layer; GCL, ganglion
cell layer; NFL, nerve fiber layer. (b) Two PR cell types (rods and cones) and additional cell types
that may be the target of processes implicated in PR cell loss. Dashed lines indicate alignment with
retinal layers in (a). A columnar unit consisting of one cone and one Müller cell and roughly 20 rod
cells is shown. (c–f) Details of PR and RPE cells. (c) PR cell OSs contain flattened discs (rod, left) or
incomplete discs (cone, right) where the light sensing apparatus is located. OS tips engulfed by RPE
cell apical processes are digested in phagolysosomes (Ph). (d) The base of the OS, the connecting cilium,
and the apical portion of a rod cell IS (adapted with permission from [24]). The axoneme (Ax) and
rootlet provide physical stability to the cilium. BB, basal bodies; CC-TZ, connecting cilium-transition
zone; PCM, pericentriolar matrix; PCC/CP, periciliary complex/ciliary pocket; RER, rough endoplasmic
reticulum. (e) The PR cell soma is largely occupied by the nucleus. (f) Rod and cone synaptic termini
include presynaptic ribbons and associated neurotransmitter vesicles.
• The inner segment (IS) contains the biosynthetic machinery and energy sources needed to produce
and assemble newly synthesized phototransduction proteins and their associated membranes
(Figure 1d). The capacity of this cellular factory is impressive, as up to 10% of the OS is shed
daily and removed via phagocytosis by the retinal pigment epithelium (see below) and must be
renewed. Most protein and lipid components are synthesized de novo, but the IS also has an
extensive recycling machinery that can reassemble components provided from outside the cell.
• The cell body or soma includes the nucleus, which is highly condensed in rod PR cells, but is
larger in cones and includes patches of heterochromatin (Figure 1e). To increase the density
of rod and cone OSs in the retina, the somas are stacked in columns within the outer nuclear
layer (ONL). This arrangement necessitates thin cell extensions reaching from the soma to the
IS or to the synapse. PR cell loss is measured by counting ONL nuclei, which are prominently
stained in retinal sections (Figure 1a), or in the case of rods, which are more abundant than cones,
by measuring ONL thickness from micrographs or by OCT.
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• The PR cell terminus contains ribbon synapses close to the presynaptic membrane loaded with
vesicles containing the excitatory neurotransmitter glutamate (Figure 1f). In the dark, a steady-state
level of glutamate is released at the synapse, which is reduced when the cells are hyperpolarized
in the light. Changes in glutamate levels at the synapse signal postsynaptic secondary neurons in
the inner nuclear layer, which communicate with ganglion cells on the vitreal surface of the retina
that connect through long axons to the visual cortex of the brain.
2.2. Neighboring Cells
Müller glia are radial cells that span much of the neurosensory retina, reaching from the internal
limiting membrane at the vitreal surface of the retina to the external limiting membrane on the scleral
edge of the ONL [25]. Within the ONL, fine Müller cell extensions appear to ensheath the PR cell
soma. As they also interact with vascular layers within the retina, Müller cells may provide essential
nutrients to PR cells, which do not directly contact the circulation. They also regulate extracellular
volume, ion and water homeostasis, serve to modify neuronal activity through release of neuroactive
compounds, and modulate immune and inflammatory responses [26]. At the external limiting
membrane, Müller cell endfeet engage rod and cone cell ISs in intercellular adhesion interactions,
including tight junctions, which create a diffusion barrier. Notably, the arrangement of an Müller cell,
rods, and a cone cell has been proposed to form a columnar unit (Figure 1b), which may result in
physiological and functional coordination of these cell types.
RPE cells (Figure 1b,c) constitute an epithelial monolayer that lies between the retina and a
capillary bed, the choriocapillaris. The flow of water, ions, small molecules, and metabolites from the
blood to the outer retina is thus regulated by RPE cells. Their apical surface features microvilli and
microplicae (Figure 1b,c) that contact roughly the outermost third of OSs and play important roles
in recycling molecules needed for PR renewal. These apical processes also mediate initial steps in
the daily phagocytosis of OS tips. As an epithelium with high-resistance intercellular junctions [27],
the RPE performs an important barrier function, disruption of which may cause PR degeneration.
Microglial cells form ramified networks within the same retinal layers as the retinal vasculature,
which includes the superficial, intermediate and deep vascular beds. Microglia at the level of the outer
plexiform layer in healthy retinas extend dendritic arms into the ONL (Figure 1b), where they contact
PR soma as part of a dynamic survey process. During development and in rare events that occur in
healthy retinas, these cells engulf and phagocytose PR soma, presumably in response to a defect in
PR function.
PRs form synaptic connections in the outer plexiform layer with secondary neurons, including
bipolar and horizontal cells. Although these connections are critical for signal transmission, they are
not as extensive as the contacts made between PRs and Müller glia, RPE cell apical processes, or the
dynamic extensions on microglial cells, and were therefore omitted from the summary diagram in
Figure 1. Nevertheless, perturbation of the interactions among these cells may lead to PR degeneration,
conceivably due to an alteration of signal transmission.
2.3. Inherited Diseases that Cause PR Cell Loss
Major monogenic inherited RDs in which PR cells are lost include: retinitis pigmentosa [28], Leber
congenital amaurosis [29], and syndromic disorders that manifest disease in multiple organs, including
the eye, particularly ciliopathies, such as Joubert [30], Bardet–Biedl [31], or Usher [32] syndrome.
The remarkable success of gene augmentation therapy for a form of Leber congenital amaurosis has
invigorated research efforts to treat these diseases [33].
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3. Methods
3.1. Public Database and Literature Searches
The search strategy employed in this review is summarized in Figure 2. Initially, the MGI
database [34] was queried to identify mutant protein-coding genes associated with a mammalian
disease phenotype indicating a loss of PR cells. MGI is a curated database that includes expert
annotation based on full-text searching of 148 selected journals, which is limited compared to literature
databases, such as PubMed. Typically, only the first paper describing a new allele is fully curated for
phenotype data in the database due to resource constraints. Although our analysis yielded 159 mutant
genes that were associated with PR cell loss, a number of mutant genes known to cause this phenotype
were absent or not annotated, possibly due to these aforementioned limitations.
 
Figure 2. Flow chart depicting the progression of the search strategy utilized in this review. The number
of records or genes identified from them is indicated at each stage of the process. The dashed line
indicates that some genes were identified from records that remain to be systematically screened.
To expand the search, we used NCBI databases, including PubMed [35] and Gene. We refined
a PubMed query by searching with keyword phrases to generate article lists, using the Gene option
of Find Related Data to yield mouse genes linked to the articles, and then assessing whether these
genes were on our MGI list. The goal was to develop a broad query that included as many genes
from the MGI list as possible but also included additional hits. The most successful was: (ONL OR
“outer nuclear layer” OR retina* OR PR OR rod OR rods OR cone*) AND (degener* OR loss OR thin*
OR thick*) AND (mouse OR mice OR murine), which captured >97% of the MGI list. Restricting this
query to entries posted to PubMed on or before October 15, 2019, yielded 9535 articles. To review these
articles efficiently we tried two approaches, the first generating a spreadsheet containing hyperlinks in
which each linked gene symbol was combined with the Boolean query, and the second using mouse
gene identification numbers corresponding to the linked genes and applying an Entrez script that
accessed the Gene and PubMed databases to find all articles satisfying the Boolean query for each
linked gene.
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3.2. Search Strategy
Each MGI database-derived entry was curated manually or automatically to identify candidate
models that reported PR degeneration as a phenotype, as described above. In the case of PubMed
entries, although the automated approaches were useful for quickly identifying genes that satisfied our
criteria, neither was comprehensive, and additional candidate models were identified by review of the
title and abstract from some of the remaining articles in the full collection of 9535 articles. Subsequently,
an independent coauthor identified an original publication for each candidate gene and determined if
PR cell loss was reported. If sufficient evidence for PR cell loss was obtained, the gene and mouse
model was assigned to one of 11 categories. Genes within each category were curated further by
coauthors who identified alternate alleles and extracted information regarding the disease phenotype
induced by the disruption of a gene. Each entry in Table S1 is the result of the examination of an
original article (indicated by PubMed ID numbers, PMIDs) and data from MGI to capture information
such as mutation type, associated human diseases, and disease onset and progression.
3.3. Comparative Analysis and Updating the MGI Database
Once our final list was completed, we used tools in Excel to compare it to a list constructed
from online tables downloaded on 8 December 2019, from RetNet, a public compilation of human
genes linked to inherited RD. We also provided our data to the MGI team at JAX, who assigned allele
nomenclature, added strain information for newly described mutants, and updated phenotype data
for alleles that were present in the MGI database but not yet annotated with respect to PR cell loss.
This review has been referenced at MGI so that the alleles documented in the article can be examined
using MGI tools or downloaded in tabular format for analysis with other software. The collaborative
approach between mouse phenotyping experts and the MGI team may be attractive for ensuring that
this useful resource remains current in the face of limited funding, personnel, and time.
3.4. Inclusion/Exclusion Criteria
Monogenic models generated from a variety of sources were included in Table S1. However, in
the case of conditional models, only those for which a germline null allele was reported in the MGI
database that resulted in embryonic, prenatal, or postnatal lethality were included. We excluded the
following models from Table S1: those for which a causative gene had yet to be identified and for
which complementation tests were unavailable; those requiring multiple genes for the presentation of
the disease phenotype; those based on overexpressing transgenes; and those in which PR degeneration
depended on experimental interventions, such as an altered diet, drug treatment, or exposure to bright
illumination. Environmental influences on retinal diseases are very important and may affect the
progression of PR cell loss, but models that depend on environmental conditions are challenging to
compare because of the significant variation among the types of environmental perturbations and the
methods used to apply them. We also excluded models that exhibited a reduction in the PR cell number
during development but not a progressive loss with age, and those where IS and/or OS dysmorphology
or reduction in length was observed without a loss of PR cells, as indicated by a reduction in nuclei
number or ONL thickness within the time frame reported in the papers. Although these models were
excluded from Table S1, examples are included in the Results.
3.5. Heterogeneity of Data
The type and frequency of data gathered varied greatly among the studies reviewed. In some
papers, only one figure with one retinal section was offered as evidence for PR degeneration, while other
papers showed extensive quantitation of their data. To document potential sources of variability in
the data, we indicate the method by which the degree of degeneration was determined, either by
measuring ONL thickness or by count of nuclei in the ONL, typically the number of rows of nuclei
spanning the ONL but sometimes a total count of ONL nuclei in a fixed area of a retinal micrograph.
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In some instances, when data was quantified in spider plots or bar graphs, mean values obtained
from the central retina were used in estimating the PR loss. We normalized the data among studies by
recording the percent degeneration as determined by dividing the mutant values by the corresponding
values from age-matched controls as reported in each publication.
3.6. Comparison of Progressive PR Cell Loss
To compare progressive PR cell loss among models, we fit normalized data from each article to an
exponential decay that includes a delay, or offset [36]. Ranges of either age or photoreceptor numbers,
if reported, were averaged. Fitting was performed in Excel Visual Basic using a piecewise equation
that modeled the delay with a straight line at 100% and the remaining points with a monoexponential
decay to 0%. Two adjustable parameters, the delay and the decay rate constant, were optimized.
We calculated the age at which PR cell numbers reached 50% of control values (D50) as a measure of
progression. Roughly one third of the datasets contained only a single point within the exponential
regime, which was insufficient to calculate D50. In these cases, D50 was calculated at the extremes of
zero delay and infinite rate, and the mean of these values was used as a D50 estimate.
3.7. Generation of Primary Data Using Fundus Imaging and OCT Scans
Fundus photographs of EMR mutants were taken in unanesthetized mice treated with 1%
cyclopentolate to dilate or enlarge the pupil with an in vivo bright field retinal imaging microscope
equipped with image-guided OCT capabilities (Micron III; Phoenix Laboratories, Inc., Pleasanton, CA,
USA) as previously described [20]. This system allows for the visualization of the location of the OCT
scan using the real-time Micron III bright-field image. A superimposed line placed directly on the
image over the retinal feature being examined delivers precise cross-sectional information, allowing
for the assessment of changes in layer thickness and morphological alterations.
Fundus photodocumentation for TVRM mutants and C57BL/6J control mice was performed using
a Micron III or IV retinal camera (Phoenix Laboratories, Inc., Pleasanton, CA, USA) as described [37],
except that 1% cyclopentolate or 1% atropine was used as a dilating agent, and in some cases, mice
were anesthetized with isoflurane. OCT imaging to assess retinal layer thickness in Nmnat1tvrm113,
Ctnna1Tvrm5, and C57BL/6J control mice was performed using a Bioptigen ultrahigh-resolution (UHR)
Envisu R2210 spectral domain OCT (SDOCT) imaging system for volume scanning as described [37,38]
with ketamine/xylazine (1.6 mL ketamine (100 mg/mL), 1.6 mL xylazine (20 mg/mL), and 6.8 mL
sodium chloride (0.9% w/v)) as an anesthetic. A representative B-scan through the optic nerve head
was derived from the OCT volume dataset. Rpgrip1nmf247 and Alms1Gt(XH152)Byg were assessed on the
same OCT system by obtaining a linear B-scan with the following parameters: length, 1.9 mm; width,
1.9 mm; angle, 0 degrees; horizontal offset, 0 mm; vertical offset, 0 mm; A-scans/B-scan, 1000 lines;
B-scans, 1 line; frames/B-scan, 20 frames; and inactive A-scans/B-scan, 80 lines. Linear scans were
registered and averaged in the InVivoVue program to merge the 20 frames into a single image.
4. Results
4.1. Summary of Studies that Report PR Cell Loss
The combined searches of MGI and PubMed databases yielded a total of 230 genes associated with
PR cell loss. Ultimately, 3834 reports at MGI and 3325 at PubMed, which most typically characterized
one mutant gene but on rare occasions described more than one, were used in the present review.
The distribution of retrieved publications sorted by functional categories is summarized in Table S1.
The genes identified in these models are summarized in Figure 3. Descriptions of gene and protein
symbols used in the text, figures, and Table S1 are provided in Table S2.
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Figure 3. Genes associated with PR cell loss in monogenic mouse models of retinal degeneration
(RD). Genes identified by combined review of the Mouse Genome Informatics (MGI) database and
articles from a PubMed query were assigned to the indicated functional categories as described in the
text. Genes for which mutant alleles are available only in the conditional form are displayed in red.
Conditional alleles were included only in instances where germline null alleles resulted in embryonic,
prenatal or postnatal lethality. For additional details on inclusion/exclusion criteria, see Section 3.4.
4.1.1. PR Cell Loss Models
The mouse models described in Table S1 were either spontaneous (12%) or chemically induced
mutants (11%), or those produced through genetic engineering approaches (77%). This latter group,
which was by far the largest, utilized standard homologous recombination, gene-traps, nuclease
mediated approaches such as CRISPR/Cas9, and conditionals to mediate genomic changes. Additionally,
four models of inadvertent transgene insertion into a unique gene, whose disruption led to PR
degeneration, were included within this group. Interesting examples of differences in the disease onset
or rate of progression were demonstrated in different models of the same gene (e.g., Aipl1) that may be
related to allelic differences, null versus missense mutations, or genetic background effects [21,39,40].
Most of the genetically engineered models in Table S1 tended to be in mixed, segregating genetic
backgrounds that might impact phenotypic expression (discussed below).
Within the genetically engineered category, a relatively large group of models, 16%, were
conditional models, representing 39 genes (Figure 3; red). Generation of conditional mutants is based
on the Cre-Lox recombination approach, which requires a floxed gene and a cre-driver to excise the
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targeted genomic region in a spatial (e.g., cell/tissue specific) or temporal manner (e.g., induction by
chemicals such as doxycycline). Since 30% of all null mutations lead to embryonic lethality, as they
represent genes that are essential during development, conditionals are often used to examine the adult
function of genes [41]. This was the case in 92% of the conditional models described here, as standard
organism-wide removal of the genes was reported to be embryonic, perinatal, or postnatal lethal. Thus,
conditionals allow us to learn the function of a gene post-developmentally. Conditionals are also
sometimes used to determine the cellular contributions to a disease phenotype. If a gene is expressed in
multiple retinal cell types, by removing them systematically and examining the consequent phenotype,
one can learn how the loss of function of the gene within particular cell types affects the disease
phenotype. For example, removal of Arl3 from rod PRs using a Rho-icre driver shows a later and
slower rate of degeneration than that found with Six3-cre, a Cre driver that expresses in early retinal
development. This suggests that Arl3 in rods is necessary for PR survival but that Arl3 function in other
retinal cell types also affects PR survival [42]. The most widely used Cre models include: for targeting
retinal progenitor cells, Tg(rx3-icre)1Mjam, Tg(Six3-cre)69Frty, Tg(Chx10-EGFP/cre,-ALPP)2Clc,
Tg(Crx-cre)1Tfur, and Tg(Pax6-cre,GFP)2Pgr; for targeting rods, Tg(Rho-icre)1Ck, Tg(RHO-cre)8Eap,
and Pde6gtm1(cre/ERT2)Eye; for targeting M-cone PRs, Tg(OPN1LW-cre)4Yzl (also known as HRGP-cre);
for targeting PRs, Tg(Rbp3-cre)528Jxm (also known as IRBP-cre); for targeting RPE, Tg(BEST1-cre)1Jdun,
Tg(BEST1-rtTA,tetO-cre)1Yzl and Foxg1tm1(cre)Skm; and for targeting adult tissues using tamoxifen,
Tg(CAG-cre/Esr1*)5Amc.
4.1.2. Mouse Models from Phenotyping Programs
The models listed in Table S1 come from many sources. In addition to individual
investigator-initiated efforts, currently the largest contributor to ocular models is the International
Mouse Phenotyping consortium, in which 19 phenotyping centers from 11 countries participate to
systematically characterize knockout mice generated in a standardized manner [41,43]. All centers do
some eye phenotyping, thus providing a window into potential models. Although only a few models
from this program are included in Table S1, as most are not yet fully characterized, it is anticipated that
this consortium will provide a wealth of models for individual laboratories to study. For example,
in the MGI database, 39 IMPC models were identified with “reduced retinal thickness” that with
further characterization may reveal PR degeneration.
At The Jackson Laboratory, the Eye Mutant Resource (EMR) and the Translational Vision Research
Models (TVRM) programs are dedicated to screen for or generate mouse models with ocular diseases.
The EMR has been screening retired breeders by slit lamp biomicroscopy, indirect ophthalmoscopy,
and electroretinography since 1988. Retired breeders from the production and genetic resources colonies
are screened. Heritable mutants are phenotypically and genetically characterized and the spontaneous
mutants are distributed worldwide. The TVRM program arose from the JAX Neuromutagenesis
Facility. Mice for this program are generated by chemical mutagenesis or genetic engineering. Carefully
characterized mutants are also distributed. Examples of mutants from the EMR and TVRM programs
are shown in Figures 4 and 5, respectively.
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(c) 
Figure 4. (a) Characterization of mouse models from the Eye Mutant Resource (EMR) program
at JAX. Example optical coherence tomography (OCT) and fundus images were taken from rapid
RD models: Pde6brd1 (B6.C3-Pde6brd1 Hps4le/J, Stock No: 000002), Pde6brd1-2J (C57BL/6J-Pde6brd1-2J/J,
Stock No: 004766), Pde6brd10 (B6.CXB1-Pde6brd10/J, Stock No: 004297), Rd4/+ (STOCK In(4)56Rk/J,
Stock No: 001379) and Cep290rd16 (B6.Cg-Cep290rd16/Boc, Stock No: 012283) (b) Example images from
slower RD models: Prph2Rd2 (C3A.Cg-Pde6b+ Prph2Rd2/J, Stock No: 001979), Rd3rd3 (B6.Cg-Rd3rd3/Boc,
Stock No: 008627), Lpcat1rd11 (B6.Cg-Lpcat1rd11/Boc, Stock No: 006947), Rpe65rd12 (B6(A)-Rpe65rd12/J,
Stock No: 005379) and Prom1rd19 (B6.BXD83-Prom1rd19/Boc, Stock No: 026803). (c) Examples from slow
and very slow RD models: Mfrprd6 (B6.C3Ga-Mfrprd6/J, Stock No: 003684), Nr2e3rd7 (B6.Cg-Nr2e3rd7/J,
Stock No: 004643), Crb1rd8 (STOCK Crb1rd8/J, Stock No: 003392), RpgrRd9 (C57BL/6J-RpgrRd9/Boc,
Stock No: 003391), and Gnat1rd17 (B6.Cg-Gnat1irdr/Boc, Stock No: 008811). Yellow bars indicate full
retinal thickness. Values correspond to the mouse age at the time of imaging (weeks).
5. Analysis
5.1. Progression of PR Cell Loss
While a host of effects can occur as a result of disruptions in genes expressed in PRs and ancillary
cell types that functionally impair vision, such as night blindness, or color vision defects, the focus of
the models described here are those that bear single gene mutations that lead to actual PR cell loss.
From a review of the models in Table S1, significant PR cell loss is reported as early as postnatal day 7
(P7) and can extend throughout the lifetime of animals examined. The progression of PR cells loss is
also highly variable and includes models that progress rapidly with complete ablation within several
weeks to models with extremely slow progression where only <10% PR cell loss is noted over the span
of time in which animals were examined. Generally, while rapid to moderate progression led to almost
complete PR ablation, slow and very slow progression, or degeneration in models that primarily affect
cone PRs left a substantial number of PR cells intact.
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Figure 5. Characterization of mouse models from the Translational Vision Research Models
(TVRM) program at JAX. A fundus image (circular panels) and corresponding OCT B-scan are
shown for homozygous (a) Rpgrip1nmf247, at one month of age; (b) Nmnat1tvrm113, at two months;
(c) Alms1Gt(XH152)Byg, at one year; and (d) Ctnna1Tvrm5, at two years. Age-matched OCT and fundus
images for C57BL6/J control mice are shown to the right of the mutant images. PR cell loss is indicated
by a decreased ONL thickness. Fundus images were acquired using a Micron III or IV retinal camera.
The vertical dimension of OCT images was doubled to emphasize changes in retinal layer thicknesses.
To compare cell loss among functionally similar genetic models, models in each category of
Table S1 were sorted based on the estimated age at which the PR cell population had degenerated by
50% compared to control values, defined as D50 (Figure 6). This quantity represents neither the rate of
PR cell loss nor the delay before loss commences, although both parameters are used to calculate it.
Rather, D50 provides a common measure of progression that allows both complete and sparse datasets
to be evaluated. With sufficient data, delay, and exponential decay constants were calculated and are
reflected by the shaded bars in Figure 6. Many datasets with fewer measurements, some containing a
single point, allowed only an estimate of D50 (Figure 6; filled circles, range lines indicate estimated
limits). Figure 6 may be used to identify models in which overall PR cell loss progresses at an
earlier age (lower D50), proceeds at a higher rate once initiated (shorter bar), or is accompanied by a
substantial delay (bar starts farther to the right), which may aid in experimental design. Values for
D50, the exponential decay constant k, and the delay, when available, are also included in Table S1.
We relate qualitative descriptions of progression to D50 as follows: rapid, <2 months; moderate, 2 to
<6 months; slow, 6 to <12 months; and very slow, ≥12 months.
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Figure 6. Progression of PR cell loss in mouse models by functional category. Models in each category
were sorted by the age at which the estimated number of PR cells reached 50% of wild-type (D50) as
determined by fitting reported data to an exponential decay function combined with a delay. Models
are identified by gene symbol, MGI allele symbol, and PMID. Models are homozygous except as
indicated by * (heterozygous) or by the presence of two allele symbols (compound heterozygous).
Left- and right-hand margins of shaded bars represent the delay and D50 values, respectively. Bars with
a delay value of ≤0.1 month derive from datasets in which no values at 100% of wild type were reported.
The midpoint and range of estimated D50 values for datasets with only one point in the 5–95% range is
indicated by closed circles and range lines, respectively. In cases where the dataset consisted of a single
point at 50%, no estimate was needed.
Figure 6 does not include models in which the age of the animal at the time of measurements
was not provided, or was reported as “adult”, although these models were included in Table S1.
We also omitted models where only cone PR cell degeneration was reported, as limited data and a
lack of cone nuclei counts made mathematical modeling of cell loss unreliable. Finally, we omitted all
conditional alleles from Figure 6, as the efficiency and specificity of inactivation of genes, as well as the
temporal expression of different transgenic Cre drivers utilized varies, making comparison of these
alleles difficult.
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5.2. Biological Processes Affected by Mutations
Categorization of PR cell loss genes (Figure 3) relied on current functional knowledge, similarity
to other genes, and localization, if known. Genes are often expressed in multiple cell types and serve
different functions within the retina. We placed genes in categories that were most pertinent to their
roles in the PR or effect on PR survival. The data in Table S1 can be explored after reassigning models
to different categories if desired. In the descriptions below, we provide an overview for the first three
categories and then a detailed description of the effect of gene disruptions on biological functions
included in these categories. Subsequent categories are described without overview.
5.2.1. Category 01: Ciliary Function and Trafficking
Overview. Disruptions in a vast number of genes associated with PR sensory cilia result in
RD [24,44]. The onset and rate of PR cell loss may vary depending on the role of a given gene in
maintaining ciliary structural integrity and function during early PR development and maintenance
in adulthood. Retinal defects within any one of the key ciliary structures and/or processes such
as ciliogenesis, OS morphogenesis, or PR homeostasis may result in the loss of rod and cone PR
cells. Understanding the pathophysiological mechanisms involved in PR cell loss requires a detailed
examination of the components and functionalities of the PR sensory cilium.
The mouse PR sensory cilium is a specialized structure comprised of a tubulin-rich axoneme with
a symmetrical “9+0” arrangement of microtubular doublets [45]. The connecting cilium (CC) is akin to
the transition zone (TZ) of primary cilia [46,47] and serves as a passageway for the movement of proteins
from the organelle-rich IS to the photosensory OS. The OS is composed of an elongated distal axoneme
with adjacent stacked membranous discs decorated with proteins necessary for phototransduction.
It has been hypothesized that extension of the PR plasma membrane towards the apical RPE provides
a convenient sink in the OS for the storage of a large number of membrane proteins [48]. In the CC-TZ,
axonemal microtubule doublets interconnect the distal axoneme and basal body, and also connect to
the periciliary membrane via Y-linkers. The CC-TZ harbors membrane-associated and soluble proteins
that coordinate as gatekeepers to regulate the entry, retention, and exit of proteins in and out of the
OS [47,49,50]. At the axonemal base, the ciliary membrane is anchored by the nine microtubular triplets
of the basal body and its associated appendages.
In developing murine PRs, the connecting cilium and OSs assemble through a series of coordinated
events. Shortly after cell cycle exit of retinal progenitor cells, the mother centriole docks to a
primary ciliary vesicle initiating its expansion and fusion with the plasma membrane. Concurrently,
the microtubular axoneme elongates towards the apical end of the neuroblastic layer [51]. In rod
PRs, ciliogenesis typically begins shortly after birth with the appearance of a mature centriolar-bound
ciliary vesicle at around P4 [52]. Subsequently, OS biogenesis occurs asynchronously between P8 and
P14 [52–54] while axoneme and PM extension continue until OS maturation around P19–25 [52,53].
During this process, intraflagellar transport (IFT) provides an efficient mechanism for the movement
and delivery of crucial proteins to the developing OS [55,56], as discussed in greater detail below.
Over the past several decades, two disparate mechanisms of rod disc morphogenesis have been
debated, a vesicular fusion model [57,58], which postulates that membrane discs originate from
rhodopsin bearing vesicles that undergo intracellular membrane fusion, and the classic evagination
model [59], which proposes that new discs result from the evagination of the plasma membrane at the
base of the OS. Recent ultrastructural studies in mouse rod PRs have provided compelling evidence that
support the classic evagination model. By high resolution microscopy, several groups demonstrated
the plasma membrane origin of the evaginated rod disc membranes [60], which subsequently flatten,
elongate, and become enclosed [52,60,61].
OS membranous discs undergo a rapid and continuous turnover with approximately 75 rod discs
being shed daily, corresponding to 10% of the OS [53,62]. At the ciliary tip, aged discs are removed by
the adjacent RPE through phagocytosis. Consequently, OS renewal requires a continuous flow of new
proteins from IS to the OS through the connecting cilium, a process that requires careful regulation.
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For the CC-TZ gate to function properly, efficient mechanisms are needed to prevent the entry of
undesired proteins and to remove the non-OS proteins improperly targeted to the OS. At the base of
the CC-TZ lie transition fibers, which act as a barrier in conjunction with other CC-TZ components,
such as the membrane-associated Meckel syndrome (MKS) complex. The BBSome, an octameric coat
complex, is thought to coordinate the delivery and removal of proteins from the OS during ciliary
formation and maturation [63,64].
Finally, protein trafficking through the CC-TZ is important for PR development and
maintenance [51,65,66]. The movement of protein cargo from the IS to the OS requires a highly
regulated passage of vesicles along microtubules that dock and fuse with the periciliary membrane to
deliver their cargo at the CC base. Movement of targeted proteins through the cilia to the OS may be
facilitated by IFT transport machinery [65] or by a lipidated protein trafficking system [67,68]. During
IFT, protein cargo associate with IFT particles that attach to kinesin and dynein motors and move along
the axonemal microtubules in both anterograde and retrograde directions, respectively. The BBSome is
known to associate with IFT particles and may provide a mechanism for the removal of non-targeted
protein accumulation in the OS [69].
Ciliogenesis. As the ciliary axoneme serves as an important conduit for the IFT movement
of signaling molecules, it comes as no surprise that the disruption of ciliogenesis genes may result
in significant developmental abnormalities causing early lethality and/or rapid PR degeneration.
Genes essential for the elongation of the proximal axoneme (A and B tubules) include Kif3a [70],
which encodes a subunit of kinesin 2, Iqcb1 [71], Arl3 [42], and Arl13b [72]. While patients with missense
mutations in ARL13B present with Joubert-associated features [73], a null mutation, Arl13bhnn, results
in embryonic lethality in mice [74]. Axonemal disturbances and a failure to form OS discs are observed
in developing retinas with conditional Arl13b disruption [72].
Axonemal and ciliary membrane extension. Disruptions in genes that affect ciliary extension
include Rp1/Rp1l1/Spata7 (distal axoneme), Mak, and Pcare (C2orf71; ciliary membrane). Mice with
knockout alleles of Rp1 (Rp1tm1Eap and Rp1tm1Jnz) and Spata7 (Spata7tm1Mrd) show a progressive, moderate
loss in PR cells through the first year of life. Rp1m1Jdun mice homozygous for a Leu66Pro missense
mutation experience a much slower degeneration with 30% of PRs left at 26 months of age. Conditional
ablation studies of Spata7 in PRs and in the RPE have shown that the disruption of SPATA7 in rod and
cone PRs, but not in the RPE, is the molecular basis of the retinal degenerative phenotype [75].
Ciliary Gate and the CC-TZ. Sensory/primary cilia and their gatekeepers (CC-TZ) are found
abundantly in most cell types [76]. Thus, the disease spectrum of ciliary proteins is extensive given
their roles in ciliary trafficking, signaling, and development. Disruptions in CC-TZ genes may result in
isolated cases of inherited retinal dystrophies such as Leber congenital amaurosis or in multisystemic,
ciliopathies such as Joubert, Meckel, or Senior-Løken Syndrome. Such syndromic ciliopathies may
include a multitude of disease phenotypes such as brain malformations, renal cysts, nephronophthisis,
and retinal dystrophy.
Within the CC-TZ reside MKS and NPHP modules that closely interact and form multiple distinct
protein complexes [47,50,77–79]. The MKS complex includes membrane-associated proteins, such as
MKS1 and TMEM67, while NPHP complex proteins, such as NPHP1 and NPHP4, associate in closer
proximity to the ciliary axoneme. Mice harboring mutations in genes coding for these complex-associated
proteins form normal cilia, however, display early abnormalities in OS morphogenesis. After ciliary
biogenesis, retinas in these mutant mice quickly degenerate, eliminating most PRs by 3–4 weeks of age.
Genes whose disruptions affect the ciliary gate functions of the CC-TZ and cause rapid degeneration
include Nphp1, Nphp4, Ahi1, Iqcb1, Tmem67, and Cep290. In humans, mutations in CEP290 can lead
to primarily single-organ diseases such, as retinitis pigmentosa and nephronophthisis, or pleiotropic
diseases, such as the Joubert, Meckel, and Bardet–Biedl syndromes. The most studied allele is rd16,
which harbors a 297 basepair in-frame deletion in Cep290. Compared to Cep290tm1.1Jgg knockout mice,
which show a rapid 78% loss at P14, Cep290rd16 homozygotes have a longer disease progression with a
60% ONL loss at three weeks of age.
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Basal bodies and associated pericentriolar material (PCM). The basal body is a structure derived
from the mother centriole and resides at the base of the cilium along with the daughter centriole,
neighboring centriolar satellites and other related PCM. Proteins positioned at the ciliary base can
also be seen in centrosomes of dividing cells (ALMS1, CEP250, and C8ORF37). Specifically, ALMS1
and CEP250 (CNAP1) localize in close proximity to each other at the proximal ends of centrioles [80].
ALMS1 encodes a 460kDa protein that when disrupted results in the Alström syndrome (ALMS) [81,82].
Mice with a gene trap, frameshift, and nonsense mutations recapitulate human ALMS disease
features such as obesity, diabetes, and neurosensory deficits [21,83,84]. The proper formation of the
connecting cilium and the slow progression of PR cell loss in Alms1Gt(XH152)Byg [83], Alms1foz [84],
and Alms1tvrm102 [21] models suggests that ALMS1 is not essential for ciliary biogenesis but necessary
for overall PR homeostasis.
The ciliary base contains supportive structures necessary for the proper docking of cargo to the
ciliary membrane. Targeted Macf1 null mutants fail to develop the ciliary vesicle needed for basal
body docking while conditional ablation of Macf1 in the developing retina disrupts retinal lamination
and maturation [85]. Mutations in Cdcc66, which encodes a component of centriolar satellites and
Sdccag8, which encodes a recruiter of PCM, result in an early onset but slow-moderately progressive
disease [86,87]. The slower RD makes these alleles attractive models for therapeutic investigations.
Genetic mutations in CC2D2A, which encodes a component of the subdistal appendages of
mother centrioles and basal bodies [88], have been observed in patients with Meckel Syndrome [89],
Joubert Syndrome [90], and non-syndromic rod-cone dystrophy [91]. Mice with null mutations in
Cc2d2a experience embryonic lethality due to the absence of subdistal appendages and nodal cilia [88].
The retinas of adult mice with tamoxifen-induced deletion of Cc2d2a in PRs have a significantly
diminished ONL (2–3 layers) 12 weeks post-injection [92], suggesting that CC2D2A is necessary for
ciliary homeostasis.
Periciliary membrane complex. At the periciliary membrane complex of PRs lies an Usher protein
interactome complex that provides a scaffold for the anchoring of fibers to the periciliary membrane [93].
Mutations in genes encoding members of this complex, Ush1c, Whrn, and Ush2a, result in Usher
syndrome, a disease that results in progressive hearing and vision loss. Multiple forms of Usher
syndrome exist resulting in different degrees of the onset and severity of disease symptoms. In the
mouse, targeted mutations in Usher genes results in a late-onset and very slow progression of PR
degeneration. Homozygous Ush2atm1Tili mice have normal retinas at 10 months of age and lose 70% of
their PRs by 20 months of age [94]. PR degeneration in Whrntm1Tili retinas is protracted with only 30%
loss observed at 28 months of age [95].
Disc morphogenesis. Although the molecular mechanisms involved in OS disc morphogenesis
are not completely understood, there has been considerable progress within the past decade with the
emergence of refined ultrastructural methods. The OS protein, peripherin-2 (PRPH2), localizes to
the rims of rod and cone discs and functions to establish and maintain the membrane rim curvature
during disc formation and maintenance [96,97]. Recent investigations using the Prph2Rd2 (rds) mouse
model [10] have suggested another role for PRPH2 during disc morphogenesis [52]. Using transmission
electron microscopy, Salinas et al. [52] demonstrated that like other forms of cilia [98,99], PR sensory
cilia have an innate ability to spew off ectosomes at the OS base. During normal development of the
OS, ectosome release is inhibited and the retained membrane at the CC-TZ is transformed into discs
upon membrane evagination. In the homozygous Prph2Rd2 mice, discs fail to form resulting in the
accumulation of ectosomes at the OS base. This finding led the authors to propose that PRPH2 may
play a role in inhibiting ectosome release during normal rim formation [52].
Knock-in mice carrying heterozygous alleles of Prph2 (Tyr141Cys [100] and Lys153Δ [101],
mimic the dominant RP disease observed in human patients. It is interesting that PR degeneration
rates vary among Prph2 mutant alleles. While homozygous Prph2Rd2 mice gradually lose their PRs
within the first year [102,103], mice harboring a homozygous null mutation, Prph2tm1Nmc undergo a
faster degeneration with most PRs lost by 4 months of age [104]. Heterozygous Prph2tm1Nmc mice also
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experience PR loss, however the rate of decline is much slower [104]. Comparative studies of Prph2Rd2
with rhodopsin double-knockout mice have suggested that abnormal accumulation of mislocalized
rhodopsin may contribute to PR degeneration in Prph2Rd2 [105]. Hence, the zygosity differences in
degeneration rates may be a result of varying rhodopsin: PRPH2 ratios. In addition, the onset and
severity of the disease may be influenced by the location of the mutation, as different PRPH2 domains
have been implicated in dual roles during disc morphogenesis, the tetraspanin core in rim membrane
curvature, and the C-terminal domain in ectosome release suppression [52].
ROM1 is thought to be involved in the regulation of OS disc formation. PRPH2 and ROM1 are
closely associated at the disc rims in the OS. In humans, a double heterozygous disruption in both
ROM1 (a PRPH2-interacting protein) and PRPH2 results in digenic RP [106]. While it is not clear
whether defects in ROM1 alone causes RP in humans, mice with a monogenic Rom1 disruption show
signs of dominant RP. At one month of age, Rom1 knockout OS discs are visible but appear enlarged
and slightly disorganized [107]. PRs slowly degenerated, reducing the ONL by 34% at 1 year of
age. In contrast, Rom1Rgsc1156 mice with a heterozygous missense mutation, p.W182R, show a 55%
loss of PRs at 35 weeks of age [108]. Furthermore, RD was more pronounced in homozygous mice.
The degeneration in Rom1Rgsc1156 mice may be a consequence of an early reduction in endogenous
PRPH2 and ROM1 levels, which may interfere with PRPH2-mediated stabilization of disc outer rims.
PRCD, progressive rod-cone degeneration, is a rhodopsin-binding protein [109] that localizes to
the OS disc rims [110]. Patients and canines with PRCDC2Y mutations have a slowly progressive form
of rod-cone degeneration [111]. The Cys2Tyr mutation results in mislocalization of PRCD from the
OS to the ONL where it is actively degraded [109]. In the PRs of mice with homozygous Prcdtm1Vya
mutations, loss of PRCD results in the formation of bulging discs that do not properly flatten and in
the accumulation of extracellular vesicles that originate at the OS base [112]. Interestingly, mutant
PRs are able to form membrane discs and the distribution of OS proteins and light response do not
appear to be perturbed. While activated microglia infiltrate the interphotoreceptor space to remove
extracellular vesicles and debris, removal is insufficient and PRs undergo a very slow degeneration.
Homozygous Prcdtm1Vya mice show only 36% ONL loss at 17 months [112] while in Prcdtm1(KOMP)Mbp
homozygotes a similar loss is observed at 30 weeks of age [110]. Both models are knockout alleles that
target the 5′ end of Prcd but are on different genetic backgrounds. Further investigations are necessary
to determine whether gene modifiers affect progressive PR cell loss in these two models.
IFT trafficking. IFT is essential for ciliogenesis in mammals [113] and disruption of this process
often leads to abnormalities in embryonic development. In the mouse, null mutations in genes
encoding subunits of the IFT-A (Ift122 [114], Ift88 [115], and Ttc21b [116]) and IFT-B (Ift172 [117],
Ift80 [118], and Traf3ip1 [119]) complexes result in embryonic lethalities, many of which are attributable
to ciliary-related disturbances in hedgehog signaling [120,121]. These findings further highlight the
integral role of cilia and IFT machinery during embryogenesis.
Hypomorphic and conditional alleles have been useful for elucidating the roles of IFT components
in retinal disease. The hypomorphic allele, Ift88Tg737Rpw, contains a transgenic insertion resulting in a
2.7 kb intronic deletion. Homozygous Ift88Tg737Rpw mice exhibit disorganized OSs as early as P10 and
a progressive degeneration of PRs that reduces the ONL to one layer at P77 [66]. Rod-specific ablation
of Ift172 [122] leads to mislocalization of rhodopsin, RP1, and TTC21B (IFT139) and rapid degeneration
of PRs. Conditional depletion of Ift20 in M cones and mature rods both results in opsin mislocalization
suggesting that proper opsin trafficking hinges on functional IFT components [123]. To gain a clearer
understanding of the roles that IFT molecules play in both rod and cone PRs, additional studies using
conditional models are warranted to elucidate the contributions of impaired IFT components to PR
cell loss.
Lipidated protein trafficking. Lipid modification of proteins, such as prenylation or acylation,
helps direct intracellular protein targeting and regulates protein activity [124]. These hydrophobic
modifications help tether their protein partners to the surface of specific membranes throughout the
cell, such as the ER, Golgi, transport vesicles, or plasma membranes. Improper trafficking of lipidated
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proteins can result in RD. RP2 is a GTPase activating protein that interacts with ARL3 to regulate
assembly and movement of membrane-associated protein complexes [125]. Homozygous mice with
mutations in the gene encoding RP2 exhibit a slowly progressive rod-cone degeneration [126,127]. ARL3,
a small GTPase, traffics lipidated membrane-associated proteins to the rod OS [128]. Although Arl3
knockout mice exhibit early postnatal lethality and Joubert-like features [42], mice with hypomorphic
mutations survive to post-wean and display OS abnormalities as early as P9 [129]. Conditional ablation
of Arl3 in the developing retina results in the absence of cilia, and therefore PR cells are rapidly lost [42].
In contrast, depletion of Arl3 in mature rods leads to mislocalization of lipidated OS proteins, shortened
OS, and a moderate progressive PR loss. These results are consistent with roles for ARL3 in ciliogenesis
during development and cargo displacement during lipidated protein trafficking.
The ciliary TZ-associated protein, RPGR, binds and directs the ciliary targeting of INPP5E [130],
a phosphoinositide phosphatase that is important for ciliogenesis [131]. Ciliary localization of RPGR
itself requires modification with a prenyl group, which interacts with PDE6D [130], a prenyl-binding
protein first discovered as a copurifying component of cGMP phosphodiesterase 6 (PDE6) [132].
Like Rpgrrd9 [133] and Rpgrtm1Tili knockout mice [134], mice with Pde6dtm1.1Wbae null mutations [135]
undergo a very slow degeneration with at least 50% of PR cells remaining at 20 months of age.
Rao et al. have demonstrated reduction of INPP5E in RPGR-deficient axonemal OSs [130]. Altogether,
these observations validate RPGRs role in ciliary trafficking and homeostasis and suggest that other
players may be involved in ciliary targeting of INPP5E.
Mutations in Aipl1 result in early and rapid loss of PR cells (Table S1). D50 < 0.55 months for the four
germline alleles shown in Figure 6, Aipl1tm1Mad, Aipl1tvrm127, Aipl1tm1Visu, and Aipl1tvrm119 [21,39,136].
AIPL1 is a protein chaperone that mediates the folding of phosphodiesterase 6 (PDE6), a key component
of the visual transduction pathway that regulates cGMP levels (see Section 5.2.2. below) [137]. AIPL1
binding is promoted by prenylation of PDE6 subunits [137]. In Aipl1 mutants, PDE6 subunits are
greatly diminished [136], providing further evidence for the importance of lipid modification in PR
viability and vision.
BBSome assembly and regulation. Disruptions in the octameric BBSome complex or associated
chaperonins may cause syndromic ciliopathies such as the Bardet–Biedl syndrome and McKusick–
Kaufman syndrome. In mice, most gene disruptions that affect the BBSome [138] (BBS1, BBS2, BBS4,
BBS7, BBIP1, TTC8, and ARL6), and its regulators (LZTFL1, MKKS, BBS10, and BBS12) result in a
moderate degeneration of PRs. For instance, PRs in homozygous mice harboring gene trap or null
mutations of Bbs4, Bbs4Gt1Nk [139], and Bbs4tm1Vcs [140] appear to progressively decline after maturation
with >90% loss at 7 months of age. The delay and lack of ciliogenesis defects suggests that there may
be some functional redundancy amongst components of the BBSome.
5.2.2. Category 02: Visual Transduction
Overview. Mutant alleles of genes encoding proteins responsible for light detection comprise
a second category of models (Category 02: Visual Transduction; Figure 1c, Table S1). The multistep
phototransduction process that detects light and amplifies this signal is similar in rod and cone
cells, but the specific proteins that catalyze many of the steps are often unique to each cell type [141].
Phototransduction is initiated by the response of opsin-based light-sensitive G protein coupled receptors
that are covalently linked to vitamin A retinal as a cofactor. The receptor rhodopsin (RHO) is expressed
exclusively in rod cells and is optimized to detect dim green light. Cone pigments that detect short or
medium wavelength visible light (OPN1SW and OPN1MW, respectively) are exclusively expressed in
cone cells, in some retinal regions coordinately within the same cell. These receptors constitute >90%
of OS protein and are localized to the disc membranes.
Light activation of RHO or cone pigments causes the bound retinal to isomerize from an 11-cis to an
all-trans configuration, ultimately leading to its release from the receptor by hydrolysis. Isomerization
results in a conformational change in the protein that alters its interaction with a bound heterotrimeric
G protein, transducin, activating the exchange of GTP for GDP bound to the α subunit of this protein.
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In turn, activated α transducin-GTP binds the inhibitory γ subunits of phosphodiesterase 6, releasing
it from the α and β subunits of this complex, which are thereby activated to catalyze the conversion
of cGMP to GMP. The ensuing reduction in cGMP levels in the OS closes the cGMP-gated cation
channel, slowing the influx of Na+ and Ca2+ ions, which hyperpolarizes the plasma membrane of the
OS and, ultimately, the entire cell. Hyperpolarization causes Ca2+ channels to close at the cell synapse,
which leads to a decrease in the calcium-dependent release of glutamate-containing vesicles into the
synapse and activates postsynaptic bipolar neurons.
The process is regulated to ensure the highest sensitivity to illumination. Following its activation,
rhodopsin is quenched by the action of arrestin, which binds to bleached opsin molecules that are
phosphorylated by rhodopsin kinase. Resetting of the cell following the light flash requires the
formation of cGMP from GTP, catalyzed by a membrane-bound guanylate cyclase, the subsequent
closing of the cGMP-gated cation channel, and the restoration of electrolyte distribution across the
plasma membrane as achieved by ion pumps and transporters. Hydrolyzed retinal is passed from the
OS to the RPE as part of the visual cycle (see below), where it is re-isomerized and returned to the PR
cell to regenerate bleached opsin. An additional visual cycle involving Müller cells contributes to the
regeneration of cone pigments.
Visual pigments. Profound effects on PR viability are observed due to mutations that affect
rod cells, which represent 97% of the PR population. Mouse models bearing Rho alleles exhibit
semidominant and recessive rod cell loss phenotypes that vary greatly in the onset and rate, consistent
with the variety of possible disease mechanisms that have been proposed for RHO mutations over
decades of study. For example, some missense alleles in Table S1, such as those that encode the
Pro23His, Cys110Tyr, Tyr178Cys, and Cys185Arg variants [21,142–146] may support a hypothesis
that excessive RHO misfolding in the endoplasmic reticulum induces cellular stress pathways that
lead to PR cell loss [147]. Although the pathways linking misfolded RHO to cell death are not fully
resolved, recent studies of the Pro23His variant in cultured cells and in rats [148] or mice [145,146]
suggest that stress pathways induced by the unfolded protein response are protective, and raise the
possibility that increased intracellular calcium due to ER stress may cause cell death [146]. Misfolding
may also explain the partial mislocalization of RHO Glu150Lys to the IS [149]. However, in this mutant,
much of the protein appears to be correctly exported to the OS, where it leads to irregularly shaped
and disorganized discs, possibly due to a defect in higher-order RHO organization [149]. Pro23His
RHO also disrupts the orientation of discs during their morphogenesis, possibly through similar effects
on higher-order structure [150].
By contrast, the effect of the Gln344Ter variant (Table S1), which is correctly folded but includes
sequence extensions at the C-terminus that interfere with export to the OS [151], as well as the graded
effect of heterozygous or homozygous knockout alleles Rhotm1Jlem and Rhotm1Phm [152,153] or the
premature truncation mutant Arg107Ter (Table S1), provides evidence that a steady flow of RHO to
the OS is essential for PR cell viability. These observations fit an emerging view that a proteostasis
network, incorporating not only cellular stress pathways but also protein trafficking and degradation,
regulates the cellular protein balance to ensure viability [147,154]. According to this view, a failure to
sort vesicles bearing RHO from the Golgi to the periciliary membrane, or a partial or complete loss of
the protein, leads to protein imbalance in the IS. This imbalance may induce cellular stress responses
and also affect the trafficking of other molecules destined for the OS, such as other phototransduction
proteins, lipids, and vitamin A, resulting in cellular toxicity. Finally, the RHO Asp190Asn variant
(Table S1) appears to traffic properly to the OSs but may have structural defects that lead to constitutive
signaling [155], which has been linked to PR degeneration [156]. The same mechanism may account for
the effect of Rho mutants that result in rapid degeneration upon bright illumination [157] but were not
included in Table S1 due to the dependence of the mutant phenotype on an environmental perturbation
(see Discussion). Future studies of these and other models may resolve or converge the many proposed
hypotheses to explain RHO-associated RD.
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Based on the often profound effect of Rho variants on rod cell viability, it might be expected
that cone pigment variants would similarly cause cone PR cell loss. However, cones remain viable
for more than 1.5 years in homozygous Opn1swtm1Pugh mice, which show a 1000-fold decrease in
transcript and produce no detectable OPN1SW by immunoblotting, histochemistry, or single-cell
recording of light responses [158]. Likewise, cones are viable for at least 10 months in homozygous
Opn1mwtm1a(EUCOMM)Wtsi knockout mice, despite an absence of OPN1MW in immunoblotting and
immunohistochemical studies [159]. These studies suggest fundamental differences in the cellular
sensitivity of rod and cone cells to visual pigment deficiency. They also highlight the concern that
reactivity to antibodies against cone opsins or other cone cell markers may be abolished even though
the cells remain viable, and therefore may not be as reliable as counting cone nuclei [160] to assess
cell loss.
Transducins. Rod transducin subunits α, β, and γ (encoded by Gnat1, Gnb1, and Gngt1,
respectively) form the heterotrimeric G protein complex that is essential for propagating the signal from
light-activated rhodopsin. Gnat1 knockout mice have attenuated rod responses and model congenital
stationary night blindness (CSNB) [161]. Although slow PR loss was reported for this model, our
measurement of ONL thickness at four weeks of age based on reported images yielded a value of 90%
of wild type, matching the author’s value at 13 weeks [161] and suggesting an early developmental
difference rather than progressive cell loss. In support of this finding, others using the same strain
reported ONL thickness was 85% of wild type at eight weeks of age with no evidence of significant cell
loss up to 52 weeks of age [162]. By contrast, IRD2 mice, which are homozygous for a Gnat1irdr allele
predicted to yield a prematurely truncated polypeptide, exhibit significant rod PR cell loss (Table S1)
accompanied by late cone cell loss and reduced rod-specific ERG responses [163]. Homozygous
Gnat1irdr mice may recapitulate recessive rod-cone dystrophy, which has recently been linked to human
GNAT1 variants predicted to encode prematurely truncated proteins [164–166]. The Gnat1irdr allele
was discovered independently in rd17 mice at JAX, suggesting a founder effect [167,168].
Gnb1 knockout mice have not been studied due to embryonic and perinatal lethality. However
knockout alleles of the gene encoding rod γ transducin, Gngt1tm1Dgen and Gngt1tm1Ogk, result in
PR loss that is more rapid than in Gnat1 mutants [169,170]. In these strains, GNGT1 deficiency is
accompanied by a 6- to 50-fold post-translational reduction of GNAT1 and GNB1, indicating a key
role of the transducin γ subunit in complex assembly. Gngt1tm1Dgen-associated degeneration is rescued
by heterozygous Gnb1Gt(prvSStrap)4B8Yiw mice [171], which express retinal GNB1 at 50% of wild type
levels. This result suggests that the toxicity of GNGT1-deficiency is due to an excess of improperly
assembled GNB1, which is targeted for degradation but exceeds the capacity of the proteasome [171].
This observation supports the proteostasis network model of PR degeneration [154].
Among genes encoding cone transducin subunits α, β, and γ (Gnat2, Gnb3, and Gngt2), only Gnat2
alleles have been reported to cause PR loss. A progressive reduction of cone cell ERG responses
and a 27% decrease in PNA-positive cells at 12 months of age in homozygous Gnat2tm1Erica mice
(Table S1) is consistent with cone PR loss [172]. However, cone nuclei were not counted directly, so it
is possible that cone cell loss is less pronounced than reported. The predicted GNAT2 Asp173Gly
substitution in this model may alter guanine nucleotide binding [172], although how this change
might cause cell loss is unresolved. Interestingly, mislocalized cone opsin OPN1MW in this model
suggests endoplasmic reticulum stress, which is often associated with PR degeneration. Gnat2cpfl3
mice (Table S1) show no cone cell loss for at least 14 weeks but exhibit a slow loss of rod cells [173].
In contrast to these models, a recently developed Gnat2 knockout strain abolishes GNAT2 function
without PR loss or dysmorphology in the oldest mice examined at 9 months of age [174]. Although
human GNAT1-variants are a rare cause of achromatopsia [175], a stationary congenital colorblindness,
the clinical presentation is variable and some cases are associated with a reduction in visual acuity
with age [176] that may suggest progressive cone cell loss. The available mouse alleles may help to
identify disease mechanisms that contribute to this phenotypic variability.
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Phosphodiesterase 6. Rod phosphodiesterase 6 consists of a catalytic αβ complex encoded by
Pde6a and Pde6b and two inhibitory γ subunits encoded by Pde6g. The control of cGMP levels by
this enzyme is expected to affect both PR function and viability, as cGMP has a central role in the
phototransduction cascade and PR cell metabolism [177], and elevated cGMP levels have been linked
to PR cell loss [178]. Indeed, Pde6a and Pde6b mutants show depressed ERG responses at an early age
and rapid PR loss with D50 values of 11–30 days (Figure 6, Table S1). A study of Pde6a mutations on the
same strain background made use of an allelic series that varied in disease severity [179]. The order of
disease progression due to the alleles reported in this study, nmf282 (Val685Met; fastest) > tm1.1Bewi
(Arg562Trp) > nmf363 (Asp670Gly; slowest), is the same as assessed by D50 (Figure 6). This allelic
series led to a correlation of more rapid PR degeneration with an increased number of cGMP-positive
PR cells [179]. The same trend in the progression of disease in Pde6anmf282 and Pde6anmf363 mice was
found earlier [180], but an opposite cGMP result was obtained, possibly due to the assessment of total
retinal cGMP rather than a count of cGMP-positive PR cells [179] (a 0.1-month difference in the D50 of
Pde6anmf363 mice measured in the two studies may reflect strain differences that might also contribute
to the difference in findings). The later study also combined two alleles that matched human PDE6A
variants to create a compound heterozygote [179], mirroring the more typical situation in human
genetic disease. Further, the allelic series highlighted a non-apoptotic cell death mechanism involving
calpain rather than the expected caspase-mediated apoptotic process [179]. Both elevated cGMP and
calpain activation have been observed in other mouse RD models [181]. Thus, allelic series as used in
these studies are informative for assessing disease mechanisms and identifying potential differences in
treatment efficacy that may reflect disease severity.
Of the Pde6b alleles described, Pde6brd1 and Pde6brd10 have been used most extensively as PR
degeneration models. Pde6brd10 disease develops later, providing a longer window of opportunity to
test therapeutic efficacy (Figure 6). The Pde6batrd1 model has an even slower progression (D50 = 0.71)
than Pde6brd10 mice (D50 = 0.65), which may make it more attractive for assessing the variation
in treatment with disease severity (Figure 6, Table S1). Finally, loss of the inhibitory subunit in
homozygous Pde6gtm1Goff mice did not lead to an expected increase in catalytic activity; instead PDE6G
was found to be essential for activation and possibly stable assembly of the holoenzyme [182].
Cone phosphodiesterase 6 includes two catalytic α subunits encoded by Pde6c and two inhibitory
γ subunits encoded by Pde6h. The Pde6ccpfl1 mutation leads to severely reduced cone ERG response
at three weeks and progressive cone PR loss with age [15] as determined by counting cone nuclei
(Bo Chang, unpublished data, presented in Table S1). This model mimics achromatopsia in humans,
which is sometimes accompanied by cone PR cell loss [183]. Surprisingly, Pde6h knockout mice show
no detectable functional cone loss or degeneration, likely due to the expression of the Pde6g subunit
in mouse cones, which may compensate for PDE6H loss [184]. Variants in human PDE6H cause
achromatopsia [185,186] but cone cell loss has not been reported.
Cyclic nucleotide gated channels and cation exchanger. The decrease in cGMP levels resulting
from PDE6 activation leads to the closing of cyclic nucleotide cation channels in the OS plasma
membrane of both rods and cones. Channel closing diminishes the inward flux of Na+ and Ca2+ ions
that maintain the PR cell in a hyperpolarized state. The rod protein encoded by Cnga1 and Cngb1 is an
α3β1 heterotetramer, in which the β subunit is a long isoform, CNGB1a [187,188]. Cnga1 mutations
have not yet been described. Rod OSs of homozygous Cngb1tm1.1Biel mice yield no detectable CNGB1a
or CNGA1, and rapid PR loss is observed [189]. Together with evidence that CNGA1, but not CNGB1a,
is capable of self-oligomerizing in heterologous expression systems, this result suggests that CNGB1
plays a critical role in stabilizing CNGA1 for channel assembly during synthesis in the secretory
pathway and/or subsequent transport to the OS. Although the mechanisms leading to PR cell loss are
unknown, low intracellular Ca2+ may overactivate guanylyl cyclase and cause toxicity due to elevated
cGMP [189].
The cone channel encoded by Cnga3 and Cngb3 functions as an α2β2 tetramer. Due to the absence
of downstream synaptic signaling associated with channel defects, mutations in both genes result in
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a loss of cone ERG responses modeling achromatopsia. In addition, the alleles included in Table S1,
Cnga3cpfl5, Cnga3tm1Biel, Cngb3cpfl10, and Cngb3tm1Dgen result in cone PR degeneration as assessed by
marker analysis, although confirmation of cell loss by a direct nuclear count was lacking in some
studies. The mechanism of cell death is unknown in these models, but by analogy may involve elevated
cGMP as hypothesized in rods.
A critical component of phototransduction is SLC24A1 (also called NCKX1), which exports
sodium and calcium ions in exchange for potassium. This activity is responsible for the decrease in
intracellular Ca2+ upon closing of the cGMP-gated channels. Homozygous Slc24a1tm1Xen mice exhibit
slow degeneration, possible due to malformation of OS discs [190].
Guanylyl cyclase and activating proteins. Photoreceptor guanylyl cyclases function as homodimers
encoded by two genes in mice, Gucy2e, and Gucy2f. In the homozygous Gucy2etm1Gar model, D50 was
>12 months (Figure 6), indicating very slow rod PR cell loss, while cone cell numbers decreased
rapidly to 33% of controls in 5 weeks [191]. Cone loss with rod preservation has been observed in
Leber congenital amaurosis cases linked to variants of the human Gucy2e ortholog, GUCY2D [192].
However, Gucy2etm1Gar mice are not considered to model this disease because rod ERG function, though
diminished, is still detectable [191]. Although Gucy2f knockout did not cause PR cell loss, double
knockout of both guanylyl cyclase genes resulted in moderate degeneration [193]. Rod and cone
ERG responses were abolished in this model, suggesting that the residual function in Gucy2etm1Gar
mice was due to compensatory activity expressed from Gucy2f. The mechanism of PR cell loss in
these models is unlikely to involve elevated cGMP as the enzymes needed for its production are
ablated. The post-translational downregulation of other phototransduction proteins in double-knockout
mice [193] may indicate a disruption of the proteostasis network that could explain PR cell loss.
Guanylyl cyclase activator proteins provide a feedback loop to restore cGMP levels.
When intracellular Ca2+ is high, these proteins inhibit guanylyl cyclase; when Ca2+ levels are
low, they switch to an activating Mg2+-bound conformation that promotes cGMP synthesis.
This Ca2+-sensitive regulation permits PR cells to reestablish cGMP levels following light exposure
due to lowered intracellular Ca2+, thereby resetting the cell for another stimulus. Double knockout of
Guca1a and Guca1b, which encode the activator proteins in both rods and cones, had no detectable
effect on retinal morphology up to eight months of age [194]. However, homozygous Guca1atm1.1Hunt
mice, which have a Glu155Gly missense substitution identical to one found associated with a severe
dominant cone dystrophy [195], result in rapid loss of cones and subsequently rods (Figure 6, Table S1).
This mutation, like others associated with the human disease, may constitutively activate guanylyl
cyclase due to a defect in calcium sensing [196], leading to cytotoxic accumulation of cGMP.
Recovery from light stimuli. Mechanisms to terminate the phototransduction cascade and recover
the PR cell for additional stimuli include the phosphorylation of activated RHO by a Grk1-encoded
kinase and the binding of Sag-encoded arrestin to the phosphorylated RHO. The binding of SAG limits
transducin access to RHO and thereby prevents further activation of transducin and downstream
processes. Significantly, defects in either gene induce photoreceptor cell loss, likely due to the
accumulation of excess cGMP arising from unregulated active RHO. Early studies aimed at elaborating
the role of the SAG or GRK1 proteins used mice raised in the dark [197,198], as typical vivarium cyclic
light–dark rearing conditions were described as leading to rapid degeneration. Subsequent studies
of homozygous Sagtm1Jnc [199] or homozygous Grk1tvrm207 mice [200] reveal slow PR cell loss with
D50 > 10 months under normal rearing conditions.
5.2.3. Category 03: Metabolism
Overview. Inborn errors of metabolism constitute a heterogeneous group of disorders that affect
metabolic pathways due to underlying genetic defects [201] and result in abnormalities in the synthesis
or catabolism of biomolecules [201,202]. Many such inborn errors of metabolism are known to be
associated with PR cell loss, manifested either as a primary ocular defect or as part of a systemic
disease [201]. PR cells, with their high metabolic activity, are particularly vulnerable to defects in
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metabolism of biomolecules such as lipids, carbohydrates, nucleotides, and proteins, which provide
energy and serve many other functions described below. Additionally, since organelles such as
mitochondria and lysosomes are the major sites for cellular energy production and homeostasis,
defects in organellar metabolism and function are also known to cause PR degeneration. The PR
cell loss associated with different metabolic diseases varies in the age of onset, severity, and rate of
progression (Figure 6, Table S1) and the underlying genetic defects can be categorized based on the
type of biomolecular metabolism or the subcellular location of the pathways affected.
Biomolecular metabolism: lipids. PRs are extremely rich in lipids, which make up to 15%
of their cellular wet weight as compared to 1% in most other cell types [203,204]. Phospholipids
and cholesterol represent 90–95% and 4–6% (w/w) of total lipids, respectively [205]. The major
phospholipids in rod outer segments include phosphatidylethanolamine, phosphatidylcholine,
large amounts of phosphatidylserine, along with small amounts of sphingomyelin, phosphatidylinositol,
and phosphatidic acid [205]. It has been suggested that the phospholipids in OS membranes are
metabolically active and involved in generation of physiological mediators, and changes in metabolism
of glycerolipids have been associated with transduction of visual stimuli [205]. Cholesterol has been
reported to modulate the function of rhodopsin, a major protein of the OS membranes, by influencing
membrane lipid properties [206]. Low-density lipoproteins (LDLs) are reported to be significant
suppliers of PR lipids, especially cholesteryl esters [207,208]. The OSs of PRs are particularly rich in
very-long-chain polyunsaturated fatty acids (PUFA), such as docasohexaenoic acid (DHA), which is
considered to be essential for visual function [209], and phospholipid-containing DHA is suggested to
help in isomerization of 11-cis-retinal to the all-trans form, which is further reduced for its entry into the
visual cycle [210]. Recently, DHA has also been implicated in the maintenance of OS homeostasis [211]
and mediating PR cell survival [212,213].
Thus, it is not surprising that disorders of lipid metabolism cause inherited PR degeneration.
For example, mouse models for mutations in the elongation of very-long-chain fatty acids-like 4 (Elovl4)
gene are reported to show features resembling Stargardt-like macular dystrophy in humans with
cone degeneration preceding that of rods [214,215]. Mutations in genes involved in phospholipid
metabolism such as Lpcat1 cause rapid PR degeneration (90% and 75% degeneration in Lpcat1rd11
and Lpcat1rd11-2J alleles, respectively by 47 days) [216]. Similarly, mutations in genes involved in
cholesterol biosynthesis such as Nsdhl [217] or in the biosynthesis and regulation of DHA-containing
phospholipids, such as Agpat3 and Adipor1, respectively [210], also cause PR degeneration, confirming
the importance of lipids in preserving PR integrity. Since membrane phospholipid asymmetry is
critical to performing various biological functions, mutations in genes important for its generation and
maintenance, also lead to PR degeneration. For example, mutations in Atp8a2, a type of P4-ATPase
that translocates and maintains phospholipid asymmetry show a 30–40% PR degeneration by two
months of age [218]. Similarly, conditional inactivation of Tmem30a, known to be required for folding
and transport of several P4-ATPases to their plasma membrane destination [219,220], also results in
severe PR degeneration [221]. Tmem30a knockout mice exhibit a more severe phenotype compared to
Atp8a2 knockout mice, possibly because Tmem30a binds multiple P4-ATPases [221].
Biomolecular metabolism: carbohydrate and nucleotide energy metabolism. The retina, and in
particular PRs, have a high metabolic rate [222,223] to support functions that are energetically
demanding, such as phototransduction during constant illumination, maintenance of ion gradients
in darkness, and performing anabolic metabolism to replace the approximately 10% of OSs that are
lost every day to phagocytosis by RPE cells [223]. RPE cells also perform many energy demanding
functions, such as maintenance of appropriate ionic and fluid composition in the subretinal space,
uptake and conversion of all-trans-retinol to 11-cis-retinal and its transport back to photoreceptor
cells, and OS phagocytosis. This high energy requirement makes the retina and RPE particularly
vulnerable to functional deficits induced by deficits in energy metabolism [222]. The retina relies
on blood-derived glucose and oxygen for its energy requirements. Additionally, PR cells use excess
lactate obtained from Müller glial cells and convert it to pyruvate to provide energy via oxidative
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phosphorylation [222]. In addition to carbohydrates, the retina uses fatty acids [224] and nucleotides
for its energy requirements [223].
Thus, neuronal activity and energy metabolism are tightly coupled and any mutations at the level
of glucose, fatty acid or nucleotide biosynthesis can lead to PR degeneration. For example, mice lacking
Hkdc1, which encodes a kinase found in the IS that phosphorylates glucose to glucose-6-phosphate,
show 40% PR degeneration by 17 months [225]. Mice mutant for Vldlr, which encodes the receptor
facilitating the uptake of triglyceride-derived fatty acids, show reduced cellular uptake and availability
of fatty acids for energy production [224]. For some alleles of Vldlr (Vldlrm1Btlr and Vldlrtm1Her),
more than 50% of PRs are lost by 12–14 months [226,227], with cones being affected more significantly
than rods [228]. The decrease in net available energy may lead to greater cone loss, as cones have been
reported to require three times more energy than rods [222]. Similarly, while in some cases, mutations
in genes involved in nucleotide metabolism such as Nampt, show embryonic lethality [229], others
such as mutation in Nmnat1, show severe PR degeneration by 4–6 months [230].
Biomolecular metabolism: hormones. The physiology of eye is also dependent on the action of
several hormones [231]. Mouse models mutant for thyroid hormone metabolizing genes, such as Dio3,
which is important for local amplification of triiodothyronine (T3), show selectively detrimental effects
on cone cells [232]. This confirms the proposed role of thyroid hormone signaling in regulating cone
viability and cone opsin expression [232,233]. Melatonin, a hormone that plays a role in sleep patterns,
is known to have protective role against oxidative stress and apoptosis, and regulates retinal circadian
rhythms [234]. A mouse model, mutant for the melatonin hormone receptor Mtnr1a, shows very slow
PR degeneration (25% in 18 months) [235].
Biomolecular metabolism: oxidative stress. The eye is constantly subjected to oxidative stress due
to daily exposure to light, atmospheric oxygen, and high metabolic activities [236]. Reactive oxygen
species (ROS) are derived from diatomic oxygen and processes such as mitochondrial respiration
that form superoxide anion radicals, toxic bis-retinoids that undergo photo-oxidation, and lipids,
such as PUFAs, that undergo peroxidation [237]. Having unpaired electrons confers a great degree
of ROS reactivity that can damage biomolecules such as DNA, lipids and proteins, and organelles
including mitochondria and lysosomes [238,239], thereby impairing their biological functions [203,236].
Compared to other cells, non-proliferative postmitotic cells such as PRs and RPE cells are particularly
sensitive to oxidative damage due to the apparent absence of a DNA damage detection system [240–242].
Under physiological conditions, cellular redox homeostasis is maintained by a balance between
ROS generation and antioxidant systems [236]. Antioxidant enzymes such as Sod1, Sod2, and Gpx4
are known to play a major role in ROS scavenging and changes in their expression or activity or both
are reported to cause increased oxidative stress and are associated with diseases such as age-related
macular degeneration (AMD) [243]. For example, mutations in the Sod1 gene, encoding a cytosolic
Cu-Zn superoxide dismutase that catalyzes the conversion of superoxide to hydrogen peroxide,
are known to cause PR degeneration [244]. Sod2, which encodes a mitochondrial Mn superoxide
dismutase, is required for survival and mutations in this gene lead to embryonic lethality [244,245].
Genes such as Nxnl1 and Nxnl2, known as rod-derived cone viability factors are also suggested to have
antioxidant function and show cone degeneration when mutated [246,247], with Nxnl1 also showing
a progressive rod cell loss [246]. Similarly, a mouse model for loss of Ttpa, coding for a protein that
transports vitamin E, which is known to have antioxidant function, also shows 40% PR degeneration
by 20 months [248].
Organellar metabolism: lysosomes. The lysosome, a subcellular organelle is critical for performing
several vital functions such as degradation of extracellular and intracellular material, nutrient sensing,
energy metabolism, and maintaining cellular homeostasis [249]. Lysosomes contain a wide variety of
hydrolytic enzymes that enzymatically degrade biomolecules such as polysaccharides, lipids, etc. [250].
Defects in lysosomal function results in lysosomal storage disorders, a group of inherited metabolic
disorders sharing a common biochemical feature of accumulating incompletely degraded metabolites
within the lysosomes. Lysosomal storage disorders are generally classified by the composition of the
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material accumulated within them and often differ depending on the lysosomal proteins affected,
which reflect different cell biological processes that are affected but terminating in a similar pathology
of reduced clearance of metabolic aggregates.
RD is an early consequence of lysosomal storage diseases, especially in neuronal ceroid
lipofuscinoses (NCL) [251], also called Batten disease, an early-onset neurodegenerative disease
with other systemic features such as dementia and epilepsy [252]. NCL may be caused by disruption
of genes encoding lysosomal enzymes (Ppt1 and Cln5) and membrane proteins (Mfsd8) as well as ER
membrane (Cln6 and Cln8) and secretory pathway (Grn) proteins, and is characterized by a common
lysosomal accumulation of ceroid. Similar to the early retinal phenotype reported for most human
NCLs, most mouse models for NCL disease show an early onset of PR degeneration, beginning at
1 month of age and showing greater than 60% degeneration by 6–9 months [253–256]. Additionally,
similar to the adult-onset reported for mutations in human GRN, the mouse model for loss of Grn also
shows a late onset PR degeneration by 12 months [257].
Mouse models for other lysosomal disorders, namely, mucopolysaccharidosis and mucolipidosis
due to mutations in lysosomal proteins required for the breakdown of glycosaminoglycans and
enzymes required for phosphorylation of glycoproteins, respectively, also develop PR degeneration.
For example, mouse models for mucopolysaccharidosis with a mutation in Naglu present with a slowly
progressive rod-cone degeneration [258], and for mucolipidosis with a mutation in Gnptab develop a
severe PR degeneration with complete PR loss by 10 months [259].
The lysosome receives materials for degradation via two major pathways, autophagy and
phagocytosis. Phagocytosis has an important function in maintaining retinal health since 10% of the
OSs are phagocytosed daily by the RPE cells to dispose of waste such as photo-oxidative products while
retaining and recycling useful contents back to the PR cells [260]. Phagocytosis by RPE requires its own
machinery for processes such as recognition (e.g., Cd36), engulfment (e.g., Mertk), and degradation
(lysosomal enzymes) of the extracellular material. Disruption of the phagocytic machinery due to
absence/mutations in proteins involved in the phagocytic pathway, therefore, have severe consequences
for PRs and can lead to PR cell death. Mouse models for mutations in genes involved in phagocytosis
such as Mertk, Cd36, and Rab28 show PR degeneration with the loss of Mertk showing a more severe
phenotype (>80% degeneration by 60 days for Mertktm1Grl and Mertktm1Gkm) [261,262] than loss of Cd36
(17% degeneration at 12 month) [263], and the model for Rab28 loss showing a more cone-specific
response [264].
Autophagy is another lysosome-mediated degradation process essential for maintaining cellular
homeostasis [265]. Autophagic flux, the complete dynamic process of autophagy, includes multiple steps
involving the formation of phagosomes and autophagosomes, autophagosome fusion with lysosomes,
the degradation of the intra-autophagosomal contents, and recycling [266]. Thus, both lysosomal
function and autophagy are interconnected wherein disruption of the hydrolytic functions of
lysosomes impairs autophagic flux and, conversely, lysosomal function requires normal flux through
autophagy [267,268]. In the retina, autophagy plays a dual role: promoting cell survival against harmful
stress, and cell death. High basal autophagic levels are maintained in RPE and PR cells. RPE cells
being post-mitotic phagocytes are not self-renewing; the autophagy of intracellular components is
therefore essential for a normal cellular function of the RPE [265]. In PR cells, autophagy occurs
during various cellular activities such as OS degeneration [269], rhodopsin protein expression [270],
visual cycle function, and PR apoptosis [271]. Mouse models of conditional inactivation of autophagy
genes such as Atg5, Atg7, and Rb1cc1 in RPE cells show that these genes are indeed important for
survival of the animal and show PR degeneration.
Organellar metabolism: mitochondria. Mitochondria, often referred to as “the powerhouse of the
cell”, are the major site for cellular energy production in the form of ATP via oxidative phosphorylation.
They also perform other important functions such as ROS generation and scavenging, calcium
regulation, steroid, and nucleotide metabolism, regulation of intermediary metabolism, and initiation
of apoptosis [272]. Oxidative phosphorylation is carried out by the mitochondrial respiratory chain,
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which consists of five complexes located along the inner mitochondrial membrane. These complexes,
in an intricately organized series of biochemical events, synthesize ATP from ADP in response to
cellular energy demands. A large number of mitochondria are present in the rod and cone IS and
in RPE cells. The total surface area of the inner mitochondrial membrane in cones is 3-fold greater
than in rods, presumably accommodating more respiratory chain enzymes to generate more ATP.
Cones require more ATP than rods as they do not saturate in bright light and use more ATP/sec for
light transduction and phosphorylation [222].
Defective cellular energy production due to abnormal oxidative phosphorylation in mitochondria
can therefore lead to PR degeneration. A mouse model for the Leu122Pro mutation of OPA3, a protein
hypothesized to be important for maintaining the inner mitochondrial membrane, is reported to
cause a multisystemic disease characterized by severely reduced vision, loss of ganglion cells and
PR degeneration (by 50%) at 3–4 months of age, a much more severe progression than observed in
humans [273]. Similarly, a mouse model for a mutation in the gene for NAD-specific mitochondrial
enzyme isocitrate dehydrogenase 3 (Idh3a), catalyzing the rate limiting step of TCA cycle, also causes
an early and severe PR degeneration (more than 90%) by 90 days [274].
Extra-mitochondrial components of the tricarboxylic acid cycle and oxidative phosphorylation
machinery have been localized to the rod OS [275]. It has been hypothesized that perturbation of this
machinery results in excess ROS production, leading to PR cell death due to oxidative stress [275–277].
Mutations in a subset of mouse RD models in Table S1 alter genes (Mpc1, Opa3, Idh3a, Impdh1, and Oat)
that encode mouse homologs of mitochondria-associated proteins identified in bovine rod OS [275].
Of these, only IDH3A is directly involved in cellular energy production [274]; the others may influence
oxidative phosphorylation or the TCA cycle indirectly, possibly altering the generation of ROS. It may
be of interest to determine whether PR cell loss in these mouse models correlates with an altered
distribution of extra-mitochondrial oxidative phosphorylation proteins in the rod OS [278], or an
increased ROS production, which can be measured in retinal explants [279].
Organellar metabolism: peroxisomes. Peroxisomes are subcellular organelles with various
catabolic and anabolic functions such as catabolism of long chain fatty acids and biosynthesis of DHA
and bile acids [280]. Several childhood multisystem disorders with prominent ophthalmological
manifestations have been ascribed to the malfunction of the peroxisomes, either at the level of
peroxisomal biogenesis (PBD) or single enzyme deficiencies [281]. While little is known about the
metabolic role of these organelles in retina, studies have shown the presence of peroxisomes in nearly all
layers of retina and RPE, albeit with differential expression of lipid metabolizing enzymes, suggesting
different functions in different cell types [282]. For example, Zellweger spectrum disorder (ZSD) is a
disease continuum known to result from inherited defects in Pex genes essential for normal peroxisome
assembly. Mice homozygous for the G844D point mutation in Pex1 show a decreased ERG response
and loss of cone PRs (up to 80%) by 22 weeks, recapitulating the abnormal retinal function phenotype in
ZSD patients with mild disease [283]. The retinal pathology in such disorders suggests the importance
of peroxisomes in maintaining retinal homeostasis and function.
5.2.4. Category 04: Visual Cycle and Retinoids
The visual cycle reisomerizes vitamin A retinal that has been released from visual pigments in PR
cells, allowing regeneration of the bleached pigments and the subsequent detection of additional light
stimuli. The process is catalyzed by enzymes located in PR and RPE cells, so the retinoid intermediates
in the process must be transported between them. Mutation of genes involved in the visual cycle
pathway cause PR degeneration, in most instances with a moderate to slow progression depending
on the allele and the genetic background. Most Rpe65 mutant alleles show moderately slow PR cell
loss (D50 = 7–11 months) [284–288]. Allelic effects are observed in models bearing missense mutations,
Rpe65tm1Lrcb [289] or Rpe65tm1.1Kpal [290], which cause slower progression than observed in Rpe65tm1Tmr
knockout mice [285–288]. Abca4tm1Ght on the BALB/c strain, which also carries a homozygous Rpe65
Leu450Met mutation, show a late-onset PR degeneration with 40% loss by 11 months of age [291].
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By contrast, the same Abca4tm1Ght mutation on a 129S4/SvJae background results in abnormal thickening
of Bruch’s membrane but normal ONL nuclei count and thickness [292]. Several visual cycle mutant
alleles have other retinal abnormalities but normal ONL nuclei/thickness. For example, Abca4tm1.1Rsmy
causes only autofluorescence and A2E accumulation [293] and Abca4tm2.1Kpal on C57BL/6*129Sv leads
to a RPE defect but normal ONL nuclei count and thickness [294]. In addition, PR degeneration in
Abca4 mutants can be induced by light exposure [295] or through interaction with other genes such as
Rdh8 [296–298]. The Lrattm1Kpal mutation on a 129S6/SvEvTac*C57BL/6J background results in mild PR
degeneration, with <10% loss at 4–5 months [299]. However, a 35% decrease in rod OS length was also
reported in this model, indicating the importance of the visual cycle for OS maintenance. Another
allele, Lrattm1.1Bok, showed a similar loss of rod OS length and 18% PR degeneration at 6 months of
age [300]. The Rbp3tmGil mutation results in the most rapid PR cell loss in this category (D50 = 0.79
months), possibly attributable to an early developmental role of the protein [301]. The Rbp4tm2Zhel
congenic mutation on C57BL/6J showed 20% PR cell loss in some peripheral areas and 10% in the
central retina an age of 40 weeks [302]. Mutations in two genes that play a role in retinoid uptake in
the eye also result in PR cell loss. The Rtbdntm1.1Itl allele causes a slow degeneration with a 20% and
37% loss of PR nuclei at 240 days of age in heterozygotes and homozygotes, respectively. Stra6tm1Nbg
mice exhibit a normal number of rod PR nuclei but significant cone PR cell loss as detected by the
cone-specific marker peanut agglutinin [303]. PR cell loss in Stra6tm1.1Jvil mice was more pronounced
with vitamin A restriction [304].
5.2.5. Category 05: Synapse
PRs absorb light that passes through the anterior portion of the eye and convert the light to
electrochemical signals that are transmitted through the neuroretina via synaptic connections to the
optic nerve and visual cortex [305]. Thus, synapses, necessary for proper cell-to-cell communication,
are critical for vision. Discussion of the complexity of PR synaptic development and function is
reviewed in [306–308], and is beyond the scope of this review. Suffice to say that mutations in many
of the components of synapses, such as presynaptic exocytotic proteins, endocytic proteins, calcium
channels, postsynaptic receptors, and associated elements, must be properly organized to mediate
transmission of signals, or can lead to visual problems [307]. It is interesting to note that disruption of
some synaptic components of the secondary neurons (e.g., GRM6, GPR179, TRPM1, NYX, GNAO1,
GNB5, and GNB3), while affecting function as assessed by ERG response, does not normally lead
to PR degeneration [309]. This is also true of some presynaptic proteins, such as dystrophin [310]
or dystroglycan [311]. However, disruption of some synaptic genes such as Ache, Cabp4, Cacna1f,
Cacna2d4, and Unc119 does lead to PR degeneration. For example, a null allele of Ache [312], causes a
50% loss of PR nuclei between 1.5 and 2 months and >80% by 6–8 months. Although it was initially
determined that the ACHE protein played an important role in hydrolyzing acetylcholine at synapses,
its isoforms are now recognized to have far reaching structural functions [313]. Additionally, it has
been shown that the loss of secondary neurons in the null allele model is likely to cause secondary
PR cell loss [312]. Null or spontaneous alleles of synaptic genes that encode subunits of calcium
channels that regulate the release of neurotransmitters, and the development and maturation of
exocytic function of PR ribbon synapses, Cacna1f [314] and Cacna2d4 [315,316], respectively, show a
slower rate of degeneration. By two months, there are approximately 10–25% of PR nuclei that have
degenerated. CABP4, a protein that regulates calcium levels and neurotransmitter release at PR
synapses, and modulates CACNA1F and other calcium channel activity shows a similar rate of PR
degeneration of 10–25% loss at 2 months [317]. UNC119, which localizes to PR synapses (and IS) and
is hypothesized to play a role in neurotransmitter release, also leads to a relatively late onset, slower
rate of PR degeneration [318]. Interestingly, Haeseleer has described an interaction between synaptic
genes Cabp4 and Unc119 [319]. It is likely that other synaptic proteins will also lead to PR degeneration
through either a primary or secondary effect and that the interactions among the synaptic proteins will
play a significant role in determining the relative rate of the degenerative process.
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5.2.6. Category 06: Channels and Transporters
Ions such as sodium, potassium, and chloride, play important roles in the visual circuitry [320].
Their intracellular concentrations and movements within the cell, and between cells and the environment
are exquisitely regulated by channels and transporters. Due to the importance of maintaining
appropriate levels of these ions for proper function and maintenance of PRs, it is not surprising
that disruption of these genes can lead to PR degeneration. Members of the ClC family of chloride
channels, such as Clcn2, Clcn3, and Clcn7, show particularly early and significant PR degeneration.
Compared to other channels in this section, they appear to have an enriched expression in the
RPE. A 50% PR cell loss can be seen as early as 14–16 days in certain models with disruptions in
these genes [231,321–323]. Indeed, rapid progression of PR cell loss is observed in mice carrying
any of the following alleles: Clcn2nmf240, Clcn2tm1Tjj, Clcn3tm1Lamb, Clcn3tm1Tjj, Clcn7tm1Tjj, Clcn7tm2Tjj,
and Clcn7tm4.1Tjj [231,321,322,324–327]. A similar rapid and complete loss of PRs is seen when
Atp1b2, a Na+/K+-ATPase thought to play a role in cell adhesion, is inactivated [328]. A targeted
mutation in Slc6a6, which encodes a taurine/beta-alanine transporter, also leads to rapid, complete
degeneration [329]. In contrast, inactivation of the bicarbonate, amino acid transporters, and Na+/H+
exchangers, Slc4a7, Slc7a14, and Slc9a8 results in a later onset, but still severe PR degeneration [330–332].
Mouse models bearing mutations affecting BSG, a protein that has a role in targeting monocarboxylate
transporters such as SLC16A1 to the plasma membrane, or REEP6, which mediates trafficking of
clathrin-coated vesicles from the ER to the plasma membrane at outer plexiform layer sites enriched
for synaptic ribbon protein STX3, also fall in this latter late onset/severe category [333,334]. Asic3,
an acid sensing Na+ channel, Clcc1, an intracellular chloride channel, and Slc7a14, an intracellular
arginine transporter, all cause moderately slow degeneration when mutated [331,335,336]. Slowly
progressive PR cell loss is also caused by mutation of Mfsd2a, which encodes a sodium-dependent lipid
transporter responsible for maintaining a high DHA concentration in the retina is important for OS
homeostasis, as discussed in Category 03 [337]. More data are needed to see if sensing and intracellular
channels/transporters generally have milder phenotypes.
5.2.7. Category 07: Adhesion and Cytoskeletal
Proper structure of the retina is developed through protein interactions between cells and within
cells. The spatial and laminar organization of the retina is maintained through junctional interactions
between cells that impart mechanical support to maintain retinal architecture, a means for bidirectional
communication (e.g., extracellular changes to the cell and from the cell to its environment), and together
can form diffusion barriers. Within cells, cytoskeletal architecture is maintained through interactions of
proteins with actin, intermediate filaments, and microtubules that serve to maintain cell morphology
and polarity, and as discussed elsewhere, intracellular trafficking, contractility, motility, and cell division.
Examples of disrupted proteins that lead to gaps between cell layers, presumably through aberrant
adhesion, are mutations in Adam9 and Rs1. The null allele of Adam9, a single pass transmembrane
protein with disintegrin and metalloprotease domains that has been shown to interact with a number of
integrins [338], leads to aberrant adhesion between the apical processes of the RPE and OS and to late
onset PR degeneration [339]. Likewise, mutations in RS1, a protein with a discoid domain, which has
been implicated in cell adhesion and cell–cell interactions [340] lead to a splitting of the inner retinal
layer and progressive PR loss [341–343]. RS1 binding to phospholipids on the membrane surface,
together with other proteins [340] may provide a stabilizing scaffold that is important in cell–matrix,
cell–cell, and cytoskeletal organization.
CRB1 and its interacting partners, such MPP3, MPP5, and PARD6A, have been shown to be
important in establishing proper retinal lamination presumably through their essential roles in
establishing cellular apical basal polarity [344]. A primary defect of a disruption in CRB1 is the
fragmentation of the outer limiting membrane [345,346]. As reviewed previously [344,347], the outer
limiting membrane consists of adherens/tight junctions formed in part by the CRB1 complexes between
Müller glia and the rod or cone IS that form a diffusion barrier. Loss of components of the CRB1
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complexes (CRB1-MPP5-PATJ, CRB1-MPP5-MPDZ, and CRB1-PARD6A-MPP5-MPP3/MPP4) leads
to lamination defects with formation of rosettes and a progressive loss of PRs. Although yet to be
reported, it is likely that mutations in PATJ, PARD3, MPDZ, and MPP4 will lead to similar disease
phenotypes, as a reduction in ERG response in MPDZ mutants [348] and a reduced ERG with abnormal
retinal morphology have been indicated for PARD3 mutants [41,43].
Equally important to the function and maintenance of the retina are the intracellular components
that make up the cytoskeletal cell structure. Disruption of proteins that interact with actin intracellularly
have been shown to lead to PR degeneration. For example, CDC42, a small GTPase that is a key
regulator of actin dynamics [349] leads to an early onset, progressive PR degeneration when disrupted.
Models caused by mutations in FSCN2, an actin crosslinking protein [350,351], and by a hypomorphic
variant of CTNNA1, a protein that coordinates cell surface cadherins with the intracellular actin
filament network [352], show slow-paced PR cell loss. The proper localization of organelles within the
cell is also mediated by the cytoskeletal architecture and can have an untoward effect when disrupted.
For example, SYNE2, a nuclear outer membrane protein that binds to F-actin, tethers the nucleus
to the cytoskeleton and is necessary for the structural integrity of the nucleus [353,354]. Without it,
early onset, moderately paced PR cell loss occurs.
5.2.8. Category 08: Signaling
Molecules such as growth factors/cytokines, hormones, neurotransmitters, and extracellular
matrix proteins, or alternatively, mechanical stimuli, are examples of signals used to communicate
environmental changes to the cell. Surface or intracellular (e.g., nuclear) receptors recognize the
signals and effect changes within the cell, often setting in motion amplifying transduction cascades
that mediate responses such as activation or inhibition of protein activity or migration to different
cellular localizations. Further, signals can also be transmitted from the cell to other cells, for example,
through neurotransmitters. Since intra- and intercellular communication is crucial for the proper
development or function of cells, it is not surprising that a large number of mutations in cellular
signaling lead to defects in retinal development, which in turn affects PR survival. For example,
vascular development is affected in mutants bearing disruptions in Fzd5, Lrp5, Ndp, and Tspan12—all
components of the Wnt signaling pathway. Integral membrane frizzled receptors, of which they are 10,
together with coreceptors, LRP5 and LRP6, mediate canonical Wnt signaling [355]. Thus, conditional
Fzd5 null mutants develop microphthalmia, coloboma and persistent fetal vasculature, and late-onset
progressive RD [356] and Lrp5 mutants exhibit similar vascular and retinal phenotypes [357]. Mice that
are null for NDP, a ligand for FZD4, exhibit delayed retinal vasculature development, retrolental
masses, disorganization of the ganglion cell layer, and occasionally focal areas of ONL absence at later
stages of the disease [358]. TSPAN12, mediates NDP-FZD4-LRP5 signaling in the retinal vasculature,
where it localizes, and a mutation leads to vascular defects that phenocopies disruptions in Ndp, Fzd4,
and Lrp5, and at 3 months exhibits a 50% loss of PRs [359]. In all of these models, it is likely that the
loss of PRs is caused by the aberrant retinal vasculature having secondary effects on PRs. A review
by Hackam suggests that Wnt signaling may affect the apoptotic pathway and neurotrophin release,
dysregulation of which may affect PR survival [360]. MFRP, which bears a CRD domain shared by all
frizzled proteins, also leads to PR degeneration when disrupted [361,362], as does the human knock-in
allele, p.S163R, of its bicistronic partner, CTRP5 [363]. The exact role or function of either protein has
yet to be fully elucidated.
Like the frizzled-associated proteins whose pathological effects on PRs are likely to be mediated
through an aberrant retinal vasculature, other signaling molecules, Ptpn11 and Fyn, appear to mediate
their effects on PRs through another cell type as well, in this case, Müller glia cells, and PRKQ through
the RPE. A Six3-cre mediated conditional knockout of Ptnp11 [364] leads to altered ERK and MAPK
signaling in Müller glia and alteration in their adhesive capabilities. FYN, a Src-kinase membrane
associated tyrosine kinase, localizes to Müller glia cells, and FYN deficiency leads to altered adhesion
properties of Müller cells and retinal dysmorphology [365]. PRKCQ, a serine threonine protein kinase,
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which localizes to the lateral surface of the RPE cells, causes a reduction in adhesion between the apical
processes of the RPE and OSs when it is disrupted. The reduction in adhesion may be responsible for
the retinal detachment and subsequent PR loss observed in this model [366].
The family of PI3Ks or phosphoinositide 3-kinases, made up of catalytic and regulatory subunits,
function to phosphorylate the inositol ring of phosphatidylinositol and thereby regulate growth,
proliferation, differentiation, motility, survival, and intracellular trafficking. For example, it mediates
insulin-stimulated increase in glucose uptake and glycogen synthesis and responds to signals such
as FGFRs and PDGFRs. Conditional knockouts of Pik3cb, encoding a catalytic subunit [367] and
Pik3r1, encoding a regulatory subunit [368], using the cone-specific CRE, Tg(OPN1LW-cre)4Yzl, lead to
progressive cone PR loss. IRS2, necessary for the integration of signals from insulin and IGF1 receptors,
causes an early-onset, moderately paced PR loss [369]. Additionally, a targeted conditional allele
of PDGFRB developed diabetic retinopathy like features with angiogenesis, proliferative DR-like
lesions, pericyte drop out, and eventual PR loss [370]. Disruption of MAP3K1, a serine/threonine
kinase, which participates in the ERK, JNK, and NF-κB signaling pathways, leads to retinal laminar
and vascular defects, aberrant RPE, and PR cell death [371]. SEMA4A, a transmembrane protein,
also causes PR loss, most probably through its effects on endosomal sorting [372].
5.3. Category 09: Transcription Factors
In mice, cone and rod PRs are born and develop between approximately E12 and P0,
and approximately E13.5 and P7, respectively, from the same multipotent retinal progenitor cell
(RPC) pool [373]. PR development, orchestrated by a network of transcription factors, is divided into
five phases: proliferation of multipotent RPCs, restriction of RPC competence, cell fate specification,
expression of genes important for PR function, and finally, PR structural maturation [374,375]. RB1 and
E2F1 function by controlling the G1 to S phase transition in the cell cycle; RB1 plays an inhibitory
role until activated by phosphorylation, balancing cell proliferation and cell fate specification [376].
OTX2 is critical for fate determination, while CRX is necessary for terminal PR differentiation and
acts at different steps in PR development. Transcriptional factors important for rod PR subtype
specification include RORβ, NRL, and NR2E3, and for generation of the cone subtypes, TRβ2 and
RXRγ [374,375]. Further, transcription factors regulate the expression of other transcription factors in
the network (e.g., CRX interacts with Nrl, Rorb, and Mef2d, to name a few, to mediate rod differentiation,
cone differentiation, and proteins necessary for the maturation of the PR, respectively).
The importance of transcription factors in retinal development has been explored in many studies
resulting in a number of mouse models with different disease phenotypes (MGI JAX). In many cases,
disruption of transcription factors, especially those affecting earlier phases of PR development lead to
a reduction in the total number of retinal cells generated. We have only included within this category
those disrupted transcription factors that eventually lead to PR degeneration. Interestingly, the onset of
degeneration of the PR transcription factor models is highly variable—14 days to 2 months of age—and
appears to be dependent upon the method used to generate the model and possibly background strain,
as variation of severity and onset differs among different models of the same gene. Interestingly,
the Crx models provide a series that recapitulate the clinical diagnoses of autosomal dominant
cone-rod dystrophy, Leber congenital amaurosis, and late-onset dominant retinitis pigmentosa. CrxRip
heterozygotes showed 34% degeneration at five weeks, compared to mice homozygous for the
mutation, which reached 55% degeneration at the same age [377]. Crxtm1.1Smgc was also noted to have
a heterozygous disease presentation more similar to a cone-rod dystrophy, while the homozygous
mutant presented with a disease phenotype similar to Leber congenital amaurosis with 70% loss of
PRs at one month of age [378].
Other transcriptional factors necessary for the proper maturation of the PRs, such as, MEF2D,
shown to be important in regulating transcription of OS and synaptic proteins [379], or NRF1 [380],
important in mitochondrial biogenesis also develop PR degeneration when disrupted. Finally, there
are transcriptional factors that are important in the development or function of supporting cells such as
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ONECUT1 for horizontal cells [381] and MITF for RPE and/or choroidal melanocytes [382], which affect
PR survival when disrupted.
5.4. Category 10: DNA Repair, RNA Biogenesis, and Protein Modification
Among the many disrupted genes that lead to PR degeneration, several instances have been
documented in genes necessary for producing fully functional proteins, from transcription through
post-translational modification. Defects in these genes are likely to impact the function of many other
genes that they act upon, and hence, have a greater effect. Since they play a central and basic role,
when disrupted they often lead to prenatal lethality in mice, and the adult phenotype is unknown
unless a conditional knockout or hypomorphic allele is generated. For example, disruption of DNA
repair genes such as Ercc1, RNA splicing genes such as Prpf3, Prpf6, Prpf8, Prpf31, and Bnc2, and miRNA
processing genes, Dicer1 and Dgcr8 are prenatal lethal in a homozygous state [34,383]. In contrast,
homozygous null alleles of Bmi1 [384] and Msi1 [385], both involved in repression of regulatory
genes in embryonic development, are viable, suggesting potential compensatory mechanisms for the
functional loss of these genes. Thus, germline, conditional or hypomorphic models were considered in
this category.
Review of genes in this category suggested that a DNA damage response network to ensure
transcription in the face of DNA lesions might be required for PR cell maintenance. DNA lesions,
such as pyrimidine dimers, interstrand crosslinks, or double-strand breaks (DSBs), are induced
by many mechanisms that include UV radiation or free radicals. Repair of such damage is
essential for DNA replication and, of particular importance for long-lived post-mitotic neuronal
cells, transcription [386–388]. Proteins encoded by Bmi1, Dgcr8, Dicer1, Elp1, Ercc1, Ercc6, Msi1, Sirt6,
Top2b, Ubb, and Uchl3 are known to participate in the DNA damage response [387,389–398], some in
transcription-coupled DNA repair. For example, BMI1 represses transcription at sites of UV-induced
DNA damage to allow repair [389]; ELP1 is a required component of the Elongator complex [399],
which couples RNA polymerase II to an alkyladenine glycosylase that initiates base excision repair [392];
ERCC6 promotes DSB repair in actively transcribed regions by displacing RNA polymerase from
the lesion site [387], and DGCR8 interacts with both RNA polymerase II and ERCC6 to mediate
transcription-coupled nucleotide excision repair of UV-induced DNA lesions [390]. Intriguingly,
topoisomerase TOP2B, which creates DSBs during transcriptional activation [396], has been identified
as a key regulator of transcription during the last stages of postnatal PR development [400]. Thus,
DSBs in PR cells may arise in part from transcriptional activation of genes that encode components
destined for the OS. Additionally supporting the importance of DNA repair to PR maintenance,
Category 01 gene Atr encodes a master regulator of the DNA damage response that has surprisingly
been linked to retinal degenerative disease and localized to the cilium [401]. Further, Category 03
gene Nmnat1 encodes an enzyme that synthesizes nicotinamide adenine dinucleotide in the nucleus,
which may regulate the large-scale polyADP-ribosylation of protein targets at sites of DNA damage [402].
Mutations in the genes encoding these proteins all result in PR cell loss [230,384,385,400,401,403–411].
Mutations in five of these genes as included in Figure 6 (Cwc27, Ercc1, Ercc6, Sirt6, and Ubb) caused
moderate to slow progression of PR cell loss (D50 ≥ 2 months), consistent with a steady accumulation
of unresolved DNA damage with age. The rapid PR cell loss observed in Atrtm1Ofc mice (D50 = 13 days)
may reflect its direct involvement in OS development [401] in addition to the DNA damage response.
Due to the high percentage of alternatively spliced genes in the human retina [412,413], it is not
surprising that mutations in mRNA splicing genes: PRPF3, PRPF4, PRPF6, PRPF8, PRPF31, PDAP1,
and BNC2 have been shown to lead to PR degeneration in humans [3]. In fact, in human retinal
disease, 14% of disease genes are categorized as playing a role in RNA metabolism [383]. Interestingly,
heterozygous humanized alleles of PRPF3 and PRPF8 and the null allele of Prpf31 in mice do not
recapitulate PR degeneration observed in humans but rather exhibit late-onset RPE degeneration [414].
In contrast, a hypomorphic allele of the mRNA splicing gene, Cwc27, with reduced viability, does lead
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to moderate onset PR degeneration [415]. The differences observed among species require additional
studies to unravel the complexities that govern genetic interactions.
Post-translational modification, which occurs by adding modifying molecules to amino acids or
removing or altering these modified amino acids, is important for proper folding, transport/trafficking,
localization, function, regulation, and/or degradation of proteins. Examples of post-translational
modifications include phosphorylation, glycosylation, acetylation, ubiquitination, sumoylation,
methylation, and lipidation [416]. Kinases that affect activity by mediating phosphorylation states
are described elsewhere, however, post-translational modification genes affecting glycosylation and
lipidation/prenylation are prominent among those that lead to PR degeneration. For example,
the encoded proteins of Fkrp, Large1, Pomt1, and PomgnT1, necessary for the glycosylation of
alpha-dystroglycan, essential for formation of the dystroglycan complex and for proper retinal
lamination, lead to moderate rates of PR degeneration when disrupted. Prenylation is critical for proper
trafficking and localization of retinal proteins. Of the three genes important in the prenylation and
postprenylation processes, conditional loss of Rce1 leads to an absence of phosphodiesterase subunits
PDE6A, PDE6B, and PDE6C from the rod OS, probably due to a failure to prenylate one or more of
these proteins [417]. By contrast, ablation of Icmt does not appear to affect phosphodiesterase transport
but rather results in lowered levels of prenylated proteins GNAT1, PDE6G, and GRK1 [418], which are
essential PR proteins. The null mutation of farnesyl-diphosphate farnesyltransferase 1, which adds a
farnesyl group to the cysteine of the CAAX amino acid motif is prenatal lethal, but as a conditional
tissue specific knockout may result in the same PR effects.
Two additional types of post-translational modification involve glycylation and glutamylation of
proteins essential for normal connecting cilia function. Disruption of Ttll3, encoding a protein-glycine
ligase necessary for glycylation of tubulin, results in an absence of glycylation in PR cells, shortening
of the connecting cilia, and slow PR cell loss [419]. Interestingly, PR tubulin glutamylation increased
in Ttll3 mutant mice. TTLL5, tubulin tyrosine ligase like 5, adds glutamate residues on proteins.
Sun et al. [420] reported that Ttll5 disruption leads to late onset, slowly progressive PR cell loss
that phenocopied retinal disease observed in Rpgr mutants. Perhaps this is not surprising as these
investigators determined that TTLL5 glutamylates RPGR, a modification that is necessary for normal
RPGR function in the PR cilium. Agtpbp1 encodes a metallocarboxypeptidase that deglutamylates
target proteins. Its disruption in pcd mutants leads to abnormal tubulin glutamylation [419] and an
accumulation of vesicles in the interphotoreceptor space [421], indicating the importance of proper
post-translational modification for PR survival.
5.5. Category 11: Immune Response
As resident immune cells, microglia survey the retina constantly, presumably with the goal of
removing unwanted debris and responding to damage arising from environmental and/or genetic
stressors. They respond to damage by eliciting various responses that can range from regenerative to
inflammatory depending on the type of injury. Thus, although microglia are unlikely to be instigators in
RD, it may well be the case that microglia influence the severity of responses to ocular damage depending
on mutations. Mutations in several genes central to the immune system lead to PR degeneration
in mouse models. Airetm1.1Doi show early onset PR degeneration with 20% of ONL thickness loss at
10 weeks with rapid progression to 60% ONL thickness loss by 18 weeks [422]. C3ar1tm1Cge mutants
show very slow PR degeneration with about 20% loss at 14 months [423]. Cd46tm1Atk show different
rates of PR nuclei loss in male and female mice with 23% and 31% at 12 months of age, respectively [424].
Mutations in Cx3cr1, normally expressed in immune cells including microglia, were associated with PR
cell loss. Homozygous Cx3cr1tm1Litt [425] and Cx3cr1tm1Zm [426] mice on the same C57BL/6J background
showed similar rates of PR degeneration with 30% and 40% loss, respectively, at 16–18 months of age.
However, Cx3cr1tm1Zm mice on the BALB/cJ background show complete nuclei loss at 4 months of
age [426]. Cxcr5tm1Lipp causes late onset PR degeneration with 20% loss of ONL thickness at 17 months
of age and RPE disorganization [427], whereas ablation of Irf3 and Igfbp3 showed mild PR degeneration
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at 2–4 months of age, about 10–14% [428,429]. Ccl2 and Ccr2 mutations also led to PR degeneration
and fundus lesions, ONL loss in some areas and development of neovascular lesions, resembling
phenotypes of AMD [430]. Cfhtm1Mbo was shown to have an impairment of rod and cone function by
ERG and 29% decreased thickness of Bruch’s membrane; however, rod opsin was distributed normally
and no significant reduction in the number of PR cells was observed [431]. Cfhtm1.1Song demonstrated
retinal whitening and cotton wool spots by fundus imaging [432]. Other genes involved in immune
function that also showed PR degeneration as conditional knockouts encode transforming growth
factor beta receptor II (Tgfbr2) [433] and aryl hydrocarbon receptor (Ahr) [434].
5.6. Omitted Models with PR Abnormalities that May be of Interest
Based on the exclusion criteria described in the Methods section, a number of models with PR
abnormalities caused by single gene mutations were not included in our final Table S1. Since we
narrowly defined PR degeneration models as post-developmental loss of PR nuclei, some models,
which were described with only OS alterations or ERG differences, were not included. For example,
mice bearing a spontaneous point mutation in the Ttc26hop [435] that leads to the generation of a stop
codon, Tyr430Ter, were reported to show OS shortening at one year of age with no PR loss. Likewise,
ectopic expression of cone opsins in rod OSs led to scotopic ERG abnormalities but not PR degeneration
in Samd7tmlTFur mice at 12 months of age [436]. The many allelic variants that cause ERG abnormalities
without PR cell loss are listed in the MGI database and can be accessed through a phenotype query.
5.7. Factors Leading to Phenotypic Variability
5.7.1. Effects of Allelic Heterogeneity
Allelic heterogeneity is frequently a cause of phenotypic variability. For mouse models, this is
often encountered when comparing a knockout model with spontaneous or induced mutations that
still allow a protein to be produced. The latter would primarily be hypomorphic alleles due to amino
acid substitutions, some splicing mutations that leave alternate splice forms intact and some C-terminal
truncating mutations, which may retain some protein function. Often the knockout allele will be the
more severe, presumably because in addition to the loss of protein function, the loss of the protein
itself may cause secondary defects such as the failure to form a molecular complex that normally needs
the native protein to form.
Mutations in the voltage gated calcium channel, Cacna1f, cause congenital stationary night
blindness in humans due to abnormal neurotransmitter release in PR synapses. A null mutation in the
Cacna1f gene (ΔEx14–17) leads to an absent b-wave, abnormal PR synapses, lack of Ca2+ response in PR
terminals and PR degeneration to 8 rows in the ONL at 8 months [314]. In contrast, an Ile756Thr amino
acid substitution found in human patients and introduced into mouse, led to a different phenotype with
reduced b-wave, some intact ribbon synapses, a strong abnormal Ca2+ response, and a more severe
degeneration (3–4 rows at 8 months of age [314]). Here the human allele represents a gain-of-function
mutation that in addition to the loss of the original enzyme activity results in a new activity, or causes
cell stress, which then induces additional phenotypes and makes the disease presentation more severe.
Within an allelic series of amino acid substitutions there are also frequently gradations of
phenotypic severity. If a protein has several functional domains, mutations in different domains may
lead to distinct phenotypes. In addition, some mutations can lead to an abnormal tertiary structure
of the protein. Such structural changes can lead to a failure to interact with binding partners or
substrates/ligands or change the nature of such interactions [437]. Structural changes can also affect
export of the protein from the endoplasmic reticulum (ER) and result in ER stress and eventually
apoptosis of the cell [438].
One of the larger allelic series available is for human PRPH2 with more than 150 disease
causing mutations reported [439]. Although only the secondary structure of the protein is available,
some clustering of disease phenotypes is apparent. For example, the area around amino acids 190–220
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on the intradiscal loop 2 is enriched for mutations causing autosomal dominant retinitis pigmentosa.
This area is thought to interact with ROM1. Mutations leading to macular degeneration are more
frequently present between amino acids 142 and 172. However, some macular degeneration and
autosomal dominant retinitis pigmentosa mutations are also found elsewhere in the protein [439,440].
Once a 3D structure is available, we may find that the disease specific mutations may well be in spatial
proximity and a clearer picture of the genotype-phenotype relation may be revealed.
Allelic heterogeneity can also arise from the intron/exon structure of the gene itself. Many genes
produce several distinct transcripts through alternative splicing of their exons [441]. These differing
transcripts can each produce proteins, which possess unique functions. For example, the Rpgrip1
gene produces two splice variants that code for proteins that differ at their C-terminus, a full-length
transcript and a shorter transcript encompassing exons 1–13 plus three additional C-terminal amino
acids. An insertion between exons 14 and 15 of the full-length transcript leads to PRs with vertically
stacked OS discs [442], whereas, a chemically induced mutation in the splice acceptor site in intron 6
that leads to a loss of both splice variant forms results in a failure to develop OSs altogether [443].
Despite the promise of genotype–phenotype correlation analyses to aid in the functional annotation
of retinal proteins as well as in the diagnosis and prognosis of retinal degenerative diseases, few allelic
series are yet available. In humans the analysis is complicated by the fact that environment and
genetic background effects can confound the allelic effect. In animal models, large allelic series are not
yet available.
Until recently allelic heterogeneity posed a problem for the generation of mouse models for human
retinal diseases because only transgenesis and the generation of knockout models by homologous
recombination were available. The removal of the gene products using knockouts can only model
recessive or haploinsufficiency diseases, and often the complete lack of the protein will lead to
embryonic lethality.
Transgenic models are associated with their own set of problems. Depending on the transgene
integration site, the expression of the transgene can be reduced or cellularly restricted. Integration
into an unrelated gene can disrupt expression of that gene and cause a phenotype that is not related
to the transgene. The use of directed transgene insertion into safe sites, such as the Rosa26 locus
(Gt(ROSA)26Sor) provides a workaround for some of these problems, although the choice of a promoter
that faithfully mimics the native expression is still a difficult process. For these reasons, transgenic
mouse models were not included in this review.
With the advent of CRISPR/Cas9 technology to produce precise cuts in genomic DNA, and the
ability to perform gene editing through homology directed repair, it is now feasible to recreate human
mutations in the mouse and directly probe for the phenotypic effects of allelic heterogeneity [444].
Comitato et al. present an interesting phenotype comparison of transgenic and knock-in rhodopsin
P23H models [445].
5.7.2. Effects of Genetic Interactions
Gene interaction, or epistasis, is frequently observed during genetic analysis when two or more
alleles at different loci combine to alter the onset, type, or severity of disease phenotypes. Such phenotype
altering interactions arise from the organization of proteins and RNAs into macromolecular complexes
and/or biochemical and regulatory pathways and networks. For example, consider hypomorphic
mutations in two proteins that are components of a linear enzymatic pathway. Individually the
reduced activity may not greatly impact the flux through the pathway, but combined in the same cell,
the pathway flux may be reduced and become severe enough to induce a disease phenotype due to a
lack of sufficient pathway product. Alternatively, a mutation may impair Pathway A, so that a disease
phenotype arises. A second mutation may arise in a Pathway B that allows it to compensate for the
malfunction in Pathway A and thus reduce the severity of the original disease phenotype. Mutations
of this latter type of interacting mutations are called suppressor mutations and are extremely useful
because they directly identify potential drug targets whose manipulation may be used to treat disease.
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In general, identification of genetic interactors can be useful for placing the primary mutated gene
in a biological context and help to define its cellular and organismal function. Often, the known function
of a gene and its biology can suggest candidate interacting genes. Similar to the first hypothetical
interaction case above, mutations in two proteins involved in iron homeostasis, ceruloplasmin (CP),
a ferroxidase associated with transferrin transport across the plasma membrane, and hephaestin
(HEPH), implicated in iron transport across cells, individually do not show obvious PR degeneration.
Combined in a double mutant mouse model, however, they lead to iron overload in the retina and
subsequent RPE abnormalities and PR degeneration [446]. Another example involves two proteins
necessary for retinoid recycling, ABCA4 and RDH8. Mutations in each alone do not show any
phenotype; combined they cause all-trans-retinoid accumulation and PR degeneration [296]. Since
previous studies had suggested that activation of TLR3 may lead to inflammation and mediating
apoptosis [447], the authors explored the role of Tlr3 in their Abca4/Rdh8 double mutant model.
Importantly, adding a targeted mutation of Tlr3 to make a triple mutant mouse resulted in rescue of
PR cells [448]. Here then the Tlr3 mutation acts as a suppressor of the degenerative phenotype of the
Abca4/Rdh8 double mutant.
Additional interacting gene pairs have been found that affect PR degeneration, among them
MertktmlGrl; Tyro3tmlGrl [449], Cep290rd16; Bbs4tm1Vcs [450], Cep290rd16; Mkkstm1Vcs [451], Rpgrtm1Tili;
Cep290rd16 [452], Cngb1tm1.1Biel; Cnga3tm1Biel; Hcn1tm2Kndl [453], Crb1tm1.1Wij; Crb2tm1.1Wij [454], Dio3tm1Stg;
Dio2tm1Vag [455], and Ercc6tm1Gvh; and Xpatm1Hvs [456].
In addition to testing candidate interacting genes, methods have been developed to identify such
interactors in an unbiased fashion that is illustrated below.
Effects of genetic background. For the calcium channel gene Cacna1f mentioned above, there is a
third allele available. Chang et al. [457] reported the phenotype of the nob2 mutation, an out-of-frame
insertion of a transposable element into the Cacna1f gene, which is predicted to cause a truncation
after 32 amino acids. The authors demonstrated by western blot that this is a null mutation and no
protein is detected. Compared to the ΔEx14–17 null mutation, however, the phenotype of nob2 is much
milder with no apparent PR degradation [457]. The most likely explanation for this discrepancy can be
deduced from the fact that the nob2 mutation arose on the AxB6 recombinant inbred strain, a strain
whose DNA is composed of alternate segments derived from C57BL/6J and A/J. It is likely that the
A/J strain carries one or more modifier loci that suppress the PR degeneration induced by a Cacna1f
null mutation.
Upon outcrossing an inbred strain carrying a mutation that leads to a particular phenotype with
a different inbred strain, it is frequently observed that the phenotype of the offspring differs from
that of the parents. This was often encountered in the past when knockout alleles were created in
embryonic stem cells derived from strain 129/Sv and the founder animals were then made congenic on
the C57BL/6 background. An early example is a study of a homozygous Rho knockout that was shown
to lose PR nuclei significantly faster on the 129Sv background than on the C57BL/6 background [458].
Corresponding differences were also found in the number of apoptotic nuclei and in ERG responses.
It was concluded that the B6 strain carries protective alleles of modifier genes that lead to a slower
rate of PR degeneration [458]. Alternatively, it is also possible that 129Sv carries modifier alleles that
accelerate degeneration.
Other inbred strains have also been reported to modify retinal phenotypes. For example, a targeted
mutation of Rp1 (Rp1tm1Eap) only showed moderate PR degeneration as an incipient congenic (N6)
on the A/J strain background, but not on C57BL/6J or DBA/1J backgrounds [459]. ONL dysplasia
and excess blue cone formation caused by loss of Nr2e3 in C57BL/6J are suppressed by the genetic
backgrounds of CAST/EiJ, AKR/J, and NOD.NON-H2nb1 strains [460].
In principle, all inbred strains will carry modifier alleles. However, which strain modifies a
particular mutation will depend on the primary mutation. It should be emphasized that an inbred strain
represents a single genotype. In order to model the phenotypic spectrum of a human disease-causing
mutation, many inbred strain backgrounds would have to be examined. Recently, advanced genetically
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diverse mouse populations have become available, such as the collaborative cross (CC) or the diversity
outcross (DO) populations, that allow for more efficient modeling of human populations compared to
the classical inbred strains [461,462].
Modifier screens. Modifier screens are a tool to identify genes that modify phenotypic traits
caused by a particular mutation. The disease modifying properties of inbred strains have been used
for many decades to identify the underlying modifier genes by using genetic crosses, marker assisted
genetic mapping of modifying loci, and positional cloning or more recently high throughput whole
exome or whole genome sequencing approaches. For example, when B6.Cg-Nr2e3rd7 homozygotes are
outcrossed to CAST/EiJ, AKR/J, or NOD.NON-H2nb1 and then the F1 mice intercrossed, homozygous
Nr2e3rd7 mice of the F2 generation are found that unlike the parental B6.Cg-Nr2e3rd7 homozygotes
have fewer spots on fundus examination and no PR layer dysplasia in histological sections [460].
This phenotypic variability is caused by the genetic interaction between the Nr2e3rd7 disease allele and
variants of so-called modifier genes that are specific to the outcross partner strain. Several quantitative
trait loci (QTL) on chromosomes 7, 8, 11, and 19 were mapped [460]. Generation of a congenic line
carrying the Chr11 modifier, along with further fine mapping, reduced the critical genomic interval to
3.3 cM. Several candidate genes were sequenced and a single nucleotide polymorphism was found in a
nuclear receptor gene, Nr1d1, that is predicted to lead to an Arg409Gln amino acid change. Causality
was confirmed by phenotypic rescue of the rd7-associated phenotypes by in vivo electroporation of a
wild-type Nr1d1 expression construct [463].
Several other modifiers have been mapped and identified based on inbred strain differences.
For example, mapping crosses have been carried out for rd3 (BALB/cJ and C57BL/6J, [464]), rd1
(C3H/HeOu and FVB/N, [465]), Crb1 (C57BL/6N and C57BL/6JOlaHsd, Chr15, [466]), Mfrp (B6.C3Ga
and CAST/EiJ, Chr 1, 6, and 11 [467]), and Tub and Tulp1 (C57BL/6J and AKR/J, Mtap1a, [468]).
Although not yet widely used as a means to explore retinal biology, a very efficient way to identify
modifier genes is the use of a sensitized mutagenesis screen in which a male mouse carrying a mutation
of interest is given a chemical mutagen and its offspring are examined for any change in the original
phenotype. Offspring carrying a potential mutation is backcrossed to the unmutagenized parental
inbred strain to test for heritability and to reduce the mutational load. Mutations are identified using
whole exome sequencing of the pheno-deviant mouse. This approach avoids the limited genetic
diversity of inbred strains since in principle all genes can be mutated. An example of the utility of
mutagenesis to search for modifier genes is the identification of a suppressor mutation in Frmd4b that
prevents the PR dysplasia and external limiting membrane fragmentation observed in Nr2e3rd7 mutant
mice [469].
5.7.3. Effects of Environment on PR Degeneration
PR cell loss has been shown to be induced by a number of environmental factors such as light,
diet, and smoking in combination with particular genotypes. Perhaps not surprisingly, light exposure
in some models bearing mutations in genes that function directly or in an ancillary fashion in the visual
transduction pathway trend toward hastening PR degeneration [470,471]. For example, transgenic
mice bearing the rhodopsin VPP mutation, widely used in visual transduction studies, is susceptible to
light-exacerbated PR degeneration [472]. Likewise, mice carrying a homozygous Prom1 null mutation
are particularly susceptible to light-induced degeneration. At eye opening, with exposure to light,
degeneration initiates at P14, and all PRs are gone by P20, whereas dark rearing from P8 to P30
leads to significant preservation of PRs [471]. Dark-rearing has also been demonstrated to delay PR
degeneration in Slc6a6tm1Dhau (10% loss vs. 90% loss in normal vivarium lighting at three weeks of
age) [473] or have no effect in C57BL/6-Mitfmi-vit/J homozygotes [474]. In some situations, light may
actually trigger the disease phenotype, as is the case in Sag knockout mice [198,199], with three Class B1
Rhodopsin missense mutations, Tvrm1 and Tvrm4 [157] or Tvrm144 [18], and in null mutation models
of Rdh12 [475], Asic2 [476], Myo7a [477], Whrn [478], or Akt2 [479]. Sag mutants must be reared in the
dark to observe any PR cells. Under normal vivarium lighting conditions, the other light-sensitive
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mouse models do not show PR degeneration or only a slight shortening of OS at one year of age, as in
the those carrying Rho alleles Tvrm1, Tvrm4, or Tvrm144, and in retinol dehydrogenase (Rdh12) mutant
mice. However, exposure to bright light or rearing under cyclic moderate-lighting, even subjecting
mice to fundus examination, leads to PR degeneration. A comprehensive list of animal models and the
effects of dark-rearing or light exposure can be found in reference [470].
Like light exposure, smoking and high fat intake have been proposed to have a negative impact
on retinal function by increasing oxidative stress and inflammation in PR and RPE cells [480]. Smoking
has been implicated as a major risk factor in the development of age-related macular degeneration
in humans [481,482], and the results have been replicated in mouse models as well. Smoking
leads to increased oxidative stress and inflammation in B6 mice [483] and in the presence of Nfe2l2
deficiency [484]. Likewise, combinations of smoking and high fat intake in the presence of an ApoB
mutation that promotes production of the APOB100 isoform [485] leads to significant loss of PRs [484].
Further, high-fat diet intake for certain genotypes, such as mutations of Ldlr [486] or certain alleles of
Apoe [487], has been shown to compromise PR integrity in mice.
The majority of pharmacological or dietary interventions that have been reported in the relationship
to PR degeneration in mouse models are associated with the goal of increasing vitamin A derivative
availability [488–490] or reducing oxidative stress [491,492] in the retina. Heritable mutations in
enzymes, such as LRAT or RPE65, required for processing of vitamin A within the retina are known to
cause early onset RD due a deficiency of the 11-cis-retinal chromophore. Efficacy of treatment with
9-cis-retinal derivatives of mice with null mutations in Lrat and Rpe65 mice is thoroughly discussed in
a review by Perusek and Maeda [488,489]. Administration of antioxidants has in some cases improved
PR survival. Rs1tm1Web homozygous females or hemizygous males fed a diet high in DHA [493] or
Pde6brd10 mice fed lutein and zeaxanthin [494] showed a significant PR preservation. Further, injections
of a mixture of antioxidants—alpha tocopheral, ascorbic acid, alpha-lipoic acid, and/or Mn(III)tetrakis
porphyrin—were able to slow the loss of cone/rod PRs in Pde6brd1 [495], and Pde6brd10 mice and in
mice with a rhodopsin Q344ter mutation [492]. Environmental enhancement of Pde6brd10 mice was
able to significantly reduce PR loss presumably by reducing retinal oxidative stress [496].
5.8. Relationship to Human Disease Genes
Of the 273 retinal degenerative disease genes in RetNet [3] for which mouse homologs exist,
mouse models are available for 110 or 40% of them, including both germline and conditional mutants
(Figure 7). Through our survey, we found 120 additional genes, in which mutations lead to PR
degeneration. These genes could serve as candidates for yet to be identified human retinal diseases.
The available mouse models, for the most part, recapitulate the human disease phenotype well and
permit mechanistic and therapeutic studies. However, apparent failures of mouse models do occur.
When mutations in MFRP were first identified in humans [497], mice were thought to be a poor
model because unlike humans [498], mice were previously reported to develop PR degeneration [499],
and the microphthalmia and hyperopia found in human patients had not been reported in homozygous
Mfrprd6 mice. In subsequent years, numerous human patients have been identified that do show a
degenerative phenotype [500] and hyperopia was detected both in a mouse model carrying a human
MFRP c.498_499insC allele [501] and the original Mfrprd6 mouse (our unpublished observations).
An important family of deaf–blindness diseases, Usher syndrome, was also thought to be poorly
recapitulated in mice, because early models like the shaker-1 mouse had only the characteristic hearing
loss, but no retinal degeneration [502]. Later, however, it was found that moderate light exposure
does result in photoreceptor degeneration in shaker-1 mice [477]. In addition, a knock-in of the
Acadian USH1C c.216G>A mutation into the mouse Ush1c gene recapitulates both deafness and
retinal degeneration phenotypes [503]. In many cases, discordance between the human and mouse
phenotypes can be attributed to insufficient information about variation in the human disease, or to
allelic effects (knockout vs. hypomorph or gain of function, expression of alternatively splice isoforms),
or strain background (modifier genes) in the mouse models. Such shortcomings in mouse models can
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often be addressed by testing multiple models, including human disease alleles, and by using multiple
genetic backgrounds.
Figure 7. Comparison of the number of RD genes identified in human (RetNet) and mouse as listed in
Table S1 and summarized in Figure 3. The total number of genes in the RetNet database that cause
monogenic disease and have mouse homologs is indicated, as is the total for which conditional or
germline mutations have been associated with PR cell loss in mice, as described in this review. Numbers
within the overlapping areas of the diagram represent genes present in both RetNet and Table S1;
the remaining numbers represent genes that are unique to the indicated category.
Although humans and mice share about 98% of their genes, species differences do exist and
need to be considered when selecting a model. Examples of vision-related genes that mice lack are
EYS, ARMS2, and CETP. Species differences are the result of different evolutionary histories; humans
and mice have encountered different pathogens, resulting in adaptations of our respective immune
systems. Mice have different nutritional requirements, resulting in differences in lipid metabolism.
Additionally, mouse eyes are adapted to a nocturnal life, resulting in a rod dominated retina with
no macula. Nevertheless, mice possess all of the same retinal cell types necessary for vision and
the vast majority of the same genes, and even when missing genes are introduced into mice they
result in relevant phenotypes. For example, in a transgenic mouse model for Stargardt-like macular
degeneration 3 due to a mutation in Elovl4, PR cell loss occurs in the central retina in a pattern that
resembles the human disease [504]. For the many retinal diseases still in need of models, including
complex diseases such as AMD or diabetic retinopathy, it remains the case that valuable new insights
into disease mechanism and basic eye biology can still be obtained from mouse studies.
6. Discussion
6.1. Variability in Measuring PR Cell Loss
We noted an extremely large variability in PR cell loss data presented in the various reports,
which were based on several different types of measures, such as ONL thickness obtained from
toluidine-stained plastic sections, hematoxylin and eosin-stained paraffin sections, or DAPI-stained
cryosections; counts of rows of ONL nuclei in the same preparations; counts of the total number
of ONL nuclei in a fixed retinal area; spider plots assessing ONL thickness over the full perimeter;
ONL thickness from OCT B-scans. Cone numbers were assessed in sections or whole mounts stained
with cone opsins, peanut agglutinin lectin, or cone arrestin. Methods to count cone cell nuclei efficiently
might benefit from studies that examine the effect of mutations in genes that specifically affect cones.
Perhaps more challenging is that many studies provided insufficient sample sizes or number of time
points to assess the progression of PR cell loss. Some of this variability reflects the evolution of methods
and quantitative approaches over several decades, and some may be attributed to the different choices
each laboratory makes depending on what works best given resources and interests. However, to aid
future efforts to compare PR cell loss between studies, we recommend that at least three ages be
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assessed, one prior to the onset of PR cell loss, and at least two within the age range where PR cells
are declining exponentially (that is, between 95% and 5% of wild-type values), and that the data be
quantified relative to gender-matched controls at these same ages.
Although a decrease in PR cell numbers as estimated above is widely accepted as evidence for
RD, an alternative explanation may apply in some instances. Mcoln1tm1Sasl homozygotes exhibit an
apparent decrease in PR cells to 54% of wild-type at one month of age, a value that remained unchanged
at two and six months [505]. TUNEL analysis revealed no increase in apoptosis at any age compared
to controls, and both histology and OCT indicated a decrease in total retinal thickness. It is possible
that the rapid initial decrease to a stable value may result from retinal thinning as the eye enlarges due
to myopia during postnatal development, an occasionally observed feature of MCOLN1-associated
disease in humans [506]. Methods are available to measure axial length in mice [507], which might be
used to determine whether the observed change in nuclear layer thickness is due to ocular enlargement.
Models in Table S1 with a similar phenotype include Guca1atm1.1Hunt and Ctnna1Tvrm5.
6.2. Correlation of PR Cell Loss with Gene Function
As a fortuitous consequence of our inquiry, in some cases, the progress of PR cell loss could be
correlated with gene function within categories. For example, in the ciliary function and trafficking
section we see trends in the onset and progression of RD depending on the role and location of gene
products within the PR. Mice with mutations in genes involved in ciliogenesis or in transition zone
protein complexes, typically result in a PR degeneration that begins at 2 weeks during OS biogenesis
and progresses rapidly through OS maturation. Null mutations in genes that encode components of
the IFT machinery tend to result in premature death or embryonic lethality, and conditional ablation of
these genes in the retina typically leads to early and rapid PR loss. Models with disruptions in protein
complexes with roles in BBSome assembly or regulation, protein/lipid trafficking, axoneme extension,
or disc morphogenesis tend to have a moderate to slow degeneration. Lastly, mice with mutations that
disturb basal body and pericentriolar anchoring and integrity such as the Usher periciliary membrane
complex undergo a very slow form of RD, which results in partial PR function throughout the life of
the mouse. It remains possible that the slower progression of PR cell loss, especially when associated
with members of protein complexes, may be the result of genetic redundancy where multiple genes
encode proteins that have similar biochemical functions.
It was also interesting to note that disruption of chloride channels appeared to be particularly
deleterious to PR survival. Many of the models we identified with early and rapid progression of PR
cell loss, including those affecting a subset of the ciliary genes discussed above or the OS components
Prom1, Prph2, and Rho, appear to be required for OS assembly. Chloride channel defects resulted in
similar progression, raising the possibility that chloride homeostasis is important for OS development.
This idea is supported by evidence that chloride transport by the chloride channel ANO1 is required
for ciliogenesis [508] and that control of intracellular chloride ion levels by this channel regulates
the membrane organization of phosphatidylinositol 4,5-bisphosphate [509], a prominent lipid that
regulates ciliary development [131,510]. Characterization of early OS development in mouse models
defective in chloride channels CLCN2, CLCN3, or CLCN7 may provide mechanistic clues on the role
of intracellular chloride in ciliogenesis.
Finally, our analysis revealed links between PR cell loss and a network of 13 genes known to
participate in the cellular response to DNA damage, four of which have been directly associated
with transcription-coupled DNA repair. Based on canonical indicators of DNA repair, such as the
colocalization of phosphorylated histone H2AX and TRP53BP1 (also known as 53BP1) at DSBs, it has
been reported that rod PR cells in mice lack a robust canonical DNA damage response, [241,511].
An attenuated response may reflect an adaptation to improve rod cell survival [241,511]. Nevertheless,
mechanisms are present in rod cells to repair DNA damage, as evidenced by the robust levels of DNA
repair factors [241] and by our results indicating that a network of DNA damage response genes is
required for maintaining PR cell viability. Together, these results support the idea that a non-canonical
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DNA damage response pathway exists in rod PR cells [512]. Further study of the DNA damage
response genes linked to PR cell loss in mice may be useful for elucidating this pathway.
7. Conclusions
This review highlights mouse models of monogenic retinal degenerative diseases that cause
rod or cone PR cell loss. The models include germline mutations and conditional alleles, in which
characterization of retinal phenotypes in germline mutations was not possible due to embryonic or
perinatal lethality. By providing an extensive list of these models as well as a means of comparing their
progression, we hope to benefit researchers who seek to optimize their experimental approaches.
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Abstract: Studies utilizing large animal models of inherited retinal degeneration (IRD) have proven
important in not only the development of translational therapeutic approaches, but also in improving
our understanding of disease mechanisms. The dog is the predominant species utilized because
spontaneous IRD is common in the canine pet population. Cats are also a source of spontaneous IRDs.
Other large animal models with spontaneous IRDs include sheep, horses and non-human primates
(NHP). The pig has also proven valuable due to the ease in which transgenic animals can be generated
and work is ongoing to produce engineered models of other large animal species including NHP.
These large animal models offer important advantages over the widely used laboratory rodent models.
The globe size and dimensions more closely parallel those of humans and, most importantly, they
have a retinal region of high cone density and denser photoreceptor packing for high acuity vision.
Laboratory rodents lack such a retinal region and, as macular disease is a critical cause for vision
loss in humans, having a comparable retinal region in model species is particularly important. This
review will discuss several large animal models which have been used to study disease mechanisms
relevant for the equivalent human IRD.
Keywords: large animal model; inherited retinal disease; progressive retinal atrophy; retinitis
pigmentosa; Leber congenital amaurosis; achromatopsia; congenital stationary night blindness
1. Introduction
Large animal models for inherited retinal degenerations (IRDs) have been identified within
populations of dogs, cats, sheep, horses and, more recently, non-human primates (NHP). Many
different IRDs have been identified in pedigree dogs, most of which mimic retinitis pigmentosa (RP) or
Leber congenital amaurosis (LCA). The term “progressive retinal atrophy” (PRA) is used to describe
this group of photoreceptor degenerations. In some instances, more detailed descriptive terms such as
rod–cone dysplasia or progressive rod cone degeneration have been used. Common dog breeding
practices have tended to bring out recessive conditions and have made the pedigree dog a rich source of
models for inherited disease, including IRDs. Engineered large animal IRD models such as transgenic
pigs have also been produced [1]. With advances in gene editing technologies, further models are likely
to be produced in species such as pigs and NHPs and possibly even cats and dogs. The advantages of
large animal models over laboratory rodent models of IRDs include the similarity in the size of the
eye to that of man [2]. This is of particular importance for the development of translational therapies
because it allows identical surgical delivery approaches to be used in the animal model to those that
will be eventually used in human patients. NHPs are obviously close relatives to humans, making
them attractive models. However, only a few spontaneous IRDs in primates have been identified [3,4],
although steps are being taken to identify more animals with disease-causing mutations and to use
genome editing to generate additional models with mutations in genes of importance, either for
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germline transmission (see [5] for a review) or somatic gene knockout [6]. Another major advantage of
large animal models is the presence of a retinal region equivalent to the macula. Laboratory mice and
rats are nocturnal rodents that do not have a macula equivalent. The macula is of major importance for
high acuity vision and some conditions specifically or differentially affect that retinal region compared
to the peripheral retina. Macular dystrophies have been associated with mutations in a number of
different genes (see [7,8] for reviews), some of which have relevant large animal models which are
discussed below, including Stargardt Disease (ABCA4 mutations), Best Disease (BEST1 mutations) and
in some patients with RDH5 mutations. Age-related macular degeneration (AMD) is a major cause of
vision loss and has genetic and environmental contributors [9,10]. Screening of primate colonies for
animals with lesions comparable to AMD have been performed [11] (for a review, including primate
models, see Pennesi et al. [12]). The large animal model species considered here have an area centralis
with high photoreceptor density, including, importantly, cones that are equivalent to the human
macula [13]. While NHP also have a fovea, most of the other model species do not, although the dog
has been reported to have a small concentration of cones in the center of the area centralis, referred to
as a “bouquet” of cones [14].
There are several important instances where laboratory rodent engineered models fail
to recapitulate the human disease; important examples including ABCA4-Stargardt disease,
RDH5-retinopathy, or where the gene involved is not present in the mouse or rat genome e.g.,
EYS [15].
The disadvantages of the large animal model species tend to be cost, generation of sufficient
animals due to the slower reproduction, and because of the longer lifespan (compared to laboratory
rodents), the disease course may be longer.
Large animal models have also been important in therapy development. The first proof-of-concept
gene augmentation therapy that eventually led to the FDA approval of the first gene therapy product,
Luxturna, for the treatment of LCA due to RPE65 mutations, was performed in a dog model [16].
Table 1 shows a list of IRDs in large animal models and their identified mutations. Retinal layers
and the genes discussed in detail within the text are shown in Figure 1. This review will cover the
models in which the studies have contributed to the understanding of the mechanism of disease and/or
protein structure and function in greater detail.
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Figure 1. Schematic of retinal layers and associated genes discussed within this review. The left image
shows a histologic section of a feline retina (with comparable anatomy to the human retina). The
right panel depicts a schematic showing the genes detailed in this review and their site of expression,
grouped per biological process. Inner limiting membrane (ILM), nerve fiber layer (NFL), ganglion cell
layer (GCL), inner plexiform layer (IPL), inner nuclear layer (INL), outer plexifom layer (OPL), outer
nuclear layer (ONL), external limiting membrane (ELM), photoreceptor inner segment (IS), connecting
cilium (CC), photoreceptor outer segment (OS), retinal pigmentary epithelium (RPE). Ganglion cell
(GC), amacrine cell (AC), bipolar cell (BC), horizontal cell (HC), rod (R), cone (C).
2. Mutations in Phototransduction Genes
There are spontaneously occurring large animal models with mutations in the genes of the
phototransduction cascade, and rhodopsin (RHO) transgenic pig models have been generated. Studies
of these models have contributed to the understanding of how the mutation of these genes leads to
photoreceptor death.
2.1. RHO
Mutations in RHO can result in a range of phenotypes, most commonly autosomal dominant
RP (adRP), but also autosomal recessive RP (arRP) and congenital stationary night blindness (CSNB).
Animal models and in vitro studies have allowed RHO mutations to be divided into seven classes
(see [17] for a recent review).
2.1.1. Dog Model
A spontaneous dog model of RHO adRP has been identified [18]. The c.11C>G, p.Thr4Arg mutant
dog (RhoT4R) develops a retinal degeneration that is greatly exacerbated by light exposure [19]. The
phenotype of this dog model closely resembles that of the human p.Thr4Lys RHO mutation which
results in dominant RP [20]. Studies of the RhoT4R dog have advanced the understanding of the disease
mechanism underlying class four RHO mutations (those with altered post-translational modification
and stability [17]).
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RHO has seven transmembrane loops with intradiscal and cytoplasmic loops and in the
dark-adapted state is combined with the chromophore 11-cis-retinal. The N-terminal of the protein,
which is affected by the p.Thr4Lys mutation, is positioned within the lumen of the outer segment
discs and creates a “cap” over one of the extracellular loops. This cap contributes towards thermal
stability and receptor activation of the protein; it also protects the chromophore to opsin protein
covalent bond from hydrolysis. Important for the cap role of the N-terminal is glycosylation at N2 and
N15. The p.Thr4Arg mutation interferes with glycosylation at the N2 site, altering the cap role. The
monoglycosylated rhodopsin is expressed and is trafficked to the outer segment; however, it loses the
chromophore faster than the normal meta-rhodopsin II and interacts poorly with the G-protein [21].
The RhoT4R dog has light dependent degeneration similar to the sector RP seen with some rhodopsin
mutations. In sector RP, the inferior retina is more severely affected as this region gets more light
exposure [22]. There is increasing awareness of the need to reduce light exposure to patients with
certain RHO mutations [23]. Studies suggested that the unliganded form of the mutant opsin has
a detrimental effect because of the loss of its structural integrity. Further evidence to support this
was provided by cross breeding RhoT4R dogs with the Rpe65−/− dog to produce RhoT4R/+ Rpe65−/−
dogs which lack 11-cis-retinal chromophore (due to the lack of Rpe65 function) and thus have only
unliganded mutant rod opsin (i.e., have a lack of rod opsin combined with 11-cis-retinal) and show a
greatly accelerated rate of retinal degeneration compared to RhoT4R/+Rpe65+/+ dogs (see details on the
Rpe65−/− dog below) [21].
2.1.2. Pig Models
A number of Rho transgenic pigs have been generated, representing different human mutations:
p.Pro23His [24], p.Pro347Leu [25] and p.Pro347Ser [26]. Studies using the p.Pro347Leu pigs showed
the development of ectopic cone to rod bipolar cell synapses [27] and also interference with the
cone to OFF-bipolar cell connection maturation [28]. The potential contribution of oxidative stress to
cone death was demonstrated in the model [29]. The light responses of single rod photoreceptors of
p.Pro347Leu and p.Pro347Ser transgenic pigs have been studied by suction pipette recording. The
recording revealed protracted recovery of the photoresponse and a progressive reduction in the time to
peak of the response with reduced sensitivity. This work suggests that the mutant rhodopsin reaches
the outer segment and that the substitution at Pro347 interferes with inactivation of the activated form
of Rho. The resulting hypothesis was that the carboxyl end of Rho may be involved in the binding of
rhodopsin kinase. Mutations at Pro347 may reduce the stability of the carboxyl end attachment to
rhodopsin kinase, potentially slowing phosphorylation and the subsequent binding of arrestin [30].
The p.Pro23His pig model has been used to study factors associated with cones developing
dormancy and whether they can be reactivated. There are stages of retinal degeneration where the
degenerating cones lose inner and outer segments. The remaining cell bodies are described as dormant
cones. One hypothesis is that a lack of glucose supply to the cones as a result of loss of surrounding
rods leads to cone dormancy. Experiments to either introduce rod precursors or to supply glucose
to the subretinal space resulted in reactivation of the dormant cones suggesting mechanisms for the
treatment of later-stage IRDs [31].
2.2. Phosphodiesterase 6 Genes
Mutations in genes encoding for the subunits forming the rod specific cyclic guanosine
monophosphate (cGMP) phosphodiesterase (PDE) holoenzyme cause about 36,000 cases of autosomal
recessive RP worldwide in humans, leading to the early onset of night blindness and retinal
degeneration [32].
The rod PDE heteromeric holoenzyme has a catalytic core made of PDE6A and PDE6B subunits
combined with two inhibitory gamma subunits [33]. Mutation in the gene encoding the alpha subunit
of cGMP-PDE (Pde6a) causes PRA in the Cardigan Welsh corgi dog [34,35] and is a model of RP43 in
humans, which accounts for 3% to 4% of recessive RP in North America [36,37]. Mutations in the gene
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encoding the beta subunit of cGMP-PDE (Pde6b) have been identified in a few dog breeds (see below),
including the Irish setter dog [38], which is a model for RP40 in humans and represents about 3% to 5%
of the recessive forms of RP [39,40]. Disease mechanisms for these canine models are detailed below.
2.2.1. PDE6A
A dog model with a null mutation in the gene encoding for Pde6a has been identified. It has a
relatively severe phenotype and is a model for RP43 in humans [34,35]. This form of PRA was given
the name rod–cone dysplasia type 3 (rcd3). The frameshift mutation, c.1939delA. p.Asn616ThrfsTer39,
results in the absence of Pde6a in the affected dog retina (Pde6a−/−) [35]. Western blot analysis
shows the absence of all Pde6 subunits, showing the requirement of Pde6a for stability and normal
trafficking of Pde6b [35]. In the absence of the Pde6 holoenzyme, the cGMP hydrolyzing activity is
absent and cGMP accumulates in the rod photoreceptors [41]. Increased cGMP is a well-established
cause of photoreceptor cell death, likely due to the increased influx of calcium ions into the outer
segment [42], triggering apoptosis [43]. The rod outer segments fail to mature in Pde6a−/− dogs and
the genetically unaffected cones have stunted outer segments, which is reflected in a reduction in
cone electroretinogram (ERG) a-waves early in the disease process [35]. Following the death of rod
photoreceptors, there is a progressive loss of cones, which is reflected in the declining cone ERG
amplitudes which eventually become undetectable at about one year of age (SMPJ unpublished data).
Adeno-associated gene therapy was able to rescue rod function and promote cone function, as well as
preserve retinal morphology [41,44].
2.2.2. PDE6B
The catalytic beta subunit (PDE6B) of the cGMP-PDE heteromeric holoenzyme is another essential
component of the rod photoreceptor phototransduction cascade located in the outer segments [33].
Mutations in the gene encoding for Pde6b causes PRA (rod–cone dysplasia type 1, rcd1) in the
Irish Setter dog [38,45,46] which is a model for RP40 in humans. RP40 is one of the most common
autosomal recessive RPs leading to blindness in midlife in humans. As with the Pde6a−/− dog, rod
photoreceptors are affected first, then cones later in the disease [47,48]. The Pde6b−/− dog phenotype
has an autosomal recessive mode of inheritance and is caused by a nonsense mutation (c.2420G>A,
p.Trp807Ter) [38,45]. This truncated protein would lack the C-terminal domain that is required for
posttranslational processing and membrane association. The failure of phosphodiesterase activity
due to a lack of function in Pde6b leads to elevated cGMP levels from an early age [47,49]. The
elevation of cGMP in rods as they develop outer segments results in the halting of outer segment
elongation followed by rod degeneration, starting in the central retina first, then spreading to the entire
retina following the same pattern of rod maturation. The cone outer segment development is also
halted and, with the loss of the rods, the genetically unaffected cone photoreceptors also progressively
degenerate [46,47]. Interestingly, in contrast to the Pde6a−/− dog retina where the lack of Pde6a leads
to the absence of both alpha and beta Pde6 subunits, the Pde6b−/− dog retina has a detectable Pde6a
subunit in Western blot, prior to rod degeneration [38]. Therefore, it appears that the alpha subunit
is necessary for the beta subunit to be maintained, while the beta subunit is not essential for the
maintenance of the alpha subunit. Adeno-associated gene therapy has been shown to halt retinal
degeneration in the rcd1 dog [50].
Mutations in Pde6b have been identified in at least two other breeds of dogs (Sloughi and American
Staffordshire terriers; see Table 1 for mutation information) [51,52].
2.2.3. PDE6C
Recently, a NHP spontaneous achromatopsia model was identified with a missense mutation
in a cone phosphodiesterase subunit gene (Pde6c; c.1694G>A, p.Arg565Gln) [4]. Affected animals
had behavioral changes, reflecting the photophobia seen in human subjects. They also had macula
changes including foveal thinning and a subtle bullseye maculopathy. In vitro studies suggested that
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the mutant protein was expressed and colocalized with its chaperones, Aipl1 and P. However, the
mutation alters the catalytic domain, meaning that the mutant protein fails to hydrolyze cGMP.
3. Visual Cycle
3.1. ABCA4
Stargardt disease is an inherited macular dystrophy which affects one in 8,000–10,000 people. It is
the most common inherited macular dystrophy and there is currently no cure. It results from mutations
in the gene ABCA4. Mutations in ABCA4 also result in cone–rod dystrophies and RP. ABCA4 is an
ATP-dependent flippase expressed in the photoreceptor disc membrane and is necessary in the visual
cycle for its transport of N-retinylidene-phosphatidylethanolamine and phosphatidylethanolamine
out of the lumen into the cytoplasm [53].
A 1 bp insertion in Abca4 was identified in a family group of Labrador retriever dogs resulting in
a frameshift and premature stop codon [54]. This mutation causes a decrease in the mRNA transcript
and the loss of the full-length protein. As seen in humans, there is an accumulation of lipofuscin in the
RPE cells. Cone and rod photoreceptors both had abnormal function and were decreased in number in
older affected dogs (10+ years). The development of a colony of these dogs as a model for therapy will
have a substantial impact on the treatment of humans with Stargardt disease because mouse Abca4−/−
models lack a phenotype [54,55]. The phenotype in the dog appears to be milder than that seen in
human subjects, with ABCA4 mutations reflecting species differences [56]. Early biomarkers of retinal
changes in the affected dogs will facilitate the use of the Abca4 mutant dog as a model for human
Stargardt disease.
3.2. RPE65
Large animal models with visual cycle gene mutations include the Rpe65−/− dog. This is a model
for LCA2. This model was crucial in the development of translational gene augmentation therapy
which led to the first FDA-approved gene therapy product. The first animal injected with a therapeutic
vector for LCA2 was an Rpe65−/− dog. Therapies were developed by three independent groups and
consisted in each instance of recombinant adeno-associated virus vectors packaged with RPE65 cDNA.
The precise details of promoters and other features such as polyadenylation signals and enhancers
differed between the groups. Four groups with colonies of Rpe65−/− dogs reported successful restoration
of rod and cone function [16,57–59]. Loss of rod photoreceptors in the Rpe65−/− dog was slow and gene
therapy showed ERG rescue even in middle-age [60]. Studies showed that S-cones were sensitive
to the lack of normal 11-cis-retinal supply and s-cone opsin immunoreactivity was lost at an early
age [61]. There were some phenotypic differences between the Rpe65−/− dog colonies, with one showing
early photoreceptor degeneration in the area centralis (canine equivalent of the human macula) [62].
Trials in human subjects have not resulted in the same restoration of function shown by the dramatic
improvement in ERG responses seen in dog and mouse models. A possible explanation for this species
difference in therapy efficacy was provided by a comparison of the Rpe65 function of primates and
dogs. This suggested that primates require a higher level of Rpe65 than dogs for the function of the
visual cycle and that the current therapy might not result in adequate levels of enzymatic function in
humans [63].
3.3. RDH5
Recently, a cat model with a mutation in another visual cycle gene, Rdh5, has been identified by
our group [64]. Rdh5 functions to convert 11-cis-retinol to 11-cis-retinal for transport to photoreceptors
for reforming the visual pigments. In humans, RDH5 mutations cause a variety of phenotypes. Fundus
albipuncatatus is the predominant phenotype [65] but a subset of patients have macular atrophy [66–69]
or cone dystrophy [70]. The Rdh5-mutant cat promises to be a valuable model because the Rdh5−/−
mouse lacks a phenotype and does not recapitulate RDH5-retinopathy in human patients [71]. In
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contrast, the cat model, similar to affected humans, shows a very delayed recovery of photoreceptor
function following light exposure and recapitulates the RDH5-macular atrophy phenotype.
4. Channelopathies/Channel-Related Mutations
Mutations that affect channel protein structure and function resulting in disease are termed
channelopathies. Spontaneously occurring retinal channelopathies have been identified in dogs
resulting from mutations in the cyclic nucleotide-gated ion channels (CNG) of the rod and cone
photoreceptors and the anion channel bestrophin 1 (BEST1).
CNG channels in the rod and cone photoreceptors are directly involved in phototransduction.
The CNG channels expressed in the rod photoreceptor consist of four subunits: three CNGA1 and
one CNGB1 [72–74]. The CNG channel in cone photoreceptors consists of CNGA3 and CNGB3
proteins, in a 3:1 or 2:2 ratio (the stoichiometry of the CNGA3/CNGB3 channel is under debate) [72].
Damaging mutations in the rod CNG channels result in RP, while mutations in cone CNG channels
result in achromatopsia.
BEST1 is a homopentameric channel expressed in the retinal pigment epithelium (RPE) and
involved in anion transport and intracellular calcium homeostasis [75]. Mutations in BEST1 result in a
collection of retinal diseases. Mutations in BEST1 often result in Best Vitelliform Macular Dystrophy,
but the age of onset, mode of inheritance, disease characteristics and prognosis can vary [75].
4.1. CNGA1
In humans, damaging mutations in CNGA1 result in RP49 representing 1% or less of arRP
cases [39]. A 4 bp deletion in Cnga1 was identified in Shetland Sheepdogs with PRA. The mutation
causes a frameshift and a premature stop codon in a highly conserved region of the protein [76].
4.2. CNGB1
There are three splice variants of CNGB1 expressed in the retina, glutamic acid rich proteins
(GARPs) GARP1, GARP2 and CNGB1a. The full-length protein, CNGB1a, is part of the heterotetrameric
CNG channel of the rod photoreceptor [72]. A complex mutation in Cngb1 was identified in Papillon
dogs with PRA. The mutation identified in these dogs is a 6 bp insertion accompanied by a 1 bp deletion,
predicted to result in a frameshift and a premature stop codon, six amino acids downstream [77]. Upon
further analysis of the Cngb1a transcript in the Cngb1−/− dogs, it was found that the mutation led to the
skipping of exon 26, resulting in a premature stop codon early in exon 27. A truncated Cngb1a protein
is produced, but does not form channels with Cnga1 and remains in the inner segments of the rod
photoreceptors [78]. Mutations in CNGB1 cause RP45 in humans, which represents less than 4% of
arRP cases [39].
Human RP45 patients with mutations downstream of the GARP splice variants, the mouse
knockout model (Cngb1-X26) and the Cngb1−/− dog have similar phenotypes [78,79]. The canine model
shows a slow loss of rod photoreceptors and the relative preservation of cones, particularly in the
area centralis and visual streak. Cone function decreases as the disease progresses, as assessed by
ERG, but cone-led vision remains normal, at least up to four years [77]. Preliminary gene therapy
trials have shown that treatment at 3.5–6.5 months of age in affected dogs rescues vision and slows the
progression of the disease in the treated areas [78].
Both the slow disease progression and the large treatment window (in dogs and anticipated in
humans [80]) make the Cngb1−/− dog an ideal model for studying therapies and outcome measures.
4.3. CNGA3
About 25% of human achromatopsia cases are caused by damaging mutations in the alpha subunit
of the cone CNG channel (CNGA3) [81]. Two canine models of achromatopsia were identified with
mutations in CNGA3. The mutations, p.Arg424Trp and p.Val644del (R424W and V644del, respectively),
provided intriguing mutation sites for in vitro testing. Modeling of these mutations lead to further
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insights into CNG channel gating and subunit interactions [82]. The residue R424 is located in the
S6 transmembrane helix and forms a salt bridge with the residue E306 in the S4–S5 linker. Protein
modeling of the canine R424W mutation found the disruption of this salt bridge plays an important
role in protein folding, subunit assembly and channel gating. In vitro expression studies of the R424W
mutation showed increased mislocalization of the mutant CNGA3 protein and the mutant channels
did not produce cyclic nucleotide-activated currents [82].
The canine V644del mutation is in the C-terminal leucine zipper (CLZ) domain, which is
involved in channel assembly and stability. The one amino acid deletion shifts all subsequent residue
interactions within the domain. In vitro studies in a heterologous expression system showed evidence
of mislocalization and a decrease in the total number of active channels, but some mutant channels
(~60%) reached the cell membrane and had normal cyclic nucleotide-activated currents [82].
Two spontaneous sheep models of Cnga3 achromatopsia have been identified [83]. The first
identified has a nonsense mutation (p.Arg236Ter) and the second a missense mutation (p.Gly540Ser) [84].
Adeno-associated virus gene therapy was able to restore cone function in both models [84,85].
4.4. CNGB3
Two unique mutations were identified in the canine Cngb3 gene—a genomic deletion that removes
the entire Cngb3 gene (Cngb3−/−) and a missense mutation (p. Asp262Asn; D262N). The missense
mutation was identified in German Shorthaired Pointers, while the genomic deletion was initially found
in Alaskan Malamutes and later found in other breeds [86,87]. Mutations in CNGB3 are responsible for
at least 50% of achromatopsia cases in humans, making it an ideal target for therapies [87,88].
The D262N mutation in Cngb3 inspired investigation into the Tri-Asp motif that is conserved
in CNG channels [89]. When this mutation was introduced to heterologously expressed CNGA3, it
abolished homomeric channel function and was responsible for mislocalization of the protein. When
the mutation was introduced in CNGB3 in coexpression studies with CNGA3, the response to cyclic
nucleotides was reduced but still present and consistent with CNGA3 homomeric channel function.
These experiments show the Tri-Asp motif is necessary for proper cone CNG channel formation, but
raises the question why mutations in CNGB3 result in the loss of cone function and achromatopsia
when CNGA3 can form a functioning homomeric channel in the absence of CNGB3. Further work in
retinal tissue and/or cone photoreceptors will be needed to elucidate this [89].
Delivery of a human CNGB3 gene via rAAV5 vector to both Cngb3−/− and the D262N mutant
dogs showed that the vector could be targeted to the medium and long wavelength (M/L) cones via a
human red cone opsin promoter and the rescue was dependent on the age of the dog and the promotor,
not on the mutation type [90].
4.5. BEST1
Best vitelliform macular dystrophy (Best disease, BVMD) has autosomal dominant inheritance
and is the most common disease associated with mutations in the gene BEST1. Four other disease
phenotypes have been described in association with BEST1 mutations: adult onset vitelliform macular
dystrophy, autosomal recessive bestrophinopathy, autosomal dominant vitreoretinochoroidopathy
and retinitis pigmentosa. BVMD is characterized by at least one vitelliform lesion in the macula but
can present with multiple lesions. The disease slowly progresses to degenerate the RPE and retina in
the affected regions, resulting in vision impairment [75]. In dogs, a similar disease has been described,
termed canine multifocal retinopathy (CMR) and is caused by mutations in the Best1 gene. In contrast
to the BVMD in humans, CMR due to Best1 mutations is an autosomal recessive disease and has a
consistent and predictable disease phenotype. This consistency and the detailed natural history of the
disease lends well to measuring the outcomes of translatable therapies.
Initially, two Best1 mutations were identified in dogs: p.Arg25Ter (Great Pyrenees and
mastiff-related breeds, cmr1) and p.Gly161Asp (Coton de Tulear, cmr2), with the former resulting in
a premature stop codon and, presumably, a lack of Best1 protein [91]. Analysis of additional breeds
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with CMR identified another breed (Lapponian herder, cmr3) with two deleterious mutations in exon
10, a 1 bp deletion leading to a frameshift and premature stop codon (p.Pro463fs) and a missense
mutation (p.Gly489Val) [92]. Interestingly, the phenotype resulting from the three mutations in dogs
is indistinguishable. The dogs present with multifocal regions of retinal separation with a pink or
tan-colored subretinal fluid, which eventually leads to retinal degeneration. Using optical coherence
tomography to image eyes from cmr1/cmr1, cmr3/cmr3 and cmr1/cmr3 dogs in vivo, the earliest detectable
sign of the disease is at ~11 weeks of age in which there is a retinal elevation in the fovea-like region
of the area centralis. As the disease progresses, this retinal elevation becomes a macrodetachment,
surrounded by microdetachments. Rates of progression, detachment location and number varied, but
the disease was typically localized to the more cone-rich regions of the retina [93].
Immunohistochemistry of CMR canine tissues showed a lack of RPE apical microvilli at the cone
photoreceptor/RPE interface along with accumulated lipofuscin within the RPE. The loss of the RPE
apical processes results in a loss of all direct contact of the cones to the RPE, severely impacting the
physiological role the RPE has on retinal maintenance. It is hypothesized that the lack of RPE apical
processes and subsequent weakened interphotoreceptor matrix is instrumental in the characteristic
detachments and lesions observed in diseases caused by BEST1 mutations [93,94]. Interestingly,
microdetachments were identified in response to light exposure in pre-clinical CMR dogs. The
detachments occurred between the photoreceptor inner/outer segments and the RPE/tapetum interface.
These light-induced detachments occurred within minutes and increased in response to time of light
exposure and would resolve within 24 h.
Using a rAAV2 vector delivered subretinally, CMR dogs were treated by gene augmentation with
wildtype canine or human BEST1. Macro and microdetachments were resolved and RPE microvilli
ensheathment of cone photoreceptors returned within the treatment area. This positive outcome was
retained in the dogs for as long as 207 weeks post injection. The same outcome was present regardless
of age of treatment (within 27–69 weeks of age), the stage of detachments or mutation (cmr1/cmr1,
cmr3/cmr3 or cmr1/cmr3). These results show promise for the treatment of human patients with BEST1
mutations [93].
5. Cilia-Related Proteins (Ciliopathies)
Photoreceptors are non-motile sensory ciliated cells. The connecting cilium between inner and
outer segment is critical for the transport of proteins to and from the outer segment. Many proteins are
expressed in this region of photoreceptors and act to control the trafficking of proteins. Ciliopathies is
a general term used to group conditions resulting from mutations in cilia proteins. As cilia are present
in many cell types, mutations in cilia proteins can cause syndromic disease where retinal degeneration
is present, accompanied by disorders in other organ systems. Mutations that have a milder effect on
function may result in a photoreceptor-only phenotype such as LCA or RP. A number of large animal
models with mutations in cilia related genes have been identified (Table 1).
5.1. BBS4
A mutation in the Bbs4, (Bardet–Biedl syndrome 4) gene, was identified in Hungarian Puli dogs
with PRA. This mutation (c.58A>T, p.Lys20Ter) is predicted to result in nonsense mediated decay of
the Bbs4 transcript. BBS4 is one of the BBS genes involved in cilia function. These dogs showed a
typical PRA phenotype along with noted obesity and abnormal sperm, although more affected dogs
may need to be examined before confirming that this is a syndromic BBS model [95].
5.2. BBS7
An NHP model of Bardet–Biedl syndrome has been recently described. A mutation in exon 3 of
the Bbs7 gene c.160delG (p.Ala54GlnfsTer18) that is predicted to produce a truncated non-functional
protein was identified. As with BBS4, BBS7 is involved in cilia function. Typically in humans, mutations
in BBS genes cause a syndromic condition. The affected NHPs had several features of BBS, including
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retinal atrophy, which was most severe centrally; the affected animals had smaller brains, renal disease,
and the males had small testes. This is the first described model of BBS in NHP and shares many
characteristics with BBS patients with truncating mutations [3].
5.3. CEP290
This cat model, rdAc (retinal degeneration, Abyssinian cat) has been studied in detail for many
years. Compared to most CEP290 (centrosomal protein 290) mutations in other species, the cat model
has a mild phenotype. The onset and rate of photoreceptor degeneration in the cat with the sparing
of the area centralis makes it a model for RP [96,97]. In humans, CEP290 mutations can result in a
spectrum of phenotypes including lethality, severe syndromic disease (e.g., Joubert syndrome) and
most commonly LCA; see [98] for a review. Milder phenotypes such as RP are less common. In the
cat, an intronic mutation (c.6966+9T>G) leads to the introduction of a stronger splice acceptor site
(the wildtype splice acceptor is a GC rather than the much more commonly used GT). The mutation
strengthens an adjacent GT, which, when used, adds 4 bps to the exon 50 sequence, the resulting
frameshift introduces a premature stop codon [99]. The truncated protein escapes nonsense mediated
decay and is expressed. In addition, the wildtype acceptor site is still used for a percentage of the
transcripts (unpublished data). The combination of a truncated protein with some remaining function
combined with a low-level production of full-length transcripts explains the mild phenotype. CEP290
is too large to be packaged in an adeno-associated virus vector and one therapeutic approach being
investigated is the use of a truncated transcript so that a miniprotein may have partial function and
convert a severe phenotype into a milder phenotype similar to that of the cat.
5.4. NPHP4
Wire-haired dachshunds have a cone–rod dystrophy resulting from a truncating mutation in
Nphp4. The identified Nphp4 mutation was a deletion involving exon 5/intron 5 that led to skipping of
exon 5 and a premature truncation in exon 6 of 30 (c.462_526del, p.Leu155LysfsTer2) [100]. A colony
was established from a single founder male [101]. Puppies had miotic pupils and cone-mediated ERGs
were reduced prior to retinal maturation. Furthermore, they did not show the normal increase in
amplitudes with retinal maturation and further declined in amplitude rapidly. The amplitudes of the
rod-driven responses were less severely affected, but were lost with age [102,103]. Interestingly, the
condition is non-syndromic in dogs, just presenting as a cone–rod dystrophy. Human patients with
NPHP4 mutations do not always develop a retinal phenotype, but typically have nephronophthisis,
with some patients having Senior–Løken syndrome, which combines the renal phenotype with a retinal
dystrophy (see for [104] a review). This phenotype difference may represent a species difference, with
Nphp4−/− mice also only having an ocular phenotype with no renal abnormalities, but also showing
male infertility [105].
5.5. NPHP5 (IQCB1)
A mutation was identified in the NPHP5 gene (aka IQCB1) resulting in a cone–rod dystrophy
in American pit bull terrier dogs (crd2) modeling non-syndromic LCA. This mutation (c.952-953insC,
p.Ser319IlefsTer13) results in a frameshift and a premature stop codon [52]. At 6 weeks of age, the crd2
dogs had no cone function and abnormal rod function. Morphologically, the cones completely lacked
outer segments, while the rods developed disorganized outer segments. Despite the lack of cone
function, the cones are retained within the central retina up to 33 weeks of age [106]. Adeno-associated
gene therapy restores and improves photoreceptor function and preserves the outer retina layer [107].
5.6. RPGR
Retinitis pigmentosa GTPase regulator (RPGR) localizes to the connecting cilium and mutations
within the RPGR gene account for>80% of X-linked RP (XLRP). There are two major retinal isoforms, one
encoded by exons 1–19 and a second isoform that consists of exons 1–15 and a retained portion of intron
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15 (ORF15; see [108] for a summary). ORF15 is a mutation hotspot [109]. Three different Rpgr mutations
cause X-linked retinal degeneration in dogs. One is caused by a genomic deletion [110] and two are
due to microdeletions in ORF15 and provide two distinct mechanistic models for RPGR-XLRP [111].
The first, known in the dog as XLPRA1, has a 5 bp deletion and a premature stop codon [111]. This is a
relatively late onset and slowly progressive degeneration [112]. The second form, XLPRA2, has a 2
bp deletion with a frameshift resulting in the addition of 34 basic residues. In vitro studies showed
that the mutant protein aggregated in the endoplasmic reticulum and is hypothesized to have a toxic
effect [111]. The phenotype presents as an early onset degeneration with early changes being outer
segment disruption and opsin (rod and cone) mislocalization. Photoreceptor cell death was shown
to occur in a biphasic manner with two distinct phases of cell death with evidence of remodeling
occurring [113]. Studies of the heterozygous females revealed that there are patches of diseased retina,
presumably resulting from regions where random X-inactivation has resulted in expression of the
mutant allele and patches of unaffected retina (where the wildtype allele is expressed). In the earlier
onset XLPRA2 migration of adjacent photoreceptors into regions where rod photoreceptors died occurs,
showing retinal plasticity in the younger animals. This remodeling was not described in the XLPRA1,
where patches of degeneration occur at a later age [114].
5.7. RPGRIP1
Retinitis pigmentosa GTPase regulator-interacting protein 1 (RPGRIP1) localizes to the connecting
cilium, where it interacts with RPGR. Mutations in RPGRIP1 are associated with autosomal recessive
LCA. A cone–rod dystrophy form of PRA in a colony of miniature longhaired Dachshunds was
reported to be due to an insertion in Rpgrip1 [115] and the rescue of the phenotype by gene therapy
was achieved [116]. When miniature longhaired Dachshunds in pet homes were investigated, the
Rpgrip1 insertion did not appear to segregate with disease status [117]. Further studies have shown
that two other loci influence the development of the phenotype [118–120]. This is an example of the
potential effect of modifying loci on phenotype.
6. Photoreceptor Development
6.1. CRX
The CRX gene encodes an OTX-like homeodomain transcription factor which is essential for
photoreceptor development, maturation and survival [121–124]. Transcription factors are essential
for control of the maturation of progenitor cells [123–126]. Only one spontaneously occurring large
animal model of a retinal transcription factor homeobox mutation has been described, the CrxRdy
cat [127,128]. The heterozygous animal has a severe phenotype of cone-led retinal dystrophy and is a
model for one form of severe early childhood onset blindness (LCA7). While most mutations in CRX
result in LCA7, other phenotypes including cone–rod dystrophy, RP and macular degeneration have
been described [129–131]. CRX mutations have been reported to account for between 0.6% and 2.35%
of LCA [131–134].
As with other transcription factors, CRX has a characteristic structure with a DNA binding domain
(homeodomain) near its N-terminal and a transactivation domain at the C-terminal. The CrxRdy/+
mutant cat models Class III CRX mutations, which are antimorphic frameshift/nonsense mutations
with intact DNA binding, but a lack of target gene transactivation [135]. The CrxRdy/+ cat mutation is
caused by a 1 bp deletion (c.546delC; p.Pro185LysfsTer2) in the final exon of the Crx gene [127]. This
mutant mRNA avoids nonsense mediated decay and produces a truncated Crx protein with an intact
DNA-binding domain but disrupted transactivation domain [128]. Both the mutant transcript and
protein accumulate at higher levels than the wildtype versions, possibly due to increased stability of
the mutant mRNA compared to the wildtype. In vitro studies showed that the mutant mRNA fails
to activate its own promoter [128]. This suggests that the mutant protein has a dominant negative
effect by binding promoter recognition sites, but fails in its transactivation function. The result is
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misregulated gene expression; for example, Rho and cone arrestin (Arr3) mRNA levels are severely
decreased. Truncated photoreceptor outer segments are produced, but the photoreceptors fail to fully
mature [128]. A decreased rod ERG is detectable, which shows evidence of partial maturation before
this is halted and the ERG amplitudes decline, paralleling rod degeneration. Cone function is more
severely affected, with no cone ERG responses being detectable [128].
6.2. STK38L
An early retinal degeneration was described in Norwegian Elkhounds in 1987 [136] in which the
dogs present with vision impairment in low light as early as 6 weeks of age. The causal mutation
was found to be a short interspersed element (SINE) insertion in exon 4 of Stk38l, a gene that had not
been associated with retinal degenerations before its discovery in the Norwegian Elkhounds [137].
The mRNA transcript is produced in the affected dog but does not contain exon 4. Interestingly, at ~6
weeks of age, the expression of the mutant Stk38l transcript is similar to control dogs, but expression
increases at ~8 and ~12 weeks [138].
Detailed histological experiments were performed on affected canine retina to understand the
role of Stk38l in retinal development and how the lack of the functional protein results in retinal
degeneration. The retina in ~4 week old Stk38l-affected dogs is normal, but by ~8 weeks of age the rod
photoreceptors begin to show mislocalization of Rho, irregularities in the outer segments and increased
TUNEL labeling. However, this increase in apoptotic cells is not accompanied by a thinning of the
outer nuclear layer (ONL), as would be expected from loss of rod photoreceptors. The maintenance
of ONL thickness is a result of proliferation of rod-like photoreceptors which express both Rho and
cone S-opsin. After ~14 weeks of age, this proliferation ceases and the ONL begins to thin as the
photoreceptors die, resulting in the loss of at least 50% of the ONL rows by 48 weeks [138].
The Stk38l-affected dogs provide an interesting and unique model of retinal degeneration in which
differentiated photoreceptors either apoptose or proliferate for a short amount of time before retinal
degeneration progresses.
7. Photoreceptor to Bipolar Cell Signaling
7.1. LRIT3
Recently, a dog model of recessively inherited CSNB has been identified due to a mutation in
leucine-rich-repeat, immunoglobulin-like transmembrane-domain 3 gene (LRIT3). Mutations in LRIT3
in humans causes a form of CSNB [139]. The ERG of the affected dogs shows a lack of ON-bipolar cell
function with preservation of cone OFF-bipolar contributions [140–142]. There is currently debate about
the positioning of the LRIT3 protein which had been described as being in the synaptic tips of the bipolar
cells; however, a recent publication showed that it was presynaptic, being present in photoreceptors,
but bridged the synapse to influence the positioning of post-synaptic glutamate signaling proteins [143].
The new availability of a large animal model may facilitate further investigations.
7.2. TRPM1
Studies of Appaloosa horses with CSNB contributed to the identification of the role of transient
receptor potential cation channel subfamily M, member 1 (Trpm1) in bipolar cell signaling [144,145].
The night-blind Appaloosa horse was first recognized as an animal model for the Schubert–Bornschein
type of CSNB in the 1970s [146]. The study published at that time reported a lack of an ERG b-wave and
night blindness but no retinal degeneration or obvious morphological abnormality of the photoreceptor
synapses with second order neurons [146]. The correlation of CSNB in the Appaloosa with the
Leopard complex spotting coat color was recognized [147]. This coat color is governed at a single
gene locus with animals homozygous for the Leopard complex spotting associated allele (LP) also
having CSNB [147]. When the LP locus was mapped, Trpm1, which is also expressed in melanocytes,
was identified as a positional candidate gene and showed markedly reduced expression in retina and
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skin from affected animals [148]. Investigation of TRPM1 in humans with complete CSNB identified
mutations in TRPM1 [149–151] and its role in ON-bipolar cell signaling was identified.
The LP mutation was identified as a retroviral insertion in intron 1 of equine Trpm1 that disrupts
gene transcription by causing premature polyadenylation [152].
7.3. Whippet Dog Model of Incomplete CSNB with Retinal Degeneration
A dog model of cone–rod synaptic dysfunction, which has been described by some authors as a
form of incomplete CSNB, has been identified [153]. The affected dogs lack an ERG b-wave and also
lack cone OFF-bipolar cell attributable ERG components [154]. Interestingly, the dog model develops a
progressive retinal degeneration, which is not reported as a feature of the condition in humans [155].
8. Structural/Other
Retinal degenerations can occur due to mutations in genes involved in the structure or maintenance
of the retina.
8.1. ADAM9
ADAM9 (a disintegrin and metalloprotease domain, family member 9) mutations are associated
with cone–rod dystrophies in humans and dogs. A genomic deletion in Adam9 was identified in Irish
Glen of Imaal Terriers, resulting in a premature stop codon and the loss of the full-length protein.
Similar to the mouse model, histological sections show that the RPE cells do not invest in the outer
segments of the photoreceptors. This mutation effects both the rod and cone photoreceptors, but the
cones are more severely affected throughout the course of the disease [156,157]. Further work is needed
to understand the role of ADAM9 in the retinal structure and RPE maintenance of photoreceptors.
8.2. AIPL1
Mutations in the gene encoding aryl hydrocarbon receptor-interacting protein-like 1 (AIPL1)
causes LCA4 accounting for about 3% to 7% of autosomal recessive LCA [132,134,158–160]. The AIPL1
gene encodes for a protein expressed in the photoreceptor and pineal gland [161]. In photoreceptors,
AIPL1 is concentrated in the tip of the inner segment in proximity to the connecting cilia, acting as a
co-chaperone involved in the folding, assembly and transport of the retinal cGMP phosphodiesterase
(PDE6) heteromeric holoenzyme within photoreceptor outer segments [162–166].
One spontaneous occurring feline large animal model of LCA4 currently exists, the Persian cat [167].
This feline model, similar to human patients with LCA4, presents as an autosomal recessive severe
retinal dystrophy. The disease is characterized by a very early photoreceptor loss, progressing to severe
retinal degeneration before adulthood. This leads to very early blindness [167]. The feline phenotype
is caused by a nonsense mutation at position c.577C>T producing a stop codon (p.Arg193Ter), leading
to the production of a truncated non-functional protein [168]. The precise mechanisms of the severe
phenotype in the feline model are yet to be investigated. The feline model represents a valuable large
animal model for mechanistic studies underlying AIPL1-LCA in humans.
8.3. MERTK
Mutations in MERTK (MER proto-concogene, tyrosine kinase) account for about 1% of arRP. Mertk
was found to be overexpressed (six-fold) in Swedish Vallhund dogs with a retinal dystrophy [169].
After whole genome sequencing of an affected dog, an intact LINE-1 insertion was identified in
intron one of Mertk. A LINE-1 retrotransposon is a long interspersed repetitive element that is found
in all mammalian genomes [170]. It is unclear how this insertion results in overexpression of the
Mertk transcript and subsequent development of retinal disease. More in-depth investigation of
this mechanism will aid a better understanding of how retrotransposon insertions can modify gene
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regulation/expression, ultimately leading to disease, in addition to understanding the specific role of
overexpression of the MERTK transcript in the context of retinal disease [171].
8.4. PRCD
Progressive rod–cone degeneration (Prcd) was a formerly unknown gene that was mapped and
sequenced first in dogs with progressive rod–cone degeneration (PRCD) PRA [172]. Dogs with this
form of PRA had been studied in detail over many years and many different breeds of dog are affected.
The mutation is p.Cys2Tyr, which is in a highly conserved region of the gene. An identical mutation
was found in a human RP patient. Additional mutations also located in exon 1 of PRCD have been
identified in RP patients [172,173]. Since the discovery of Prcd, a mouse knockout model has been
generated and experiments have shown Prcd’s involvement in photoreceptor disc formation and
maintenance [174–176]. Studies in the PRCD dog showed an early ultrastructural change that may
have resulted from this purported function. This was the development of vesicular profiles adjacent to
outer segments being consistent with abnormality in disc formation, furthermore studies also showed
affected dogs had slower photoreceptor disc renewal than normal controls [177].
8.5. RD3
Mutations in RD3 result in LCA12 in humans, a severe retinal degeneration in mice and rod–cone
dysplasia type 2 (rcd2) in Collie dogs [178–180]. RD3 is thought to act as competitor for guanylyl
cyclase-activating proteins, preventing premature cyclase activity in inner segments [181].
Collie dogs have a 22 bp insertion in the Rd3 gene resulting in altered amino acids and an extended
open reading frame [182]. Three splice variants of the gene were identified in the canine retina. In
the Rd3-mutant Collie, the rod and cone photoreceptors outer segments do not fully develop and the
retina degenerates rapidly. By 6 months, there are no photoreceptor inner or outer segments and the
outer nuclear layer contains only one layer of nuclei [183].
9. Conclusions
IRDs that lead to visual impairment and blindness show considerable heterogeneity, where even
similar disease phenotypes can result from mutations in a wide range of different genes. Closer
examination of the broad phenotypes such as RP and LCA show the genetic heterogeneity with altered
function of a range of genes leading to photoreceptor loss. Large numbers of different mutations within
a single gene exist and can result in a range of phenotypic differences.
The mechanisms by which the gene mutation leads to cell death differs between genes and between
mutations within individual genes. Laboratory rodents have been the workhorses for studying disease
mechanisms because of the ease with which their genome can be engineered, the short reproductive
time and relatively low costs of maintenance. They have allowed identification of disease pathways
and allowed the study of how and why degeneration occurs. However, laboratory rodents have very
significant shortcomings. Rodents are nocturnal animals with a different pattern of distribution of
photoreceptors to humans. The large animal models discussed in this review have retinal photoreceptor
distribution that is much closer to that of humans. This is particularly important when considering
conditions that have a major effect on the macula. Large animal models have also been of value for the
development and testing of translational therapies. They are particularly valuable for this because the
larger eye size and proportions of lens and vitreous is much closer to that in humans, allowing for
identical surgical approaches for trials of translational therapies. The several, mostly spontaneously
occurring, large animal models mentioned here have provided valuable information about disease
phenotypes and disease mechanisms. They offer great potential for even more detailed studies to
understand how photoreceptor function and survivability is affected by the gene mutations and to
study the extensive inner retinal remodeling and glial cell activation that occurs in IRDs. Modeling of
IRDs using retinal organoids developed from induced pluripotent stem cells from IRD patients is an
exciting field of research. These potentially allow the study of the effect of the exact mutation that is
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present in the patient and in a human cultured tissue. However, they do not yet fully recapitulate the
specific environment within the retina of a living animal, so, while showing great promise, they cannot
yet replace whole animal studies. Improving our understanding of how and why photoreceptors die
may suggest novel therapies to preserve function and slow down vision loss. There remain untapped
populations of companion animals (dogs and cats) with spontaneous IRDs, with new potential models
being identified with increasing frequency. The advances in gene editing also expand the opportunity
to develop additional large animal models with specific mutations that even more accurately model
human IRDs.
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Abstract: Peripherin 2 (Prph2) is a photoreceptor-specific tetraspanin protein present in the outer
segment (OS) rims of rod and cone photoreceptors. It shares many common features with other
tetraspanins, including a large intradiscal loop which contains several cysteines. This loop enables
Prph2 to associate with itself to form homo-oligomers or with its homologue, rod outer segment
membrane protein 1 (Rom1) to form hetero-tetramers and hetero-octamers. Mutations in PRPH2
cause a multitude of retinal diseases including autosomal dominant retinitis pigmentosa (RP) or
cone dominant macular dystrophies. The importance of Prph2 for photoreceptor development,
maintenance and function is underscored by the fact that its absence results in a failure to initialize
OS formation in rods and formation of severely disorganized OS membranous structures in cones.
Although the exact role of Rom1 has not been well studied, it has been concluded that it is not necessary
for disc morphogenesis but is required for fine tuning OS disc size and structure. Pathogenic mutations
in PRPH2 often result in complex and multifactorial phenotypes, involving not just photoreceptors,
as has historically been reasoned, but also secondary effects on the retinal pigment epithelium (RPE)
and retinal/choroidal vasculature. The ability of Prph2 to form complexes was identified as a key
requirement for the development and maintenance of OS structure and function. Studies using
mouse models of pathogenic Prph2 mutations established a connection between changes in complex
formation and disease phenotypes. Although progress has been made in the development of
therapeutic approaches for retinal diseases in general, the highly complex interplay of functions
mediated by Prph2 and the precise regulation of these complexes made it difficult, thus far, to develop
a suitable Prph2-specific therapy. Here we describe the latest results obtained in Prph2-associated
research and how mouse models provided new insights into the pathogenesis of its related diseases.
Furthermore, we give an overview on the current status of the development of therapeutic solutions.
Keywords: peripherin 2; retinal degeneration; retina; tetraspanin; photoreceptor
1. Introduction
Tetraspanins represent a family of highly conserved membrane proteins involved in a variety of
functions. These functions include membrane organization and compartmentalization, cell signaling,
adhesion and migration [1–4]. Structurally, tetraspanins consist of a short cytoplasmic N-terminus,
four transmembrane domains (TM), one small and one large extracellular loop (EC1 and EC2,
respectively), as well as a short cytoplasmic C-terminus [3,5,6]. The EC2 loop can be further divided
in a conserved and a variable region [7,8]. The highly conserved part of the EC2 loop was shown to
mediate the dimerization of tetraspanin proteins, while the variable region is required for specific
interactions of the tetraspanins with their variable interaction partners [7–10]. Tetraspanin interactions
can be divided into three levels of interactions [1]. The primary level consists of direct associations
between two tetraspanin proteins as well as between tetraspanin and a non-tetraspanin interacting
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partners, interactions that resist the treatment with strong detergents [1,4]. Binding of these primary
complexes to each other represents the secondary level which is indirect and in some cases supported
by palmitoylation [1,4,11]. In the third level, tetraspanins can indirectly associate with their interacting
partners to form large insoluble complexes, which only resist mild detergents like CHAPS [1,4,12,13].
The ability of tetraspanins to interact with each other and with other partners allows them to form
tetraspanin-enriched microdomains known as the tetraspanin web [4,14].
Peripherin 2 (Prph2, formally known as retinal degeneration slow, RDS) represents
a photoreceptor-specific tetraspanin. It is a structural protein that is critical for the proper development
of rod and cone outer segments (ROS and COS, respectively) and thus for vision [15,16]. The main
function of Prph2, in the morphogenesis of ROS and COS, is to promote membrane curvature,
flattening and fusion; processes that are required for the rim formation of the OS discs and
lamella [15,17–20]. Like the other members of the tetraspanin family, Prph2 contains two loops,
referred to as intradiscal loops (D1 and D2, respectively). The D2 loop is equivalent to the EC2 loop
of other tetraspanins and mediates the bulk of interactions of Prph2 [21–23]. Prph2 interacts with
another photoreceptor-specific tetraspanin, called rod outer segment membrane protein 1 (Rom1) [24].
Prph2 forms non-covalently associated homo- and hetero-tetramers with Rom1. These tetramers
associate and form covalently linked intermediate complexes. In addition to that, Prph2 is able to form
higher order complexes consisting of several Prph2 homo-tetramers. Interestingly, hetero-tetramers
including Rom-1 are excluded from these higher order complexes [21,25,26]. Formation of these
complexes is required for Prph2 to promote the development of rim domains essential for OS
formation [18,27,28]. In line with its key role in OS formation, mutations in PRPH2 are connected
with a multitude of retinal diseases ranging from autosomal dominant retinitis pigmentosa (ADRP) to
macular degeneration (MD) [29]. The associated phenotypes show a high degree of variability of onset
and phenotype even between patients carrying the same mutation. In addition to the degeneration of
the retina, some Prph2 related diseases were found to cause secondary effects on the retinal pigment
epithelium (RPE) or the choroid [29–31].
This review describes the importance of Prph2 in the development of both ROS and COS. Recent
data provided new insight into the steps necessary for OS morphogenesis and the role of Prph2 in
orchestrating these events. Furthermore, we will summarize how the precise formation and regulation
of Prph2/Rom1 complex affects the function of Prph2 in rods versus cones. Finally, we will discuss the
animal models expressing pathogenic Prph2 mutations and provide a short summary about therapeutic
approaches so far aimed to treat Prph2 related diseases.
2. The Role of Prph2 in Photoreceptor Outer Segment Morphogenesis
Since mice lacking Prph2 (Prph2−/−) fail to form ROS, it became clear that the major function of
Prph2 is in the initialization and elaboration of ROS [32]. Recent data confirmed this function and
identified the C-terminus of Prph2 as the motif responsible for the initialization of ROS formation [33,34].
The photoreceptor outer segment (OS) represents a highly specialized form of a modified primary
cilium [35]. The initial steps in the development of the OS are similar to the development of other
primary cilia, starting with the attachment of the ciliary vesicle to the basal body [36–38]. After this
initial step, the elongation of the ciliary axoneme and the expansion of the plasma membrane happen
in a synchronous fashion. A recent study showed that these initial steps in ciliogenesis take place in
both wild type (WT) and Prph2−/− photoreceptors, an observation which was in line with previous data
showing the presence of an intact connecting cilium (CC) in the Prph2−/− photoreceptors [32,33,39].
Additionally, the same study revealed that the Prph2 C-terminus mediates suppression of the formation
of ectosomes at the distal part of the CC in rod photoreceptors [33]. Ectosomes are thought to play
an important role in the processes of ciliary resorption, regulation of the ciliary protein content and
regulation of signal transduction [40–44]. The ability of Prph2 C-terminus to suppress the release of
ectosomes offers an explanation to why photoreceptor cilia are able to form the highly complexed
intra-ciliary membranous structures like that of the ROS [33]. Further evidence for a key role of
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the Prph2 C-terminus in the initialization of ROS formation was provided by a recent study that
generated a chimeric protein composed of the C-terminus of Prph2 fused to the body of Rom1,
the non-glycosylated homologue of Prph2 [34]. Expression of the chimeric protein was sufficient
to initialize the formation of ROS structures but failed to elaborate them proving that the Prph2
C-terminus is responsible for the formation of the initial membrane outgrowth while the other parts of
Prph2 are required for the development of the highly organized structure of the OS.
Prph2+/− mice show defects in both function and structure of photoreceptor OS, which proves
that the role of Prph2 is not restricted to the initialization of OS formation but also important for
its structural development and maintenance [16]. In mature ROS discs, Prph2 is restricted to the
rim [15]. In addition, previous studies demonstrated that Prph2 displayed membrane fusion activity,
which led to the theory that Prph2 is involved in the shaping of the closed rim of fully developed
discs in ROS [45,46]. Indeed, a function of Prph2 in inducing the curvature of the plasma membrane
was observed in several studies [25,33,47,48]. While all these studies agree that Prph2 is involved in
the generation of membrane curvature, they are contradictory in defining the exact region of Prph2
responsible for this activity. Two studies pinpointed the membrane curvature inducing activity to
an α-helix motif located in the C-terminus of Prph2 [47,48], while a third study argues that this motif
is rather preventing membrane curvature than inducing it [25]. A recent study found evidence for
a function of the tetraspanin core of Prph2 in generating membrane curvature while the C-terminus
was unable to perform this function [33]. The localization of Prph2 in newly formed ROS discs
provided further evidence for the importance of Prph2 in membrane curvature and disc closure [17].
Newly formed discs in the ROS have a close rim at the site adjacent to the axoneme of the photoreceptor
cilium while the opposing side of the disc remains open [49]. In these newly formed discs, Prph2 is
restricted to the axonemal closed side of the disc [17]. A recent study confirmed the localization of
Prph2 on the axonemal side of newly formed discs in the ROS [50]. An additional finding in this study
was that Prph2 is more abundant at the closed rim of newly formed discs than at the rim of mature
discs, indicating that Prph2 is not only involved in the closure of this rim but also required for the
initialization of the formation of new discs.
The membrane curvature of the open end of newly formed discs in ROS is opposite to the
curvature on the closed rim, and thus unlikely to allow the binding of Prph2 [26]. This led to the
question of whether a different transmembrane protein may promote the curvature of the open ends.
Prominin-1 was identified as a potential candidate involved in the shaping of newly synthetized
discs in ROS. Prominin-1 is a membrane protein with five transmembrane domains that localizes at
the open end of newly synthesized discs in ROS, thus opposite to the localization of Prph2 [51–55].
The vital role of Prominin-1 in the structural integrity of the photoreceptor OS is supported by
the finding that mutations in Prominin-1 are connected to retinal diseases causing degeneration of
the photoreceptors [54,56–59]. Earlier studies on Prominin-1 demonstrated that it shows a binding
preference for curved membranes, but does not induce the curvature itself [60,61]. Thus, Prominin-1 is
a promising candidate for the maintenance of the curvature on the open end, while the protein
responsible for inducing the curvature at these ends remains elusive. A second question, which remains
open thus far, is what mechanism restricts Prominin-1 to the newly synthesized discs? When ROS
discs mature and reach their final diameter, the open ends close; presumably through the activity of
Prph2 and become separated from the plasma membrane of ROS. While Prph2 is located on the entire
rim of these closed discs, Prominin-1 is no longer found after the closure of the now matured disc [55].
While rod OS discs are closed and separated from the plasma membrane, cone OSs on the other
hand contain open discs also referred to as lamellae and are contiguous with the plasma membrane.
Although amphibian COS consists exclusively of open discs, the number of open discs in mammalian
COS varies depending on the species [38,62–65]. The localization of Prph2 in the open discs of COS is
comparable with its localization in the newly synthesized ROS discs, with Prph2 being restricted to the
side adjacent to the axoneme of the photoreceptor cilium [55]. The discs in COS display a closed rim
formation on the axonemal sides. Prominin-1 is localized on the open side, in line with its localization
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in the newly formed ROS. Studying the role of Prph2 in the development of cones in mice has proven
to be difficult due to the low percentage of cone photoreceptors in the murine retina, whereby only
~3–5% of photoreceptors are cones. We have analyzed the effect of loss of Prph2 in the background of
an Nrl knockout (Nrl−/−), in which all rods are converted to S-cone-like cells [66–68]. Here the cones in
the double knockout mice (Prph2−/−/Nrl−/−) displayed disorganized COSs lacking the flattened lamellae
characteristic of WT COS [69]. Furthermore, this study provided evidence for the trafficking of many
OS proteins to this altered OS structure, indicating that the transport of those proteins towards the
OS does not rely on Prph2 [68]. The ability of Prph2−/− retinas to form disorganized COSs argues
for a different role of Prph2 in cones than in rods. As mentioned above, ROSs fail to develop in the
Prph2−/− mice, thus demonstrating a vital role for Prph2 in the initialization of the formation of this
complex intra-ciliary membrane structure in ROS. The discovery of a role for the C-terminal region of
Prph2 in inhibiting the release of ectosomes from the rod photoreceptor cilia [33] added new interesting
aspect to the process of the rod OS formation. Future studies are needed to determine if this function
of Prph2 is preserved in cones.
The identification of Rom1 as a Prph2 interactor initiated a multitude of studies investigating the
complex formation between Prph2 and Rom1 [24,26,70]. Like Prph2, Rom1 is a photoreceptor-specific
membrane protein and a member of the tetraspanin superfamily [71]. While only sharing a sequence
identity of 35% with Prph2, both proteins form a highly conserved and similar secondary and tertiary
structures with four transmembrane domains and two intradiscal loops [24]. Prph2 and Rom1 form
heteromeric and homomeric tetrameric complexes, held together by non-covalent bonding mediated
by the second intradiscal (D2) loop [21–23]. These tetramers can assemble into intermediate complexes
consisting of both hetero- and homotetramers to establish a mix of covalent and non-covalent linked
complexes [72]. These intermediate complexes were found to include at least two tetramers. In addition
to the intermediate complexes, higher order complexes containing only Prph2 were also identified [72].
The core of both intermediate and higher order complexes consists of tetramers [21,25]. Interestingly
Rom1 is excluded from these higher order complexes [21,25]. How this exclusion is mediated is not
fully understood. A possible explanation is that Prph2 can utilize both the conventional secretory
pathway through the Golgi apparatus as well as the unconventional pathway which bypasses the
Golgi apparatus [26,73]. The presence of Rom1 results in more Prph2 being transported through the
conventional pathway [34]. It is likely that this level of sorting during the initial steps of protein
trafficking provides a possible mechanism mediating the exclusion of Rom1 from higher order
complexes. Studies verifying this mechanism are a possible direction for future work. The higher
order complexes are localized at the closed rim of discs indicating an important role for them in the
membrane folding necessary to close the disc rim [25,74]. Biochemical evidence supported the idea
that during the formation of Prph2/Rom1 complexes, intermolecular disulfide bonding between Prph2
and Rom1 are formed [72,75,76].
The ability of Prph2 and Rom1 to form complexes was proven to be vital for their function in
OS formation [18,27,74]. The cysteine at position 150 (C150) in the D2 loop of Prph2 was found
to be critical for the formation of higher order Prph2/Rom1 complexes [21,28,77]. C150 of Prph2
forms an intermolecular disulfide bond with C150 of another Prph2 to make homodimers or with
C153 of Rom1, thus allowing the formation of Prph2/Rom1 heterodimers and heteromeric tetramers.
A knock-in mouse expressing a point mutation at C150 of Prph2 (C150S) provided further evidence
for the importance of this cysteine in the formation of higher order complexes and thus for the role
of Prph2 and Rom1 in the development of the OS [78]. The formation of intermediate as well as
higher order complexes was fully abolished by the C150S mutation and both ROS and COS were
severely disorganized. Despite being disorganized, the OS structure of the C150S mice were somewhat
better when compared to Prph2+/− while no functional improvement was observed, indicating that the
ability of Prph2 to form intermediate complexes with Rom-1 as well as its ability to form higher order
complexes consisting of Prph2 homo-tetramers is not only relevant for maintaining the OS structure
but also for its function [78].
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The development of higher order complexes seems to be expendable for the initiation of OS
formation, since generation of both ROS and COS is initiated in the C150S mutant retinas that are
devoid of these complexes. Comparable results were obtained for a mutation deleting lysine at
position 153 in the D2 loop of Prph2 (K153Δ) [79]. K153Δ represents a mutation found in patients
resulting in variable phenotypes ranging from ADRP to more cone specific MD [80]. This mutation
also obliterates the ability of Prph2 to form higher order complexes [79]. The initiation of ROS and COS
structures was unaffected while both displayed structural and functional decline. While the C150S
and K153Δ mutations prevent the formation of higher order complexes, some pathogenic mutations
of Prph2 lead to the formation of an abnormal high molecular weight aggregates that include both
Prph2 and Rom1 [81,82]. A patient mutation causing the exchange of the tyrosine at position 141 for
a cysteine (Y141C), effectively adding another cysteine in the D2 loop, causes mostly defects in the
macula but some cases of RP were also reported [30,82,83]. The Prph2 and Rom1 complexes in Y141C
knockin retinas were significantly altered, showing the formation of abnormal high molecular weight
aggregates containing both Prph2 and Rom1. This is a remarkable finding considering that Rom1 is
normally excluded from higher order complexes [82]. These mice display structural and functional
defects in ROS and COS. The formation of abnormal high molecular weight aggregates could also be
found in another patient mutation in which tryptophan in Prph2 is substituted by arginine at position
172 (R172W) [81]. Transgenic mice carrying this mutation displayed the formation of high molecular
weight aggregates of Rom1 while Prph2 complexes were not affected. Additionally, these high
molecular weight Rom1 aggregates were more abundant in cones, a result that is in line with the
decline of cone function in this mouse model [81].
Taken together, these results demonstrate that the exact regulation of the Prph2/Rom1 complex
formation is critical for proper OS development, maintenance and disc size in both rods and cones as
well as for their function. For OS initiation, proper complex formation seems to be irrelevant. It is
worth noting that these studies point to a striking difference between rods and cones with regard to
how they are affected by the different Prph2 mutations. Mutations, which primarily affect the rods,
seem to be resulting from haploinsufficiency or loss-of-function effects [78,84,85], while those effecting
cones seem to be more susceptible to changes in the complex formation, likely due to gain-of-function
defects [78,79,81,82,86–88]. Another differentiation between rods and cones is how they process Rom1.
While ablation of Prph2 results in the complete loss of ROS and severely disorganized COS, elimination
of Rom1 (Rom1−/−) is less severe, indicating that Rom1’s role is more in fine tuning of disc sizing [27].
It is worth noting that most studies considering these functions were performed in WT murine rods.
A recent study performed on a Nrl−/− background using the K153Δ mutation of Prph2 demonstrated
a loss of Prph2/Rom1 interaction specifically in cones [79]. In order to unravel the precise differences
in the roles of Rom1 in rods versus cones, further studies are needed.
The D2 loop of Prph2 contains a motif for N-linked glycosylation, a motif which is absent in the
D2 loop of Rom1 [24]. In rods, the N-glycosylation on Prph2 was found to be expendable for ROS [89].
In transgenic mice expressing the unglycosylated form of Prph2 specifically in rods, the interaction
with Rom1 or the formation of complexes was not affected. Furthermore, expressing unglycosylated
Prph2 on a Prph2−/− background achieved a full rescue of the phenotype, further proving that the
N-glycosylation of Prph2 is unnecessary for its function in rods [89]. A knockin mouse model
expressing unglycosylated Prph2 [75] recapitulated the rod results observed by Kedzierski et al. [89].
However, while rods were unaffected, cone function was found to decrease significantly in these mice.
Furthermore, a significant decrease in Prph2 and Rom1 levels in the cones of the knockin mice was also
observed. These results further highlight the differential functional roles of Prph2 in rods versus cones.
Apart from its interaction with Rom1, Prph2 was found to interact with additional OS specific
proteins. One of those interactors is with cyclic nucleotide gated channel B1a (CNGB1a) [90,91].
CNGB1a was shown to be relevant for the correct sizing and alignment of the rod discs, supporting the
hypothesis that the interaction between Prph2 and CNGB1a plays a role in the proper shaping of the
discs [92,93]. Additionally, Prph2 was also found to directly interact with rhodopsin (Rho), thus forming
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a complex of Prph2, CNGB1a and Rho to anchor the rim of the discs to the OS plasma membrane and
the rims of adjacent discs. It has been hypothesized that these interactions are responsible for correct
alignment and stacking of the discs [94]. This was supported by findings that co-depletion of these
three proteins exacerbated both functional and structural defects in rod photoreceptors [95].
3. Insight from Mouse Models into the Pathophysiology of Prph2 Mutations
3.1. Transgenic Mouse Models of Prph2 Mutations
Genetically engineered mouse models expressing pathogenic mutations of Prph2 have proven to
be valuable tools in studying the pathophysiology of Prph2 related blinding diseases. These models
have been generated as transgenic expressing Prph2 under the control of heterologous promoters that
in some cases are specific to rods, cones or both.
3.1.1. Prph2R172W
One of the most common disease-causing mutations of PRPH2 is the substitution of tryptophan
to arginine at position 172 (R172W) [96–99]. Patients carrying this mutation display a decrease in cone
function, while rods’ function remains unaffected [96]. The R172W mutation is located in the D2 loop,
which is the region that promotes complex formation and where the vast majority of pathogenic PRPH2
mutations are located [22,87]. Interestingly, the R172W mutation is located outside the part of the D2
loop involved in the formation of complexes [22]. Expressing the R172W mutation in the presence of
the full complement of WT Prph2 led initially to normal rod function and structure [87]. In contrast,
the retina of these mice exhibited a significant loss in the number of blue and green cones and associated
with a decrease in their photopic responses. When expressed on Prph2+/− background, the R172W
mutation led to a late-onset reduction in the number of rod cells and in scotopic responses, besides the
cone phenotype. This varies from the cone exclusive phenotype observed in patients carrying this
mutation and is most likely due to haploinsufficiency of Prph2. Expression of the R172W mutation in
the Nrl−/− retina reproduced the functional decline in the photopic responses and provided evidence
as to how the R172W mutation disrupted COS structures by causing the formation of abnormal high
molecular weight Prph2/Rom1 aggregates [81]. This result demonstrates how the functional decline of
the cones occurs in patients carrying this mutation.
3.1.2. Prph2C214S
The substitution of a cysteine at position 214 in Prph2 with a serine (C214S) was shown to cause
ADRP, a degeneration of rods followed by a late-onset degeneration of cones [100]. Expression of
the C214S transgene in the presence of the full complement of WT Prph2 mice failed to produce
any phenotype, proving that the phenotype observed in patients is through a mechanism other
than dominant gain-of-function [85]. However, when expressed in Prph2+/− or Prph2−/− retinas,
the C214S protein failed to rescue the functional and structural phenotypes in both rods and cones,
indicating that the C214S mutation is resulting in a loss of function. An interesting finding was that the
C214S mutant Prph2 was unable to interact with Rom1, indicating an alteration in the formation of
complexes caused by this mutation. Although an ample amount of Prph2 C214S transgene message
was detected, only a trace amount of the mutant protein was identified, which led to the conclusion of
a loss-of-function phenotype associated with the C214S mutation. It is unclear whether the low levels
of mutant protein are due to a low rate of synthesis or instability of the mutant protein.
3.1.3. Prph2P216L
A substitution of a proline at position 216 in Prph2 with a leucine (P216L) was found to cause
RP in patients [101]. Expression of P216L in mice in presence of WT Prph2 (Prph2+/+) levels led to an
age-dependent significant decrease in scotopic responses and shortened rod OSs with normal disc
alignments, indicative of a dominant-gain-of-function effect [84]. Moreover, in the presence of one
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WT allele of Prph2 (Prph2+/−), expression of the P216L caused a significant decrease in rod function
compared to Prph2+/− mice. In these mice, a more severe OS shortening and disorganization of the
discs could be observed in presence of the P216L mutant protein. Interestingly, expression of the P216L
protein in a Prph2−/− retina caused the formation of small, highly ROS, which represents a limited
rescue when compared to the complete absence of ROS in Prph2−/−. Taken together, these results
prove that the P216L mutation in Prph2 results in a dominant-gain-of effect, in agreement with the rod
dominant phenotype observed in patients.
3.1.4. Prph2L185P
The substitution of leucine at position 185 to proline (L185P) in Prph2 causes a rare digenic form of
RP. Patients heterozygous for both the L185P mutation and a null mutation in Rom1 exhibit symptoms
of RP, while carriers of any of the two mutations do not show a phenotype [102,103]. Transgenic mice
expressing the L185P mutation in a Prph2+/− or a digenic Prph2+/−/Rom1+/− background displayed a late
onset thinning of the outer nuclear layer (ONL) concomitant with reduced scotopic electroretinograms
(ERG) [104].
The transgenic mouse models described above provided valuable insights into the pathophysiology
of Prph2 related diseases. Since the promoters used to express the transgene are heterologous, often
levels of expression of the transgene differ considerably from that of the endogenous leading to
a varied phenotype.
3.2. Prph2 Knockin Mouse Models
The variation in expression levels of the transgene observed in transgenic mouse models is
particularly problematic in cases of reduced levels of the expressed protein since reductions in the
expression level of WT Prph2 were shown to result in haploinsufficiency leading to severe retinal
defects [16,105]. Haploinsufficiency makes it hard to distinguish between the effects seen in transgenic
mice that are due to the mutation or those resulting from the reduced levels of expressed protein.
In order to overcome this, recent studies relied on Prph2 knockin mouse models for a set of mutations
found in patients of Prph2 related diseases. Below are the models currently presented in the literature
and comparison of their retinal phenotypes to patient’s phenotype carrying the same mutation.
3.2.1. Prph2307/+ and Prph2307/307
A deletion of a single base pair at codon 307 in human PRPH2 results in a slow progressing form
of ADRP [106]. A mouse model in which a targeted single base deletion at codon 307 in Prph2 was
introduced and showed a severe decline in photoreceptor survival and function [107]. ERG revealed
a decrease in photoreceptor function in heterozygous animals starting at two months of age, while no
ERG responses were detected in the homozygous animals even at one month of age. Retinal phenotypes
in the heterozygous or homozygous mice were more severe than in age-matched Prph2+/− and Prph2−/−
mice, respectively. Thus, the deletion mutation resulted in a strong dominant gain-of-function effect.
This knockin model represents a drastic case of a retinal phenotype that differs greatly from that
observed in the patients whereby the structural and functional decline is slow, starting in the fifth
or sixth decades of life. The mouse model, on the other hand, displays a rapid degeneration with
an early onset. The deletion at codon 307 in the human PRPH2 gene causes a frameshift and creates
a stop codon after the addition of 16 amino acids. If the resulting mutant protein is stable, it is
expected to be 26 amino acid shorter than the wildtype. It is likely the case since the phenotype
seen in patients is mild due to gain-of-function defect, but if the mutant protein is unstable, then the
phenotype would be loss-of-function defect similar to that of haploinsufficiency. However, in the
mouse genome, such one base deletion at codon 307 is predicted to result in the alteration of the last
40 amino acids of the C terminus of the protein and the addition of 11 extra amino acids. This results
in the translation of 51 amino acids after codon 307 in the mouse [107]. The different effects on the
translated protein caused by the deletion in codon 307 observed between human and mouse explains
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the differences in the severity of the retinal phenotypes. It is important to note that retinal phenotype in
the homozygous mouse is reported to be worse than the complete-loss-of-function phenotype seen in
the Prph2 null mice. This observation suggests that the mouse phenotype is likely a combination of loss-
and gain-of-function defects and that the toxicity beyond that seen in the Prph2 knockout is probably
the outcome of the latter. Since the mouse model was not assessed for the presence of the mutant
protein, at this point, it is unclear whether the toxicity arises from the absence of the protein, the 51
altered amino acids at the C-terminus or the lack of endogenous 40 amino acids at the C-terminus.
Obviously, the addition of 16 altered amino acids in the human PRPH2 and shortening the protein
by 26 amino acids at the C-terminus have less drastic effect on the retina than those modifications
occurred in the mouse protein.
3.2.2. Prph2C213Y/+ and Prph2C213Y/C213Y
The C213Y mutation is located in the D2 loop of Prph2, in the motif that mediates intramolecular
and intermolecular disulfide bonds, thus responsible for the formation of Prph2/Prph2 and Prph2/Rom1
tetramers as well as for the formation of intermediate and higher order complexes [77]. The heterozygous
mice (Prph2C213Y/+) displayed a shortened and disorganized ROS. When compared to Prph2+/− mice,
the ROS of Prph2C213Y/+ mice showed a slight improvement in the stacking and alignment of the discs
(Figure 1A,B) [76].
Figure 1. Mutations in the mouse Prph2 gene lead to varying degrees of photoreceptor degeneration.
(A) Representative light microscopic images from hematoxylin and eosin stained retinal sections at
P30 aligned at the upper edge of the retinal pigment epithelium (RPE). (B) Transmission electron
microscopic (TEM) images of the interface between the IS and OS of photoreceptors of the indicated
genotypes. OS, outer segments; IS, inner segment; ONL, outer nuclear layer; OPL, outer plexiform layer.
Scale bars: 20 μm for A and 2 μm for B. Eyes used in this study were dissected, fixed and embedded as
previously described [79]. Images were captured at 40× and converted to black and white using ZEN
Image Analysis software. The plastic-embedding and TEM methods were as described previously [85].
Images were adjusted and cropped using Adobe Photoshop CS5.
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This is evident from the well stacked OS discs seen in some photoreceptors while others looked
like whorls similar to those seen in the Prph2+/− (arrows in Figure 1). Scotopic ERG responses of the
Prph2C213Y/+ mice were significantly reduced starting at P30 (Figure 2) and persist all the way to P365.
The scotopic response was nearly completely abolished in Prph2C213Y/C213Y animals and the OS was
almost non-existent. The photopic responses were significantly decreased in both heterozygous and
homozygous animals at P30. At later time points, the photopic response decreased further in the
Prph2C213Y/+ mice and was completely absent in the Prph2C213Y/C213Y animals. A key finding in this
study was that the Prph2C213Y/+ mice, that represent the genotype present in patients, showed better
retinal structure despite the fact that both of rod and cone ERG responses were reduced when compared
to Prph2+/− animals.
Figure 2. Mutations in Prph2 hinder OS function assessed via scotopic and photopic electroretinograms
(ERGs) at P30. Full-field ERGs were recorded under scotopic and photopic conditions. Shown
are representative ERG waveforms from the indicated genotypes at P30. Full-field ERG tests were
performed as previously described [85]. After overnight dark adaptation, mice were anesthetized
and their pupils dilated. ERGs were recorded with a UTAS system (LKC, Gaithersburg, MD, USA).
Waveforms were exported into GraphPad software to obtain wave traces and then exported into
Photoshop using a uniform scale.
A key requirement for the function of Prph2 is its ability to interact with Rom1 and to form
oligomeric complexes [18,27,74]. Co-immunoprecipitation (co-IP) experiments using retinal lysate
from Prph2C213Y/C213Y mice revealed the inability of Prph2C213Y to interact with Rom1. The homomeric
interaction of Prph2 was also reduced in these mice as evident from reduced ability of Prph2C213Y to form
intermediate and higher order complexes as determined by sucrose gradient velocity sedimentation [76].
The reduction in oligomeric complexes offers an explanation for the functional decline observed in
both Prph2C213Y/+ and Prph2C213Y/C213Y mice and no abnormal high molecular weight aggregates were
observed under non-reducing conditions. Prph2C213Y/+ retina retains some Prph2 in the IS, shown by
immunofluorescence (IF) staining of Prph2 (green and arrows in Figure 3) and IS maker syntaxin 3B
(STX3B) (red, Figure 3). However, Prph2C213Y/C213Y lacks the ability to form complexes which leads to
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complete retention of Prph2 in the inner segments (IS), and perinuclear region while a smaller amount
of Rom1 was retained in the IS [76].
Patients carrying the C213Y mutation in PRPH2 display a butterfly-shaped pattern/macular
dystrophy, while a rod dominant RP phenotype is absent [29,108–110]. The knockin mouse model for
the C213Y displays functional defects in both rods and cones. While the defects in the cones are in line
with the defects observed in the cone rich macula of the patients, the defects in the rods displayed by
the model are not. The difference between phenotypes in patients and the mouse model may be due
to the fact that the mouse retina consists almost exclusively of rod photoreceptors. Since the murine
retina lacks a macula, it was not possible to reproduce the butterfly shaped macular dystrophy in the
mouse model. One interesting finding in the Prph2C213Y mouse model was the observation of a yellow
flecking in the fundus of both Prph2C213Y/+ and Prph2C213Y/C213Y mice at P180. This phenotype mimics
funduscopic anomalies found in patients carrying the C213Y mutation [110].
Gene supplementation was performed by crossing a WT Prph2 overexpressing mouse line (NMP)
onto hetero- (Prph2C213Y/+) or homozygous (Prph2C213Y/C213Y) mice. The defects observed in the protein
trafficking as well as in OS structure were rescued in Prph2C213Y mice. A rescue on the functional level
however could not be observed [76]. These results show that the presence of the mutant protein has
a detrimental effect on photoreceptor function.
Figure 3. Mutated Prph2 protein traffics to the OS while a small pool is retained in the inner segment.
Retinal sections at P30 from the indicated genotypes were probed with antibodies against Prph2 (green)
and syntaxin 3B (STX3B) (red). Arrows indicate regions of mislocalization of Prph2. OS, outer segments;
IS, inner segment; ONL, outer nuclear layer. Scale bar: 20 μm. Primary antibodies used for
immunostaining were polyclonal antibody against Prph2 C-terminus (Prph2-CT) [22] and monoclonal
antibody against STX3B [111] (inner segment marker) diluted at (1:1000). AlexaFluor conjugated
secondary antibodies (Alexa 488 Rabbit and Alexa 555 Mouse, Life Technologies/ThermoFisher) were
used at a dilution of 1:1000 for 2 hours at room temperature. Images were captured on a ZEISS Confocal
LSM 900 microscope equipped with a Zeiss Axiocam (Zeiss, Jena, Germany) using a 63× (oil, 1.4 NA)
objective. Images were then processed using ZEN Image Analysis software (Zeiss, Jena, Germany).
All images shown are orthogonally projected from an eight slice confocal z-stack.
3.2.3. Prph2Y141C/+ and Prph2Y141C/Y141C
Like the C213Y mutation, the Y141C mutation of Prph2 is also located in the D2 loop. The OSs in
the Y141C knockin mouse model (Prph2Y141C/+ and Prph2Y141C/Y141C for heterozygous and homozygous
animals, respectively) displayed structural anomalies. In Prph2Y141C/+ mice, the OS was shortened
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with some structural alterations of the discs, including lengthening and vesicular structures [82].
When compared to the Prph2+/− mice, the structure was better conserved in the Prph2Y141C/+ retina
(Figure 1B). In the Prph2Y141C/Y141C mice, OS formation is initialized but neither mature discs nor
lamellae could be observed. Instead, the OS contained flattened whorl shaped membranous structures
with vesicular arrangements lining up adjacent to them. Scotopic ERG revealed a significant decrease
in rod function displayed by the Prph2Y141C/+ mice at P30 (Figure 2). Interestingly, the scotopic ERG
did not deteriorate further at P180 [82].
Non-reducing SDS-PAGE/immunoblots of Prph2Y141C/+ retinal lysates showed abnormal high
molecular weight aggregates at 250kDA. This was further evaluated by sucrose gradient velocity
sedimentation experiments which revealed the formation of the expected intermediate and higher order
complexes with an aberrant high molecular weight band indicating that the Y141C mutation results in
the formation of abnormal large aggregates [82]. In the Prph2Y141C/Y141C retinas, the observed phenotype
was even more pronounced with an increase in the aberrant high molecular weight aggregates at the
expense of the formation of the normal intermediate and higher order complexes. While in WT mice
Rom1 is normally excluded from higher order complexes, in the mutant retina, a portion of Rom1 was
incorporated in the aberrant high molecular weight aggregates. Surprisingly though, mutant Prph2
was transported correctly to the OS which is shown by IF staining of Prph2 (green) and IS marker
STX3B (red) (Figure 3). However, the formation of these high molecular weight aggregates likely
interfered with the normal function of Prph2 and likely Rom1 in the OS. This offers an explanation for
the structural and functional phenotypes observed in the knockin mice.
Patients carrying the Y141C mutation in PRPH2 display primarily defects in the macula with
some reported cases of more rod-associated phenotypes such as night blindness and RP [30,82,83].
The Prph2Y141C/+mice, which represent patients’ genotype, exhibit a decline in rods’ function, mimicking
the observed rod phenotype in some patients. Again, the difference between the knockin model and the
patient’s phenotypes can be seen in the cone function. The most prominent phenotype found in patients
with the Y141C mutation is the functional and structural decline in cones. The Prph2Y141C/+ mice on
the other hand displayed only a slight functional decline in the photopic ERG which was not found
to be significant [82], indicating that the cone function in these mice is not severely affected. While
the heterozygous mice do not show significant decline in cone function, they do display a flecking
in funduscopic analyses [82], which mimics findings in the fundus of patients. Recently, a study
was undertaken to identify a potential explanation for the huge variation in phenotypes observed
in patients by determining the role Rom1 plays in the observed phenotype [88]. Mice heterozygous
or homozygous for the Y141C mutation were crossed with Rom1 knockout mice to produce mice
that express mutant Prph2 in absence of Rom1 (Prph2Y141C/+/Rom1−/− and Prph2Y141C/Y141C/Rom1−/−).
Absence of Rom1 abolished the formation of the abnormal high molecular weight aggregates and
accumulation of mutant Prph2 in the IS and ONL in Prph2Y141C/Y141C/Rom1−/− retinas [88]. The depletion
of Rom1 also changed the symptoms seen in the Y141C model. While the photopic ERG amplitudes in
Prph2Y141C/+/Rom1−/− mice were comparable to that of the WT, a significant reduction in the scotopic
ERG responses were observed [88].
When compared to the cone-rod functional defects noted for the Prph2Y141C/+ mice,
Prph2Y141C/+/Rom1−/− mice mainly displayed a rod-dominant functional defect. In addition,
the funduscopic anomalies were almost completely abolished in the Prph2Y141C/+/Rom1−/− mice.
The results obtained in this study prove that alteration in the level of Rom1 can change the phenotype
caused by a pathogenic Prph2 mutation, and thus potentially provide an explanation to the variable
phenotypes seen in patients carrying the same PRPH2 mutation. Further studies combining Prph2
mutations and mutations in Rom1 should provide further insights into the complexity of phenotypes
seen in the various PRPH2 related diseases.
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3.2.4. Prph2K153Δ/+ and Prph2K153Δ/K153Δ
Another mutation in PRPH2 that leads to variable phenotypes among patients is the deletion
of codon 153 (K153Δ) that results in the elimination of the lysine at position 153 in the D2 loop of
Prph2. This mutation is found to associate with RP, pattern dystrophy and fundus flavimaculatus [80].
K153Δ-Prph2 knockin mouse model was generated and provided evidence that the mutant protein
cannot form the complexes required for OS formation [79]. The heterozygous knockin mice
(Prph2K153Δ/+) displayed a shortened OS with minor structural defects at P30 [79] (Figure 1). At P180,
these animals also exhibited a reduction in ONL thickness without further structural deterioration
of the OS [79]. The overall Prph2 protein level in these mice was around 80% compared to the level
in WT mice, thus demonstrating that the observed structural defects are most likely caused by the
dominant effect of the mutant protein rather than due to haploinsufficiency.
The heterozygous animals displayed a significant progressive reduction in scotopic responses that
started as early as P30 (Figure 2) and worsened with age. The photopic response in the Prph2K153Δ/+ was
also significantly reduced at P30, albeit this reduction did not worsen as the animals aged (Figure 2).
In the homozygous animals, the scotopic and photopic responses were minimal at P30. Biochemical
analysis showed that the formation of covalently linked Prph2 dimers in Prph2K153Δ/K153Δ mice was
abolished while Rom1 homodimers were present [79].
Due to the observed effects on cone function, Prph2K153Δ/+ animals were crossed into the Nrl−/−
background in order to assess the effects of the K153Δ mutation on cones. Photoreceptor cells in the
resulting Prph2K153Δ/+/Nrl−/− retina displayed a highly disrupted structure with many photoreceptors
having no lamellae what so ever. Interestingly, the mutant Prph2 was able to interact with Rom1 in
the rod-dominant Prph2K153Δ/K153Δ retinas, but this interaction was abolished in Prph2K153Δ/K153Δ /Nrl−/−
retina, indicating a defect in the Prph2/Rom1 interaction specific to cones [79]. Sucrose gradient
velocity sedimentation showed no significant alteration in complex formation in Prph2K153Δ/+ retina
when compared to WT while in the Prph2K153Δ/K153Δ retina, the formation of intermediate and higher
order complexes is abolished [79]. Here, both Prph2 and Rom1 are restricted to the tetramer fractions.
The same was observed in the Prph2K153Δ/K153Δ /Nrl−/− retinas. Sedimentation profile showed that the
amount of higher order complexes in the Prph2K153Δ/+/Nrl−/− retina was reduced, while unaffected in
Prph2K153Δ/+ retina [79]. This provides further evidence for a differential role of the lysine at position
153 in rods and cones, and hence emphasizes the notion for potential varied roles for Prph2 in rods
versus cones. Localization studies performed in Prph2K153Δ/+ mice demonstrated that most of Prph2
and Rom1 were successfully transported to the OS with some amount of Prph2 mislocalized to the IS
(arrows in Figure 3). Small amount of rhodopsin (Rho) and M-opsin were also found to be mislocalized
to the ONL and outer plexiform layer (OPL) in this model [79].
In the Prph2K153Δ/K153Δ retinas, the majority of Rho and Prph2, but not Rom1, were found to be
mislocalized to the ONL. As stated above, patients with the K153Δ mutation exhibit a highly variable
phenotype, ranging from rod dominant RP to more cone related defects in the macula [80]. The K153Δ
knockin mouse model displayed functional and structural defects in both rods and cones, and thus
mimics the phenotype seen in patients carrying this mutation. While the lack of a macula in the
murine retina made it impossible to observe the macular pattern dystrophy often found in patients [80],
the knockin mouse still showed funduscopic anomalies [79] which are characteristic of the pattern
dystrophy in patients. Prph2K153Δ/+ mice show a flecking in the fundus at P180 which is more severe in
the Prph2K153Δ/K153Δ mice. This phenotype does not deteriorate further in P365 heterozygous animals
while the flecking was replaced by large splotches in the homozygous animals [79].
Gene supplementation using the NMP mouse that over-express Prph2 (NMP/Prph2K153Δ/+ and
NMP/Prph2K153Δ/K153Δ) rescued the structural defects but failed to rescue the functional decline seen
in scotopic and photopic ERGs [79]. This indicates that the presence of the mutant protein alone is
sufficient to deteriorate the photoreceptor function and suggest that gene silencing along with gene
augmentation is the best strategy for this model.
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The knockin models for PRPH2 related patient mutations proved to be very useful in highlighting
dominant-effects of the Prph2 mutations. In general, the models were more successful in mimicking
patient phenotypes related to a decline in rod function. Patient phenotypes related to functional
defects in the cones or pattern dystrophies in the macula were more difficult to reproduce in mice due
to the lack of a macula and a lower overall percentage of cones in the murine retina. Crossing the
knockin mouse models with Nrl−/− mice, as done in the studies with the K153Δ model [79], has proven
to be a successful approach in studying the effects of the mutation on cones in detail. While the
knockin models could not reproduce the macular pattern dystrophy, they successfully reproduced the
funduscopic aberrations, which connect with the pattern dystrophy.
3.2.5. Prph2N229S/+ and Prph2N229S/N229
The knockin mouse that alters the N-linked glycosylation at asparagine 229 (N229S) in the D2 loop
was used to study if Prph2 glycosylation plays a role in its interaction with Rom1. Heterozygous mice
(Prph2N229S/+) did not have any significant changes in structure or function of the OS [75]. However,
homozygous mice (Prph2N229S/N229S) displayed a late onset thinning of the outer nuclear layer (ONL)
and occasional abnormal disc staking in cones and a slightly reduced photopic ERG at P180. Since Prph2
could not be glycosylated, higher order complexes were decreased and there was an increase of Prph2
and Rom-1 in the intermediate complexes [75]. Therefore, it was concluded that the glycosylation plays
a major part in regulating the interaction between Prph2 and Rom1, which is critical for cone health.
Tables 1 and 2 summarize the phenotypes associated with the Prph2 knockin models, highlighting
rod and cone structure, Scotopic and Photopic ERG, complex formation and protein localization. It also
summarizes fundus observations, and patient’s phenotypes whether mainly rod- or cone-specific
defects or the combination of the two. Figures 1 and 2 show structural and functional differences
between Prph2 heterozygous knockin mutations, while Figure 3 is a representative IF showing retinal
localization of Prph2 among the models.
Table 1. Prph2 mutations and correlating phenotypes.
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Table 1. Cont.
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4. Gene Therapy of PRPH2 Mutations
There is a vast variety of PRPH2 mutations associated with autosomal dominant retinal
degenerative diseases, including RP, several forms of macular dystrophy and cone rod dystrophies [29].
Gene therapy seems to be a promising approach in the treatment of those PRPH2 associated diseases.
The small size of the Prph2 cDNA, which is approximately 1.1 kb, is advantageous since many vectors
used for gene therapy can only carry DNA of a limited size. Despite the variety of feasible approaches
available for the gene therapy of Prph2, thus far no treatment ready for clinical trials has been developed.
The expression of the WT Prph2 in the background of pathogenic Prph2 mutations represents
one of the most promising approaches. Pioneer studies using transgenic mice expressing WT Prph2
under different promoters in a Prph2+/− or Prph2−/− background revealed a significant increase in
both structural and functional properties of rods and cones [105,112]. Replacing Prph2 in Prph2−/−
mice utilizing adeno-associated virus (AAV) carrying Prph2 regulated under the rhodopsin promoter
provided promising results [113]. Here the subretinal injection of the AAV resulted in a partial rescue
of ROS structure as well as scotopic ERG response. A follow up study was able to show that repeated
injections with the AAV resulted in an even more pronounced rescue of the phenotype with an increase
in the scotopic b-wave response observed in the injected mice [114]. In this study, several time points
after the injections were analyzed in order to validate whether the observed rescue was long lasting.
This analyses revealed that the rescue achieved by the AAV injection was lost after 15 weeks post
injection [114]. In addition to the loss of the rescue with time, the amplitude of the scotopic b-wave
was significantly lower than in WT mice and the scotopic a-wave was not improved by the injection of
the AAV. A reason for this is that the injection of the AAV in mice only resulted in a low transduction
rate of roughly 30% [114]. An improvement in the transduction rate will thus be necessary in order to
develop a viable AAV based gene therapy.
Nanoparticles (NP) represent a second promising approach in transferring WT Prph2.
These particles were found to be well tolerated by the retina, even after multiple injections, and have
a high DNA capacity up to 14 kb, as tested in the eye [115–120]. NP carrying full-length murine Prph2
cDNA under the control of either rod or cone specific IRBP promoters or ubiquitous chicken beta actin
promoter was injected in the retina of Prph2+/− mice [121]. The injection resulted in a partial rescue of
OS structure and also prevented the thinning of the ONL. These rescue effects lasted 15 months post
injection and were most pronounced near the site of injection [121]. While the NP treatment could
overcome the decline in rescue overtime, the effect on the photoreceptor function remained limited.
NP injection resulted in a small yet insignificant improvement in the scotopic a-wave but a significant
improvement in the photopic b-wave. The results obtained with the different promoters used were
comparable. The small benefit of the NP injection observed in the functional tests might be due to
an incomplete distribution of the NPs in the retina. In line with this, the structural improvements
observed after NP injection were best close to the site of injection. Improving on the distribution and
uptake of the used vector in the retina, regardless if AAVs or NPs are used, seems to be a necessary
next step in order to achieve a more pronounced functional rescue.
The studies above described the replacement of Prph2 in either Prph2+/− or Prph2−/− mice,
thus in a scenario whereby Prph2 is either absent or haploinsufficient. However, most patients
suffer from a dominant mutation in PRPH2. In order to analyze the efficiency of treatment in
a scenario closer to actual PRPH2 related diseases, the knockin mouse models carrying a disease
related Prph2 mutation were analyzed. Both Prph2K153Δ/+ and Prph2C213Y/+ mice were crossed with
a normal-Prph2-overexpressing mouse line (NMP) [76,79]. The resulting Prph2K153Δ/+/NMP+/− and
Prph2C213Y/+/NMP+/− mice displayed a rescue in OS structure, protein expression levels and trafficking,
but no rescue in both rod and cone functions [76]. In both cases, the presence of the mutant protein
continues to affect the photoreceptor function. This is due to dominant-gain-of-function effects caused
by these mutations. These results show that, in addition to gene augmentation therapy, silencing
the mutant Prph2 allele is essential for ultimate rescue. A combined approach of short hairpin
(sh)-RNA mediated knockdown and expression of a shRNA resistant protein has been performed
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in models for ADRP carrying pathogenic mutations of rhodopsin [122,123]. Here, both WT and
mutant Rhodopsin were knocked down by sh-RNA carried in AAV together with a sh-RNA resistant
rhodopsin. The expression of the sh-RNA resistant rhodopsin following the knockdown rescued the
phenotype. Studies combining the knockdown of mutant Prph2 with the expression of WT Prph2
provided first promising results thus far showing partial functional and structural rescue in mice
expressing pathogenic mutations of Prph2 [124,125].
The examples above show that while progress was made in the gene therapy of PRPH2 related
diseases, there are many factors, which need to be considered for the development of a successful
therapy. Further complications might arise from the fact that the functional role of Prph2 seems to
vary in rods and cones. In addition to that, secondary effects of PRPH2 mutations on the RPE and the
choroid could be observed [29–31]. A high variability in the clinical phenotypes displayed by patients,
even when carrying the same mutation, represents another challenge, which has to be overcome in
order to treat PRPH2 related diseases.
5. Conclusions and Perspectives
Prph2 plays a key role in the maintenance as well as the development of photoreceptor OS. While
Prph2 is found to be vital for both rods and cones, there seem to be distinct differences in its function
in these two types of photoreceptor cells. A complete knockout of Prph2 results in the complete
absence of ROS while COS formation is still initialized even though the resulting COS are severely
disorganized and lack lamellae and discs. This begs the question, which protein is mediating the
formation of the COS and if it works in an interplay with Prph2. The OS of both rods and cones
represent a highly modified primary cilium. The Prph2 mediated suppression of ectosomes shedding
from the photoreceptor cilium was found to be a prerequisite for the formation of the ROS. Thus far
there is no study demonstrating a similar mechanism in the formation of COS. The investigation of
the formation of ectosomes and membrane dynamics in the development of COS in WT and Prph2−/−
mice might be a potential approach for further studies aiming to unravel the different function of
Prph2 in ROS versus COS. While the function of Prph2 in the initialization of ROS and COS varies,
it seems to be indispensable for the correct shaping, sizing and stacking of discs and lamellae in both.
Furthermore, not only the presence of Prph2 is needed for developing and maintaining these structures
but also the precise regulation in the formation of the different Prph2/Rom1 and Prph2/Prph2 complexes.
Changes in the ratio of the tetramers, intermediate complexes and higher order complexes were proven
detrimental to the function as well as the structure of the photoreceptors. The transgenic and knockin
mouse models discussed here proved the importance of the precise regulation of the complex formation.
Each of the knockin mouse models carrying a pathogenic Prph2 mutation displayed an altered ratio of
the different Prph2/Rom1 and Prph2 complexes resulting in disorganized OS structure and decreased
response found in ERG measurements. Interestingly rods and cones were differently affected by the
alterations in complex formation, providing further evidence for the differential use of Prph2 by the
two photoreceptor cell types. In addition to that, the mouse models used helped identify whether
a mutation results in a loss-of-function or a gain-of-function effect.
While there is agreement in the numerous studies concerning the ratio between tetramers,
intermediate and higher order complexes and its vital importance for OS structure and function,
the precise roles of the different complexes are still not fully understood. In the C150S knockin
mouse model, both Prph2 and Rom1 are found exclusively as tetramers, while intermediate and
higher order complexes are absent. Still the formation of both ROS and COS is initiated, proving that
the tetramers alone are sufficient to initiate OS formation. Homozygous animals fail to form disc
and lamellae, indicating that the intermediate and higher order complexes are more likely to be
involved in the formation of the rim, membrane closure and disc stacking. The knockout of Rom1
showed minor effects on disc alignment, sizing and stacking while the disc rim formation is unaffected.
Rom1 is found in non-covalent hetero-tetramers and in intermediate complexes but it is excluded from
higher order Prph2 complexes. It seems plausible that the Prph2 higher order complexes, which are
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unaffected in the Rom1 knockout retinas, mediate the membrane curvature and rim closure, while the
intermediate hetero complexes support disc spacing, sizing and alignment. Additional studies targeting
the formation of the different complexes specifically and analyzing their function in rods and cones are
needed to further pinpoint the roles of the different Prph2 and Rom1complexes.
Progress in the development of a feasible gene therapy of Prph2 related diseases has been made
in recent years. Transducing the photoreceptors of Prph2−/− and Prph2+/− mice either via AAVs or NPs
showed a partial rescue of the knockout phenotype, even though the magnitude of the rescue and (in
case of the AAVs) the persistence of the rescue effect is still low. The small magnitude of the rescue
is most likely due to a low transduction rate of photoreceptors by the vectors used. Improving the
transduction rate achieved by the vector as well as its distribution in the eye is one obstacle which
needs to be overcome in future attempts. A second obstacle is that pathogenic PRPH2 mutations do not
result in a knockout scenario, but instead in a scenario where the mutant protein is still expressed. The
knockin mouse models summarized in this review have proven to be a valid approach in understanding
how the presence of the mutant protein affects both rod and cone photoreceptors, and also how stable
the mutant protein is. In addition, these models helped to identify mutations, which result in dominant
effects. Using a sh-RNA-mediated knockdown of both WT and mutant proteins followed by the
expression of a sh-RNA resistant form of the WT protein provided a promising approach in the therapy
of dominant gain-of-function mutations of Rho and Prph2. The fact that rods and cones utilize Prph2
differently could lead to further complications; this issue needs to be taken into consideration when
developing effective therapeutic strategies for PRPH2 related diseases. Testing these strategies in the
murine models adds another layer of complication due to the low percentage of cones, which makes it
difficult to address cone-dominant phenotypes in mouse models. Analyzing Prph2 mutations in the
Nrl−/− background provides an approach for studying functional and structural effects of mutation
specifically on cones. The lack of a macula in the murine retina continues to be the rate limiting
factor which prevents conclusive studies aimed at developing therapies for mutations associated
with macular defects and pattern dystrophy using mouse models. In addition to this, several PRPH2
mutations were found to cause secondary effects in the choroid and RPE. The reasons for these
secondary defects as well as their impact on the pathogenesis of PRPH2 associated diseases are not
well understood. Characterizing these secondary defects has to be achieved in future studies in order
to devise a successful therapy.
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Abstract: Phosphatidylinositol and its phosphorylated derivatives, the phosphoinositides, play
many important roles in all eukaryotic cells. These include modulation of physical properties of
membranes, activation or inhibition of membrane-associated proteins, recruitment of peripheral
membrane proteins that act as effectors, and control of membrane trafficking. They also serve
as precursors for important second messengers, inositol (1,4,5) trisphosphate and diacylglycerol.
Animal models and human diseases involving defects in phosphoinositide regulatory pathways have
revealed their importance for function in the mammalian retina and retinal pigmented epithelium.
New technologies for localizing, measuring and genetically manipulating them are revealing new
information about their importance for the function and health of the vertebrate retina.
Keywords: phosphoinositides; retinal lipids; membrane trafficking
1. Introduction
Phosphoinositides are membrane phospholipids with the six-member cyclic polyol myo-inositol,
(CHOH)6, or O-phosphorylated forms of inositol, as their headgroup (Figure 1). The phosphorylated
forms are of low abundance in eukaryotic cells of all types, generally comprising 1% or less of total
phospholipid. Nevertheless, they play critical roles in cellular regulation, and defects in their synthesis
and regulation lead to devastating diseases [1–6]. The retina is clearly no exception to this generality,
but surprisingly few details have been worked out in what is arguably one of the most extensively
studied tissues in our bodies, about the regulation and regulatory roles of retinal phosphoinositides.
Recent technological advances make it possible to make substantial advances in this field in the next
few years.
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Figure 1. Structures of the cellular phosphoinositides and enzymes responsible for their synthesis and
interconversion. Phosphoinositides (PI) species are shown with the acyl chains most commonly found
on phosphatidylinositol, which is the starting point for all the others, arachidonic acid (20:4) and stearic
acid (C18). Relative font sizes correlate with relative abundance.
2. Chemical Structures of Phosphoinositides
Phosphoinositides (abbreviated here as “PI”) include phosphatidylinositol (PtdIns), in which the
1′-position of the inositol ring is attached via a phosphodiester bond to the sn-3 position of (1, 2) diacyl
glycerol, and derivatives of PtdIns with one, two, or three phosphates attached in various combinations
to the 4′, 5′ or 3′ hydroxyls of PtdIns. Including PtdIns, a total of eight different PI head groups are
commonly found in eukaryotic cells (Figure 1) [4,5].
3. Phosphatidylinositol Content in the Retina and RPE
PtdIns is a relatively substantial component of the membranes of most cells in metazoans, with
mole fractions ranging from ~4%–20% of total phospholipid [4]. Early reports stated that retina
phospholipids contained 4.4%–6.4% PtdIns across six different mammalian species [7–9]. Interestingly,
rod outer segment (ROS) membranes were found to have much lower levels, 1.5% to 2.5% in bovine
and 2.1% in frog [10–13]. Retinal pigment epithelial cells (RPE), in contrast, have higher levels of PtdIns,
at 6.5% of total phospholipid [14], while ER membranes isolated from bovine retinas contain 9.6%
PtdIns [10]. The general picture that emerges is that total PtdIns content in total retinal membranes
outside of outer segments and that of RPE are more or less “normal” as compared to other tissues and
cell types, consistent with the notion that widespread roles of PI are likely to be conserved in many
retinal cell types. In contrast, ROS have an unusually low PtdIns content, suggesting different roles
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for this lipid class in that organelle. This idea is consistent with findings discussed below, indicating
different lipid compositions in plasma membranes as compared to ciliary membranes.
4. Content of Minor Phosphoinositides in the Retina and RPE
As a negatively charged lipid, which typically contains one polyunsaturated side chain fatty acid,
such as arachidonic acid [8], PtdIns has a major impact on the physical properties of the membrane
domains containing it. In contrast, the phosphorylated forms are much less abundant, and exert
their influence on cell physiology largely through interactions with proteins with high-affinity and
high-specificity PI-binding domains [15–17]. There have been few measurements of phosphorylated
PI in retina or cells isolated from retina, although there have been several papers addressing the
turnover of PtdIns and other PI, or activity of enzymes involved in PI metabolism [18–21]. The likely
reason for the absence of information on PI levels is their low abundance and the lack of sensitivity
provided by conventional methods for lipid analysis. More sensitive techniques have been developed
recently, including one based on recombinant phosphoinositide-binding domains fused to an epitope
tag, allowing sensitive detection by enzyme-linked immunosorbent assays (ELISAs) and measurement
of chemiluminescence [22]. This technique was used to quantify PI(3)P and PI(3,4,5)P3 in preparations
of rod cells that contain both outer segments and fragments of the inner segments and demonstrated
levels of PI(3)P at 0.0035 mol% of total phospholipid under illumination conditions that yielded the
highest levels of that lipid, and at least 10-fold lower (i.e., undetectable) levels of PI(3,4,5)P3. PI(4)P
and PI(4,5)P2 are, in general, found at much higher levels than the 3-phosphorylated PI, but even those
appear to be present in rods at very low levels, which are only about 10-fold higher than the levels of
PI(3)P, i.e., on the order of 0.04 mol% (He and Wensel, unpublished observations).
Comparison to Other Tissues and Cell Types
These numbers are comparable to those found in other eukaryotic cells, reported as PtdIns3P,
0.002% of phospholipid mass; PtdIns4P, 0.05%; PtdIns5P, 0.002%; PtdIns(4,5)P, 0.05%; PtdIns(3,4)P,
0.0001%; PtdIns(3,5)P, 0.0001% [17], see also references in [23]. A more recent mass spectrometry
study reported PI(3,4,5)3 levels as 50-fold or more lower than those of the more common PIs in
mammalian U87MG cells [24]. An interesting observation derived from measurements of PI levels
in cultured cells is that, generally, they do not change greatly upon activation with extracellular
stimuli; for the more common forms, PtdIns, PI(4)P, PI(4,5)P2 and PI(3)P, the change is generally
less than 30% [17]. The implication, for PI(4,5)P2, which is rapidly degraded to form InsP3 and
diacylglycerol upon activation of phospholipase C isozymes by G-protein-coupled receptors or growth
factor receptors [25,26], is that homeostatic mechanisms are in place to regenerate rapidly the pools of
both PI(4,5)P2 and its precursor PI(4)P upon PLC activation. In contrast, PI(3,4,5)P3 level changes due
to receptor stimulation are generally too low to have a major impact on levels of its precursor, PI(4,5)P2.
5. Importance of PI Generally
Despite their low abundance, phosphoinositides play major roles in regulation of cell signaling and
membrane dynamics, and are essential for control of a wide range of processes including development,
proliferation and differentiation, membrane excitability, exocytosis, phagocytosis, cell motility, and
detection of extracellular signals [4]. These functional roles are primarily mediated by a plethora of
enzymes, scaffold proteins and complex-nucleating proteins containing phosphoinositide-binding
domains of high affinity and high specificity. Genetic defects in the enzymes responsible for their
regulation are, in most cases, lethal at the embryo stage, except for some cases of redundancy (i.e.,
more than one gene encoding enzymes or PI-binding proteins with similar activities). Cell-type specific
deletion of these enzymes leads to more specific pathologies, e.g., neurodegeneration in the case of
the type III PI-3 kinase, Vps34 (also known as PIK3C3) [27,28]. Some of these enzymes, such as type I
PI-3 kinases, can act as oncogenes when mutations disrupt their regulation, and are considered prime
targets for cancer chemotherapy, whereas others, such as the phosphoinositide phosphatase, PTEN,
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are considered tumor suppressor genes [29]; these therapeutic targets are present in the retina, where
their roles in retinal function, and any effects of drugs targeting them are unknown.
Importance of Phosphoinositides for Dynamics and Functions of Membranes in Retina and RPE
Among the most important roles of phosphoinositides and their protein effectors are those
mediating intracellular membrane traffic, by directing membrane proteins and lipids from one
compartment to another in response to cellular needs and changing environments. For example, PI(3)P
is found in early and recycling endosomes, and is important for recruiting key proteins that regulate
trafficking to these compartments [30]. It is also important for autophagy, a survival-promoting
pathway leading to the lysosomal degradation of organelles [31]. PI(4)P is enriched in the Golgi
apparatus, and is thought to be important for membrane trafficking through the Golgi compartments
and from the Golgi to the plasma membrane and other subcellular compartments [32], likely including
disk membranes. PI(4,5)P2 plays a key role in clathrin-mediated endocytosis, and serves to direct many
effector proteins to the plasma membrane where it is primarily found [33].
PI(4,5)P2 and other phosphoinositides directly regulate the activity of ion channels, transporters
and enzymes in membranes [34,35]. In addition, PI(4,5)P2 serves as the substrate for
phosphoinositide-specific phospholipase C, leading to production of the important second messengers,
inositol (1,4,5) trisphosphate (InsP3) and diacylglycerol [25,26,36,37]. Phosphoinositides are also
critically important for regulating interactions between membranes and cytoskeletal elements [38,39].
Changes in these interactions are critical for cell growth and mobility, and for remodeling of intracellular
structures. They may well play a role in cytoskeleton-dependent disk morphogenesis in rods.
6. Membrane Trafficking in Retina and RPE
Every aspect of retinal biology depends heavily on the correct organization and composition of
highly specialized membranes, from the unique disc membranes of the photoreceptor sensory cilia, to
the ribbon synapses of rods, cones, and bipolar cells, to the apical processes of RPE (retinal pigmented
epithelium) cells, uniquely tuned to the detection and engulfment of shed outer segment fragments.
The formation, maintenance, and functions of these membranes rely heavily on the phosphorylated
phosphoinositides [2–4,40]. Despite the intense interest in phosphoinositide research in recent decades,
surprisingly little is known about their regulation and functional roles in the retina, although it is
known that disruption of phosphoinositide regulation can lead to blindness in human patients and
animal models [41–48]. The membranes and pathways they regulate are known to be essential for the
function and health of the retina as well as for disease processes and cellular responses to disease states.
One of the reasons for the dearth of knowledge has been a lack of tools for studying these very
low-abundance lipids within the multiple cell types of the retina and the adjacent retinal pigment
epithelium. Recently, tools developed by the broader PI field have begun to be applied to the unique
challenges and opportunities posed by the retina [22,49]. Doing so will have enormous impact on
our understanding of the cell biology of the retina and its disruption in disease. This can help to
inform the design and optimization of therapies aimed at treating and preventing retinal dysfunction
and degeneration.
7. Features of the Retina that Make It Ideal for Studies of Phosphoinositide Regulation In Vivo
The field of phosphoinositide regulation has long been dominated by studies in cultured
immortalized cell lines, giving rise to a critical need for elucidation of their physiological regulation in
terminally differentiated neurons. For this reason, in vivo studies have broad significance for this field.
There are several features of the retina that make it particularly amenable to studies of phosphoinositide
regulation in vivo. These include the ability to assay both structure and function non-invasively,
the ease of making cell-type-specific knockouts, the ability to isolate rod cells for either biochemical
analysis or ultrastructure determination, an extensive understanding of biochemistry and cell biology,
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especially of rods, which exceeds that of any of other vertebrate neurons, and a wealth of knowledge
of RPE cell biology.
8. Importance of Phosphoinositides for Membrane Trafficking in Retina
Despite years of study, no convincing evidence has accumulated for an important role for
phosphoinositides in the phototransduction cascade. In contrast, a steady stream of evidence supports
a central role for these lipids in membrane trafficking and sorting in all mammalian cell types, just as a
critical role in photoreceptors for membrane sorting and trafficking has long been established [3,50,51].
A review article in 2011 covered advances in understanding the roles of phosphoinositides in
photoreceptors [6]. It is highly likely that events such as endocytosis and exocytosis, endosomal
sorting, membrane budding, post-Golgi vesicle trafficking, and disk morphogenesis all depend on
phosphoinositide dynamics, and published reports support a role for PI(3)P and PI(4,5)P2 in rhodopsin
trafficking [52,53]. For example, PI(4,5)P2-binding proteins, ezrin and moesin, were reported to
colocalize with Rac1 and Rab8 on rhodopsin transport carrier vesicles at the site of their fusion with the
plasma membrane. A recent report suggesting the involvement of actin-nucleating proteins Arp2/Arp3
in basal disc extension [54] potentially implicates local pools or PI(4,5)P2, which are known to be critical
for their function [55,56].
In cone photoreceptors, ablation of a type I PI-3 kinase leads to enhanced sensitivity to light
damage [57]. Mutations in the phosphoinositide phosphatase, synaptojanin 1 lead to defects in synaptic
vesicle trafficking in cone cells [44].
9. Retinal Cilia and Phosphoinositides
Phosphoinositides, and especially PI(4,5)P2 and PI(4)P, have been proposed to play important
roles in assembly, disassembly, and regulation of primary cilia [52,58–62]. The lipid content of cilia is
different from that of the plasma membrane, and a membrane diffusion barrier surrounding the cilium
has been demonstrated (see [63] for a review). Two PI-5-phosphatases, INPP5E and OCRL, essential
for cilium function have been reported to be localized to the cilium [41,64–66]
Phosphoinositides and the BBSome
The BBSome, a heterooctameric protein complex involved in ciliary trafficking, whose defects
lead to the blinding ciliopathy, Bardet–Biedl syndrome, binds to membranes, and shows a preference
for acidic lipids, including phosphoinositides [67,68], and isolated BBS5 which contains pleckstrin
homology domains, binds to phosphoinositides, especially PI(3)P [68]. More recently, it was shown
that a core BBSome complex containing BBS 1, 4, 5, 8, 9 and 18 and a smaller sub-complex lacking
BBS1 and BBS5 bind phosphoinositides with similar specificities. A caveat for these studies is that
the commercial “PIP strips” used have local surface densities of phosphoinositides that far exceed
anything found under physiological conditions, so further investigation of phosphoinositide-binding
of the BBSome and its sub-complexes is warranted.
10. Autophagy and other Stress Responses Involving Redirection of Membrane Traffic and
Phosphoinositides
It has been reported that light exposure induces elements of the autophagy pathway in rods
and that autophagy plays an important role in photoreceptor homeostasis [69–73]. This pathway has
been suggested to be a neuroprotective one that forestalls apoptosis under conditions of stress [69,74].
This process may be part of a more general neuroprotective response involving re-direction of membrane
traffic and phosphoinositides. As discussed below, Synaptojanin-1 has been implicated in autophagy
in zebrafish cones [75].
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11. Evidence for Effects of Light on Phosphoinositide Metabolism
A number of early reports in the 1980s suggested that light had measurable impacts on PI
metabolism in photoreceptors or the retina generally. Based on measurement of 32Pi incorporated into
PtdIns by metabolic labeling, it was reported that exposure of isolated frog retina to light decreased
levels of PIP2 by 14% after 5 s and 37% after 15 s, while levels of PI(4)P, PtdIns and other acidic lipids
remained essentially constant [76]. Subsequent publications from the same group reported increased
levels of 3H inositol and 32P into phosphoinositides upon illumination [77]. They also reported
PI(4,5)P2-specific phospholipase C (PLC) activity in frog photoreceptors, and PLC immunoreactivity
in bovine rod outer segments [78,79], as well as PI-kinase and PIP-kinase activities in frog ROS [19].
Another group found that exposure of rat retinas to light led to decreased staining of rod outer segments
with anti-PI(4,5)P2 antibodies [80,81]. The caveats of those experiments are that it is known that
physical properties of outer segment membranes and their protein composition are altered by bright
light exposure, and that it is difficult to establish the specificity of such antibody staining. In addition to
light, reports on regulation of photoreceptor PLC by Ca2+ [82] or by subunits of the phototransduction
G protein, transducin [83], were published, also suggesting a possible influence of light exposure,
which is known to control levels of Ca2+ and active and inactive forms of transducin subunits.
In contrast, another group [84] reported that bovine rod outer segments have very little PIP
kinase activity as compared to the rest of the retina (consistent with the previously reported low
level of PI(4,5)P2 in outer segment membranes), and that light adaptation had no measurable effect
on phosphoinositide metabolism as compared to in vivo dark adaptation. Yet another group, using
metabolic labeling with [3H]inositol, reported that light led to decreases in PIP2 levels without
generation of InsP3, suggesting light-dependent activity of a phosphatase rather than of phospholipase
C [85]. In vitro studies demonstrated that the presence of PI(4,5)P2 in membranes could affect the
activity of components of the phototransduction cascade [86,87], including the cGMP-gated cation
channel and the cGMP phosphodiesterase-transducin complex. The physiological relevance of effects
of PI(4,5)P2 on phototransduction or of effects of light on PI(4,5)P2 metabolism remains untested, and
it seems to be possible to explain the entire time-course of rod light responses without invoking any
participation by phosphoinositide metabolism [88]. Antibodies specific for isoforms of phospholipase
C or Gαq/11 PLC-coupled subunits revealed the presence of PLCβ4 and Gαq/11 in rod outer segments,
and Gαq and other PKC isoforms elsewhere in the retina [89]. The functional roles of these proteins in
outer segments are not known. There have been suggestions that slower effects of prolonged light
exposure, such as arrestin translocation from the inner to outer segments of rod cells, may be mediated
by a phospholipase C cascade [90].
Light Regulation of PI-3 Kinase
Interest has turned toward Type I PI-3 kinase and PI(3,4,5)P3, with reports of effects of light on the
activity of this enzyme in bovine rod outer segments [91,92], which were reported to be mediated by
light-stimulated activation and tyrosine phosphorylation of the insulin receptor [93–95]. Deletion of
the p85α regulatory subunit of Type I PI-3 kinase in cone cells resulted in progressive degeneration of
cones, without observable effects on rod survival [57]. Likewise, cone-specific inactivation of the gene
encoding the p110α catalytic subunit also resulted in defects in cone survival [96].
In contrast, Type I PI-3 kinase and its product, PI(3,4,5)P3, seem to be much less important for rod
function. Rod-specific ablation of the p85α gene using two different rod-specific Cre transgenes yielded
no obvious defects in retinal morphology or rod cell survival [22,97], although modest effects on kinetics
of light response recovery and arrestin translocation were reported in one case [97]. Quantitative
analysis of PI(3,4,5)P3 levels in rods isolated from dark-adapted or light-adapted retinas revealed levels
of this phosphoinositide of more than one order magnitude lower than those found for PI(3)P in the
light, or at least two orders of magnitude lower than light-stimulated levels of PI(4,5)P2 [22].
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12. PI(4,5)P2 and Phospholipase C in Intrinsically Photosensitive Ganglion Cells
In addition to image-forming light detection mediated by rods and cones, the vertebrate retina
also contains intrinsically photosensitive retinal ganglion cells. These contain phototransduction
cascades reminiscent of that found in invertebrate rhabdomeric photoreceptors [98–104]. Light activates
melanopsin, encoded by the Opn4 gene, a visual pigment which is more closely related to invertebrate
opsins than to vertebrate opsin [105]. In M1-type ganglion cells, melanopsin photoisomerization leads
to activation of a Gαq/11/14 class G-protein, which activates the phosphoinositide-specific phospholipase
C isoform, PLCβ4; the phospholipase presumably acts on PI(4,5)P2 as in other cell types, including
Drosophila photoreceptors, which contain a homologous phospholipase, to produce diacylglycerol
and InsP3. PI(4,5)P2 hydrolysis, in turn, leads to the activation of the cation channels TRPC6 and
TRPC7 [104]. In M4 ganglion cells, a different phototransduction cascade involving cyclic nucleotides
and cyclic nucleotide-regulated HCN channels, whereas in M2 ganglion cells, both of these cascades
operate [102].
13. Studies of PI Metabolism in the RPE
A variety of extracellular stimuli acting on tyrosine kinase-associated receptors or G
protein-coupled-receptors have been reported to stimulate release of inositol phosphates in cultured
RPE cells, presumably derived from PLC action of PI(4,5)P2, on a timescale of tens of minutes; effective
stimuli included fetal bovine serum, agonists for muscarinic, histamine, and serotonin, peptides,
including bradykinin, arginine vasopressin, bombesin and oxytocin, [106–109]. The physiological
relevance of these observations was not explored, but an in vivo study using frogs demonstrated
dramatic acceleration of inositol phosphate release, especially of InsP3, following stimulation by
light [21]. Acutely isolated rat RPE cells were reported to release InsP3 in response to induction of
phagocytosis by addition of isolated rod outer segments [110]; this InsP3 release was not observed
in cells from Royal College of Surgeon (RCS) rats, which have a defect in OS phagocytosis due to a
deficiency in the receptor tyrosine kinase, MERTK [111]. As in many other cell types, insulin has been
reported to stimulate activity of Type I PI-3 kinase to produce PI(3,4,5)P3 [95,112,113]. Responses to
hypoxia [112,114,115] and elevated glucose [116,117] are also reported to involve this pathway in RPE.
A number of important processes in RPE are known to rely on phosphoinositides, but how they are
regulated in these cells is not well understood. Phagocytosis, autophagy, endocytosis and endosome
processing, establishment of epithelial cell polarity and extension of microvilli membranes are all
known to critically depend on phosphoinositides. For example, both autophagy and phagocytosis
involve the recruitment of the ubiquitin-like protein, LC3 [118–120], whose recruitment to membranes
depends on PI(3)P. Phagocytosis is also thought to require PI(4,5)P2 and lysosomal fusion may involve
other phosphoinositides such as PI(3,5)P2 and PI(5)P [22,121–125].
14. Phosphoinositide Kinases and Phosphatase
In mammals, there are 47 genes encoding 19 PI-kinase and PIP-kinases and 28 PIP
phosphatases [126].
14.1. Kinases
The kinase isoforms are divided into three major families: PI 4-kinases (PI4Ks), the PI 3-kinases
(PI3Ks), and PIP (PIP) kinases (PIPKs) [127]. The nomenclature for these is a bit confusing, as some
enzymes termed “PI-kinases” actually act primarily as PIP kinases. For example, Type I PI-3 kinases
primarily use PI(4,5)P2 as their substrate to produce PI(3,4,5)P3, and there is little evidence for a
substantial portion of cellular PI(3)P being formed by these enzymes. When the Type III PI-3 kinase,
Vps34, was knocked out in mouse rod cells and phosphoinositide levels measured, the results suggested
complete ablation of PI(3)P despite the presence of the Type I enzyme [22]. Several of these have been
reported to be expressed in retina or RPE at the level of protein, mRNA or enzyme activity and most,
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if not all, are likely present at some level; however, as far as their functions, only the Type I and Type
III PI-3 kinase have been studied using gene knockouts in the retina and RPE [22,49,57,128]. Global
knockouts have been produced for the α, β, and γ isoforms of Type I PIP-kinases, which are the major
source of PI(4,5)P2 in most cells [16]. Of these, the γ isoform seems to have the highest expression
in the retina [129] and in other neurons [130,131] and leads to severe neuronal phenotypes and early
postnatal mortality when knocked out [132]. Type II PIP-kinases have been observed in retina and are
reported to be regulated by tyrosine phosphorylation [133]. The proteins encoded by the mouse genes,
Pip4k2a, Pip4k2b, Pip4k2c, Pip5k1a, and Pip5k1c were all observed in a proteomic study of mouse
retina [134].
14.2. Phosphatases
The phosphoinositide phosphatases encoded by Inpp1, Inpp4a, Inpp4b, Inpp5e, Mtmr2 and Synj1
(synaptojanin-1) have also been detected in retina by proteomics [134]. As noted below, defects in
synaptojanin-1 and INPP5E are associated with retinal defects, as is the phosphoinositide 5-phosphatase,
OCRL (oculocerebrorenal syndrome of Lowe) [135,136]. Among the other enzymes detected, almost
none were enriched in the rod outer segment fraction as compared to the rest of the retina, consistent
with the relatively low PI content of that organelle. One exception was Pip4k2c, the PI(5)P-4-kinase
Type II γ isoform. Inactivation of the mouse Pip4kc2 gene was found to lead to hyperactivation of the
immune system, but the retinal phenotype was not examined [137].
15. Retinal Phenotypes of Genetic Defects in Genes Related to Phosphoinositide Metabolism
and Signaling
Rods and cones have a very high rate of metabolism and biosynthesis of membrane components,
due to the energetic demands of the phototransduction cascade and the daily shedding of ~10% of
the disk membranes (based on observation of a rate of 9%–13% in the rhesus monkey [138], which
have to be engulfed and recycled by the RPE. As highly polarized cells, their function and health
depend critically on efficient and accurate transport of the correct proteins and lipids to the correct
compartments. A host of human blinding diseases have been linked to defects in membrane transport
and sorting [139,140]. In RPE cells, massive amounts of membrane traffic are associated with their
role as professional phagophores. Defects in RPE phagocytosis, as in MERTK deficiency [111,141] and
Bestrophin deficiency [142–145], cause retinal degeneration in humans and animal models and have
been proposed to play a role in age-related macular degeneration [146].
15.1. Phosphatases and Inherited Retinopathies
Inherited defects in the phosphoinositide phosphatase, INPP5E, are associated with the
multi-syndromic ciliopathies, Joubert syndrome and Bardet–Biedl syndrome [147–150], and with
retinal degeneration. The substrates for this phosphatase are PI(4,5)P2 and PI(3,4,5)P3, and its critical
role in the cilia suggests that regulating levels of PI(4,5)P2 may be important in ciliogenesis and
cilium stability.
Synaptojanins are phosphoinositide phosphatases associated with synaptic function [151–153],
including vesicle uncoating and endocytosis. Synaptojanin-1 deficiency causes severe cone defects in
zebrafish and has been implicated in the regulation of autophagy in cones [45,46,75].
Defects in another phosphoinositide phosphatase, OCRL, are associated with a severe ciliopathy,
oculocerebrorenal syndrome of Lowe [136]. Symptoms of this disease include glaucoma, a disease of
the retina.
15.2. PI3NM3
The phosphatidyl inositol transfer protein PIT3NM3 (aka CCL118) is the mammalian homologue
of the Drosophila retinal degeneration gene, rdgB, and defects in it are associated with autosomal
dominant cone-rod dystrophy CORD5 [154–159]. The protein has also been implicated in cancer
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metastasis [160]. In zebrafish, the Class I phosphatidylinositol transfer protein β isoform, Pitpnb,
is essential for biogenesis and maintenance of double cones [161].
15.3. PI Binding Proteins
Proteins with phosphoinositide-binding domains have also been associated with retinal disease.
These include the product of the tub/TUB gene [162,163] and a related protein, TULP1 [47,164–166].
Tub was discovered as the protein encoded by a gene whose mutation in tubby mice causes obesity,
deafness and blindness. The widely expressed members of the tubby family, including TULP1-TULP4,
have a characteristic carboxyl-terminal tubby domain consisting of an alpha helix surrounded by a
beta barrel which has been shown to bind to specific phosphoinositides [167]. Both Tub and Tulp1 are
expressed in the retina, and TULP1 mutations cause retinitis pigmentosa [47,168].
16. Conclusions
While the overall field of phosphoinositide regulation and signaling has made dramatic advances
in recent years, our understanding of specific regulatory pathways in specific cell types of the retina
remains limited. The emergence of new technologies for cell-type-specific gene manipulation, along
with imaging techniques for subcellular localization of phosphoinositides, their regulatory enzymes and
their effector proteins, and the development of more sensitive methods for measuring PI levels, bodes
well for rapid progress in understanding the roles of retinal phosphoinositides in the coming years.
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Abstract: Iron is essential for cell survival and function. It is a transition metal, that could change its
oxidation state from Fe2+ to Fe3+ involving an electron transfer, the key of vital functions but also
organ dysfunctions. The goal of this review is to illustrate the primordial role of iron and local iron
homeostasis in retinal physiology and vision, as well as the pathological consequences of iron excess
in animal models of retinal degeneration and in human retinal diseases. We summarize evidence
of the potential therapeutic effect of iron chelation in retinal diseases and especially the interest
of transferrin, a ubiquitous endogenous iron-binding protein, having the ability to treat or delay
degenerative retinal diseases.
Keywords: iron; retina; transferrin
1. Introduction
Iron is a major element in biology. Besides its well-known role in prebiotic conditions after the
rise of oxygen in the atmosphere, its insolubility led to the development of many mechanisms to allow
the primitive cells and organisms to use it. They are driven by the transition of ferrous iron (Fe2+) to
ferric iron (Fe3+) involving an electron which is particularly available and is the basis of vital functions
and dysfunctions in the organs.
In this review, we analyze several of the well-known or recently discovered functions of iron in
the eye, mainly in the retina, and the most promising approaches to regulate it and improve a large
number of its negative side effects which can lead to vision impairment. We will focus on the main
functions of transferrin (TF) as a partner in the systemic and cellular mechanisms that underlie the
regulation of iron homeostasis and its disorders.
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2. The Retina Structure and Retinal Oxygen Supply
The eye is a complex and confined organ formed by different compartments and structures
essential for the transmission and focus of photons from the cornea to the photoreceptors (PRs), which
convert them into an electrical signal transmitted to the brain. The neural retina comprises the PRs,
cones, rods, the interneurons, the ganglion cells, the glial cells such as retinal Müller’s glial cells (MGC),
astrocytes, and microglia (Figure 1). The retina is vascularized by two separate vascular systems, the
retinal vessels, branches of the central retinal artery that vascularize the inner retinal layers, and the
choroidal vessels, branches of the ciliary arteries that supply the avascular PR layer through the retinal
pigment epithelium (RPE) cells. In primates and human, visual acuity, photopic vision, and color
vision are ensured by the macula, a highly specialized retinal area that comprises less than 5% of the
total retinal surface, located at the center of the visual axis. The center of the macula, the fovea, is
devoid of retinal vessels and composed exclusively of cones and MGC cells.
Figure 1. Schematic drawing of the cellular components of the retina. Legend Figure 1: There are three
retinal vascular plexuses tightly coordinated with retinal neurons and a choroid plexus underlying RPE.
GCL: Ganglion cell layer; NFL: Nerve fiber layer; INL: Inner nuclear layer; IPL: Inner plexiform layer;
MGC: Müller glial cell; ONL: Outer nuclear layer; OPL: Outer plexiform layer; OS: Outer segments; IS:
Inner segments; PR: Photoreceptors; RPE, retinal pigment epithelium.
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The retina is separated from the circulation by two blood-retinal barriers (BRB). The inner BRB
consists of a neuro-glio-vascular complex formed by tight junctions between endothelial cells of the
retinal capillaries, pericytes, astrocytes, MGC, and microglia [1]. The outer BRB is formed by the
tight-junction monolayer of RPE cells that are in close contact with the choriocapillaries, which control
exchanges through diaphragmed fenestrations [1]. Oxygen is the most supply-limited metabolite
in the retina [2]. Its supply to the retina is ensured by the choroid, which provides oxygen to the
outer retina, whilst the retinal circulation provides the oxygen requirements of the inner retina. In
normal condition, the level of oxygen tension (Po2) in the outer retina is ten times lower than in the
inner retina [3]. Oxygen and glucose consumption are metabolized to lactate, while aerobic glycolysis
dominates energy production in the outer retina. Several factors modify Po2 level and utilization at the
cellular level: the retinal depth, the light, and hyperoxia [4,5]. PRs have almost all mitochondria in
their inner segments far from blood vessels. Light decreases oxygen utilization on the outer retina as
much as by a factor of two and increase Po2. Hyperoxia dramatically increases Po2 in the retina with
the increase higher in outer retina compared to inner retina. The development and maintenance of
retinal vasculature is regulated by α subunits of hypoxia-inducible factor (HIF), which induce genes
required for retinal homeostasis, such as vascular endothelial growth factor (VEGF) under hypoxic
conditions [6]. HIF proteins, which act as regulators of oxygen homeostasis, also depend on iron for
their activity, and they regulate genes involved in iron metabolism [7]. Hyperoxia is deleterious to the
outer retina as the oxygen leads to the formation of reactive oxygen species (ROS) according to the
Fenton and Haber–Weiss reaction catalyzed by iron to generate RO◦ radical (review in [3]). Iron and
oxygen are thus closely linked in retinal metabolism in health and disease conditions.
3. Iron Homeostasis in the Retina
3.1. Distribution of Iron in the Retina
Iron is widely and unevenly distributed throughout the adult rat retina. The highest concentrations
of ironwere observed by proton-induced X-ray emission in the choroid, the RPE, and the inner segments
of the PR. PR outer segments also contain iron, as inclusions inside the discs [8]. Iron and iron-related
parameter (total iron binding capacity, TF and TF saturation percentage) distribution in the eye are
different between diurnal and nocturnal animals. In cow and pig retina, iron concentration is higher
than in rat retina, suggesting that the nocturnal habit of living could influence iron-related parameters
in the retina [9]. The iron level also varies during retinal development and aging. Moos et al. have
shown that in rats, iron entry is very high during retinal development and maturation, then decreases
in adulthood, and increases again with aging [10]. In rodents, there are gender and strain-specific
influences on iron regulation in the neural retina [11]. Human sex-associated differences in iron levels
have also been reported, women having more retinal iron than men at all ages [12]. With aging, iron
deposits are found in the RPE/choroid complex in rats and in the stroma of the choroid in non-human
primate regardless of serum iron concentration [13]. Increased iron levels in the retina have also been
reported in human eyes with age [12]. In rodent eyes, both neural retina and RPE/choroid present an
increase of iron concentration which is associated with modifications of iron-related proteins mRNA
and protein levels [14,15].
247
Cells 2020, 9, 705
3.2. Proteins Involved in Retinal Iron Homeostasis
3.2.1. General Iron Homeostasis
Under physiological conditions, almost all non-heme iron (Fe3+) in the circulation is transported
bound to TF (transferrin-bound iron: TBI)with high affinity (for review on cellular ironmetabolism [16]).
At cellular level, the TF with two Fe3+ (holo-TF) is bound by its receptor (TFR1), and the complex is
internalized. The Fe3+ is released from TF in the endosome under the effect of acidification through
the action of an ATP-dependent proton pump. Iron is then reduced into the ferrous form, Fe2+,
by endosomal ferrireductase six transmembrane epithelial antigen of the prostate 3 (STEAP3) and
exported by divalent metal transporter 1 (DMT1) in the cytosol where it contributes to the labile iron
pool (LIP). In case of iron overload, TF is saturated with iron, and the non-transferrin-bound ferrous
iron (NTBI) could be up-taken by iron importers such as the ZRT/IRT-like proteins (ZIPs) or DMT1 and
joined intracellular LIP. The LIP consists of a transitory pool of iron species associated with a variety
of ligands with low affinity (citrate, phosphate, inorganics irons) and easily oxidized, in transit to be
distributed to the organelles (in particularly in mitochondria or nucleus) for cell metabolism in iron
requiring proteins, stored or released.
In non-erythroid cells, the majority of iron is stored in ferritin (FT). Composed of 24 subunits of
both heavy (HFT) and light (LFT) chains, FT forms a tissue-specific heterocomplex which can store up
to 4500 Fe3+. Fe2+ from LIP is transported to FT by Poly(rC)-binding proteins (PCBP1 and PCBP2) and
is oxidized by ferroxidase activity of HFT in an oxygen-dependent manner. Then Fe3+ is stored in the
cavity formed by LFT. Iron is released from FT in a controlled manner by autophagy involving a cargo
receptor, the nuclear receptor coactivator 4 (NCOA4).
The only known mammalian iron exporter is ferroportin (FPN), a transmembrane protein which
requires a multicopper ferroxidase to convert Fe2+ to Fe3+, allowing binding to TF. Hephaestin (HEPC),
ceruloplasmin (CP), amyloid-beta precursor protein (APP), and the newly identified zyloklopen (ZP)
are co-localized with FPN at the surface membrane or secreted.
3.2.2. Iron Flux in Retina
A local retinal homeostasis of iron, independent from the systemic regulation, is suspected by
the fact that main proteins involved in iron homeostasis, previously confined to systemic expression,
are locally synthesized in the retina (Table 1). In addition, the outer and inner BRB prevents the entry
of large quantities of iron into the eye in case of systemic iron overload. The study of mouse models
invalidated for iron homeostasis proteins (Table 1) led to a hypothetical model in which iron entry and
homeostasis in the retina is divided into two compartments, carried by the RPE and MGC, delimited
by the external limiting membrane, and having limited exchanges in physiological condition.
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Transferrin-Bound Iron Transport in the Retina
The RPE imports iron bound to TF from the choriocapillaries through the transcytosis of TFR1
present at the basal membrane of the RPE (Figure 2). The transcytosis of the TF/TFR1 complex along
microtubules via galectin 4 and Rab11a [42] has been described in vitro. The presence of TFR1 on the
apical side of RPE is ambiguous and suggests that TF/TFR1 transcytosis or a potential iron-TF uptake
by RPE could egress iron from the outer retina to choriocapillaries. Six hours after an intravitreal
injection of holoTF tagged with a fluorochrome, TF is localized in RPE and choroid, which favors
the later hypothesis [43]. Another iron entry in RPE is the phagocytosis of PR outer segments which
contains high quantities of iron [8]. Once in RPE cytosol, iron is stored in FT and in melanosomes [44].
The release of iron from cell is possible through FPN present at the basal membrane of RPE and a
multicopper ferroxidase. HEPH, CP, and APP but not ZP are expressed in RPE [26].
 
Figure 2. Ironuptake fromcapillaries and transport in the retina. Legend Figure 2:Under physiological
condition, non-heme iron (Fe3+) in the circulation is transported bound to transferrin (TF). A. At the
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choroidal side, Fe3+ linked to TF is captured by its receptor 1 (TFR1) (1) at the basolateral level of the
retinal pigment epithelium (RPE) (blue arrows). The internalized TF/TFR complex is transported to
the apical pole by transcytosis (T) (2) or to the endosome (E) (3). In this case, Fe3+ is released from TF
and reduced by the metaloreductase six transmembrane epithelial antigen of the prostate 3 (STEAP3)
to ferrous iron (Fe2+) and then exported to the cytosol by the transporter divalent metal transporter
1 (DMT1) where it constitutes the free iron pool (LIP) (4). TF and TRF1 are recycled to membrane
(5). Iron is then transported from LIP to the organelles as needed, either stored in ferritin (FT) and
melanosomes (Me), or exported by ferroportin (FPN) coupled to ferroxidases such as ceruloplasmin
(CP) or hephaestin (HEPH), amyloid-beta precursor protein (APP) or zyloklopen (ZP) (black arrows).
Hemochromatosis protein (HFE) and beta-2 microglobulin (B2M) associated to TFR1, shift to TFR2 in
case of iron overload (saturation of TF) and activate hepcidin (HEPC) transcription (6). B. At retinal
capillaries side, Fe3+ bound to TF is up-taken by TFR1 at the luminal side of retinal endothelial cells
(REC) (a), and TF/TFR1 pass directly through transcytosis into the retina (b) or endocytosed then
exported by FPN (c). TF synthetized by RPE, Müller glial cells (MGC) or photoreceptors (PR) up-taken
retinal iron (d) and distributed it throughout the retina, especially to PR. Phototransduction performed
on the outer segments of PR is a highly iron-dependent process. PR uptake Fe3+ bound to TF by
TFR1 presents in inner segments and export it by FPN or by phagocytosis (P) of the outer segments
of PR by RPE. TF-independent iron delivery to the retina can occur, especially in case of systemic
iron dysregulation (black dotted lines). Serum FT has a specific receptor, the scavenger receptor class
A, member 5 (SCARA5) localizes at the basal membrane of RPE, luminal side of REC, PR and MGC.
Lactoferrin (LF), a member of TF superfamily and its receptors (LFR) are present in RPE. Fe3+ captured
by a siderophore (2,5-dihydroxybenzoic acid (2,5-DHBA)) is bound by lipocalin 2 (LCN2) and its
receptors (24p3R) in RPE. The non-TF-bound iron (NTBI) is up-taken by MGC, REC, PR and RPE by
DMT1 or ZRT/IRT-like proteins (ZIP) importers. BM: Bruch’s membrane; CEC: choroidal endothelial
cell; E: endosome; Me: melanosome; MGC: Müller’s glial cell; MI: mitochondria; P: phagosome; PR:
photoreceptor; REC: retinal endothelial cell; RPE: retinal pigment epithelium; T: transcytosis.
In the inner retinal layers, iron is imported through retinal endothelial cells (REC) which express
TFR1 at their luminal side [45]. Two mechanisms of iron transfer across the abluminal membrane of
REC into the retina are evoked: TF/TFR1 transcytosis or/and TF/TFR1 endocytosis following by iron
released from endosome and iron export by FPN. The abluminal membrane of REC expresses FPN
colocalized with HEPC, CP, and APP [24,31]. Iron is bound by TF and distributed to the retina or the
vitreous. With its unique position extending from the vitreous to PRs and its capacity to synthetize
TF [46] and to express FPN [24], MGC plays a crucial role in the distribution of iron from the inner
retina to the inner segment of the PR.
Iron presents in the non-vascularized subretinal space, between the apical side of RPE and the PR,
is mainly bound to TF, secreted by PRs and RPE, and up-taken by PRs for their highly metabolism
activities, by TFR1 express at inner segments. The PR inner segment is the iron storage compartment
for PR segments, where both FT chains and mitochondrial FT are highly concentrated [30]. Iron export
from the PR is ensured mostly by FPN also present in inner segments, CP and HEPH being poorly
involved in favor of APP [26].
Non-Transferrin-Bound Iron Transport in the Retina
Whereas iron-bound TF is the main transport system to cross the BRB, transferrin-independent
iron delivery to the retina can occur (Figure 1). Serum FT, exclusively composed of LFT has specific
receptor, the scavenger receptor class A, member 5 (SCARA5) expressed in cytoplasm and nucleus
in retinal endothelial cells, ganglion cells, astrocytes, the inner nuclear layer, MGC, microglia, outer
nuclear layer, cones segments and RPE. After intravenous injection, serum FT remained confined in
retinal endothelial cells in the inner retina [47]. Another protein possibly involved in iron transport is
lactoferrin (LF), a multifunctional protein which shares 65% of homology with TF. It is synthesized in
various human ocular tissues mainly in the RPE but not in the neural retina [18]. LF receptors have
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not been studied in the eye but are present in the brain [48]. Lipocalin 2 (LCN2) does not bind to iron
directly, but through interaction with siderophores (catecholate and carboxylate) as cofactors [49] could
also be implicated in iron transport in the retina [20]. β-hydroxybutyrate dehydrogenase-2 (Bdh2), an
enzyme that is critical for the synthesis of 2,5-dihydroxybenzoic acid (2,5-DHBA), the mammalian
siderophore, is found throughout the retina in all cell layers, including ganglion cells, MGC, and RPE
cells [50]. Two major membrane-bound receptors for LCN2, megalin and 24p3R, have been identified
in RPE [21,22]. Although LCN2 is being recognized as an important factor in retinal diseases [21], its
exact contribution in iron retinal transport in health and diseases remain to be determined.
In case of iron overload, the NTBI could be up taken by iron importer ZIP or DMT1. This
could explain why in retinal iron overload models, iron continues to accumulate despite the reduced
expression of TFR1 in retina and RPE [31]. The specific localization of DMT1 in PRs and bipolar and
horizontal cells suggests that it could be involved in providing iron to these cells, for phototransduction
or neurotransmitter synthesis [30] ZIP8 and ZIP14 are expressed in RPE, choroid, REC, choroidal
endothelial cells (CEC), ganglion cells, PRs, and MGC. At a high degree of TF saturation in the retina,
there is a decreased ZIP14 expression whereas ZIP8 expression remains stable [31].
3.2.3. Iron Regulation in Retina
Cellular iron uptake and release and the intracellular LIP size are tightly controlled. Transcriptional,
post-transcriptional, and post-translational processes regulate iron homeostatic proteins (for a review,
see [51]). The main mechanisms of intra- and extra-cellular regulation of iron levels are limited to two
extremely controlled systems.
The first system includes iron regulatory proteins (IRP) 1 and 2—intracellular iron regulatory
proteins which, depending on the amount of iron, bind iron responsive element (IRE) sequences
present on the mRNAs of iron homeostasis proteins such as FPN, TFR1, FT, and DMT1. Depending on
the position of the IRE site, IRP controls their translation or degradation. Under conditions of increased
cellular iron, IRP1 loses its IRE-binding activity by acquiring an iron in the 4Fe–4S cluster, whereas
IRP2, is degraded by proteasome. In this condition, tfr1 and dmt1 mRNA are degraded, whereas ft, fpn,
and hif-2αmRNA are translated. The localization of IRP1 and IRP2 has not yet been identified in the
retina but their expressions are ubiquitous in mammalian cells. Mice with Irp1+/− Irp2−/− genotype
show more severe neurodegenerative disease than Irp2−/− animals [30]. These IRP deficient retinas
have increased FPN and FT in the inner segments, MGC endfeet, and inner retina compared to age
and strain matched wild type retinas, suggesting that FPN and FT levels are regulated by IRPs in the
retina [23]. In a model of light induced retinal degeneration, 2 h after light exposure, Irp2 but not Irp1
mRNA increased in the retina [32].
The second system focuses on hepcidin (HEPC), a peptide hormone principally synthetized by
the liver. However, HEPC is also synthesized by PR, RPE, and MGC [39]. It is activated by two cellular
signaling pathways induced by excess of iron, the transferrin receptor 2 (TFR2)/Human homeostatic
iron regulator protein (HFE) pathway and the Bone Morphogenetic protein (BMP6)/Mothers against
decapentaplegic homolog 1 (SMAD) pathway. When the TF saturation is high at the basolateral level of
the RPE, the HFE is released from TFR1 and binds to TFR2, which activates the transcription of HEPC.
BMP6 secreted by the retina and the RPE, binds to its receptors coupled to hemojuvelin (HJV) protein at
the apical level of RPE in order to activate the synthesis of HEPC [35]. HEPC binds to the extracellular
domain of FPN on the cell surface, leading to its internalization and degradation, effectively preventing
cellular iron export and limiting the amount of iron that gets into the extracellular fluid. The specific
deletion of HEPC in the retina does not lead to age-associated retinal iron accumulation, whereas
liver-specific HEPC silencing leads to early serum, RPE, and retina iron accumulation followed by
retinal degeneration [52].
Finally, the hypoxia inducible factor (HIF) acts as a transcription factor for certain iron homeostasis
genes such as the Tf, tfr1, Dmt1, Fpn, and Cp genes by binding to a specific hypoxia-responsive element
(HRE) site present on their mRNAs. Expression and degradation of HIF are also dependent on iron. In
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fact, Fe2+ is the cofactor of prolyl hydroxylase involved in the degradation of HIF-1α, and at the same
time HIF-2α has an IRE sequence in the 5′UTR of its mRNA, which in the condition of iron deficiency,
inhibits its translation. Nuclear staining of HIF-1α was observed in the GCL, the inner nuclear layer
and the outer nuclear layer in human and rat [41]. Under retinal hypoxia, both HIF-1α and HIF-2α are
activated but have cell specific expression within the inner retina. Specifically HIF-2α activation seems
to play a key role in regulating the response of MGC to hypoxia [53].
4. Physiopathological Role of Iron in the Retina
4.1. Iron in Cellular Metabolism/Functions
4.1.1. Iron as a Fe-S Structural Motif Involved in Various Cellular Machinery Proteins
Iron sulfur (Fe-S) proteins are characterized by the presence of Fe-S clusters localized in different
cell compartments (for review [54]). IRP1 is a Fe-S cluster that participates in sensing and regulating
iron homeostasis in the retina. Frataxin is a nuclear-encoded mitochondrial protein involved in Fe-S
cluster assembly, heme synthesis, and intracellular iron homeostasis. Frataxin is an allosteric activator
which binds to this assembly complex [55]. It is present in the retina [56] and in the RPE [57] and could
be responsible for retinal neurodegeneration induced by defective mitochondrial function [58]. In
addition, Fe-S clusters may act as biological sensors by their binding properties to molecular oxygen
and nitric oxide [59] both critical for the retinal physiology and pathology.
4.1.2. Iron in Nucleic Acids Machinery, Cell Proliferation, and DNA Repair
A recent review has reported the multiple implications of iron in DNA synthesis and repair, as well
as in RNA metabolism [60]. Cytosolic and nuclear Fe-S proteins intervene in the genome stability [61].
Iron has been implicated in DNA synthesis and repair as a cofactor of sirtuin 2, an histone deacetylase,
involved in iron homeostasis [62]. Sirtuin 2 maintains cellular iron levels by binding the nuclear factor
erythroid-2-related factor 2 (NRF2) leading to a reduction in total and nuclear NRF2 levels. NRF2 is a
transcription factor that plays key roles in retinal antioxidant and detoxification responses and has
been linked with the development of age-related macular degeneration (AMD) [63].
Mitochondria are a major source of ROS and mitochondrial DNA is very susceptible to oxidative
damage [64]. In RPE cells, mitochondrial DNA is damaged by hydrogen peroxide [65]. Deletions in
mitochondrial DNA occurred in function of age in human neural retina [66], and the accumulation of
age-related mitochondrial mutations in the eye has been correlated with a decrease in ATP production
and increase ROS output, leading to oxidative stress, inflammation, and degradation [67].
4.1.3. Iron in Oxygen Transport and Regulation
Hemoglobin is synthetized in the retina [68]. It is one of the main protein synthesized in primary
cultures of human RPE and secreted in vivo through the basolateral membrane [69].
Under physiological condition, free hemoglobin is bound by haptoglobin, but in case of massive
hemolysis, hemoglobin releases free heme which binds hemopexin. Both hemopexin and haptoglobin
have been described in the human retina [70,71]. The mRNAs for both haptoglobin and hemopexin
were detected in the neural retina and PR as well as ganglion cells but not in RPE cells.
Neuroglobin is a highly conserved oxygen-binding protein reviewed in [72] and highly expressed
in the retina. Its role is to facilitate oxygen metabolism, being localized in mitochondria. Hemin,
the ferric chloride salt of heme enhances neuroglobin expression and protects animal model of
N-methyl-N-nitrosourea-induced retinal degeneration [73]. In this model, hemin protects also cones
from apoptosis. Neuroglobin has also been associated with retinal damage induced by light [74] which
may reflect the changes in iron metabolism first described with light on retina [32]. It has also been
associated with VEGF expression and thus could participate in retinal angiogenesis [75].
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Heme, Fe2+ protoporphyrin IX, the prosthetic group of hemoproteins including hemoglobin,
neuroglobin, oxidases/peroxidases, or cytochromes can be released after auto-oxidation. Heme
transporter proteins also intervene in iron metabolism in the retina, and their dysregulation could
potentially cause oxidative cell damage. All three heme transporters feline leukemia virus subgroup
C receptor (FLVCR), breast cancer resistance protein (BCRP), and proton-coupled folate transporter
(PCFT/HCP-1) are expressed in the retina and RPE. In the RPE, the expression of FLVCR is restricted to
the apical membrane and the expression of BCRP and PCFT to the basolateral membrane. In cases
of iron overload, the expression of FLVCR and PCFT is upregulated and BCRP is downregulated,
suggesting an important role of heme transporter proteins in retinal iron regulation [76].
4.1.4. Iron and Visual Function
The involvement of iron in the vision cycle was discovered with the characterization of the enzyme
RPE65, as an iron-dependent isomerohydrolase [77]. RPE65, abundant in the RPE [78], ensures the
isomerization and hydrolysis of all-trans retinyl ester to 11-cis retinol. RPE65 is essential for vision, and
mutations in rpe65 genes induce Leber congenital amaurosis, a form of retinitis pigmentosa that leads
to blindness [79]. Recently, RPE65 was also shown to intervene in the production of meso-zeaxantin,
an ocular specific carotenoid which protects the fovea from oxidative stress [80].
An alternate pathway for 11-cis retinol recycling has been described in MGC by isomerases 1 or 2
that also appear to be iron dependent [81]. Few studies have analyzed the iron flux in the retina with
the diurnal cycle conversely to what has been performed in brain in mice [82,83]. Among the sensory
guanylate cyclase proteins and signaling network, guanylyl cyclase activating protein 5 is the only
protein that binds strongly Fe2+ in zebrafish [84]. It is proposed as redox sensor in visual transduction.
Phototransduction depends on the phagocytosis of outer segments from PR by the RPE. The
constant release of the outer segments from PR and their digestion during phagocytosis by RPE implies
membrane biogenesis, a process which needs iron as a cofactor of fatty acid desaturase [85]. Royal
College Surgeon (RCS) rats invalided for the phagocytosis protein Myeloid-epithelial-reproductive
tyrosine kinase (MERTK) have increased iron in retina and particularly in RPE phagosomes and also
increased retinal FT and TF expression [86].
Iron is also involved in neurotransmitters secretion as it regulates glutamate secretion by RPE
cells via the cytosolic aconitase pathway [87]. Dopamine biosynthesis in specialized amacrine cells
results from the conversion of the amino acid L-tyrosine in L-3,4-dihydroxyphenylalanine (L-DOPA)
using oxygen and Fe2+ [88]. Synaptosomal nerve-associated protein 25 (SNAP-25) is a Fe-S protein
involved in synapse vesicle fusion with plasma membranes highly present in retina [89].
A significant number of ATP binding cassette (ABC) transporters, involved in lipid trafficking
in retinal cells, have been linked to severe genetic ocular diseases [90]. ABCA4 is present in the PR
and transports 11-cis and all-trans isomers of N-retinylidene-phosphatidylethanolamine across disc
membranes, preventing the accumulation of toxic bisretinoid lipofuscin compounds in PR and RPE
cells. In Abca4 null mutant mouse which presents accumulation of N-retinylidineN-ethanolamine
(A2E) bisretinoids and lipofuscin in the RPE, intracellular iron accumulation is also observed which
contributes to enhancing oxidative cell death [91]. The intracellular accumulation of iron in cells of the
RPE in culture decreases the expression of the transporters of cholesterol ABCA1/ABCG1, increasing
the level of pro-inflammatory cholesterol in retina [50].
4.2. The Dark Side of Iron
4.2.1. The Crucial Role of Iron in Oxidative Stress-Mediated Damages in the Retina
The ability of iron to change easily its valence and switch between the Fe2+ and Fe3+ forms,
providing or accepting electrons, respectively, ensures a privileged position in living matter as mediator
of key biochemical reactions. However, the presence of free labile iron in cell or NTBI in circulation is
prone to generate highly ROS in the Fenton/Haber–Weiss reaction.
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Fe2+ + H2O2 → Fe3+ + OH− + HO· : Fenton reaction
O2·− + Fe3+ → O2 + Fe2+ : Haber–Weiss reaction
O2·− + H2O2
Fe2+ ; Fe3+→ O2 + OH− + HO·: Fenton/Haber–Weiss reaction
The toxicity of free iron has been extensively studied on neuronal and retinal cells, and they are
not sensitive to the same doses of iron [46,92,93], the cones being the most sensitive to iron [94]. In
RPE cells, the interaction of iron with bisretinoids and lipofuscin induces cell damage and retinal
degeneration [91]. Conversely, melanin can bind large amounts of iron to preserve the RPE and
the choroid from a pro-oxidant environment, intensified by light exposure. However, with age, the
accumulation of iron in melanosomes associated with a reduction in the amount of melanin in RPE
promotes the formation of free radicals [95]. Exposure of RPE cells to high non-lethal doses of iron
leads to a decrease in phagocytic and lysosomal activity [15], favoring the accumulation of breakdown
products of Vitamin A (lipofuscin) leading to the formation of glycation end products (AGE) present
in drusen, RPE, and Bruch’s membrane of AMD patients [91]. In addition, phagocytosis of PR discs,
peroxidized by ferrous ions, damage the membranes of phagosomes and lysosomes in RPE cells in
culture [15,96].
In hypoxic conditions, an efflux of iron from RPE to the basolateral direction [97] could explain, at
least in part, that PRs tolerate better hypoxia than hyperoxia [98]. Fe2+ contributes also to light-induced
PR cell death through the production of hydroxyl radicals [99]. The ascorbate-Fe2+ complex induce
lipid peroxidation in rod outer segment membranes and subsequently damage proteins such as
rhodopsin by carbonylation or loss of thiol groups [100]. Finally, free heme can be also a source of
redox-active iron and therefore highly toxic for the retina and for RPE cells [101].
In optic neuropathy, such as glaucoma, several mechanisms involved in ganglion cell death seem
to be enhanced by iron-dependent oxidative stress [102,103].
Iron is thus a key component of oxidative-induced damages in the retina and in the RPE and
involved in major cell death mechanisms.
4.2.2. Retinal Cells Death Mechanisms in Iron Overload
Iron overload, induced experimentally by the implantation of iron particles in rat vitreous cavity
caused apoptosis (TUNEL-positive nuclei) in the outer nuclear layer after only 2 days [104]. Rat retinal
explant exposed to iron showed an early increase of necrotic markers, such as lactate deshydrogenase,
receptor-interacting serine/threonine-protein (RIP) kinase, and incorporation of propidium iodide,
even before intraretinal iron accumulation was detected. Using retinal organo-culture, it was observed
that iron deposits in retinal explants induced a shift from necrosis to apoptosis with activation of
caspase 3 and TUNEL-positive nuclei [105]. Increased intraocular iron levels following intravitreal
FeSO4 injection caused oxidative damage of PR, as shown by the increase of superoxide radicals;
hydroxynonenal, a marker of lipid peroxidation; and increased expression of heme oxygenase 1 [94].
Retinal iron overload also activates the NOD-like receptor family, pyrin domain containing 3 (NLRP3)
inflammasome signaling pathway. In fact, the expression levels of NLRP3, activated caspase-1, a
downstream target of NLRP3, and interleukin (IL) 1ß were higher in the retinas of HFE KO mice, a
model of genetic iron overload [106]. Ferroptosis, a newly characterized form of necrosis, is induced
by the accumulation of iron in degenerative diseases and has been described in RPE cells in culture
subjected to oxidative stress [107]. Glutathione depletion also induced ferroptosis, autophagy, and
premature senescence in RPE cells [108].
4.2.3. Inflammation
The general implication of iron in inflammation has been recently reviewed, and it will not
be detailed here [109]. In RPE cells, the intracellular accumulation of iron activated the NRLP3
inflammasome pathway via the repression of the degradation of aluRNA by double-stranded
RNA-specific endoribonuclease (DICER1). This mechanism involved the sequestration of the cofactor
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PCBP2 [110] and has been advocated in AMD. It has been also reported that iron induces the synthesis
of complement C3 by activation of the Extracellular signal-regulated kinases (ERK)/SMAD3/CCAAT
Enhancer Binding Protein Delta (CEBPD) 48 pathway [111]. The complement factor C5 carries between
13 and 15 iron atoms necessary for its conversion into an active form C5b by C5 convertase, a complex
formed from the cleavage products of C3 [112], which shows the importance of iron in complement
pathways activation, a recognized risk factor for AMD [113].
The prion protein (PrPC), the principal protein implicated in the pathogenesis of human and
animal prion disorders, is also implied in retinal degeneration due to iron metabolism dysfunction.
This neuronal protein is expressed in many tissues of the eye, such as the retina and the cornea
trabeculum. PrPC is also expressed on the basolateral membrane of RPE, where it facilitates uptake of
iron from choriocapillaries to neuroretina by functioning as a ferrireductase partner for divalent metal
transporters. PrP-scrapie (PrP(Sc)), a misfolded isoform of this PrPC accumulates in the neuroretina
resulting in iron accumulation [114].
In the brain, IL6 produced by microglia in response to lipopolysaccharide, induced the production
of HEPC by astrocytes [115]. HEPC prevented the iron overload-activated neuronal apoptosis [115].
LPS induced also an HFE-independent expression of HEPC in MGC and in the RPE, both in vitro
and in vivo. The increase in HEPC levels in retinal cells, occurring with a decrease in FPN levels,
led to oxidative stress and apoptosis within the retina in vivo [116]. On the other hand, in both
in vitro and in vivo models of amyloid β-induced pathology, HEPC downregulates the inflammatory
and pro-oxidant processes in astrocytes and microglia and protected neurons from cell death [117].
Microglia and MGC activation associated with reactive gliosis has been observed in HJV knockout
mice (Hjv−/− mice) with aging and subsequent retinal iron accumulation [37].
The role of LCN2 has been suspected in AMD where its expression is increased in aqueous humor
and in the infiltrating cells present in the retina and choroid [118]. An age-related increase in LCN2
was described in RPE cells of Beta-crystallin A3 (Cryba1) conditional knockout mouse, a model of
AMD associated with chronic inflammation response [49], but the exact implication of LCN2 in iron
metabolism in these models remains to be studied.
4.2.4. Angiogenesis
Increased iron levels in the retina could also have a role in the development of new vessels by
inhibiting the anti-angiogenic effect of cleaved high molecular weight kininogen (Hka) [119], promoting
the expression of succinate receptor 1 (SUCNR1 or GPR91) [120] which stimulates production of
pro-angiogenic factors VEGF and angiopoietin [121]. In Hjv−/− mice, that leads to abnormal retinal
iron overload. Proliferation of new leaky blood vessels in the vitreous was associated with reactive
gliosis involving MGC and microglia [37]. In addition to proliferation by migratory cells, intravitreal
hemoglobin also stimulates a transient proliferation in cells of the RPE and possibly in some supportive
cells of the neural retina, such as MGC and astrocytes [122]. Iron also plays a role in HIF transcriptional
regulation of pro-angiogenic genes [51]
5. Role of Iron in Retinal Diseases
5.1. Siderosis and Retinal Hemorrhages
Eye siderosis is probably the first known manifestation of iron toxicity for the eye. The presence
of a foreign body containing iron inside the eyeball leads to various clinical complications including
heterochromia of the iris, mydriasis, cataract, and retinal and RPE atrophy. Electroretinography
analysis shows a decrease in a and b wave amplitudes, due to the progressive degeneration of the cones
and rods (for a review, see [123]). The increase in iron can be observed histologically as a granular
structure with FT or hemosiderin into cells. The level of vitreous iron also increases [124].
Retinal hemorrhages are present in several retinal pathologies, such as exudative AMD, diabetic
retinopathy, or myopic degeneration, and they are particularly deleterious for vision when located
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in the subretinal space. Vision loss is dependent on the size of the hemorrhage and the ability of the
tissue to shed blood [125,126]. During sub-macular hemorrhage early PR damage has been reported
within 24 h [127]. In rabbits, the injection of their own blood into the subretinal space leads to a
progressive degeneration of the PRs from one day after injection until a total destruction at 7 days,
with an accumulation of iron in the outer segments of PR and in RPE [128]. The increased release
of iron from hemoglobin induces peroxidation of unsaturated phospholipids, which are extensively
present in the retina and affects particularly retinal neurons compared to the retinal glial cells [129].
5.2. Retinal Manifestations of Inherited Iron Disorders
Iron can accumulate in the retina of patients with inherited diseases involving mutations in genes
encoding proteins of iron homeostasis, which can cause an imbalance in the metabolism of retinal
iron. The most common hereditary hemochromatosis is related to a mutation in the Hfe gene resulting
in excessive absorption of iron by the intestine and its accumulation in the organs. Mutations in the
Tfr2, Fpn, Hjv, and Hepc genes are also involved in the development of hemochromatosis. The clinical
findings associated to the retinal iron accumulation in these patients, as well as the impact on visual
function, are quite rarely reported due to the variability of penetrance and the existence of a treatment
reducing systemic iron overload. However, iron deposits and other changes in the RPE as well as
visual acuity loss have been already reported [130].
Aceruloplasminemia is an autosomal recessive disorder caused by mutations in the Cp gene,
resulting in a defect in the export of iron from cells. The retina, brain, and pancreas are overloaded
with iron, leading to the clinical consequences as retinal degeneration, dementia, and diabetes. Several
cases associating yellow discoloration of the fundus, atrophy of the RPE, and drusen-like deposits in
the macula have been described. In post-mortem sections, an accumulation of iron associated with an
enlarged RPE and loss of pigment of the RPE was observed (for a review, see [27]).
In animal models invalidated for the genes coding for iron-related proteins, an accumulation
of iron in the RPE and PR is systematically observed as well as abnormalities in the RPE and PR
degeneration [25,35,39,52,131].
Studies carried out in aging rodents have shown that the increase in iron intakes in food or by
intravenous injection leads to local iron deposits in the choroid, the RPE, and the segments of PR, as
well as deposits of complement C3 in the Bruch’s membrane, hypertrophy, and vacuolation of RPE
and changes in the choriocapillaries [132,133].
5.3. Age-Related Macular Degeneration
AMD is a leading cause of worldwide blindness in the elderly population, affecting 200 million
individuals by 2020 and nearly 300 million by 2040 [134]. The pathological aging of the macula can
cause dry or non-neovascular and wet or neovascular AMD. At the early stage, accumulation of
extracellular material forms drusen between the basal lamina of the RPE and the inner layer of Bruch’s
membrane in the eye. At the late stages, degeneration of the PR overlying the drusen can cause severe
central vision loss in the dry form, whilst formation of new abnormal blood vessels from the choroid
growing into the retina can cause subretinal fluid accumulation and bleeding. The wet form progresses
rapidly and is responsible for 90% of severe vision loss associated with AMD. The pathogenesis of
AMD is multifactorial, with genetic and environmental factors such as smoking. It is associated with
dysregulations in the angiogenic, oxidative stress, lipid, inflammatory, and complement pathways [135].
Patients with early AMD have more iron in the macula than healthy patients. Iron deposits are found
in the melanosomes of the choroid and the RPE, in the central layer of the calcified Bruch’s membrane,
in the drusen, and at the level of the PR [136]. Part of this iron, found in the pathological retina of AMD
patients, is in the toxic free form [137]. Patients with dry AMD have more than twice the concentration
of iron in their aqueous humor than in patients with cataract surgery [138]. The macular region of
AMD patients with geographic atrophy showed an increase in the expression of proteins involved in
iron homeostasis such as TF, FT, and FPN in the PR layer and feet MGC [139]. TF and CP mRNAs
258
Cells 2020, 9, 705
are increased in the two advanced forms of AMD [140]. In the serum of patients with the different
forms of AMD, a significant increase in TF and TFR1 and a significant decrease in the concentration of
soluble FT were observed while iron levels were unchanged [141]. Several polymorphisms of the iron
homeostasis genes have been associated with risk factors for AMD: Tfr1, Tfr2 (obesity, tobacco) [142],
Dmt1 [143], Irp1 and Irp2 [143], and heme oxygenases 1 and 2 (HO1/2) [144]. A recent study has shown
that the expression of several miRNA, small non-coding RNA molecules binding in 3’UTR genes, was
modified in the serum of AMD patients, especially those controlling the translation of the TFR1 and
DMT1 proteins [145].
5.4. Diabetic Retinopathy
Diabetic retinopathy is a vision-threatening complication of diabetes affecting approximately 93
million in the middle-aged and elderly populations [146]. Chronic hyperglycemia causes progressive
damage to retinal cells and to the retinal capillaries, leading to ischemia, VEGF-mediated retinal
vascular abnormalization, and neovascular vessels that leak and bleed into the retina. Macular edema
is also a major cause of vision loss in diabetic retinopathy [1]. Clinical reports have shown the link
between iron levels in the vitreous and proliferative diabetic retinopathy [124,147]. A strong iron label
was observed in the RPE and outer plexiform layer of patients with diabetic retinopathy [148]. In
a mouse model of diabetic retinopathy, higher iron concentrations in the retina led to an increased
expression of renin by a mechanism dependent on the GPR91 receptor [106].
5.5. Glaucoma Neuropathy
Glaucoma is increasingly a cause of irreversible blindness in the world. Its global prevalence is
expected to be 76 million by 2020 and 112 million by 2040. Progressive damage to the optic nerve,
leading to severe vision loss results from increased ocular pressure and other multiple favoring
factors [149,150]. Although the link between iron and glaucoma is not yet fully understood, there
is a change in iron homeostasis in glaucomatous eyes. TF concentration is increased in the aqueous
humor [151], and mRNA of TF are increased in retina [152]. Whilst no differences were found in iron
levels in aqueous humor of patients with primary open-angle glaucoma [153], serum levels of iron
and FT were significantly increased [154,155], and serum CP level was lower [156]. A glaucomatous
mice model had lower retinal iron concentrations than pre-glaucomatous DBA/2J and age-matched
C57Bl/6J mice [157]. The expression of FT, CP, and TF was increased in monkey and rat glaucoma
models [152,158]. In addition, the role of glutamate excitotoxicity in the pathogenesis of glaucoma is
well documented; yet, there seems to be a link between the toxicity of glutamate and the increase in
the entry of iron into neurons [159], and iron chelation seems to protect neurons against excitotoxicity
and intraocular pressure-induced toxicity [160,161]. A mutation in the autophagy receptor optineurin
is associated with the pathogenesis of glaucoma. It induces the degradation of the TFR1 and the
Rab12-dependent autophagy mechanism leading to retinal ganglion cell death. The addition of iron in
this model reduces cell death [162]. It seems that iron metabolism is dysregulated in glaucoma, but the
exact role of iron is optic nerve damage and remains to be studied in the pathogenesis of glaucoma.
5.6. Inherited Retinal Dystrophies and Associated Diseases
Retinitis pigmentosa affects approximately 1.8 to 2.4 million people around the world. The
disease is characterized by degeneration of the PR and progressive complete blindness [163]. Although
iron has been shown to accumulate in several models of retinal degeneration, as in rd10 mouse or
RCS rat [86,164], the direct link between iron and retinitis pigmentosa has not been established in
human disease.
Macular telangiectasia type 2 (MacTel 2) is a complex macular disease, characterized by abnormal
perifoveal vessels (telangiectasia), loss of retinal organization, and ultimately loss of macula function.
MacTel2 is the only human disease recognized as primarily associated with MGC cells loss. It has
been shown that iron accumulates in the retina of patients with MacTel 2. In a murine model of MGC
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ablation that mimics part of MacTel 2 phenotype, there is also an accumulation of iron in retina and
in the RPE [148]. Knowing the importance of MGC cells in the regulation of iron levels in the retina,
it could be hypothesized that iron accumulates in MacTel 2 as a consequence of MGC loss in the
fovea [165].
6. Iron Neutralization as a Therapeutic Strategy for Retinal Diseases
6.1. Chemical Chelators
Whether iron dysmetabolism in the retina is a cause or a consequence of various retinal diseases,
iron accumulation is pathogenic, and its neutralization was shown to protect the retina from oxidative
damage and retinal cell death in various models using different neutralizing strategies [133] (Table 2).
As early as in the 1970s, an iron chelator, Deferroxamine, was used in humans to reduce the amount of
“rust” deposited on the eye with satisfactory results. Used in many other models of retinal degeneration
(retinitis pigmentosa [166] or light-induced retinal damage models [167]), this chelator reduces the
iron load and preserves the retina. Other chelators, such as Deferriprone, have shown significant
protection of the retina in mice with impaired mechanisms of iron homeostasis [168–171]. These
chemical chelators are mainly used clinically to treat hemosiderosis induced by frequent transfusions.
Administered orally, subcutaneously or intramuscularly, they could led to several eye side effects,
including vision loss [172,173]. These side effects could be explained because chemical iron chelators
also bind the iron necessary for RPE and PR function [133,174].
As highlighted in a recent review [175], the clinical use of chemical chelators is complex because
they should (1) target only the organ or tissue which is affected by the iron excess; (2) have a sufficient
half-life; (3) cross the different barriers that surround the tissue; and (4) have a rapid elimination route.
Table 2. Comparation between chemical iron chelators and transferrin in clinical use.
Deferoxamine Deferiprone Deferasirox Transferrin




Intravenous (IV) (5 days/week) Oral (t.i.d) Oral (q.d) Intravenous [176]
Half-Life(after IV
administration) 20–30 min 3–4 h 8–16 h 4–8 d [176]
Excretion Urinary/fecal Urinary Fecal Unknown
Usual Doses
(mg/Kg/d) 25–60 [177] 75–100 [177] 20–40 [177] 100 [176]










visual loss [179], impaired night











Legend Table 2: Tid: 3 times a day; q.d: once a day.
6.2. Natural Chelators
Other natural molecules generally coming from plants, such as curcumin, polyphenols, and
flavonoids, are iron chelators and have shown effectiveness in mouse models of retinal degeneration
(for a review, see [186,187]).
6.3. Transferrin
TF is part of the TF superfamily, which also includes lactoferrin, melanotransferrin, and
ovotransferrin, which are found in many species of both mammals and invertebrates. It consists
in two lobes, each binding a Fe3+ atom with a very high affinity (1022M−1). Its primary role is to
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maintain an environment devoid of free iron. TF synthesized by RPE, PR, and neuronal cells is found
in the aqueous and vitreous humors [8,105]. By single-cell RNA sequencing of human neural retina,
mRNA for TF was enriched in peripheral retina compared to fovea [188]. Its expression is amplified
during inflammation or immunity to increase the buffering capacity of iron. In light-induced retinal
degeneration, TF and TFR1 mRNA increased in retina immediately after light exposure and then
decreased at basal level. One day after light exposure, TF was increased, whereas TFR1 was reduced
compared to not illuminated mice [32]. TF has long been of therapeutic interest due to its antimicrobial
capacity and the ubiquitous presence of TFR1 allowing penetration of the blood-brain barrier [189]. TF
has also been used successfully in humans in iron metabolism pathologies and for its cytoprotective
capacity [190].
Our laboratory is interested in the potential of TF for the treatment of retinal pathologies (Table 3).
Our work has shown that administration of the iron-free form (apoTF) by intraperitoneal injections in
rd10 mice, a model of retinitis pigmentosa, preserves PRs better compared to the use of other chelators
or antioxidants [46,164]. Injected into the vitreous, TF is present throughout the neural retina (MGC)
and is eliminated via its receptors by RPE and the choroid without any immunogenic or toxic effect
on the retina [46,105]. Thus, TF administered in a model of light-induced degeneration, allows the
restoration of iron homeostasis, decreases iron accumulation, reduces inflammation and apoptosis,
and preserves PRs and visual function [43]. In an ex vivo model of retinal detachment, TF inhibits
the degenerative processes activated by the iron excess by reducing necrosis, apoptosis, gliosis, and
oxidative stress. In vivo, human TF constitutively expressed in transgenic mice (TG) reduces loss of
cones, cleavage of caspase 3, an apoptosis effector, DNA breaks, and necrosis (Figure 3). In rats, TF
injected at the time of the detachment, reduces retinal edema, cell death and preserves PRs. In addition
to its ability to reduce the accumulation of iron in the retina following detachment, TF also acts on
other cellular pathways, no doubt through its interaction with molecular partners which remain to be
discovered [105].
Table 3. Transferrin as a therapeutic drug in retinal diseases models.
Model Experiment Physiopathology Administration Mode Therapeutic Action of Transferrin References
Primary culture of
Müller glial cells. Iron exposure
Cell isolation from transgenic
mice carrying the human
transferrin gene (TghTF)
Cell number preservation. Lower necrosis revealed by




Müller glial cells Iron exposure
Addition of apo- or
holo-human TF







Crossing rd10 mice with
TghTF mice
Preservation of retinal histology (outer and inner nuclear
layers thickness).








injections of apo-human TF
Dose-dependent preservation of retinal histology (outer and
inner nuclear layers thickness).
Less apoptotic-positive retinal cells.




Model of acute degenerative
retina
Intravitreal injection of
apo-human TF before and
after light-induced
degeneration
Preservation of retinal histology and functions.
Preservation of ONL thickness and PR morphology.
Lower ONL apoptotic- positive cells.Regulation of iron
homeostasis balance.
Lower retinal iron accumulation and oxidative stress.
Regulation of retina inflammation and diminution of




Model of acute degenerative
retina
Electrotransfer of cDNA of
human TF for in oculo
production
Preservation of retinal histology and ONL layer thickness. [43]
P23H rats Model of retinitispigmentosa
Electrotransfer of cDNA of
human TF for in oculo
production










Diminution of iron accumulation in retina pigment
epithelium [43]
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Table 3. Cont.




iron exposure Retinas from TghTF
Preservation of cones number and rod outer segments
length.
Lower necrosis






Addition of apo-human TF
after iron exposure
Preservation of rhodopsin expression level and cones
number
Lower necrosis and apoptosis










Preservation of retinal histology, rods outer segments length
and number of cones Diminution of retinal oedema and
Müller glial cells activation
Lower apoptosis and necrosis











Preservation of retinal histology, rods outer segments length
Diminution of retinal oedema [105]
Legend Table 3: ApoTF: transferrin without iron; HoloTF: transferrin binding iron; INL: inner nuclear layer; ONL:
outer nuclear layer; PR: photoreceptors; TF: transferrin; TghTf: transgenic mice carrying the complete human
transferrin gene.
Figure 3. Transferrin expression preserves the detached retina. Legend Figure 3: After retinal
detachment (RD), photoreceptors died by apoptosis and necrosis. Transgenic mice (TG) expressing
human transferrin (TF) were used to demonstrate the protective effects of TF. (A) Arrestin staining
revealed cones in retinal sections of TG mice (arrows) after RD. Cone number was higher in TG
compared with WT mice. (B) The ratio of cleaved/pro–caspase 3 protein level was lower in TG mice
compared to WT mice after RD. (C) The number of nuclei positive apoptotic-DNA breaks, stained
by TUNEL, was reduced in TG mice compared to WT mice. (D) Necrotic RIP kinase protein level
was reduced in TG mice compared with WT mice. All values are represented as the mean ± SEM.
Mann–Whitney test (n = 3–6), * p ≤ 0.025. ONL: Outer nuclear layer. Scale bar, 100 μm. From [105].
Reprinted with permission from AAAS.
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7. Conclusions
Iron is one of the most common elements on Earth. Two-hundred years ago, it was discovered
that, after desiccation, the residual ashes of an aged human retina could be mobilized by a magnet
(as quoted in [191]). Nowadays the chemical study of iron structure and its outer electrons has been
revealed by the discovery of quantum effects of iron electron in biology. The best illustrations have
been described by Cedric Weber who demonstrated that very specific quantum effects are involved
to explain the energy in the binding of iron to oxygen and CO to hemoglobin [192]. This transition
metal plays a main role in retinal physiology, but overload leads to retinal degeneration and loss
of function. Iron chelation is a potential therapeutic target to prevent retinal degeneration. TF, as
an endogenous iron binding protein, avoids toxic effects of iron depletion and activates additional
neuroprotective pathways.
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Abbreviations
ABC ATP binding cassette
AMD Age-Related Macular Degeneration
APP amyloid-beta precursor protein
BMP Bone Morphogenetic Protein
BRB Blood Retinal Barrier
CEC Choroidal Endothelial Cell
CP Ceruloplasmin
DFO Deferroxamine







HFT Heavy Ferritin chin
HIF Hypoxia Inducible Factor
HJV Hemojuveline
HRE Hypoxia Responsive Element
IL Interleukin
IRE Iron Responsive Element
IRP Iron Regulatory Protein
LCN2 Lipocalin 2
LF Lactoferrin
LFT Light Ferritin chain
LIP Labile Iron Pool
MacTel 2 Macular telangiectasia type 2
MGC Muller Glial cell
NTBI Non-Transferrin Bound Iron
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REC Retinal Endothelial Cell
ROS Reactive Oxygen Species
RPE Retinal Pigment Epithelium
SCARA5 Scavenger receptor class A, member 5
SMAD Mothers against decapentaplegic homolog 1
TBI Transferrin Bound Iron
TF Transferrin
TFR Transferrin Receptor
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Abstract: We are witnessing an exponential increase in the use of different nanomaterials in a
plethora of biomedical fields. We are all aware of how nanoparticles (NPs) have influenced and
revolutionized the way we supply drugs or how to use them as therapeutic agents thanks to their
tunable physico-chemical properties. However, there is still a niche of applications where NP have
not yet been widely explored. This is the field of ocular delivery and NP-based therapy, which
characterizes the topic of the current review. In particular, many efforts are being made to develop
nanosystems capable of reaching deeper sections of the eye such as the retina. Particular attention
will be given here to noble metal (gold and silver), and to polymeric nanoparticles, systems consisting
of lipid bilayers such as liposomes or vesicles based on nonionic surfactant. We will report here the
most relevant literature on the use of different types of NPs for an efficient delivery of drugs and
bio-macromolecules to the eyes or as active therapeutic tools.
Keywords: retinal diseases; noble metals NPs; bio-inspired NPs; drug delivery
1. Introduction
The human eye is a unique and fragile structure prone to different types of pathologies. It is
characterized by an anterior and the posterior segment [1]. Pupil, cornea, iris, ciliary body, aqueous
humor and lens make up the anterior segment, whereas vitreous humor, macula, retina, choroid, and
optic nerve are parts of the posterior segment [1]. The macula is a small area of the retina that contains
photoreceptor, special light-sensitive cells, connected to a neuronal network [2]. Retina contains five
types of neurons: photoreceptor, bipolar, ganglion, horizontal, and amacrine cells (Figure 1) [3,4]. The
retina is the nerve layer that receives visual information, creating impulses that are transmitted through
the optic nerve to the visual cortex in the brain [5]. Two types of photoreceptor cells exist: the rods and
the cones. It is estimated that there are approximately 120 million rods and about six million cones in
the human eye. The unique properties of photoreceptor cells expose them to a variety of genetic and
environmental threats. Any dysfunction or deterioration of vital ocular tissue has a dramatic impact
on a patient’s quality of life. Therefore, the retina is susceptible to several diseases that result in visual
loss and blindness. As countries become wealthier and the per capita income increases, prevalence of
blindness decreases, and causes of blindness change. In a poor African country, the major of blinding
conditions are likely to be cataract and corneal scar. In the middle-income countries such as Latin
America, the leading causes of blindness are glaucoma and diabetic retinopathy. Because cataract
surgery is more readily available, fewer people become blind from cataract [6]. In wealthy countries,
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glaucoma and cataract continue to be very common and important conditions, but most of the blindness
is due to retinal degenerative diseases (RDDs) [7], an heterogeneous group of phatologies characterized
by progressive death of photoreceptors. RDDs can be caused by defects in proteins involved in photo
transduction, synaptic transmission, retinal pigment epithelial (RPE) integrity function, intracellular
trafficking and cilia function. It can be also related to toxic accumulation of retinoids. Each of these
RDDs can lead to visual loss or complete blindness [8].
The most common RDDs include age-related macular degeneration (AMD), diabetic retinopathy
(DR), and retinitis pigmentosa (RP). Cytomegalovirus (CMV) retinitis, proliferative vitreoretinopathy,
Stargardt disease, and retinoblastoma can also occur and are usually associated with toxic retinoid
biogenesis and accumulation [9]. Retinal diseases are already the most common cause of childhood
blindness [10] with an incidence of 1.5 million people suffering worldwide. RP is characterized by a
progressive loss of photoreceptors and its specific mechanisms are not fully understood. Following the
loss of photoreceptor functionality, a retinal remodeling phenomenon is triggered as the final step,
which then culminates with cell death and topological restructuring of the retina. The progression of
retinal remodeling is similar to negative plasticity that occurs in some pathologies like trauma and
epilepsy constituting substantial impediments to rescue strategies of all types [11]. Another process
that involve the retina segment is neovascularization, a pathological phenomenon that provokes
vision loss causing blindness due to its correlation with diabetic retinopathy and AMD [12]. In the
neovascularization phenomenon, endothelial growth factor (VEGF) pathway has a key role [13,14].
Ocular diseases, and retinal diseases in particular, are still approached using rather invasive
treatments, which are also not completely effective. The development of efficacious therapeutics is
thus a primary research goal. So far, many delivery strategies have been explored, and the progress in
the field of molecular genetics has led to the identification of genes involved in retinal disruption. For
this reason, gene delivery systems represent one of the most promising approaches [15,16]. Delivery
approaches can be broadly classified in two groups, whether they are based on a viral or non-viral
method of delivery. Each system comes with advantages and disadvantages. For instance, although
Adeno-Associated Virus (AAV) based vectors have high gene transduction efficiency, they face a
major obstacle in terms of biosafety for clinical applications. The development of effective non-viral
approaches for ocular disease is thus crucial. However, how to adequately deliver therapeutic agents
to the back of eye (i.e., retina) remains a challenge. With the development of nanotechnology and
bioengineering science, a wide range of innovations in this area have been achieved. This holds the
promise for developing more effective ocular drug delivery systems.
In this review, we carefully report the last studies in which noble metal and soft (bioinspired)
NPs were applied as new delivery agents for treatment of ocular disease in vitro and in vivo. We also
provide perspective on opportunities and challenges for future nanotechnology in retinal drug delivery
and therapies.
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Figure 1. Retinal neuronal and vascular structure and retinal disease. (A) Diagram of a human eye.
Light passes through the pupil and is focused by lens onto macula of the retinal layer at the back of
the eye. (B) Retina consists of three layers of neurons, photoreceptor, bipolar, and ganglion cells. The
retinal pigment epithelial (RPE) monolayer together with Bruch’s membrane (BM) form outer blood
retinal barrier that separates the neuroretina from the choroid. Choroidal circulation provides oxygen
and nutrients to outer retina. (C) The retina has an interconnected network of three vascular layers
located in the ganglion cell/nerve fiber layer, inner plexiform layer (IPL), and outer plexiform layer
(OPL). (D) retinal tissue and cells that are affected under different disease conditions. Adapted from
reference [17].
2. Drug Ocular Administrations
The delivery of drugs in the eyes presents many difficulties. As in the case of the brain, it
presents multiple physical boundaries: corneal and conjunctival epithelium, blood-aqueous barriers
(BAB), and blood-retinal barriers (BRB). These barriers finely control the transit of molecules and
fluids across eye and, in most cases, the drug is unable to enrich the deeper layers. The BRB consists
of two different barriers: (i) the outer BRB characterized by endothelial cells lining the choroidal
vasculature (fenestrated blood vessels) and by tight-junction-coupled RPE cells, and (ii) inner BRB.
The latter is made by endothelial cells in conjunction with pericytes, astrocytes, and Müller glial
cells. The inner BRB shows a lot of similarities with blood–brain barrier (BBB) with the exception
of Müller glia [18]. In general, the most common drug administration is through eye drops and
suspensions’ that target only the anterior segment of eye, mainly due to the patient compliance. With
such a method, less than 5% of topically applied dose is delivered to deeper ocular tissues, such
as in vitreous cavity [19]. The chemical nature of bioactive molecules also influences the uptake.
For example, BRB is selectively permeable to lipophilic molecules in the presence of specific eye
drugs transporters. In this way, the formulation of new therapies should take in consideration this
limitation [20]. Ocular transporters are divided in two groups: the solute carrier (SLC) family and the
ATP-binding cassette (ABC) family. The electrochemical gradient was used by SLC transporters to
induce the uptake of molecules through cell membrane, whereas ABC transporters employ ATP [21].
However, physiological eye phenomena, such as tear turnover, reflex blinking, ocular static, or lacrimal
drainage reduce the action of the drug and consequently the eye drop administration fails to treat
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retina disease [22]. As a matter of fact, in unstimulated conditions, total aqueous tear volume is 7 μL
and the normal tear turn-over is about 1.2 μL/min [23]. Thus, the precorneal drug half-life is about
3 minutes [24]. Therefore, treatment of posterior segment injuries still remains a challenge. For all
the reasons explained above, medical research seeks alternative routes such as intravitreal injections.
This method consists of direct administration into vitreus via pars plana using a needle. In this way, a
high concentration of drug is guaranteed at the retina level, but the molecule half-life depends on its
molecular weight. In fact, proteins and peptides characterized by high molecular weight (ranging from
40 kDa to 70 kDa) and steric hindrance showed longer retention [25,26]. However, a lot of complications
(hemorrhages, retinal detachment, cataracts) can manifest after injection [27]. An alternative method
is periocular route (Figure 2) that was demonstrated to be an effective route to direct drugs to the
posterior eye segment consisting of subconjunctival, sub-tenon, retrobulbar, peribulbar, and posterior
juxtascleral [28]. Administration of drug by sub-tenon injection was found to be more suitable as
demonstrated by Ghate et al. [29], where sodium fluorescein was used in rabbits’ eyes by subocular
administration. The study concluded that injection of drug via sub-tenon resulted in highest vitreous
concentration of sodium fluorescein (two sodium fluorescein (NaF) concentrations, 2.5 mg in 0.1 mL
(c1) and 2.5 mg in 0.5 mL (c2)) compared to the other routes. However, also in this case, a lot of adverse
effects have been observed, such as strabismus, hyphema, and intraocular pressure [30].
Figure 2. Common drug administration routes through the eye. Topical administration (1,2),
subconjunctival injection (periocular route) (3), subretinal injection (4), and intravitreal injection
(5). Adapted from reference [31].
3. Physico-Chemical Properties of Nanomaterials
A “Nanomaterial” is defined as a “material with any external dimension in the nanoscale or
having internal structure or surface structure in the nanoscale” (ISO, 2010) [32]. Similarly, a definition of
“nanoparticle” is a “nano-object with all three external dimensions in the nanoscale” where nanoscale
was defined as size ranging from 1 nm to 100 nm (ISO, 2008) [33]. NPs can be obtained by many synthetic
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routes, starting from chemical elements such as carbon, metals, metal oxide, biological molecules, and
polymers [34]. The biological effects are strongly affected by physico-chemical properties of NPs such
as surface charge, size, shape, and solubility. In addition, they exhibit greater surface area per unit
mass compared to bulk materials [35]. Because of the above mentioned properties and of the material
they are made, NPs are ideal tools to treat retinal disease as active components of the therapy without
the help of drugs [36,37]. In addition, NPs with a smaller size (<20 nm) are demonstrated to have the
ability to cross eye barriers including cornea, conjunctiva, and BRB [38,39]. NPs for ocular therapy
include inorganic NPs (metal oxide and noble metal NPs), as well as soft-biopolymer-based NPs. Metal
NPs are more suitable as active therapy tools (for their intrinsic properties), and soft-NPs are more
efficient in encapsulating drugs and macromolecules due to their ability to form aqueous-suspended
vesicles having a hollow lumen. All these nanomaterials are different in charge, shape, and size, but
they are able to be internalized by cells to treat retinal disease [40]. Finally, recent applications of
soft nanorobot (with size range in the molecular scale) have been studied. These structures have the
capability to deliver active biomolecules in ocular sections due to their ability to make changes in a
controlled and predictable manner to the environment following external stimuli [41].
3.1. Noble Metal NPs: The Case of Gold (Au) and Silver (Ag)
Noble metals, especially AuNPs and AgNPs, are characterized by unique optical properties. For
this reason they are used for a variety of applications owing to collective oscillations of conduction
electrons coupled with incident light [42–45]. This phenomenon, known as Localized Surface Plasmon
Resonance (LSPR) is strongly influenced by NPs’ shape and the metal they are formed. The surface
plasmon resonance bands of metal NPs can be tuned from visible to Near Infrared Region (NIR), which
is a typical wavelength to penetrate and analyze biological tissues [46]. Even if AuNPs are the most
studied in nanomedicine field due to their good chemical stability and well-controlled size/surface
functionalization and biocompatibility, AgNPs have the advantage of possessing an antibacterial and
antiangiogenesis effect [47,48].
3.2. Au and AgNPs: Safety Studies in In Vitro and In Vivo Retinal Models
3.2.1. AuNPs
The use of novel nanomaterials necessitates a better understanding of potential adverse effects on
biological entities [49]. These effects are strictly dependent on physico-chemical properties of NPs and
evaluation of cytotoxicity is critical, especially from a medical field application perspective [50]. A lot of
studies were conducted to assess biocompatibility in order to ensure safe drug release with low toxicity.
In general, high degree of biocompatibility is verified when NPs interact with the living organisms
without triggering unacceptable toxic, thrombogenic, carcinogenic, and immunogenic responses [51].
The unique physico-chemical properties of AuNPs make them a powerful tool in the biomedical
field. They are widely used in photothermal treatment of cancer and in drug and gene delivery. For
their synthesis, auric salts such as HAuCl4 are used as starting materials to obtain stable AuNPs with a
size ranging from 1–100 nm (Brust or Turkevish [52,53]). In recent years, green syntheses of AuNPs
has also been developed to reduce solvents and reduce/cap agents’ toxicity so that AuNPs can be
synthetized from plant extracts or biomass [54,55]. AuNPs are easy to functionalize with a wide range
of ligands ranging to polymer, DNA, peptides, RNA, and fluorescent molecules particularly suitable
for bio-imaging applications [56]. Furthermore, various cytotoxicity studies demonstrated their low
toxicity due to the inert nature of Au [57,58].
Regarding the biodistribution, a recent work demonstrated a rapid elimination of colloidal AuNPs
from blood circulation in a rats model, and liver and spleen accumulation without inducing adverse
effects or inflammation [59]. Au comprised in passion fruit-like nanoarchitectures (NAs) were studied
in murine models demonstrating the excretion by renal and biliary pathways without nephrotoxicity
up to 150 mg kg−1 [60]. Some studies reported pro-inflammatory cytokines expressions induced by
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AuNPs in different organs of rats [61] and mice [62]. However, the cytotoxic effects were temporary
and normalized in a short time. The biocompatibility of Au is strictly correlated to their size, shape,
concentration, as well as surface area as demonstrated by Biswas’s group [63]. They investigated the
effects of Au spheres (5, 10, 20, 30, 50, and 100 nm), cubes (50 nm), and rods (10 × 90 nm) in cells in
adult retinal pigment epithelial cell line 19 (ARPE-19). The cubes with an average diameter of 50 nm
and spheres (50–100 nm) resulted in being biocompatible up to 750 μg of concentration. NPs with
a smaller size (<30 nm) and nanorods (10 nm) showed higher toxicity, but they are more able to be
uptaked by cells. Kim et al. [64] used C57BL/6 mice to demonstrate the ability of AuNPs (20 nm) to
cross BRB and enriched retinal layers after intravenous administration. NPs greatly accumulated in
neurons (75 ± 5%), followed by endothelial cells (17 ± 6%) and peri-endothelial glial cells (8 ± 3%)
without affecting both viability of endothelial cells, astrocytes, retinoblastoma cells, and expression of
functional biomolecules. After five weeks of post administration, the thickness of retinal layers was
undisturbed without any damage. Bakri et al. [65] used Dutch-belted rabbits to test biocompatibility of
AuNPs. They used two groups of rabbits receiving a 67 μmol/0.1 mL and 670 μmol/0.1 mL of AuNPs
into one eye respectively by intravitreal injection. After one month, evident inflammation or adverse
effects were not detected also at a high dosage. Soderstjerna et al. [66] used AuNPs and AgNPs with
19 and 89 nm citrate capped to test biocompatibility in in vitro cultured retinas using 800 NPs/cell.
The retina tissue model offered a sustained long-term retinal organization and controlled serum-free
conditions. This study demonstrated that low concentrations of Au and AgNPs have adverse effects on
retina and can induce apoptosis and oxidative stress. A strong connection between NPs hydrodynamic
diameter, surface functionalization/concentration and the biological effects is evident. In particular,
the authors showed that NPs size should be large enough to avoid their fast flow into circulation, but
small enough to be administrated and easy cross the BRB [67].
Starting from this assumption, the application of AuNPs is influenced by these parameters that
should be taken in consideration to customize nanotools for a specific biomedical application.
3.2.2. AgNPs
Numerous in vitro and in vivo studies demonstrated the toxicity of AgNPs that perturbs several
cellular pathways [4]. The most accepted mechanism through which they induce side effects, despite
still under investigation, seems to be related to Ag ions released from NPs surface [68–70]. In terms of
production process, AgNPs can be synthetized by different chemical routes such as chemical-based
reduction [71], sol-gel, or green synthesis [72,73].
Jun et al. [74] used zebrafish embryos as model organism to test their delivery at an ocular level.
They investigated the toxicity of AgNPs at concentration of 0.4 mg/L and observed down- expressions
of different lens crystalline genes by unknown mechanisms that either induced apoptosis or blocked
nuclear DNA or RNA export.
Sriram et al. [75] demonstrated the cytotoxicity and Reactive Oxygen Species (ROS)-induced
apoptosis after exposure of AgNPs with two different size (22.4 and 42.5 nm) in bovine retinal
endothelial cells (BRECs) finding size-dependent toxicity. As a matter of fact, smaller NPs induced
adverse effects on cells. Kim and colleagues [76] exposed New Zealand white rabbits (according to
OECD test guidelines) to AgNPs in order to understand the possible eye irritation effect. Oedema
and conjunctival redness have been observed after 1 h of AgNPs incubation, but the cornea, iris, or
conjunctiva resulted unaffected after 24, 48, and 72 h of NPs exposure. In similar experiments, the
instillation of AgNPs (5000 ppm) were tested on another in vivo model, the guinea pigs, observing a
transient conjunctivae irritation during 24 h of early observation [77].
4. Noble-Metal NPs as Therapy and Diagnostic for Retinal Disease
AuNPs scatter or absorb light at specific wavelengths as a function of their physico-chemical
properties. This characteristic is particularly suitable for bioimaging and to treat some diseases like
cancer by NIR-triggered photothermal therapy (PTT), in which light is converted to heat in the tumor
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site where NPs accumulate [78]. In the NIR (650–900 nm), the absorption coefficients of haemoglobin
and water are very low, and for this reason, the penetration of NIR wavelength in tissues is very
high, allowing NPs stimulation without causing damage [79]. Song et al. [80] reported application
of gold nanodisks (GNDs) on human retinal microvascular endothelial cells (HRMEC) and mouse
oxygen-induced retinopathy model. The GNDs were optically suitable for nanomedicine applications
due to their ability to produce detectable signals regardless of polarization or direction of light source
and to scatter in NIR region (830 nm). In addition, GNDs were internalized less efficiently in cells with
respect to AuNPs or Au rods (AuNRs), thus minimizing the ROS production and other several adverse
effects. The authors used differently charged anisotropic NPs (nanorods or nanodisks) and compared
them with AuNPs. After simulating the role of different sizes to select the best diameter (160 nm), they
showed that GNDs were able to bind vascular endothelial growth factor (VEGF) inhibiting in vitro
angiogenesis with high performance and abolished the VEGF-induced migration of endothelial cells.
When these nanostructures were applied to mice eyes, a strong signal in optical coherence tomography
(OCT) was detected with a consequent reduction of retinal degeneration (Figure 3). The OCT system
involves the use of light energy that, once absorbed by tissues, causes a thermos-elastic expansion
generating ultrasonic waves detected by a transducer.
 
Figure 3. Schematic representation of gold nanodisks (GNDs) effects in retinal degeneration and
Optical Coherence Tomography (OCT) imaging. The GNDs were particularly suitable for their optical
properties connected to the shape: GNDs absorbed in the Near Infrared Region (NIR). The size and
surface charge also influenced the eye diffusion. In OCT images, GNDs exhibited a strong signal
compared to the dual window (DW) processing method, which is used to detect modulation of
OCT signals due to scattering or absorption. Reprinted from [80] Copyright (2017), with permission
from Elsevier.
Recent therapies to treat some diseases strictly connected to retinal degeneration consider the
transplantation of photoreceptor precursors (PRPs) as efficient support improving visual acuity [81].
The analysis of cell survivor in the host retina is a key factor in this kind of treatment. Chemla et al. [82]
used AuNPs in order to improve the tracking of transplanted PRPs. Cells were labelled with
photothermic AuNPs and transplanted in the vitreous and sub-retinal space of Long-Evans pigmented
rats (4–8 weeks old) by gauge needle.
By using coherence tomography, computed tomography and fluorescence fundus imaging, NPs
have been tracked for 1 month without recording adverse effects. Real-time tracking is essential for
evaluating the efficiency of retinal cell replacement therapies. These studies confirmed the possibility
to use AuNPs to improve retinal cell therapy in humans. AuNPs-based photothermal therapy has
been also used to treat eye tumors in vitro and in vivo. Some eye cancers provoke retinal detachment
leading to a decreased visual eye activity.
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In this framework, Kim et al. [83] tested anticancer properties of Doxorubicin (Dox)-conjugated
Fucoidan (Fu)-encapsulated AuNPs (Dox-Fu@AuNPs) for the treatment of VX2 squamous carcinoma
cells and xenograft tumors in New Zealand White rabbits. After intra-tumoral injection
of Dox-Fu@AuNPs in the eye, a complete suppression of the tumor has been observed by
dual-chemotherapy and PTT treatment. No damage to retina has been also detected. These composite
nanostructures enabled the improvement of the OCT imaging technique (thanks to the selective light
absorption of AuNPs) [84].
The quality of photoacoustic-based imaging was also improved thanks to selective light absorption
of AuNPs. In this way, a double effect in terms of therapy and diagnostic was achieved.
As reported above, OCT is largely used for imaging in ocular clinical research due to the
possibility to take structural information based on the reflectivity of tissue. In this respect, Gordon
and colleagues [85] confirmed that Au nanorods (with a peak absorption of 750 nm and diameter
of 10–35 nm) injected in the retina of Wild-type C57BL/6 mice are able to enhance the contrast, thus
significantly improving the quality of a scanned lesion. Additionally, intravitreal injection of Au
nanorods functionalized by anti-VEGF antibody triggered a reduction in the extent of anatomic laser
damage and lesion-associated photothermal signal density in mice treated in laser induced choroidal
neovascularization (LCNV) model and injected with ICAM2-targeted GNR. AuNPs (3–5 nm) were also
used as inhibitor of VEGF on choroid-retina endothelial cells (RF/6A) [86]. A similar effect was showed
using AgNPs, which have been found to reduce the VEGF activation and induced cell proliferation
and migration in bovine retinal endothelial cells [87]. In addition, AgNPs were shown to inhibit
the angiogenesis, typical of metastasising cells and of retinal neovascularization development. Ag
is widely used because it has the great advantage of being a cost-effective material. For this reason,
it is a good candidate for the replacement of the current therapies used for the treatment of various
retinal angiogenic disorders. In this respect, Sheikpranbabu and co-workers [88] investigated the
effect of green AgNPs, obtained from Bacillus licheniformis, on VEGF-and Interleukin 1 β (IL-1β)
expression—that induced retinal endothelial cell permeability. AgNPs were able to stop VEGF-and
IL-1β-induced permeability in retinal endothelial cells from porcine retina.
5. Bio-Inspired NPs for Ocular Drug Delivery
The use of bio-inspired materials mimicking natural components for applications in living
organisms has widely spread recently [89]. In fact, inorganic NPs have the serious drawback of not
being degradable and are also difficult to get excreted from the body [90]. Bio-inspired nanomaterials,
including liposomes, niosomes, and chitosan/alginate NPs have been then explored as valid alternatives
to metal NPs for treatment of several diseases [91]. In addition, these ‘soft’ NPs have been applied for
drug delivery in the posterior segment of eye, including retinal photoreceptors.
5.1. Liposomes as Drug Delivery Carrier
Liposomes consist of a lipid bilayer, resembling a cellular membrane, that surrounds an aqueous
core. These structures are widely used in pre-clinical studies to improve drug delivery, for example
through Blood Brain Barrier (BBB) [92]. The BBB and BRB have the same functional properties [93,94]:
so liposomes improve drug delivery to the retina and its photoreceptors due to their high half-life,
permitting the long term drug absorption [95]. Liposomes also offer the ability to significantly
improve pharmacokinetics and pharmacodynamics of any loaded drug compared to its free-circulating
counterpart. They are also considered as highly biocompatible and biodegradable as well up to
some extent both in vitro and in vivo. For this reason, several anticancer drugs such as doxorubicin,
daunorubicin, and epirubicin were encapsulated in liposomes core with results demonstrating a
significant decrease of many severe adverse effects (nausea, weakness, vomiting) with respect to the
same concentration of free (non-encapsulated) drug. In this context, Zhang et al. [96] subcutaneously
injected tacrolimus-encapsulated liposomes in Lewis rats with autoimmune uveoretinitis (EAU) by
subcutaneous injection. Confocal analysis over rhodamine-conjugated liposomes (containing also the
282
Cells 2020, 9, 679
tacrolimus) revealed that such vesicles remained in ocular fluids even after 14 days. They found a
reduced intraocular inflammation and decrease of EAU development without observing significant
adverse effects.
Liposomes encapsulated with the anti-inflammatory and anti-angiogenic drugs berberine
hydrochloride and chrysophanol were applied in myoblasts and in ischemic animal models. These
drugs have the ability to contrast oxidative stress by enhancing the activities of antioxidant enzymes such
as superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) [97,98]. Berberine hydrochloride
and chrysophanol have been used in ocular liposome-mediated delivery to overcome their low stability.
In this respect, a recent study [99] showed a liposome system that can entrap the two drugs at same
times using the third polyamidoamine dendrimer (PAMAM G3.0) as a delivery carrier for age-related
macular degeneration (AMD) therapy in the ocular posterior chamber.
PAMAM G3.0-coated compound liposomes were used to evaluated HCECs (Human Corneal
Epithelial Cells) internalization, trans-corneal permeability in New Zealand white rabbits (weighing
2.0–2.5 kg) and male Sprague–Dawley rats (weighing 210–250 g). Pharmacokinetics were evaluated
together with in vitro assessments of anti-reactive oxygen species (ROS) efficacy. The PAMAM
G3.0-coated compound liposomes enhanced bio-adhesion on rabbit corneal epithelium after topical
administration and exhibited great permeability in HCECs cells. The possibility to deliver a
protective agent against photo-oxidative retinal damage in a light-damaged animal model was also
investigated through the use of dendrimers (Figure 4A). Results showed that dendrimers encapsulated
with chrysophanol–berberine hydrochloride induced the greatest protection of retinal function in
light-exposed rats compared to unloaded dendrimers and free drug. In addition, no inflammation and
damage of cornea, iris, and conjunctiva was observed after drug-loaded dendrimers instillation for 14
days. Upon exploring the fundus of the eye (interior surface of eye opposite the lens including the
retina, optic disc, macula, fovea, and posterior pole) [100], modifications in the vessel structure and
distribution have not been observed after different treatments. (Figure 4B).
Figure 4. (A) Protection evaluation against photo-oxidative retinal damage in a light-damaged animal
model by the use of different formulation: chrysophanol–berberine hydrochloride suspension (CBs),
compound liposomes (CBLs), and PAMAM coated compound liposomes (P-CBLs). Retina was stained
with hematoxilyn/eosin (scale bare = 20 μm). (B) Fundus retinography after incubation with the
different formulations. Adapted from [99] under the terms of the Creative Commons Attribution 4.0
International License.
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Liposomes offer also the great ability of an easy surface functionalization with a plethora of
active macromolecules and targeting moieties that bind in a selective manner some specific receptors
constitutive of different cell lines [101,102].
The surface modification of liposomes has also been widely studied to improve their specificity
of targeting and to deliver them in different eye compartments. It has been reported [103] that the
cationic PEGylated liposomes having an average zeta potentials below +20 mV were able to efficiently
penetrate the murine retina. In contrast, liposome having surface zeta potential values above +20 mV
were retained on vitreous section. This did not change whether PEGylated or non-PEGylated liposomes
were used. Another critical factor for a liposome-based therapy is the phospholipids composition
characterizing them. For example, edaravone-loaded egg L-phosphatidylcholine liposomes prevent
retinal ganglion cells (RGCs) from undesired apoptotic processes [104]. This drug is a free radical
scavenger used for acute brain infarction and amyotrophic lateral sclerosis treatment [105]. Surprisingly,
minor RGC protection was observed with edaravone-loaded distearoyl phosphatidylcholine (DSPC)
liposomes. This evidence suggest a link between the viscoelastic properties of the lipid bilayer and the
final biological effect. In this specific case, the higher fluidity was a key factor to improve the ocular
therapy. Another study [106] also tested the use of liposomes for the treatment of different kinds of
hereditary degeneration of the retina. The degeneration of retina affects rod photoreceptors important
for capturing light under low illumination conditions. Because of the pathology development, the
patients affected by retina degeneration become aware of defects only when lesions are in an advanced
stage. A key factor for this disease seems to be rods-specific Pde6b gene mutation in the transduction
pathway that triggers an excessive accumulation of cGMP (that have two effectors: cyclic nucleotide
gated ion channels (CNGCs) and cGMP-dependent protein kinase (PKG) [107]. Consequently, rod cell
death was induced and in some cases the secondary loss of cones was observed [108]. The authors
identified a liposomal cGMP analogue that was able to overcome the blood–retinal barrier (BRB) while
strongly preserving retinal function and reducing rod photoreceptor loss in three different in vivo
models for retina degeneration [106,109]. The vesicle structure of liposomes was suitable to confine
proteins and peptides into aqueous core overcoming potential agglomeration and protein misfolding
events. However, the surface functionalization with peptides is the most common method used for
retina therapy. For example, liposomes functionalized with tanticoagulant annexin A5 have been
demonstrated to have enhanced uptake levels through corneal epithelial barriers [110].
This vector has been injected topically to deliver 127 ng/g of bevacizumab to
posterior segment of both rats and rabbit eye. Annexin A5-functionalized liposomes
loaded with bevacizumab were also rapidly delivered to retina of the two animal
models. Annexin A5 unilamellar liposomes made by different polymers (2-dipalmitoyl-
sn-glycero-3-phosphocholine,1,2-dioleoyl-sn-glycero-3-phospho-l-serine and cholesterol) have been
also used to target transforming growth factor (TGF)-ß1 into the vitreous of rabbits [111]. It has been
found that a higher concentration of molecule with respect to the experimental group treated with the
unloaded drug only. The choice for human recombinant TGF-β1 relied on the drug’s ability to prevent
retinal damage elicited by Aβ oligomers.
5.2. Niosomes for Drug and Gene Delivery
Gene therapies is an approach where diseases are cured by modifying the expression of specific
genes regulating pathology. This happens through the administration of nucleic acids aiming to
replace abnormal gene sequence [112]. Liposomes and lipoplexes have been taken into consideration
as suitable non-viral vectors platform for gene editing. Non-viral gene delivery approaches were
widely applied in clinical trials since 2004 to attempt replacing the use of viral vectors that possess
high risk of inducing oncogenesis, immunogenicity, mutagenicity phenomena [113].
Among non-viral vectors, niosomes have been recently tested as a potential candidate for gene
delivery. Niosomes are vesicular systems comprising of bilayer made up of nonionic surfactants and
they can internalize several types of bio-macromolecules such as nucleic acids and drugs. The most
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commonly used surfactant are Sorbitan fatty acid esters, Spans (Span 20, 40, 60, 65, 80, and 85), Tweens
(20, 40, 60, and 80) [114] and brij (30, 35, 52, 58, 72, and 76) [115].
In a recent study [116], niosomes made by cationic lipid 1,2-di-octadecenyl-3-trimethylammonium
propane, Squalene, and Tween 20 have been combined with GFP-encoding genetic materials consisting
on minicircle (MC-GFP, 2.3 kb), its parental plasmid (pGFP, 3.5 kb), and a larger plasmid (pEGFP,
5.5 kb). Their efficacy in retinal disease treatment has been investigated. These noisome-DNA
complexes, named as nioplexes, demonstrated good transfection ability in human ARPE19 retinal
pigment epithelium cells (in vitro) and in embrionary rat retinal primary cells (in vivo). Fluorescence
showed GFP positive signal emission after transfection with the nioplexes carrying plasmidic DNA.
In addition, such transfected cells showed physiological glial cell morphology confirming good cell
viability in all tested cases. (Figure 5). The successive injections of nioplexes in rat retinas confirmed the
higher capacity of cationic niosomes vectoring minicircle DNA to deliver genetic material into retina
cells. Therefore, nioplexes based on cationic niosomes vectoring minicircle DNA are demonstrated
as powerful agents in retinal diseases therapies. Cationic formulations made by a combination of
Tween-60:DOTMA:lycopene have been used to transfect ARPE-19 cells with pCMS-EGFP plasmid
with a transfection efficiency close to 35% [117]. Also in case, in vivo experiments in rat eye showed
the efficiency of nioplexes to transfect outer segments of the retina, Niosomes constituted by Span 40 or
Span 60 and cholesterol were produced to encapsulate and topically deliver in vivo acetazolamide. The
intraocular pressure (IOP) after drug delivery system application was reduced in rabbits. In particular,
multilamellar acetazolamide niosomes developed with Span 60 and cholesterol (7:4 molar ratio) were
more efficient in reducing IOP, and at same time, no irritation and retinal damage were observed [118].
Gugleva et al. [119] prepared niosomes by different surfactants to deliver doxycycline hyclate in rats
eye. Doxycycline hyclate is an antibiotic used for the treatment of eye infections. It was demonstrated
to inhibit effect on matrix metalloprotease 9 (MMP-9) activity and mitogen activated protein kinase in
experimental murine dry eye [120]. Niosomes were synthesized using several surfactants (Span 20,
Span 60, Span 80, Tween 60) and cholesterol in different molar ratios and tested on male albino rabbits.
The experiments clearly showed that the prepared niosomal formulations were high tolerated and did
not induce any irritations.
Figure 5. Fluorescence immonostaining by GFP expression in embrionary rat retinal primary cells.
The green signal was referred to the transfection event of DST20 nioplexes with MC-GFP, (B) pGFP
3.5 kb, or (C) pEGFP 5.5 kb. (D–F) Positive controls incubated with Lipofectamine™ 2000. Nuclei
were stained with Hoechst 33,342 (blue) and neuronal dendrites with MAP2 (red). Scale bars: 20 μm.
Reprinted from [116] Copyright (2019), with permission from Elsevier.
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5.3. Hydrogels-Based Nanocarriers
Hydrogels are three-dimensional, cross-linked networks of natural or synthetic water-soluble
polymers that are suitable for applications like tissue engineering and controlled/sustained drugs
delivery [121,122]. The aqueous environment is particularly advantageous to confine soluble active
molecules, oligonucleotides, and proteins. For this reason, they are powerful tools in retinal treatment
disease [123]. In addition, smart or environment-responsive hydrogels were synthetized to improve
drug delivery efficacy [124].
5.3.1. Natural Hydrogels: Chitosan NPs (CHNPs)
Chitosan is a natural hydrogel cationic polysaccharide of co-polymers glucosamine and N-acetyl
glucosamine [125] obtained by alkaline deacetylation of chitin that is constitutive of crustacean shells
of shrimps, lobster, and crab. It presents a positive charge that can be exploited to form polyelectrolyte
vesicular complexes able to act as delivery systems. The positive charged chitosan is also ideal to
bind a negatively charged corneal surface, to improve precorneal retention time and to decreases
clearance [126]. In addition to chitosan, also the biocompatible alginate is extensively employed
in biomedical applications. Alginate can also be a useful biopolymers for designing responsive
hydrogels [127]. Because of its characteristics, alginate is also used for ophthalmic applications often
in combination with chitosan [128]. For example, chitosan coated sodium alginate NPs [129] loaded
with Fluorouracil (5-FU) have been successfully tested for eye delivery demonstrating a high 5-FU
release in aqueous humor compared to free drug in rabbit eye. In another approach, chitosan NPs
were encapsulated with levofloxacin for the treatment of ocular infection [130]. The formulation of
NPs were optimized to enhance corneal retention without inducing eye irritation. These nanovectors
demonstrated strong antibacterial agents against Pseudomonas aeruginosa and Stafiloccocus aureus.
Andrei and co-workers [131] designed biocompatible chitosan and alginate-based micro/NPs
with a specific morphology aiming to deliver cefuroxim, a second-generation cephalosporin antibiotic.
The authors performed an in vivo assessment to evaluate the biodistribution following an intravitreal
administration of fluorescein-chitosan NPs on wistar rats. They observed an efficient NPs distribution
in lens and retina. Similarly, chitosan-dextran NPs have been employed to deliver the antibiotic
moxifloxacin that has been retained for a long time in vivo thanks to the mucoadhesive properties of
NPs [132].
In recent work, humanin, a neuronal peptide that mediated inflammatory responses, was used in
the treatment of age-related macular degeneration (AMD) [133]. This peptide was a suppressor of the
IL-6 cytokine receptors and protects neuronal cells from necrosis [134]. The authors studied the effect
on the inflammatory response reduction using chitosan NPs as vector vesicle (with a size of 346 ± 52
nm) in which humanin (a micropeptide encoded in the mitochondrial genome) derivative AGA-(CR8)
HNG17 (AGA-HNG) were encapsulated. The effects of NPs were assessed in retinal pigment epithelial
cells. The percentage release profile of free protein after five days was 60%, after which it enriched
a plateau whereas the nanostructured exhibited a slow and substantial release with 80% of protein
released after fifteen days. Cheng et al. [135] developed a thermosensitive hydrogel containing
latanoprost and curcumin-loaded NPs (CUR-NPs). Curcumin was selected because of its antioxidative
and antiinflammatory properties that made it suitable also for treatment of eye pathologies such as
chronic anterior uveitis and light-induced retinal degeneration [136]. Latanoprost was chosen because
it acted on IOP restore due to uveoscleral outflow increase [137]. In glaucoma disease, IOP is generated
by loss of aqueous humor drainage through the uveoscleral or trabecular outflow pathway that can be
damaged by oxidative stress at trabecular meshwork level [138]. In this condition, Latanoprost and
CUR-NPs were demonstrated to decrease the oxidative stress in trabecular meshwork (TM) cells that
resulted in decreased levels of apoptosis, inflammation-related gene expression, and mitochondrial
damage [135]. In another work [139], neuroprotective and neuro regenerative agent Erythropoietin
(EPO) was encapsulated in chitosan/hyaluronic acid (HA) nanoparticulate (size ≤300 nm). Different
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formulations have been tested and delivered to porcine corneas, scleras, and conjunctivas by ex vivo
permeation, finding out a good combination between targeting efficiency and biocompatibility.
Pandit et al. [140] encapsulated high levels of bevacizumab (an anti-angiogenesis drug) within
chitosan-coated PLGA NPs (size 222.28 ± 7.45) and demonstrated its efficient deliver to the retina
followed by efficient release. As matter of fact, CS-coated NPs showed better permeability of the
bevacizumab across sclera as compared to the free drug solution. Another category of carrier is made
by glycol chitosan (GCS) NPs [141]. These biocompatible NPs, demonstrated to load high amount of
plasmid DNA, have been successfully delivered to retinal pigment epithelium of adult wild-type albino
mice. More importantly, the encapsulated pDNA was intact and maintained a proper conformation.
5.3.2. Synthetic Hydrogel Based Nanocarriers
The synthetic hydrogels are easy to customize and indeed are a close model of biological matrices.
Hydrogels exhibit high hydrophilicity and high hydration [142]. The most commonly used are
poly(hydroxyethyl methacrylate) (PHEMA), poly(ethylene oxide) (PEO, also called poly(ethyleneglycol)
(PEG)), polyvinylpyrrolidone (PVP), poly(acrylic acid)(PAA), polyacrylamide (PAM), and poly(vinyl
alcohol) (PVA) [143]. These polymers are all used in several ophthalmic applications with good
results [144–147].
Anti-VEGF antibodies (anibizumab or aflibercept) were loaded within poly(lactic-co-glycolic
acid) microspheres, and successively suspended within poly(N-isopropylacrylamide)-based hydrogel
and injected into a laser-induced rat model of choroidal neovascularization (CNV). Upon ocular
administration, the rats showed smaller CNV lesions (less than 60%) with respect to non-treated
animals [148].
Agrahari et al. [149] obtained novel pentablock (PB) copolymer (PB-1: PCL–PLA–PEG–PLA–PCL)
based nanoformulations suspended in a thermosensitive gelling copolymer (PB-2: mPEG–PCL–
PLA–PCL–PEGm) with a size of 150 nm. This composite nanoformulation was used to deliver
macromolecules to slowly release drugs without toxic effects on the posterior segment of the eye. In vitro
tests performed on ocular and mouse macrophage (RAW 264.7) demonstrated their biocompatibility
and potential to be clinically translated.
Yang et al. [150] reported the production of non-toxic polyamidoamine (PAMAM) dendrimer
hydrogel/poly(lactic-co-glycolic acid) (PLGA) NP platform (HDNP) to treat glaucoma. The dendrimers
were loaded with brimonidine and timolol maleat, which underwent an enhanced uptake together
with a slow release in vitro up to 28–35 days. The topical administration of the same drug-loaded
denndrimers in normotensive adult Dutch-belted male rabbits strongly reduced the introcular pressure
(IOP) of about 18% maintaining a glaucoma reduction for four days. Conversely, Individual Dendrimer
Hydrogel Formulations (DH) and NP Formulations (NP) decreased the disease symptoms only for
48 h (Figure 6).
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Figure 6. Fundus camera acquisitions of rabbits’ eyes after hybrid polyamidoamine (PAMAM)
dendrimer hydrogel/poly(lacticco-glycolic acid) (PLGA) nanoparticle platform (HDNP) and NP
Formulations (NP) topical administration FluoSpheres were confined in nanosistems to follow the
distribution and retention in the eye. The analysis was performed at the end of 1, 3, 5, and 7 days of
formulations instillation. Left: regular fundus camera images of the eyes; right: fluorescent fundus
camera images. Adapted with permission from [150], copyright (2012), American Chemical Society.
5.4. Active and Self-Propelling Nanoparticles: New Generation of Nanobots in Retinal Disease
The customization of NPs formulation at a molecular level has interesting outcomes
for reproduction of fundamental phenomena such as macro- and microorganisms’ survival
mechanisms [151]. For example, bacteria, uni- or multicellular organisms, and sperm cells are
able to sense and actively respond to external stimuli by the generation of movement. In particular,
they convert an external energy sources (temperature, magnetic fields, adhesion forces, chemical
gradients) into mechanical work that induce migration. This is typical in processes such as thermotaxis,
magnetotaxis, haptotaxis, chemotaxis [152]. By taking inspiration from nature, we have also now a
panel of NPs able to self-propel towards a gradient of nutrients and to mimic biological taxis [153].
However, the development of such NPs still has many challenges because at nanoscale level, the physical
principles of propulsion are different due to the presence of the Brownian effect that can interfere
with nanomptors by collisions with solvent molecules. One of these challenges is the generation of
particles having asymmetrical geometries at the nanoscale, as this provides guidance for the movement
directionality. Bacteria like Escherichia coli, in fact, achieve propulsion by non-time-reversible motion
of long flagella, and this asymmetric shape of the body is critical for motion generation in a specific
direction [154].
It is clear that self-propelling NPs represent a new powerful tool in drug delivery, which is usually
dominated by NPs passive diffusion. It should not come as a surprise that such strategies have been
employed also for delivery in ocular medicine. For example, Wu et al. [155] designed micro-vehicles
that can actively propel through the vitreous humor to enrich retina. The movement can be activated
by helical magnetic micropropellers (~120 nm in diameter and ~400 nm in length) with liquid layer
coating to reduce the adhesion of biopolymeric network. These nanovectors propelled in nanoporous
hyaluronan solution, a fluid mimicking the vitreous. The inspiration for nanotool development is due
to the liquid layer that characterizes carnivorous Nepenthes pitcher plant, which presents a slippery
surface on the peristome to catch insects [156,157]. Porcine eyes were used as a model of human eyes:
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applying the external magnetic field, micropropellers exhibited controllable propulsion from eyeball to
retina within 30 minutes. Instead, passive silica microparticles did not penetrate the vitreus (Figure 7).
Nanorobots were also used to perform microsurgery on the retina and surrounding membranes thanks
to the possibility of injecting them elsewhere in the body and bringing the drug to the target eye
region [158]. Some intravitreal implants have recently developed to perform more clinical-inspired
experiments. These nanotools, constituted by polymeric containers (silicon, poly(vinyl alcohol), or
ethylene vinyl acetate), were placed in the posterior segment of the eye and they are permeable to
lipophilic drugs. They did not display any toxicity and had a long retention time. These nanosystems
have been extremely useful to treat proliferative diabetic retinopathy, retinal vascular occlusion, and
uveitis [159].
Figure 7. (a) SEM and ESB-SEM images of the micropropellers. (b,c) incomplete rotation of an uncoated
micropropeller for one period (p) in the vitreous was showed in schematic and time-lapse microscopy,
whereas the coated propeller exhibited propulsion under magnetic stimuli in vitreous for 1.5 s (nine
periods). Red arrows showed the propulsion direction of propeller. The original position of nanotools
and after the rotating magnetic field application were showed with green and red dashed lines. Scale
bars, 1 μm. (d) Schematic illustration of micropropeller movement in the vitreous. (e) Left: fluorescent
acquisitions showed the micropropellers labelled red on retina. Right: passive fluorescent particles were
accumulated near center of vitreous. Nuclei of cells were stained with DAPI. Scale bar, 20 μm. Adapted
from reference [155] under the terms of the Creative Commons Attribution-Non Commercial license.
6. Conclusions and Perspectives
It is established that eye damage is a leading cause of irreversible vision loss resulting from ocular
diseases. The current standard treatments helped in both preventing and curing several pathological
conditions, especially when related to the deep sections of the eye. However, many of these methods
are rather invasive in terms of procedures, with a consequent possibility of promoting infection,
inflammation, or even retinal detachment with potential risk of vision loss. These limitations impose
considerable costs on patient quality of life and have an enormous economic impact on the health care
system. The progress in the nano-engineering field can help boosting the discovery of a new approach
for ocular diagnosis and therapy. Noble metals NPs and bio-inspired NPs represent a powerful tool to
overcome all the limitations coming with standard treatments due to their physico-chemical properties.
NPs can in fact penetrate deeper inside the ocular segments and also locally deliver high dosages of
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drugs, enriching local drug concentration when applied topically. In addition, the plasmonic properties
of Au and Ag can have an added value to contrast eye diseases. However, numerous challenges still
remain to be addressed as there are still limited numbers of in vivo studies. In addition, a deeper
toxicology assessment is required for the development of new systems for ocular treatments.
Author Contributions: Conceptualization, V.D.M.; writing—original draft preparation, V.D.M.; review and
editing, L.R. All authors have read and agreed to the published version of the manuscript.
Funding: This research received no external funding.
Acknowledgments: VDM kindly acknowledges Programma Operativo Nazionale (PON) Ricerca e Innovazione
2014-2020 Asse I “Capitale Umano”, Azione I.2, Avviso “A.I.M: Attraction and International Mobility”
CUP F88D18000070001.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Davson, H. The Physiology of The Eye; Elsevier: Amsterdam, The Netherlands, 2012.
2. Stephen, R.; Wilkinson, C.; Schachat, A.; Hinton, D.; Wilkinson, C. Retina; Elsevier: Amsterdam,
The Netherlands, 2012.
3. Günhan, E.; van der List, D.; Chalupa, L.M. Ectopic Photoreceptors and Cone Bipolar Cells in the Developing
and Mature Retina. J. Neurosci. 2003, 15, 1383–1389. [CrossRef]
4. Reichenbach, A.; Schnitzer, J.; Friedrich, A.; Brückner, G.; Schober, W. Development of the rabbit retina. Anat.
Embryol. 1991, 183, 287–297. [CrossRef] [PubMed]
5. Dilnawaz, F.S.S.K. Nanotechnology-Based Ophthalmic Drug Delivery System. In Focal Controlled Drug
Delivery; Domb, A., Khan, W., Eds.; Advances in Delivery Science and Technology; Springer: Boston, MA,
USA, 2014.
6. Rakhi Dandonaa, L.D. Socioeconomic status and blindness. Br. J. Ophthalmol. 2001, 85, 1484–1488. [CrossRef]
[PubMed]
7. Yorston, D. The Retina Retinal Diseases and VISION 2020. Comm Eye Health 2003, 16, 19–20.
8. Veleri, S.; Lazar, C.H.; Chang, B.; Sieving, P.A.; Banin, E.; Swaroop, A. Biology and therapy of inherited retinal
degenerative disease: insights from mouse models. Dis. Models Mech. 2015, 8, 109–129. [CrossRef] [PubMed]
9. Jiang, S.; Franco, Y.L.; Zhou, Y.; Chen, J. Nanotechnology in retinal drug delivery. Int. J. Ophthalmol. 2018, 11.
[CrossRef]
10. Gilbert, C.; Foster, A. Childhood blindness in the context of VISION 2020—The Right to Sight. Bull. World
Health Organ. 2001, 79, 227–232.
11. Jones, B.W.; Marc, R.E.; Pfeiffer, R.L. Retinal Degeneration, Remodeling and Plasticity. In Webvision: The
Organization of the Retina and Visual System; Salt Lake City (UT): University of Utah Health Sciences Center,
UT, USA, 2016.
12. Rajappa, M.; Saxena, P.K.J. Ocular angiogenesis: Mechanisms and recent advances in therapy. Adv. Clin.
Chem. 2010, 50, 103–121.
13. Aiello, L.P.; Avery, R.L.; Arrigg, P.G.; Keyt, B.A.; Jampel, H.D.; Shah, S.T.; Pasquale, L.R.; Thieme, H.;
Iwamoto, M.A.; Park, J.E.; et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic
retinopa-thy and other retinal disorders. N. Engl. J. Med. 1994, 331, 480–1487. [CrossRef]
14. Weis, S.M.; Cheresh, D.A. Pathophysiological consequences of VEGF-induced vascular permeability. Nature
2005, 437, 497–504. [CrossRef]
15. Kim, S.J. Novel Approaches for Retinal Drug and Gene Delivery. Transl. Vis. Sci. Technol. 2014, 3, 7.
[CrossRef] [PubMed]
16. Bennett, J.; Chung, D.C.; Maguire, A. Gene delivery to the retina: From mouse to man. Methods Enzym. 2012,
507, 255–257.
17. Xu, H.; Chen, M. Targeting the complement system for the management of retinal in fl ammatory and
degenerative diseases. Eur. J. Pharmacol. 2016, 787, 94–104. [CrossRef] [PubMed]
18. Díaz-Coránguez, M.; Ramos, C.; Antonetti, D.A. The inner Blood-Retinal Barrier: Cellular Basis and
Development. Vis. Res. 2017, 139, 123–137. [CrossRef]
290
Cells 2020, 9, 679
19. Gaudana, R.; Jwala, J.; Boddu, S.H.S.; Mitra, A.K. Recent Perspectives in Ocular Drug Delivery. Pharm. Res.
2009, 26, 1197–1216. [CrossRef]
20. Kati-Sisko, V.; Hellinen, L. Expression, activity and pharmacokinetic impact of ocular transporters. Adv.
Drug Deliv. Rev. 2018, 126, 3–22.
21. Souto, E.B.; Dias-ferreira, J.; Ana, L.; Ettcheto, M.; Elena, S. Advanced Formulation Approaches for Ocular
Drug Delivery: State-Of-The-Art and Recent Patents. Pharmaceutics 2019, 11, 460. [CrossRef]
22. Le Bourlais, C.; Acar, L.; Zia, H.; Sado, P.A.; Needham, T.; Leverge, R. Ophthalmic drug delivery
systems—Recent advances. Prog. Retin. Eye Res. 1998, 17, 33–58. [CrossRef]
23. Sugrue, M.F. The pharmacology of antiglaucoma drugs. Pharmacol. Ther. 1989, 43, 91–1989. [CrossRef]
24. Himawan, E.; Ekström, P.; Buzgo, M.; Gaillard, P.; Stefánsson, E.; Marigo, V.; Loftsson, T.; Paquet-Durand, F.
Drug delivery to retinal photoreceptors. Drug Discov. Today 2019, 24, 1637–1643. [CrossRef]
25. Marmor, M.F.; Akira Negi, D.M.M. Kinetics of macromolecules injected into the subretinal space. Exp. Eye
Res. 1985, 40, 687–696. [CrossRef]
26. Meyer, C.H.; Krohne, T.U.; Issa, P.C.; Liu, Z. Routes for Drug Delivery to the Eye and Retina: Intravitreal
Injections. Retin. Pharmacother. Dev. Ophthalmol. 2016, 55, 63–70.
27. Falavarjani, K.G.; Nguyen, Q.D. Adverse events and complications associated with intravitreal injection of
anti-VEGF agents: A review of literature. Eye 2013, 27, 787–794. [CrossRef] [PubMed]
28. Raghava, S.; Hammond, M.K.U. Periocular routes for retinal drug delivery. Expert Opin. Drug Deliv. 2004, 1,
99–144. [CrossRef]
29. Ghate, D.; Brooks, W.; McCarey, B.E.; Edelhauser, H.F. Pharmacokinetics of Intraocular Drug Delivery by
Periocular Injections Using Ocular Fluorophotometry. Invest. Ophthalmol Vis. Sci. 2007, 48, 2230–2237.
[CrossRef] [PubMed]
30. Castellarinand, A.; Pieramici, D.J. Anterior segment complications following periocular and intraocular
injections. Ophthalmol. Clin. N. Am. 2004, 17, 583–590. [CrossRef]
31. Tsai, H.-H.; Wang, P.-Y.; Lin, I.-C.; Huang, H.; Liu, G.; Tseng, C.-L. Ocular Drug Delivery: Role of Degradable
Polymeric Nanocarriers for Ophthalmic Application. Int. J. Mol. Sci. 2018, 19, 2830. [CrossRef]
32. ISO, Int. Organ Stand Nanotechnologies Vocab Part 1 Core Terms ISO/TS 80004-12010. 2010. Available
online: https://www.iso.org/standard/51240.html (accessed on 1 March 2020).
33. ISO International Organization for Standardization. Technical Specification: Nanotechnologies Terminology and
Definitions for Nanoobjects Nanoparticle, Nanofibre and Nanoplate. ISO/TS 80004-2:2008. 2008. Available online:
https://www.iso.org/standard/44278.html (accessed on 1 March 2020).
34. De Matteis, V.; Rinaldi, R. Toxicity Assessment in the Nanoparticle Era. In Cellular and Molecular Toxicology of
Nanoparticles; Springer: Cham, Switzerland, 2018; pp. 1–19.
35. Mu, Q.; Jiang, G.; Chen, L.; Zhou, H.; Fourches, D.; Tropsha, A.; Yan, B. Chemical Basis of Interactions
Between Engineered Nanoparticles and Biological Systems. Chem. Rev. 2016, 7740–7781. [CrossRef]
36. Bhatia, S. Nanoparticles Types, Classification, Characterization, Fabrication Methods and Drug Delivery
Applications. In Natural Polymer Drug Delivery Systems; Springer: Cham, Switzerland, 2016.
37. Ruth Duncan, R.G. Nanomedicine(s) under the Microscope. Mol. Pharm. 2011, 8, 2101–2214. [CrossRef]
38. Diebold, Y.; Calonge, M. Applications of nanoparticles in ophthalmology. Prog. Retin. Eye Res. 2010, 29,
596–609. [CrossRef]
39. Farjo, K.M.; Ma, J. The potential of nanomedicine therapies to treat neovascular disease in the retina. J.
Angiogenes Res. 2010, 2, 21. [CrossRef] [PubMed]
40. JeffreyAdijanto, M.I.N. Nanoparticle-based technologies for retinal gene therapy. Eur. J. Pharm. Biopharm.
2015, 95, 353–367.
41. Soto, F.; Chrostowski, R.; Soto, F. Frontiers of Medical Micro/Nanorobotics: In vivo Applications and
Commercialization Perspectives Toward Clinical Uses. Front. Bioeng. Biotechnol. 2018, 6, 1–12. [CrossRef]
42. Khlebtsovab, N.G.; Dykman, L.A. Optical properties and biomedical applications of plasmonic nanoparticles.
J. Quant. Spectrosc. Radiat. Transf. 2010, 111, 1–35. [CrossRef]
43. Anker, J.N.; Hall, W.P.; Lyandres, O.; Shah, N.C.; Zhao, J.V. Biosensing with plasmonic nanosensors. Nat.
Mater. 2008, 7, 442–453. [CrossRef] [PubMed]
44. Daniel, M.; Astruc, D. Gold Nanoparticles: Assembly, Supramolecular Chemistry, Quantum-Size-Related
Properties, and Applications toward Biology, Catalysis, and Nanotechnology. Chem. Rev. 2004, 104, 293–346.
[CrossRef]
291
Cells 2020, 9, 679
45. Asahi, T.; Uwada, T.; Masuhara, H. Single particle spectroscopic study on surface plasmon resonance probing
local environmental conditions. Handai Nanophotonics 2006, 2, 219–228.
46. Boken, J.; Khurana, P.; Thatai, S. Plasmonic nanoparticles and their analytical applications: A review. Appl.
Spectrosc. Rev. 2017, 52, 774–820. [CrossRef]
47. Loiseau, A.; Asila, V.; Boitel-aullen, G.; Lam, M. Silver-Based Plasmonic Nanoparticles for and Their Use in
Biosensing. Biosens 2019, 2019, 9. [CrossRef]
48. Rizzello, L.; Pompa, P.P. Nanosilver-based antibacterial drugs and devices: Mechanisms, methodological
drawbacks, and guidelines. Chem. Soc. Rev. 2014, 43, 1501–1518. [CrossRef]
49. Draslera, B.; Sayreb, P.; Günter, K.; Steinhäuserc, A.-R. In vitro approaches to assess the hazard of
nanomaterials. NanoImpact 2018, 9, 51. [CrossRef]
50. De Matteis, V. Exposure to Inorganic Nanoparticles: Routes of Entry, Immune Response, Biodistribution and
In Vitro/In Vivo Toxicity Evaluation. Toxics 2017, 5, 29. [CrossRef] [PubMed]
51. Naahidi, S.; Jafari, M.; Edalat, F.; Raymond, K.; Khademhosseini, A.C.P. Biocompatibility of engineered
nanoparticles for drug delivery. J. Control. Release 2013, 10, 182–194. [CrossRef] [PubMed]
52. Turkevich, J.; Stevenson, P.C.; Hillier, J. A study of the nucleation and growth processes in the synthesis of
colloidal gold. Faraday Soc. 1951, 11, 55–75. [CrossRef]
53. Brust, M.; Walker, M.; Bethell, D.; Schiffrin, D.J. Synthesis of thiol-derivatised gold nanoparticles in a
two-phaseliquid–liquid system. J. Chem. Soc. Chem. Commun. 1994, 7, 801–802. [CrossRef]
54. Kumar, P.V.; Kala, S.M.J.; Prakash, K.S. Green synthesis of gold nanoparticles using Croton Caudatus Geisel
leaf extract and their biological studies. Mater. Lett. 2019, 236, 19–22. [CrossRef]
55. Molnár, Z.; Bódai, V.; Szakacs, G.; Erdélyi, B.; Fogarassy, Z. Green synthesis of gold nanoparticles by
thermophilic filamentous fungi. Sci. Rep. 2018, 8, 1–12. [CrossRef]
56. Giljohann, D.A.; Seferos, D.S.; Daniel, W.L.; Massich, M.D.; Patel, P.C. Gold Nanoparticles for Biology and
Medicine. Angew. Chem. Int. Ed. Engl. 2010, 26, 3280–3294. [CrossRef]
57. Orlando, A.; Colombo, M.; Prosperi, D.; Corsi, F.; Panariti, A.; Rivolta, I.; Masserini, M.; Cazzinga, E.
Evaluation of gold nanoparticles biocompatibility: A multiparametric study on cultured endothelial cells
and macrophages. J. Nanopart. Res. 2018, 18, 58. [CrossRef]
58. Aghaie, T.; Jazayeri, M.H.; Manian, M.; Khani, l.; Erfani, M.; Rezayi, M.; Ferns, G.A.; Avan, A. Gold
nanoparticle and polyethylene glycol in neural regeneration in the treatment of neurodegenerative diseases.
J. Cell. Biochem. 2019, 120, 2749–2755. [CrossRef]
59. Bailly, A.-L.; Correard, F.; Popov, A.; Gleb Tselikov, F.; Appay, R.; Al-Kattan, A.; Andrei, V.; Kabashin, D.B.;
Esteve, M.-A. In vivo evaluation of safety, biodistribution and pharmacokinetics of lasersynthesized gold
nanoparticles. Sci. Rep. 2019, 9, 12890. [CrossRef] [PubMed]
60. Cassano, D.; Summa, M.; Pocoví-Martínez, S.; Mapanao, A.-K.; Catelani, T.; Bertorelli, R.; Voliani, V.
Biodegradable Ultrasmall-in-Nano Gold Architectures: Mid-Period In Vivo Distribution and Excretion
Assessment. Part. Part. Syst. Charact. 2019, 36, 1800464. [CrossRef]
61. Khan, H.A.; Abdelhalim, M.A.K.; Alhomida, A.S.; Al-Ayed, M.S. Effects of Naked Gold Nanoparticles on
Proinflammatory Cytokines mRNA Expression in Rat Liver and Kidney. Biomed. Res. Int. 2013, 2013, 590730.
[CrossRef] [PubMed]
62. Khan, H.A.; Alamery, S.; Ibrahim, K.E.; El-Nagar, D.M.; Al-Harbi, N.; Rusop, M.; Alrokayan, S.H. Size and
time-dependent induction of proinflammatory cytokines expression in brains of mice treated with gold
nanoparticle. Saudi J. Biol. Sci. 2019, 26. [CrossRef]
63. Karakoçak, B.B.; Raliya, R.; Davis, J.T.; Chavalmane, S.; Wang, W.N.; Ravi, N. Biocompatibility of gold
nanoparticles in retinal pigment epithelial cell line. Toxicol. Vitr. 2016, 37, 61–69. [CrossRef]
64. Kim, J.H.; Kim, J.H.; Kim, K.-W.; Kim, M.H. Intravenously administered gold nanoparticles pass through the
blood–retinal barrier depending on the particle size, and induce no retinal toxicity. Nanotechnology 2009, 20,
505101. [CrossRef]
65. Bakri, S.J.; Pulido, J.S.; Mukherjee, P.; Marler, R.J. Absence of histologic retinal toxicity of intravitreal nanogold
in a rabbit model. Retin 2008, 2008, 147–149. [CrossRef]
66. Söderstjerna, E.; Bauer, P.; Cedervall, T.; Abdshill, H.; Johansson, F.; Johansson, U.E. Silver and Gold
Nanoparticles Exposure to In Vitro Cultured Retina—Studies on Nanoparticle Internalization, Apoptosis,
Oxidative Stress, Glial- and Microglial Activity. PLoS ONE 2014, 9, e0105359. [CrossRef]
67. Nakhlband, A. Impacts of nanomedicines in ocular pharmacotherapy. Bioimpacts 2011, 1, 7–22.
292
Cells 2020, 9, 679
68. Kittler, S.; Greulich Diendorf, M.; Köller, M.E. Toxicity of Silver Nanoparticles Increases during Storage
Because of Slow Dissolution under Release of Silver Ions. Chem. Mater. 2010, 22, 4548–4554. [CrossRef]
69. Yang, X.; Gondikas, A.P.; Marinakos, S.M.; Auffan, M.; Li, J.; Hsu-Kim, H. Mechanism of Silver Nanoparticle
Toxicity Is Dependent on Dissolved Silver and Surface Coating in Caenorhabditis elegans. Environ. Sci.
Technol. 2012, 46, 1119–1127. [CrossRef] [PubMed]
70. De Matteis, V.; Malvindi, M.A.; Galeone, A.; Brunetti, V.; De Luca, E.; Kote, S.; Kshirsagar, P.; Sabella, S.;
Bardi, G.; Pompa, P.P. Negligible particle-specific toxicity mechanism of silver nanoparticles: The role of
Ag + ion release in the cytosol. Nanomedicine Nanotechnology. Biol. Med. 2015, 11, 731–739. [CrossRef]
[PubMed]
71. Abbasi, E.; Milani, M.; Fekri Aval, S.; Kouhi, M.; Akbarzadeh, A.; Tayefi Nasrabadi, H.; Nikasa, P.; Joo, S.W.;
Hanifehpour, Y.; Nejati-Koshki, K.; et al. Silver nanoparticles: Synthesis methods, bio- applications and
properties. Crit. Rev. Microbiol. 2016, 42, 173–180. [CrossRef]
72. Zhang, T.; Song, Y.J.; Zhang, X.Y.; Wu, J.Y. Synthesis of silver nanostructures by multistep methods. Sensors
(Switzerland) 2014, 14, 5860–5889. [CrossRef] [PubMed]
73. Singh, C.; Kumar, J.; Kumar, P.; Singh Chauhan, B.; Tiwari, K.N.; Mishra, S.K.; Srikrishna, S.; Saini, R.;
Nath, G.; Singth, J. Green synthesis of silver nanoparticles using aqueous leaf extract of Premna integrifolia
(L.) rich in polyphenols and evaluation of their antioxidant, antibacterial and cytotoxic activity. Biotechnol.
Biotechnol. Equip. 2019, 359–371. [CrossRef]
74. Jun, Y.; Zi, Z.; Wanga, Y.; Zhaoa, G.; Liu, J.-X. Silver nanoparticles affect lens rather than retina development
in zebrafish embryos. Ecotoxicol. Environ. Saf. 2018, 163, 279–288.
75. Sriram, M.I.; Kalishwaralal, K.; Barathmanikanth, S. Size-based cytotoxicity of silver nanoparticles in bovine
retinal endothelial cells. Nanosci. Methods 2012, 1, 56–77. [CrossRef]
76. Kim, J.S.; Song, K.S.; Sung, J.H.; Ryu, H.R.; Choi, B.G.; Cho, H.S.; Lee, J.K. Genotoxicity, acute oral and dermal
toxicity, eye and dermal irritation and corrosion and skin sensitisation evaluation of silver nanoparticles.
Nanotoxicology 2013, 7, 953. [CrossRef]
77. Maneewattanapinyo, P.; Banlunara, W.; Thammacharoen, C.; Ekgasit, S.; Kaewamatawong, T. An evaluation
of acute toxicity of colloidal silver nanoparticles. J. Vet. Med. Sci. 2011, 73, 1417–1423. [CrossRef]
78. De Matteis, V.; Cascione, M.; Cristina, C.; Rinaldi, R. Engineered Gold Nanoshells Killing Tumor Cells: New
Perspectives. Curr. Pharm. Des. 2019, 25, 1477–1489. [CrossRef]
79. Weissleder, R. A clearer vision for in vivo imaging. Nat. Biotechnol. 2001, 19, 316–317. [CrossRef] [PubMed]
80. Song, H.B.; Wi, J.S.; Jo, D.H.; Kim, J.H.; Lee, S.W. Intraocular application of gold nanodisks optically tuned
for optical coherence tomography: inhibitory effect on retinal neovascularization without unbearable toxicity.
Nanomedicine 2017, 13, 1901–1911. [CrossRef] [PubMed]
81. Gasparini, S.J.; Llonch, S.; Borsch, O. Transplantation of photoreceptors into the degenerative retina: Current
state and future perspectives. Prog. Retin. Eye Res. 2019, 69, 1–37. [CrossRef]
82. Chemla, Y.; Betzer, O.; Markus, A.; Farah, N.; Motiei, M. Gold nanoparticles for multimodal high-resolution
imaging of transplanted cells for retinal replacement therapy. Nanomedicine 2019, 14, 1857–1871. [CrossRef]
83. Kim, H.; Nguyen, V.; Manivasagan, P.; Kim, S.W.; Oh, J. Doxorubicin-fucoidan-gold nanoparticles composite
for dualchemo-photothermal treatment on eye tumors. Oncotarget 2017, 8, 113719–113733. [CrossRef]
[PubMed]
84. Valluru, K.S.; Chinni, B.K.; Rao, N.A.; Bhatt, S.; Dogra, V.S. Basics and Clinical Applications of Photoacoustic
Imaging. Ultrasound Clin. 2009, 4, 403–429. [CrossRef]
85. Gordon, A.Y.; Lapierre-Landry, M.; Skala, M.C.; Penn, J.S. Photothermal Optical Coherence Tomography of
AntiAngiogenic Treatment in the Mouse Retina Using Gold Nanorods as Contrast Agents. Transl. Vis. Sci.
Technol. 2019, 8, 18. [CrossRef] [PubMed]
86. Chan, C.-M.; Hsiao, C.-Y.; Li, H.-J.; Fang, J.-Y.; Chang, D.-C.; Hung, C.-F. The Inhibitory Effects of Gold
Nanoparticles on VEGF-A-Induced Cell Migration in Choroid-Retina Endothelial Cells. Int. J. Mol. Sci. 2020,
21, 109. [CrossRef]
87. Gurunathanab, S.; Leeb, K.; Kalishwaralala, K.; Sheikpranbabua, S.; Vaidyanathana, R.; Eom, S.H.
Antiangiogenic properties of silver nanoparticles. Biomaterials 2009, 30, 6341–6350. [CrossRef]
88. Sheikpranbabu, S.; Kalishwaralal, K.; Venkataraman, D.; Eom, S.H.; Park, J.; Gurunathan, S. Silver
nanoparticles inhibit VEGF-and IL-1β-induced vascular permeability via Src dependent pathway in porcine
retinal endothelial cells. Nanobiotechnol. 2009, 7, 8. [CrossRef]
293
Cells 2020, 9, 679
89. Ngandeu Neubi, G.M.; Opoku-Damoah, Y.; Gu, X.; Han, Y.; Zhou, J.; Ding, Y. Bio-inspired drug delivery
systems: an emerging platform for targeted cancer therapy. Biomater. Sci. 2018, 6, 958–973. [CrossRef]
[PubMed]
90. Yang, L.; Kuang, H.; Zhang, W.; Aguilar, Z.P.; Wei, H.; Xu, H. Comparisons of the biodistribution and
toxicological examinations after repeated intravenous administration of silver and gold nanoparticles in
mice. Sci. Rep. 2017, 7, 3303. [CrossRef] [PubMed]
91. Madamsetty, V.S.; Mukherjee, A.; Mukherjee, S. Recent Trends of the Bio-Inspired Nanoparticles in Cancer
Theranostics. Front. Pharmacol. 2019, 10, 1264. [CrossRef] [PubMed]
92. Birngruber, T.; Raml, R.; Gladdines, W.; Gatschelhofer, C.; Gander, E.; Ghosh, A.; Kroath, T.; Gaillard, P.J.;
Pieber, T.R. Enhanced Doxorubicin Delivery to the Brain Administered Through Glutathione PEGylated
Liposomal Doxorubicin (2B3-101) as Compared with Generic Caelyx,®/Doxil®—A Cerebral Open Flow
Microperfusion Pilot Study. J. Pharm. Sci. 2014, 203, 1945–1948. [CrossRef]
93. Trost, A.; Lange, S.; Schroedl, F.; Bruckner, D.; Motloch, K.A.; Bogner, B.; Kaser-Eichberger, A.; Strohmaier, C.;
Runge, C.; Aigner, L.; et al. Brain and Retinal Pericytes: Origin, Function and Role. Front. Cell Neurosci. 2016,
4, 20. [CrossRef] [PubMed]
94. Haque, S.; Shadab, M.D.; Alam, I.; Sahni, J.K.; Ali, J. Nanostructure-based drug delivery systems for brain
targeting. Drug Dev. Ind. Pharm. 2012, 38, 387–411. [CrossRef] [PubMed]
95. Diebold, Y.; Jarrín, M.; Sáez, V.; Carvalho, E.L.; Orea, M.; Calonge, M.; Seijo, B. Ocular drug delivery by
liposome-chitosan nanoparticle complexes (LCS-NP). Biomaterials 2007, 28, 1553–1564. [CrossRef] [PubMed]
96. Zhang, R.; He, R.; Qian, J.; Guo, J.; Xue, K.; Yuan, Y. Immunology and Microbiology Treatment of Experimental
Autoimmune Uveoretinitis with Intravitreal Injection of Tacrolimus (FK506) Encapsulated in Liposomes.
Investig. Ophthalmol. Vis. Sci. 2010, 51, 3575–3582. [CrossRef] [PubMed]
97. Yan, J.; Zheng, M. Chrysophanol liposome preconditioning protects against cerebral ischemia–reperfusion
injury by inhibiting oxidative stress and apoptosis in mice. Int. J. Pharmacol. 2014, 10, 55–68. [CrossRef]
98. Choi, Y.H. Berberine hydrochloride protects C2C12 myoblast cells against oxidative stress-induced damage
via induction of Nrf-2-mediated HO-1 expression. Drug Dev. Res. 2016, 77, 8. [CrossRef]
99. Lai, S.; Wei, Y.; Wu, Q.; Zhou, K.; Liu, T.; Zhang, Y.; Jiang, N.; Xiao, W.; Chen, J.; Liu, Q.; et al. Liposomes for
efFective drug delivery to the ocular posterior chamber. J. Nanobiotechnol. 2019, 17, 64. [CrossRef] [PubMed]
100. Wolin, L.R.; Massopust, L.C. Characteristics of the ocular fundus in primates. J. Anat. 1967, 101, 693–699.
[PubMed]
101. Wang, J.-L.; Liu, Y.-L.; Li, Y.; Dai, W.-B.; Guo, Z.-M.; Wang, Z.-H.; Zhang, Q. EphA2 targeted doxorubicin
stealth liposomes as a therapy system for choroidal neovascularization in rats. Ophthalmol. Vis. Sci. 2012, 53,
7348. [CrossRef] [PubMed]
102. Ravar, F.; Saadat, E.; Gholami, M.; Dehghankelishadi, P.; Mahdavi, M.; Azami, S. Hyaluronic acid-coated
liposomes for targeted delivery of paclitaxel, in-vitro characterization and in-vivo evaluation. J. Control.
Release 2016, 10, 10–22. [CrossRef]
103. Lee, J.; Goh, U.; Lee, H.J.; Kim, J.; Jeong, M. Effective retinal penetration of lipophilic and lipid-conjugated
hydrophilic agents delivered by engineered liposomes. Mol. Pharm. 2017, 14, 423–430. [CrossRef]
104. Hironaka, K.; Inokuchi, Y.; Fujisawa, T.; Shimazaki, H.; Akane, M.; Tozuka, Y.; Tsuruma, K.; Shimazawa, M.;
Hara, H. Edaravone-loaded liposomes for retinal protection against oxidative stress-induced retinal damage.
Eur. J. Pharm. Biopharm. 2011, 79, 119–125. [CrossRef]
105. Yamamoto, Y.; Kuwahara, T.; Watanabe, K. Antioxidant activity of 3-methyl-1-phenyl-2-pyrazolin-5-one.
Redox Rep. 1996, 2, 333–338. [CrossRef]
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Abstract: In the past, the importance of serine to pathologic or physiologic anomalies was inadequately
addressed. Omics research has significantly advanced in the last two decades, and metabolomic
data of various tissues has finally brought serine metabolism to the forefront of metabolic research,
primarily for its varied role throughout the central nervous system. The retina is one of the most
complex neuronal tissues with a multitude of functions. Although recent studies have highlighted
the importance of free serine and its derivatives to retinal homeostasis, currently few reviews
exist that comprehensively analyze the topic. Here, we address this gap by emphasizing how
and why the de novo production and demand for serine is exceptionally elevated in the retina.
Many basic physiological functions of the retina require serine. Serine-derived sphingolipids and
phosphatidylserine for phagocytosis by the retinal pigment epithelium (RPE) and neuronal crosstalk
of the inner retina via D-serine require proper serine metabolism. Moreover, serine is involved in
sphingolipid–ceramide balance for both the outer retina and the RPE and the reductive currency
generation for the RPE via serine biosynthesis. Finally and perhaps the most vital part of serine
metabolism is free radical scavenging in the entire retina via serine-derived scavengers like glycine
and GSH. It is hard to imagine that a single tissue could have such a broad and extensive dependency
on serine homeostasis. Any dysregulation in serine mechanisms can result in a wide spectrum of
retinopathies. Therefore, most critically, this review provides a strong argument for the exploration of
serine-based clinical interventions for retinal pathologies.
Keywords: serine; retinal degeneration; diabetic retinopathy; macular degeneration; macular
telangiectasia; oxidative stress; sphingolipids; retina; RPE; Müller cells
1. Why Is Serine Important to the Entire Retina?
Serine is a non-essential amino acid directly involved in cellular homeostasis, proliferation, and
differentiation [1,2]. The cells of the neural retina are no exception, and, in fact, exhibit a great
dependence on serine and its exhaustive variety of metabolic intermediates [3]. Serine uptake occurs
either by delivery from the bloodstream or it can be synthesized by the anabolism of the glycolytic
intermediate, 3-phosphoglycerate (3-PG) [4] in the retina (neural retina-RPE, Figure 1). After uptake or
synthesis, serine becomes available and serves as a central node in many cellular processes [5].
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Figure 1. Pathway depicting serine biosynthesis from glycolysis. Metabolic intermediates involved in
the enzymatic synthesis of L-serine from glycolysis is shown here with the rate limiting step marked
with a dashed grey arrow. The enzymes involved in respective steps are shown in bold italics below
the arrow for the individual reaction.
Other than being an integral amino acid in multiple essential proteins, free serine is essential for
generating cysteine, glycine, methionine, and sphingolipids [5]. Glycine and cysteine are essential
intermediates. Glycine is a precursor molecule for porphyrins and purine nucleotides [6]. Cysteine on
the other hand is important in the protection of neuronal cells and for the production of taurine [7].
Together they form glutathione (GSH), a critical anti-oxidant in the retina [8]. Sphingolipids are elemental
components of the phospholipid bilayer and are indispensable to cellular viability, homeostasis and
function [2,3,5]. Furthermore, serine derived-metabolites have proven essential to methylation [2],
apoptosis, and synaptic receptor activation [6].
The integrality of serine to cellular function has been appreciated by dysregulatory events
appearing in many retinopathies. Reduced serine levels have been implicated in the etiology of macular
related diseases such as macular telangiectasia type 2 (Mac Tel), age related macular degeneration,
and diabetic retinopathy (DR) [9,10]. The retina is a complex stratified tissue consisting of the retinal
pigment epithelium (RPE), a critical layer of cells for retinal homeostasis, and the neural retina
containing the two types of photoreceptor cells. The neural retina also harbors the second order
neurons and the retinal ganglion cells (RGC) that form the optic nerve. Serine proves to be a vital
intermediate in many of these processes. Consequently, our goal is to provide a focused review of the
role of serine homeostasis in maintaining optimum retinal function and proper oxidative balance.
2. Why Does the Retina Need to Synthesize Serine?
In most tissues, serine uptake from either blood or proteolysis sufficiently meets cellular metabolic
requirements. However, there are tissues that mandate an elevated level of serine and, accordingly,
upregulate enzymes for serine biosynthesis. As previously highlighted, this biosynthetic pathway
(Figure 1) helps in maintaining the redox potential of the cell [11]. The primary source of serine
biosynthesis is glucose [12], which in most cells is utilized via glycolysis. Serine biosynthesis
branches from one of the glycolytic intermediates, 3-phosphoglycerate. The rate limiting step for
serine biosynthesis is the reaction involving phosphoglycerate dehydrogenase (PHGDH), which
converts 3-phosphoglycerate into phosphoserine. This is followed by the removal of the phosphate to
generate l-serine.
It has been previously shown that the retina expresses high levels of all enzymes involved in serine
biosynthesis. However, the RPE appears to express even higher levels than the neural retina [13] as
has been shown by flux studies, whereby the RPE readily converts glucose into serine [10,14]. Further
experiments verified that the neural retina possess an efficient system for serine uptake. [15].
De Novo Serine Synthesis in Müller Cells
Transport of serine, a neutral amino acid, across the tight blood–retinal barrier into the RPE
or across the endothelial cells and to the neural retina is supposedly inadequate [16]. So the retina
increases the levels of intracellular serine through de novo synthesis [12]. Further supply of serine to
photoreceptors and the inner retina is provided by the RPE and retinal Müller cells [15]. The latter was
demonstrated by co-immunofluorescence with anti-PHGDH and anti-cellular retinaldehyde–binding
protein (CRALBP) antibodies showing that the serine de novo synthesis pathway is indeed present in
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the Müller cells [17]. Since serine metabolism is central to maintaining redox and oxidative balance,
ion flux, glutamate levels, and many other support functions [18], Müller cells through their de novo
synthesis of serine play major roles in these functions [17].
Many retinopathies are associated with loss of Müller glia [17]. Mac Tel, is a pathology of the
retina recently characterized by significant reductions in serine synthesis and loss of central vision [16].
Although the macula (anatomic) is a small cone-dense region of the retina occupying only 1.4% of
the total area of the retina, it harbors approximately 8% of the total cone population and 60% of
all RGCs [19]. The macula is incredibly metabolically active and relies heavily on Müller glia [18].
Not only has localization of serine synthesis in the neural retina been demonstrated in Müller cells,
but relative to peripheral Müller cells, those of the macula seem to show increased expression of
PHGDH [10]. Moreover, the macular Müller cells show increased GSH and glycine production and are
more susceptible to induced stress [10].
3. Serine Homeostasis Plays an Important Role in the Maintenance of the Retina
3.1. Serine and Sphingolipids
One of the many fates of biosynthesized L-serine is to combine with palmitoyl-Co-A to form
sphingolipids (Figure 2) catalyzed by the enzyme serine palmitoyl-Co-A transferase (SPT) [20].
Even though there are multiple interconnected pathways, which can control the formation of various
sphingolipids, the most common pathway is serine incorporation [21]. Neural retinal sphingolipids
have been well characterized addressing their beneficial and toxic capacities [3,22–25]. It is very well
known that the most vital role of sphingolipids is aiding in sphingomyelin formation, which enables
efficient synaptic transmission [3]. Perhaps, that is one reason why the sphingolipid content in the
inner retina is quite high [3]. Moreover, sphingolipids in the form of sphingosine-1-phosphate are
thought to have anti-apoptotic role, further rationalizing the abundance of sphingolipids in the outer
retina [3]. It is important to note that the role of sphingolipid levels and their derivatives have not yet
been assessed in the RPE. Given that the RPE may be a vital source of serine for the neural retina, it is
imperative to determine how its transport might be facilitated.
Figure 2. Pathway depicting sphingolipid biosynthesis from L-serine. Metabolic intermediates involved
in the enzymatic synthesis of sphingolipids from L-serine are shown here. The enzymes involved in
respective steps are shown in bold italics below the arrow for the individual reaction.
3.2. Serine and RPE Phagocytosis
The efficient phagocytosis of photoreceptor outer segments by the RPE is elemental to retinal
health. From extensive examination of the process, it has been determined that any delay or inefficiency
in the phagocytosis can lead to gross abnormalities for both the neural retina and the RPE [26].
The metabolism of the RPE is largely dependent on recycling the outer segment phospholipids, as
they provide an important source of fuel [27–29]. The neural retina eliminates older disks in order to
maintain optimal function. So how is serine vital for maintaining such an important step? In order for
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the RPE to recognize and phagocytose the correct portion of the outer segments, phosphatidylserine
will localize to the extracellular surfaces of those digestible regions [30]. Since almost 10% of the entire
outer segment is daily phagocytosed from each photoreceptor, it helps us appreciate the enormous
amount of serine that needs to be available. Furthermore, it has been suggested that sphingolipids may
also play a regulatory role in order to ensure efficient phagocytosis, since disruption of sphingolipid
metabolism via SPT and ceramide synthase inhibition impaired phagocytosis [31,32]. In addition,
glycosphingolipids like lactosylceramides and gangliosides are major lipid raft components and assist
in cell adhesion, membrane polarity and phagocytosis initiation [33–36]. This raises the possibility
that the sphingolipid pool in RPE may assist in facilitating outer segment phagocytosis as well as
maintaining the tight junction barrier and cellular polarity. Since serine is an integral component of
sphingolipids, it goes without saying that this presents another facet of serine availability contributing
to efficient neural retina:RPE interdependence.
3.3. The Role of D-Serine
D-serine, an enantiomer of L-serine, is primarily released by glial cells, Müller cells and
astrocytes [13]. Initially, it was discovered in the brain but has more recently been studied in the neural
retina [13]. D-serine, formed by the racemization of L-serine by serine racemase (SRR) [13], functions
as a neurotrophic factor and as a co-agonist for N-methyl-D-aspartate receptors (NMDARs) [37].
In the brain, NMDARs normally bind glutamate and glycine, but data suggests preferential or higher
affinity binding to D-serine in the retina [13,38]. NMDARs locate at the synaptic terminals of RGCs
and sparingly to photoreceptor terminals [39]. The role of NMDARs in the synaptic terminals has
not been entirely substantiated, however, studies have indicated that they function in an excitatory
role [13]. In the presence of D-serine, NMDA-mediated currents and light-evoked response showed
increased amplitude over the D-serine absent control [13]. Irrespective of NMDAR functions, the
importance of D-serine is evidenced by pathologies that are directly linked to D-serine irregularities.
D-serine insufficiency has been associated with psychiatric and neurodevelopmental disorders [37].
Supplementation with D-serine has proven to mitigate some of the symptoms of psychosis [37]. Patients
with DR, by contrast, suffer from increased SRR activity and over production of D-serine, which elicits
an excitotoxic effect on RGCs and ultimately contributes to cell death [40]. This will be addressed in
more detail in the following sections.
3.4. Serine and Epigenetic Regulation
One carbon metabolism is a fundamental process for purine, thymidine, and amino acid
biosynthesis that involves the transfer of a one carbon unit to generate critical metabolites [8].
Serine is essential in this group of metabolic reactions [41] and, in this context, is a precursor for the
synthesis of methionine. Briefly, serine donates a methyl group which reacts with homocysteine,
originally derived from aspartate [42,43]. This reaction is catalyzed by serine transhydroxymethylase
to ultimately form methionine [42,43].
An adenosylation reaction of adenosine triphosphate (ATP) and methionine will yield
S-adenosyl-L-methionine, which is the critical methyl donor for global methylation of DNA [41,44,45].
DNA methylation, an absolutely essential process to maintain cellular homeostasis [46], occurs on
CpG islands of DNA and suppresses gene expression [47]. Therefore, irregularities in serine levels
cause downstream hypo- or hyper-methylation of DNA [48], effecting stress responses, proliferation,
metabolism, and even responses to extrinsic stimuli [46].
The link between epigenetic modulations and retinal disease is currently at a nascent phase [49],
so correlations between aberrant serine metabolism, DNA methylation, and retinal disease remain
unclear. However, recent studies performed on three pairs of monozygotic twins with different
presentations of AMD indicated significant changes to DNA methylation patterns of genes that may be
implicated in disease pathogenesis [50]. More critically, the diet of the studied twins also highlighted
nutritional significance in epigenetic regulation. Subjects with reduced dietary methionine, vitamin D,
302
Cells 2020, 9, 674
and betaine had worse disease prognosis [50], implicating the importance of nutrient bioavailability
and epigenetics. As serine is involved in the synthesis of methionine, further studies should explore
serine levels in retinal disease in relation with epigenetic changes that may contribute to disease onset
and/or progression.
4. Serine Is an Anti-Oxidant and Mediator of Inflammation
The role that serine plays as a central junction for critical intermediates also extends to anti-oxidative
and inflammatory mechanisms. Experimental evidence has indicated that the retina shares some
metabolic patterns with neoplastic cells [16]. In these systems, the Warburg effect predominates [51],
and energy is generated primarily through glycolysis to ensure accelerated ATP production [16].
As explained earlier, the retina is one of the highest energy consuming tissues and thus a source of
excessive reactive oxygen species (ROS). Emerging data has shed light on extra-mitochondrial sources
of ROS specifically in the outer retina and even in the outer segment of photoreceptors [52,53]. It was
previously shown that oxygen is mainly absorbed at the level of the photoreceptors [54] and thus this
site is most prone to oxidative stress, both in physiology and pathology [55]. To build on that, it seems
that blue light exposure on outer segment discs as well as ectopic oxidative phosphorylation in the
outer segment both pose a greater need for effective free radical scavengers in the outer segment–RPE
interface [56–58]. Glycine and GSH and thus serine supply are essential for this ROS mitigation system
of the rods and cones [59].
Fundamentally, intracellular redox homeostasis represents the equilibrium between oxidative and
anti-oxidative species, creating a balance in which the environment is not cytotoxic and is sensitive
enough to redox changes that may mandate an intracellular or extracellular response. Clearly, oxidative
stress is caused by aberrations to this balance. Serine metabolism contributes to redox homeostasis
through synthesis of glycine and its essential downstream products GSH and nicotinamide adenine
dinucleotide phosphate (NADPH), as well as nicotinamide adenine dinucleotide (NADH) generation
during serine biosynthesis [60]. In addition, GSH and NADPH deactivate ROS and other oxidative
molecules [60]. GSH is the direct result of combining cysteine and glycine, both of which, as previously
explored, are synthesized from serine [61]. NADPH is generated in many pathways, but recent studies
suggest that metabolism of serine is a significant contributor of NADPH to the mitochondria, especially
during hypoxic conditions [11]. During serine synthesis from 3-phosphoglycerate, serine donates a
single carbon to folate forming glycine as well as tetrahydrofolate (THF). THF reductase forms NADP+.
Then, GSH mediated-reduction of electrophilic molecules helps to maintain the balance of NADPH to
NADP+, which is principle to redox homeostasis.
GSH anti-oxidative activity is vital for proper retinal function [62]. So in malignancies where
serine is deficient, there is an obvious reduction in GSH level and activity, and, as a consequence, the
supply of the precursor molecules have been significantly affected. However, it is not as simple as
reduced supply. 5’ adenosine monophosphate-activated protein kinase (AMP-K) can also influence the
availability of GSH. AMP-K, like nuclear factor erythroid-derived 2-like 2 (NRF-2), is a “cellular sensor”,
and responds to metabolic and redox irregularities [63]. AMP-K supports cell survival by upregulating
anti-oxidant molecules such as GSH. Elevating serum serine levels in mice fed high fat diet showed
increased levels of phosphorylated AMP-K, which resulted in reduced oxidative side-effects and
increased GSH expression [63]. AMP-K and NRF-2 are, by no means, the only transcription factors
involved in moderating the anti-oxidative response, but they represent the profound integration of
serine metabolism and retinal oxidative homeostasis.
NRF-2 is an important redox-activated transcription factor under conditions of stress and
imbalance of damaging oxidative species [64]. NRF-2 targets critical anti-oxidant genes such as
superoxide dismutase, catalase, and GSH by upregulating transcription. In culture of non-small
cell lung cancer cells (NSCLCs), gene enrichment analysis has demonstrated a correlation between
PHGDH, the enzyme necessary for shunting 3-phosphoglycerate to serine synthesis, and genes that
target the activation of NRF-2 [64]. The correlation suggests that biosynthesis of serine is involved
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in the expression and regulation of essential anti-oxidant proteins [64]. In addition to the cohort of
anti-oxidant proteins, NRF-2 also has some regulatory involvement in the bioavailability of nitric
oxide (NO) [65], which has the ability to mitigate the effects of H2O2 and superoxide [66]. Treatment
with serine increases NO levels in culture which directly links NO production to serine [65], whether
endogenously or exogenously presented.
Oxidative stress can also elicit tremendous damage to membranes, DNA, and mitochondria.
However, in many pathologies, oxidative stress and inflammation are intimately interlinked [67].
In particular, AMD and DR have been characterized by the slow infiltration of pro-inflammatory
constituents of the innate immune system [68]. Serine is currently being explored as a possible therapy
for addressing inflammation in these pathologies. However, the involvement of serine metabolism in
inflammation and innate immunity remains unclear [69].
Interesting observations have demonstrated a contradictory picture. Exogenously administered
serine has been shown to reduce levels of inflammatory cytokines such as interleukin-1β and
interleukin-6 [63]. Serine has also been shown to weaken the pro-inflammatory response necessary
for macrophage recruitment after bacterial infections in mice [70]. The conflict emanates from the
upregulation of inflammatory elements by way of increased glycolytic flux. In DR and AMD, dietary
mismanagement and genetic mutations lead to metabolic dysregulation [71–74], which may increase
glycolysis in cells. This may lead to increased synthesis of serine since it is produced from the PHGDH
shunt. The increase in serine glycolytic synthesis is linked to the amplified activation of toll-like
receptor 4 (TLR-4) after activation by lipopolysaccharide (LPS) [69] or hydrogen peroxide [75]. TLR-4
then induces a cytokine response, namely interleukin-1β [69]. Furthermore, GSH, whose activity
and expression is upregulated by stress and higher levels of serine, further contributes to cytokine
production and maintenance of redox balance in the cellular environment [69].
Serine deprivation was shown to be effective in reducing the activation of TLR-4, and reducing
cytokine levels [69]. Activation of TLR-4 has also been implicated in the etiology of AMD [76]. Contrarily,
serine supplementation is being explored as a potential therapy. Exogenous supplementation has
proven to be effective in many cases reducing oxidative stress and reducing cytokine levels, but
endogenous synthesis (as discussed above) augments the inflammatory response [77]. Therefore,
balancing the anti-oxidant effects of serine with the pro-inflammatory nature of its endogenous
synthesis is something to consider when developing a serine-based therapy for retinopathies in which
inflammation contributes to the pathogenesis.
5. Consequences of Aberrations in Serine Metabolism
Our exploration has thus far presented the extensive involvement of serine metabolism in
retinal homeostasis. Therefore, aberrations to this important keg in the metabolic machinery can
negatively influence retinal pathologies. Glycolytic serine synthesis provides the largest contribution to
intracellular serine stores, so deficiencies generally result from abnormalities in that synthetic process.
For instance, deleterious mutations in PHGDH have been associated with microcephaly, reduced
cognition, and psychomotor abnormalities [78]. Neu-Laxova is a fatal congenital disease marked
by serious systemic abnormalities and is attributed to homozygous mutations in enzymes involved
in serine biosynthesis [1]. This is recapitulated in the PHGDH−/− mouse model, where mice suffer
from embryonic lethality [1]. These irregularities can affect every part of the cell, from mitochondrial
biosynthesis to oxidative imbalance.
An extensive comparative metabolomics study was performed by Gao et al., analyzing the
metabolic and mitochondrial changes of colon cancer cell lines that occur as a result of serine
deprivation [79]. Primarily, glycine, serine, threonine, pyrimidine, and sphingolipid pathways were the
most significantly affected. Cells exhibited reduced fatty acid synthesis, and reduced TCA intermediates,
consequently cells had a 45% reduction in ATP. Serine deprivation also caused major changes
in mitochondrial membrane potential and increased fragmentation. However, phospholipid and
phosphatidylserine levels remained comparably similar to standard culture conditions; sphingosine and
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ceramide levels on the other hand were significantly lowered [79]. It was concluded that mitochondrial
fragmentation was exacerbated by reduced production of ceramides that serve as major constituents
of the mitochondrial membrane. Ultimately, Gao et al. was able to isolate effected pathways that
attenuated proper mitochondrial functions critical for cellular viability [79]. Considering the metabolic
demands in the retina, such deficits would be extremely detrimental and could play a significant role
in the etiology of many retinal diseases associated with metabolic dysregulation.
Cytotoxic aggregation of deoxysphingolipids is another important feature of serine deficiency [78].
As plasma serine levels decline, alanine flux increases and promotes the production of
deoxysphingolipids [78]. As previously indicated, serine sphingolipids are synthesized through
the condensation of serine and palmitoyl-CoA mediated by SPT. In cases of serine deficiency, SPT may
incorporate alanine or glycine into the formation of the lipid, forming a cytotoxic analogue [78]. These
lipids have been shown to aggregate and induce apoptosis in in vitro and in vivo models [78]. Retinal
organoids treated with deoxysphingolipids exhibited dose-dependent apoptosis [9].
6. Retinal Degeneration and Dysregulated Serine Metabolism
6.1. Inherited Retinal Degeneration
Inherited retinal degeneration (IRD) can arise from mutations in various genes linked to
photoreceptor development and structure or genes involved in phototransduction. To add to the
complexity of IRDs, patients with similar mutations may present with very different phenotypes [80].
This is indicative of other underlying factors that can contribute to disease manifestation. It has been
shown that metabolic dysregulation is a common element of various IRD models [81]. One example
that has recently emerged is the dysregulation of sphingolipid metabolism [3]. Many investigators
have shown that ceramide toxicity is elevated in various models of IRD [22]. In contrast, levels of
the protective sphingolipid, sphingosine-1-phosphate, are significantly reduced [22]. What is yet to
be determined is why and how the toxic ceramides are increased while sphingosine-1-phosphate
levels diminish. One mechanism that has been postulated suggests that serine deficiency forces the
sphingolipid metabolism to switch to the incorporation of alanine for sphingolipid synthesis [22].
However, in doing so, the reaction is skewed towards the formation of ceramides. Further investigation
is required to determine why there is reduced serine availability. Since the glycolytic precursor,
phosphoglycerate, is the primary source for serine biosynthesis, it is possible that dysregulation in
glucose metabolism is the cause for the reduced serine availability.
6.2. Diabetic Retinopathy
Studies have demonstrated a correlation between serine deficiency and systemic diabetes [77].
Inflammation potentially increases the expression and activity of SRR, and consequently increases
the availability of D-serine for receptor binding [40]. The elevated levels of D-serine contribute to
glutamate toxicity and induce RGC apoptosis [40]. More precisely, as more D-serine binds to NMDARs,
an excitotoxic response is induced [40]. As part of glutamate signal propagation in the retina, NMDAR
excitation may be involved in decreasing neurotransmitter sensitivity [40]. Nevertheless, when
D-serine levels are substantially elevated, the NMDAR-mediated excitation has a toxic effect in the
retinal environment and induces cell death in RGCs [40]. In SRR null models with streptozocin (STZ)
induced DR, degeneration of RGCs appeared attenuated, there was a reduction in neovascularization
and the retina appeared significantly healthier than the control [40]. Most interestingly, multiple
studies have found that if diabetic patients are treated with a serine supplement, blood glucose levels
were reduced [77,82]. Currently, no mechanism is known to explain how this happens. But it is
known that upon onset of diabetes, similar to serine deficiency, toxic sphingolipid accumulation starts
occurring [83]. In fact, deoxysphingolipids have been shown to be potent biomarkers for diabetes
mellitus [84]. As in IRD, DR results in similar toxic build-up of these aberrant sphingolipids, but
this occurs far before any retinopathic complications start to develop [25]. These ceramides can
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actually be used as an early indicator of disease. It appears as if serine deprivation and toxic ceramide
accumulation occur concomitantly. Perhaps, as the retina relies most heavily on serine, any deficiencies
may cause the tissue to exhibit the first signs of disease in DR.
7. Novel Insights: Macular Telangiectasia
It has been elucidated recently that a dysregulated lipid metabolism can lead to increased and
leaky vasculature [16]. Given the fact that serine homeostasis closely regulates lipid metabolism, it
becomes a prime candidate for such monitoring. Interestingly, it was found in patients suffering from
Mac Tel that their PHGDH activity is also compromised [85]. This led to severe serine deficiency,
which contributed to vascular abnormalities [9]. As explained earlier, serine deficiency further leads to
toxic deoxysphingolipid accumulation, which indeed plays a role in the etiology of Mac Tel type 2 [86].
However, administering exogenous serine to patients as a promising therapeutic approach has been
marginally successful [87,88]. Importantly, how serine deficiency may affect the RPE and whether that
has a role in Mac Tel is not yet known. Nevertheless, it is to be determined whether the restoration of
physiological levels of serine in the retina can prevent further neovascularization in Mac Tel patients.
8. Concluding Remarks
Serine metabolism has vast interconnectivity with many of the homeostatic mechanisms that
work in concert to maintain retinal health and function, as depicted in Figure 3. As reviewed above,
considerable evidence has indicated that both the RPE and Müller cells of the inner retina have the
requisite enzymes for serine biosynthesis. Besides the significant contribution of these two tissues to
the serine pool of the entire retina, we also established the role de novo serine synthesis plays in redox
currency generation and in mitigating free radical stress for both the neural retina and RPE. Given the
retina is a metabolically high functioning tissue with high-energy demands and recent advancements
indicating extra-mitochondrial contribution to the elevated presence of free radicals compared to other
tissues, it calls for such extensive measures. Thus we show that while the pentose phosphate pathway
might be sufficient to maintain the redox balance for other tissues, the retina depends upon additional
tools, which it obtains primarily from serine metabolism: like NADPH from de novo biosynthesis,
glycine, GSH and NADH. In addition, a review of the literature on serine-based lipid derivatives
like phosphatidylserine, sphingolipids, and their toxic form, i.e., ceramides, helped us conclude the
essential role these play in both RPE phagocytosis and membrane integrity in retinal homeostasis,
while their imbalance is a critical factor in inherited retinal dystrophies. Coupled with the above
observations and the recent advance on using D-serine as therapeutic candidate for diabetic retinopathy,
we further postulate that there are a multitude of potential therapies targeting serine metabolism that
hold tremendous promise against retinal diseases. We highlighted the prospect of using PHGDH
replacement gene therapy or serine supplement therapy for Mac Tel patients and serine racemase and
ceramide synthase inhibition for DR patients. Careful evaluation of recent literature also helped us align
with the growing consensus that metabolic vulnerabilities add an extra layer of susceptibility for IRD
patients. Thus, boosting serine biosynthesis and serine metabolism by pharmacological activators or
complimentary gene therapy in these patients may reduce this risk factor and help postpone their onset
of degeneration. Consequently, and in this review, our goal was to delineate some of the important
roles of serine and demonstrate how they are imperative to the health of the retina. By providing a
comprehensive view of the relationship between serine and retinal health, we hope to bring more
awareness to the importance of serine to the retina so it can be further assessed for treatment options,
and proteins that mediate its metabolic processes can be considered as viable targets for gene therapy.
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Figure 3. Graphical summary of serine metabolism in the retina. Serine homeostasis is primarily
maintained by the RPE and retinal glia. The RPE transports and generates serine, which is ultimately
transported to the photoreceptors. Additionally, important serine metabolic products such as glycine
and cysteine are transported or catabolized to be used as fuel, as the energetic requirements of the
RPE are very high. Photoreceptors also receive serine from the Müller glia and astrocytes. Glial cells
are vital to the macula and generate serine from glycolysis, which is crucial in maintaining the redox
balance in the photoreceptors, controlling neurotransmission, and mediating inflammation response
elements. (IS, inner segment; OS, outer segment; ONL, outer nuclear layer; OPL, outer plexiform layer;
INL, inner nuclear layer; IPL, inner plexiform layer).
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Abstract: Substantive evidence demonstrates the contribution of mitochondrial dysfunction in
the etiology and pathogenesis of Age-related Macular Degeneration (AMD). Recently, extensive
characterization of Mitochondrial-Derived Peptides (MDPs) has revealed their cytoprotective role in
several diseases, including AMD. Here we summarize the varied effects of MDPs on cellular and
mitochondrial health, which establish the merit of MDPs as therapeutic targets for AMD. We argue
that further research to delve into the mechanisms of action and delivery of MDPs may advance the
field of AMD therapy.
Keywords: MDPs; mitochondrial-derived peptides; Humanin; HNG; SHLPs; MOTS-c; Age-related
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1. Introduction
In the United States, geographic atrophy in dry AMD (Age-related Macular Degeneration) is a
primary cause of vision loss in the elderly [1], and it has limited treatment options compared to those
available for wet AMD [2,3]. Among the wide variety of factors that are instrumental in the etiology
and pathogenesis of AMD, mitochondrial damage in the Retinal Pigment Epithelium (RPE), leading
to RPE dysfunction, contributes significantly. AMD mitochondria are fragmented, have a higher
number of lesions, altered ATP synthase activity, as well as compromised protein expression and
nuclear-encoded protein import [4–6]. Furthermore, as confirmed by ATAC-sequencing, chromatin
accessibility is decreased significantly in the RPE in AMD retinas [7].
The human mitochondrial genome is ~16.5 kilobases, circular, double-stranded, and consists of
37 genes that code for 13 proteins of the respiratory chain complexes. These 13 proteins are a part
of the electron transport chain and aid in oxidative metabolism and ATP production [8,9]. Some of
the critical functions of mitochondria include, but are not limited to, ATP production via respiration,
promoting thermogenesis via proton leak, regulation of cellular metabolism and calcium signaling,
ROS generation, regulation of apoptosis, ion homeostasis, and heme synthesis [10]. The retina is a
part of the central nervous system and is one of the highest energy-demanding tissues in the human
body. Glycolysis in the cytosol and mitochondrial oxidative phosphorylation are the two primary
sources of energy, i.e., ATP (adenosine triphosphate) generation. Retinal neurons derive their energy
mostly from oxidative phosphorylation, which has a substantially higher ATP yield than glycolysis [11].
Unmet retinal energy demand puts the retinal neurons at a high risk of cell death that in turn causes
impairment or loss of vision [12]. Mitochondrial function declines with age as a result of accumulated
mtDNA damage/mutations [13]. The majority of proteins that support mitochondrial health and
function are encoded by the nuclear genome. Therefore, coordinated regulation of mitochondrial and
nuclear gene expression is essential to maintain cellular homeostasis [14]. Mammalian mitochondrial
retrograde signaling, i.e., transmission of information from the mitochondria to the nucleus, is mediated
Cells 2020, 9, 1102; doi:10.3390/cells9051102 www.mdpi.com/journal/cells313
Cells 2020, 9, 1102
by G-Protein Pathway Suppressor 2 (GPS2), which also functions as a transcriptional activator of
nuclear-encoded mitochondrial genes. GPS2-regulated direct translocation from the mitochondria to
the nucleus is essential for the transcriptional activation of a nuclear stress response to mitochondrial
depolarization and for supporting basal mitochondrial biogenesis [15].
The mitochondrial genome encodes 22 tRNAs and two ribosomal RNAs, i.e., 12S rRNA and 16S
rRNA, both of which are essential in synthesis of mitochondrial proteins. The 12S rRNA gene is 954
base pairs (bp) in length and spans 648–1601 bp of the mtDNA; it occupies 1/16 of the entire mtDNA and
has 297 nucleotide substitutions, which account for 31% of the 12S rRNA gene. Furthermore, the 16S
rRNA gene is 1559 bp long, spanning 1671–3229 bp of the mtDNA; it occupies 1/10 of the entire mtDNA
and has 413 nucleotide substitutions, which account for 25% of the 16S rRNA gene [16]. Both 16S rRNA
and 12S rRNA genes carry ORFs (Open Reading Frames) that encode mitochondrial-derived peptides.
2. Mitochondrial-Derived Peptides (MDPs)
Novel mitochondrial-derived peptides (MDPs), which are encoded within the mtDNA, serve as
signals for organism cytoprotection and energy regulation. The MDPs encoded from the 16S rRNA
region of the mtDNA include Humanin and SHLPs, which regulate cell survival and growth via distinct
pathways. MOTS-c, encoded from the 12S rRNA region of the mtDNA, plays a key role in regulation
of muscle and fat metabolism and prevents hepatic steatosis. Numerous MDPs are well-characterized
and are in preclinical development for aging-related diseases [17–20].
3. Humanin
Humanin was the first MDP discovered within the mammalian mitochondrial genome and is
encoded from the 16S rRNA coding region of the mtDNA. Humanin cDNA was first discovered in
2001 by functional expression screening of a cDNA library preparation from the occipital cortex of an
Alzheimer’s disease patient brain [21]. The study identified clones that protected against neuronal
cell death induced by neurotoxic amyloid-β peptides and by mutants of FAD (Familial Alzheimer’s
Disease) genes, namely APP (Amyloid Precursor Protein), PS1 (Presenilin 1), and PS2 (Presenilin 2).
A 75 bp open reading frame that codes for a 24-residue peptide was identified and its sequence was
found to be similar to that of a human cDNA and 99% identical to the mtDNA sequence; it was therefore
named Humanin. Humanin antagonized the cytotoxicity caused by APP (Amyloid Precursor Protein
(APP), PS1 (Presenilin 1), and PS2 (Presenilin 2) mutants, by suppressing amyloid-β1-42-triggered
neurotoxicity and attenuating neuronal cell death.
3.1. Structure
Humanin is a secretory 24-amino acid peptide with the amino acid sequence H-Met-Ala-Pro-Arg-Gly-
Phe-Ser-Cys-Leu-Leu-Leu-Leu-Thr-Ser-Glu-Ile-Asp-Leu-Pro-Val-Lys-Arg-Arg-Ala-OH (H-MAPRGFSCL
LLLTSEIDLPVKRRA-OH) and a molecular weight of 2687.26 Da (Figure 1). Following its discovery, the
structure and biological functions of Humanin have been very well characterized. Using a combination
of oligonucleotide synthesis, dimerization experiments, and bioinformatics, Yamagishi et al. conducted
a comprehensive investigation that led to the identification of the amino acids essential for Humanin
secretion and for its neuroprotective function [22]. This study revealed that Humanin is a signal peptide
and the core domain of Humanin is formed by Leu9-Leu10-Leu11 residues with Leu10 being the key
player. Leu9-Leu10-Leu11 and Pro19-Val20 are absolutely essential for the extracellular secretion of
full-length Humanin. The neuroprotective action of Humanin requires Pro19, Ser14, Thr13, Leu12,
Leu9, Cys8, Ser7, and Pro3. Ser7 and Leu9 residues are required for the self-dimerization of Humanin,
which is necessary for its neuroprotective function. Providing critical insights into the amino acid
requirements of Humanin would be useful in synthesis of peptides tailored to perform a specific
biological function and for targeted improvement of particular cellular functions.
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Figure 1. Humanin and Small Human-Like Peptides (SHLPs) Open Reading Frames (ORFs) in the
human mitochondrial DNA.
3.2. Tissue Distribution
Measurable levels of Humanin are detectable in plasma, seminal fluid, and cerebrospinal fluid.
A circulating Humanin pool has been demonstrated in various tissues of the human body, including
hypothalamus, liver, heart, kidney, colon, testes, vasculature, and skeletal muscle [23–28]. Circulating
plasma levels of Humanin decline with age in both humans and mice [29]. Demonstrating a proportional
relationship between Humanin levels and human aging is of particular importance, as this could
promote research that aims to boost Humanin levels and thereby delay aging in humans.
3.3. Humanin Analogs
Amino acid substitutions in Humanin have led to the development of synthetic Humanin analogs,
which are more potent than the endogenous Humanin. Humanin G (HNG) is formed by a Ser to Gly
amino acid substitution at position 14. HNGF6A is formed by the Phe to Ala amino acid substitution
at position 6 [30].
3.4. Humanin Receptors and Regulation
Humanin exerts its cytoprotective effects by binding to receptors intracellularly/extracellularly,
regulating the intrinsic mitochondrial pathway, and mediating downstream signaling. Humanin
binds to the Formyl-Peptide Receptor-Like Receptor-1 (FPRL-1) and the IL-6 (Interleukin-6) receptor
family trimeric receptor complex, comprised of CNTFRα (Ciliary Neurotrophic Factor Receptor α),
WSX-1, and GP130 (glycoprotein 130kDa), which are key contributors to the neuroprotective action of
Humanin [31–33]. Substantial evidence suggests that mitochondrial retrograde signaling is involved in
the endocrine regulation of aging and age-related pathologies. IGF-1 (Insulin Growth Factor-1) is a key
player in the conserved endocrine pathway, which contributes to lifespan and healthspan. Humanin, a
potent mediator of mitochondrial retrograde signaling, is directly regulated by IGF-1, and the levels of
Humanin and IGF-1 simultaneously decline with age [34]. Humanin and IGF-1 are known to have
distinct yet overlapping functions. By interacting with the C-terminal domain of IGFBP-3 (Insulin-like
Growth Factor Binding Protein-3), Humanin interferes with the binding of Importin-β to IGFBP-3,
thereby suppressing IGFBP-3-mediated apoptosis [35]. Humanin regulates peripheral insulin action.
In this study, peripherally administered HNGF6A in rats conferred insulin sensitivity via hypothalamic
STAT3 (Signal transducer and activator of transcription 3) activation [29].
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4. Humanin Functions
4.1. Prevents Apoptosis
Humanin binds to the pro-apoptotic protein BAX and prevents its translocation to the nucleus,
thereby antagonizing the apoptotic activity of BAX and inhibiting the release of cytochrome c [36]. This
finding reported by Guo et al. in the journal Nature was the first thorough study that delineated and
reported the interactions of Humanin with the pro-apoptotic BAX protein. Since Humanin is encoded
by the mitochondria, this report also suggested a possible retrograde signaling mechanism between
the mitochondria and the nucleus that might be contributing to regulation of BAX-mediated apoptosis.
Humanin also binds and inactivates BAX-like proteins, such as Bid and BidEL [37]. Exogenously
added HNG exerts substantive protective effects in transmitochondrial AMD RPE cells in vitro by (a)
rescue of mitochondrial structure and function, (b) inhibiting the action of pro-apoptotic genes/proteins,
and (c) intracellular and extracellular humanin receptor modulation (Figure 2) [38].
Figure 2. Effects of Humanin/Humanin analogs in RPE/AMD.
Humanin is cytoprotective against amyloid-β-mediated toxicity in neuronal cells, both in vitro and
in vivo [17,18]; against cerebral ischemia and cardiac damage in mouse models [19,20]; and in numerous
neurodegenerative disease models for Alzheimer’s disease, Parkinson’s disease, Huntington’s disease,
and Prion diseases [18,19,39,40]. Moreover, Hinton et al. in a comprehensive study published in
the highly reputed IOVS eye journal demonstrated that Humanin rescues primary RPE cells from
oxidative damage and subsequent death in vitro [41]. This showed that Humanin conferred RPE cell
protection via two mechanisms: by enhancing mitochondrial biogenesis and function and by activation
of STAT3. Further, Humanin mediated suppression of oxidative stress-induced cell senescence and
maintained transepithelial resistance in human RPE monolayers. In summary, this study by Hinton et
al. suggested the potential of Humanin as a therapeutic candidate for the treatment of geographic
atrophy in dry AMD.
Each of the 24 amino acids in the Humanin peptide have a specific function. Serine at position
14 confers neuroprotection [22], but its substitution with glycine generates a variant called Humanin
G/HNG that is 1000-fold more potent than its parent analog Humanin [16]. HNG is known to protect
against cell death by preventing mitochondrial dysfunction [26].
Humanin potentially inhibits silver nanoparticles-induced cell death in human neuroblastoma
cells by (a) protecting against redox imbalance and oxidative stress-induced DNA damage, (b)
increasing mitochondrial membrane potential and enhancing the activity of mitochondrial succinate
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dehydrogenase, and (c) deactivation of the ER stress pathways that were upregulated by the silver
nanoparticles [42].
4.2. Prevents Amyloid-β-Induced Toxicity
Amyloid-β is a key component of drusen deposits that are formed in the AMD retinas.
Administration of Humanin G reduces amyloid-β loads and inhibits amyloid-β-induced cell apoptosis by
(a) restoring amyloid-β-mediated decline in calcium homeostasis, (b) suppressing amyloid-β-induced
membrane fluidity changes, (c) restoring mitochondrial membrane potential, and (d) decreasing
intracellular reactive oxygen species [43]. This finding is crucial as Humanin G’s ability to mitigate
amyloid-β-induced cytotoxicity might be used as a therapeutic approach to delay the progression of
dry AMD.
4.3. Stress Resistance Against ER Stress-Induced Apoptosis
Humanin exerts its therapeutic benefits by antagonizing the action of a plethora of cellular
insults, thereby protecting the RPE cells against cytotoxicity. Treatment with Humanin downregulates
the expression of an ER stress marker CHOP (C/EBP Homologous Protein), inhibits ROS (Reactive
Oxygen Species) production, and regulates intracellular calcium influx, thereby preventing RPE cell
apoptosis [44,45]. Treatment of primary human RPE cells with three ER stress sensors, i.e., Tunicamycin,
Brefeldin A, and Thapsigargin, induced mitochondrial damage and dose-dependent loss of RPE cells.
However, pretreatment with Humanin provided significant cytoprotection against ER stress-induced
cell death by restoring the depleted mitochondrial glutathione (GSH) levels to normal, reducing
mitochondrial superoxide generation, and downregulating ER stress-induced apoptotic Caspase 4 and
Caspase 3 [46].
4.4. Activation of the ERK, AKT, and STAT3 Signaling Pathways
As a secretory peptide, Humanin regulates both intracellular and extracellular signaling pathways.
Exogenously administered Humanin both in vitro and in vivo rapidly increases AKT-1 phosphorylation
and activates the PI3K (Phosphoinositide 3-Kinase)/AKT pathway; AKT-1 is the AKT Serine/Threonine
Kinase-1 protein that plays a role in cell motility, metabolism, and proliferation [47]. Moreover,
intraperitoneal injection of Humanin in vivo elevates endothelial NOS (Nitric Oxide Synthase)
phosphorylation and also increases the phosphorylation of AMPK (5′ Adenosine Monophosphate-
Activated Protein Kinase), a protein which contributes to cellular energy homeostasis [25]. The signaling
pathway mediated by Humanin involves its interaction with various molecular entities, including
protein kinases, integral membrane receptors, and transcription regulators. In neuronal cell lines,
Humanin interacts with and activates the GP130 receptor and mediates its effects via its canonical AKT,
ERK1/2 (Extracellular Signal-Regulated Kinase 1/2), and STAT3 signaling cascades. Humanin acts as a
primary agonist for the GP130 receptor in neuronal cell lines in vitro, and Humanin treatment transiently
activates GP130, thereby mediating cellular protective effects, such as anti-apoptosis, enhanced insulin
sensitivity, and protection from hypoxic and ischemic stressors [48].
4.5. Preserves Endothelial Function in Atherosclerosis
Oh et al. demonstrated that sustained administration of Humanin G (a more potent analog of
Humanin) to ApoE-knockout mice inhibited the progression of atherosclerotic plaques and preserved
endothelial function [49].
4.6. Prevents Vascular Remodeling and Inflammation
Exogenously added Humanin attenuated angiogenesis, inflammation, apoptosis, and microvascular
remodeling in an ApoE-deficient mouse model of atherosclerosis [23].
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4.7. Cytoprotective Against LDL-Induced Oxidative Stress
Bachar et al. demonstrated that Humanin is expressed in the endothelial cell layer of human
blood vessels. In human endothelial cells in vitro, exogenous supplementation of Humanin attenuated
oxidized (Ox)-LDL-induced ROS generation and apoptotic cell death by 50% and reduced the levels
of cellular ceramide, which is a lipid second messenger that initiates apoptotic signaling cascades.
Therefore, Humanin renders protection against Ox-LDL-mediated oxidative stress and is cytoprotective
in human vasculature [50].
4.8. Protects Germ Cells/Leukocytes—Reduces Cancer Metastases
A recent study by Jia et al. provided evidence of the role of Humanin in maintaining germ
cell homeostasis. Substantive Humanin-mediated protection against chemotherapy-induced male
germ cell apoptosis both in vivo and ex vivo was observed. The study also demonstrated that this
anti-apoptotic effect is primarily mediated via STAT3 and BAX signaling [51].
4.9. Germ Cell Apoptosis by Chemo Drugs
Another similar study by Lue et al. demonstrated that Humanin G prevents cyclophosphamide-
induced toxicity and death of male germ cells and leukocytes. In this study, HNG protected normal
cells against stress and suppressed cancer metastases [52].
4.10. Cytoprotection in Carotid Atherosclerotic Plaques
In addition, it has been reported that Humanin is present in carotid atherosclerotic plaques and
higher expression of Humanin in symptomatic patients compared to asymptomatic patients could be a
part of a stress-response defense mechanism to delay the progression of the disease [53].
5. SHLPs (Small Humanin-Like Peptides)
The 16S rRNA region of the mitochondrial DNA also codes for another category of MDPs called
Small Humanin-Like Peptides (SHLPs), which include SHLP1, SHLP2, SHLP3, SHLP4, SHLP5, and
SHLP6. SHLPs are 24–38 amino acids long and each SHLP may differentially regulate mitochondrial
and cellular health and functions. Extensive characterization of SHLP2, SHLP3, and SHLP6 has been
detailed in recent literature but the specific biological functions of the SHLPs are still being studied.
5.1. SHLP2
SHLP2 has a molecular weight of 3017.54 Da and is 26 amino acids long with the sequence
H-MGVKFFTLSTRFFPSVQRAVPLWTNS-OH (Figure 1). The plasma SHLP2 levels decline with age,
suggesting its critical role in aging. SHLP2 stabilizes the AMD mitochondria by preserving the
mitochondrial oxidative phosphorylation protein complex subunits (I-V) in AMD RPE transmitochondrial
cells, and also promotes mitochondrial metabolism. This study also highlighted the potential of an
exogenously added SHLP2 peptide to enhance mitochondria-specific mtGFP fluorescence staining,
increase mtDNA copy numbers, and upregulate the PGC-1αgene, which is a master regulator of
mitochondrial biogenesis [54]. This in vitro study by Nashine et al. is the first study that demonstrates an
association between SHLP2 and AMD transmitochondrial RPE cells, and therefore provides a basis for
further explorative studies in the field of AMD. Pretreatment with SHLP2 inhibited apoptotic cell death
as evidenced by higher live cell numbers and substantive downregulation of effector caspases, namely
Caspase-3 and Caspase-7, in AMD RPE cells. Moreover, SHLP2 rescued and protected AMD RPE cybrid
cells against amyloid-β-induced toxicity in vitro (Figure 3). Therefore, SHLP2 could be considered a
potential therapeutic candidate for macular degeneration. SHLP2 also mediates chaperone-like activity,
prevents the misfolding of amyloid polypeptides, and prevents neuronal cell death [55].
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Figure 3. Effects of SHLP2 in AMD.
5.2. SHLP3
SHLP3 is a 38 amino acids-long peptide with the sequence H-MLGYNFSSFPCGTISIAPGFN
FYRLYFIWVNGLAKVVW-OH and has a molecular weight of 4380.15 Da. SHLP3 increases cellular ATP
levels and mitochondrial oxygen consumption rate (OCR) in vitro. SHLP3 suppresses ROS generation,
mediates ERK signaling, promotes adipocyte cellular differentiation, and blocks staurosporine-induced
apoptosis, thereby promoting mitochondrial and cellular survival and functions. SHLP2 and SHLP3
have insulin-sensitizing effects both in vivo and in vitro, and are known to increase leptin levels. SHLP2
functions as an insulin sensitizer both peripherally and centrally as it enhances peripheral glucose
uptake and inhibits glucose production in the liver. SHLP3 also increases IL-6 and MCP-1 levels.
SHLP4 increases cell proliferation in the NIT-1 and 22RV-1 cell lines in vitro. SHLP6 drastically
enhances apoptotic cell death in the NIT-1 and 22RV-1 cell lines, and exerts an effect opposite of SHLP2
and SHLP3, which are cytoprotective molecules [56]. Among all the SHLPs, SHLP2 is the only peptide
whose cytoprotective function has been established in AMD (Figure 3).
6. MOTS-c
MOTS-c (Mitochondrial ORF (Open Reading Frame) within the Twelve S rRNA c) is encoded in
the 12S rRNA region of the mtDNA, and is a 16-amino acid peptide with the sequence H-MRWQEMG
YIFYPRKLR-OH and a molecular weight 2174.7 Da (Figure 4). It is associated with insulin resistance and
is found in plasma, brain, liver, and muscle tissues. MOTS-c enhances insulin sensitivity and regulates
plasma metabolites in three metabolic pathways, namely sphingolipid metabolism, monoacylglycerol
metabolism, and dicarboxylate metabolism. MOTS-c indirectly decreases cellular oxidative stress by
reducing plasma oxidized glucose levels. MOTS-c also activates AKT phosphorylation and AMPK
pathways. Moreover, MOTS-c reduces skeletal muscle fatigue and improves performance in vivo [57].
This is the first report by Cohen et al. that delineates the specific roles of MOTS-c and opens new avenues
for further research with this MDP. MOTS-c enhances mitochondrial respiration in senescent cells by
regulating fatty acid oxidation and increasing the senescence-related effectors [58]. Since MOTS-c levels
also decline with age, it has been implicated in the regulation of lifespan and healthspan in organisms.
This lifespan/healthspan prolonging ability of MOTS-c may be attributed to (1) MOTS-c-mediated
increase in intracellular NAD+, a key redox metabolic coenzyme that activates sirtuins, which in turn
regulate aging; and (2) MOTS-c-mediated reduction in methionine metabolism via inhibition of the
folate/methionine cycle [59]. Although the function of MOTS-c as a crucial player in cell longevity,
mitochondrial function, and metabolic homeostasis has been well-established, its specific protective
function in the eye is yet to be reported. Since the AMD etiology involves a metabolic component as
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well as mitochondrial dysregulation, it would be interesting to investigate the cytoprotective effects of
MOTS-c in AMD pathology (Figure 5).
Figure 4. MOTS-c ORF in the human mitochondrial DNA.
Figure 5. Effects of MOTS-c.
CohBar, a clinical-stage biotechnology company focused on the research and development of
mitochondria-based therapeutics, has successfully completed a Phase 1a clinical study and initiated
the Phase 1b stage of a double-blind, placebo-controlled clinical trial of CB4211 as a potential treatment
for nonalcoholic steatohepatitis (NASH) and obesity. CB4211 is the first therapeutic candidate based
on a mitochondrial-derived peptide to enter clinical testing in humans. The completed Phase 1a stage
of the CB4211 clinical study evaluated safety and tolerability, and the drug was safe and well tolerated
after seven days of dosing. The Phase 1b stage of the study will be an assessment of safety, tolerability,
and activity in obese subjects with nonalcoholic fatty liver diseases (NAFLD). Assessments will include
changes in liver fat assessed by MRI-PDFF, body weight, and biomarkers relevant to NASH and
obesity [60].
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7. Conclusions and Future Directions
The dry and wet forms of AMD have some common denominators in terms of AMD disease
pathology, since the characteristic features of dry AMD, i.e., RPE cell apoptosis and accumulation
of drusen deposits (in which amyloid-β is a key component), may subsequently lead to choroidal
neovascularization observed in wet AMD pathology. To our knowledge, differential effects of MDPs in
dry AMD versus wet AMD have not been delineated and reported yet.
Since this manuscript presents the literature that establishes the role of MDPs in mitigating
RPE cell apoptosis and reducing amyloid-β-induced toxicity, it suggests that MDPs are potential
therapeutic candidates for treatment of dry AMD, and may delay its progression to the late form,
i.e., wet AMD. However, the specific therapeutic effects of MDPs in reducing or preventing choroidal
neovascularization in wet AMD need to be characterized. Experimentally, the effects of MDPs on the
angiogenesis-promoting factors should be tested to evaluate if MDPs are able to downregulate the
pro-angiogenic factors and related pathways, and thereby prevent or suppress neovascularization in
wet AMD.
In conclusion, MDPs, especially Humanin (and its analogs) and SHLPs, provide cytoprotection in
ocular diseases, including AMD, and may be considered as potential therapeutic targets for AMD.
However, the use of MDPs as therapeutic agents for AMD will require development of appropriate
delivery techniques and formulations. Currently, nanoparticles encapsulating Humanin are being
tested in some labs to subsequently facilitate its efficient delivery and sustained action. In a recent
study by Li et al., it was demonstrated that the Humanin peptide mediates elastin-like polypeptide
nano-assembly and protects human RPE cells against oxidative stress-induced apoptotic cell death.
This technology may facilitate cellular delivery of biodegradable nanoparticles with potential protection
against AMD [61]. Furthermore, with the development of precision medicine, the use of MDPs can be
customized for AMD therapy to match patient needs.
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